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Abstract 
Chapter 1. In the Tan laboratory, we developed synthetic methods to control reaction 
selectivity (regio-, stereo-, and site-selectivity) using scaffolding catalysis. Our strategy 
utilizes directing groups that induce intramolecularity through the formation of a labile 
covalent bond between the substrate and a binding site in a catalytic system. In the first 
part, we described site-selective functionalization of various carbohydrates and complex 
polyhydroxylated molecules which contain cis-1,2-diol motif using a chiral organic 
scaffold. In the second part, meta-selective C–H functionalization of arenes was 
demonstrated. High meta-selectivity was achieved by the use of a nitrile-based silyl tether 
which is cleavable and recyclable.  
Chapter 2. In the Liu laboratory, we focuses on studies of boron-nitrogen containing 
heterocycles. In this chapter, synthesis of 1,2-azaborines and their binding study with T4 
lysozyme mutants were described. Specifically, we directly compared binding of NH-
containing 1,2-azaborines and their carbonaceous analogs to probe hydrogen bonding 
  
interaction between the NH group of azaborine and a carbonyl oxygen of protein residue. 
Structural and thermodynamic analysis provided us the first evidence of H-bonding of 
azaborines with a biological macromolecule.  
Chapter 3. Described are the synthesis of regioisomers of ethyl-substituted 1,2-azaborines 
and their binding thermodynamics to T4 lysozyme mutants. To access the azaborine 
ligands used in the binding study, we developed synthetic methods for regioselective 
functionalization of six positions of 1,2-azaborines. Isothermal titration calorimetry 
experiments showed differences in binding free energy for regioisomers to the L99A T4 
lysozyme. This result could originate from electronic differences of the isosteric ligands 
inducing dipole-dipole interaction between ligand and surrounding protein residues or it 
may be from local dipolar interactions.   
Chapter 4. A general method for late-stage N-functionalization of 1,2-azaborines is 
described to afford libraries of BN-containing complex molecules. The chemical 
transformations include electrophilic substitution reactions, N–C(sp2) bond forming 
reactions under Buchwald-Hartwig amination conditions, and N–C(sp) bond forming 
reactions using copper-catalyzed N-alkynylation. As applications in materials science and 
medicinal chemistry, synthesis of the first parental BN isostere of trans-stilbene and 
lisdexamfetamine derivative is described utilizing the methodology developed in this work. 
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1. Chapter 1: Site-Selective Reactions via Scaffolding Catalysis 
1.1 Introduction 
 There are growing demands to improve efficiency of synthesis by avoiding pre-
functionalization. As a consequence, selective functionalization is desired to synthesize 
complex molecules in shorter steps (i.e. by involving late-stage modification). However, 
controlling reaction selectivity (site-, regio-, and stereo-) still remains one of the main 
challenges for synthetic chemists when the precursor to the target compound displays 
multiple similarly reactive sites. Creating strategies and methodologies that robustly solve 
selectivity issues offers to solve synthetic challenges in an array of chemical space. For 
example, traditional methods for site-selective functionalization of carbohydrates typically 
feature protection-deprotection sequences; a representative four-step protocol to 
monoacetylate α-D-galactose (1.1) at the C2-OH position (Scheme 1.1) amply 
demonstrates the inefficiency inherent to this approach.1 It requires several purification 
steps and results in loss of overall yield.  
 
 
 
 
 
                                                 
1 Barili, P. L.; Berti, G.; Catelani, G.; Colonna, F.; Marra, A. Tetrahedron Lett. 1986, 27, 2307–2310. 
2 
 
Scheme 1.1 Traditional method for acetylation of methyl α-D-galactose C2-OH 
 
 
 Similarly, selective activation of a specific arene C–H bond would enable more 
streamlined syntheses of drugs and natural products. Early methods relied on substrate 
control in the form of electronic and steric differences among ortho-, meta-, and para-
positions induced by the substituents already present. More recent developments in 
directing group-assisted and catalyst- and ligand-controlled reactions have paved the way 
to control reaction selectivity. This approach obviates use of protecting group strategy or 
functional group manipulation. A recent example by Baran and Yu demonstrates the power 
of site-selective functionalization to enable more efficient syntheses.2 The authors reported 
a short synthesis of (+)-hongoquercin A (1.4) through consecutive late-stage C–H 
alkylation and oxidation of compound 1.3a, which can be accessed from (+)-sclareolide in 
seven steps (Scheme 1.2, eq. 1). This new method avoids the need for pre-functionalized 
                                                 
2 Rosen, B. R.; Simke, L. R.; Thuy-Boun, P. S.; Dixon, D. D.; Yu, J.-Q.; Baran, P. S. Angew. Chem. Int. Ed. 
2013, 52, 7317–7320. 
3 
 
starting materials such as 1.5, which had been used in previous syntheses.3 Direct C–H 
functionalization also allows diversity-oriented synthesis to prepare analogs of (+)-
hongoquercin A; thus, in addition to methylation, compound 1.3a or 1.3b can undergo a 
range of other ortho-directed C–H functionalization reactions, including longer-chain 
alkylation, lactonization, oxidation, vinylation, amination, arylation, and carbonylation 
(Scheme 1.2, eq. 2).  
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
3 For previous syntheses of (+)-hongoquercin A, see: a) Tsujimori, H.; Bando, M.; Mori, K. Eur. J. Org. 
Chem. 2000, 297–302. b) Kurdyumov, A. V.; Hsung, R. P. J. Am. Chem. Soc. 2006, 128, 6272–6273. 
4 
 
Scheme 1.2 Synthesis of (+)-hongoquercin A and its analogs by C–H functionalization 
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1.2 Background 
1.2.1 Directing Groups in Site-Selective Functionalization 
 In 1973, Breslow demonstrated the feasibility of using a stoichiometric directing group 
covalently and irreversibly bound to the substrate to control the reaction selectivity. 4 
Specifically, he employed a remote benzophenone group to achieve selective 
dehydrogenation of the C14–C15 bond in steroid derivative 1.6; the reaction selectivity is 
believed to derive from the structural rigidity of 1.6 during photoloysis as this maintains 
the required proximity of the benzophenone unit to the C14–C15 bond (Scheme 1.3).  
 
Scheme 1.3 Selective oxidation of steroid ester using benzophenone as a directing group 
 
 
 More recently, there have been intensive studies of directed reactions through metal 
complexation for geometric pre-organization of reaction components. Through the 
complex formation selective functionalization at a desired site can be achievable. In this 
process, the use of a proximal directing group plays a key role in controlling selectivity. 
                                                 
4 Breslow, R.; Baldwin, S.; Flechtner, T.; Kalicky, P.; Liu, S.; Washburn, W. J. Am. Chem. Soc. 1973, 95, 
3251–3262. 
6 
 
The Sharpless epoxidation of allylic alcohols serves as a classic example of this strategy 
(Scheme 1.4).5 The chemoselectivity arises from geometric control exerted by coordination 
of the titanium catalyst to the allylic alcohol and t-butylhydroperoxide. The 
enantioselectivity observed in product 1.9 is the result of (+)-diethyl tartrate inducing a 
chiral environment for the peroxide oxygen atom to approach from the Re face of the alkene. 
 
Scheme 1.4 Sharpless epoxidation of allylic alcohol 
 
 
 C–H activation has been the focus of intense research efforts for the past several 
decades and generally requires some form of directing group to achieve site-selectivity. 
Notably, the directing groups most commonly used in arene C–H activation reactions, 
pyridine, amide, carboxylate, imine, oxime, and oxazoline, involve coordination of one or 
more heteroatoms to a catalytic metal center.6 One of the early examples of pyridine used 
for directing effect can be found in Moore’s regioselective acylation of the aromatic C–H 
                                                 
5 Katsuki, T.; Sharpless, K. B.  J. Am. Chem. Soc. 1980, 102, 5974–5976. 
6 For selected reviews on C–H activation, see: (a) Shilov, A. E.; Shul'pin, G. B. Chem. Rev. 1997, 97, 2879–
2932. (b) Davies, H. M. L.; Beckwith, R. E. J. Chem. Rev. 2003, 103, 2861–2903. (c) Omae, I. Coord. Chem. 
Rev. 2004, 248, 995–1023. (d) Colby, D. A.; Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624–655. 
(e) Yeung, C. S.; Dong, V. M. Chem. Rev. 2011, 111, 1215–1292. (f) Kuhl, N.; Hopkinson, M. N.; Wencel-
Delord, J.; Glorius, F. Angew. Chem. Int. Ed. 2012, 51, 10236–10254. (g) Lyons, T. W.; Sanford, M. S. Chem. 
Rev. 2010, 110, 1147–1169. (h) Giri, R.; Shi, B.-F.; Engle, K. M.; Maugel, N.; Yu, J.-Q. Chem. Soc. Rev. 
2009, 38, 3242–3272. 
7 
 
bond ortho to the pyridyl nitrogen. The recation afforded the desired ortho-functionalized 
product 1.11 in 65% yield with 93:7 linear:branched selectivity for carbonyl insertion 
(Scheme 1.5, eq. 1).7 A plausible mechanism involves the nucleophlic attack of pyridine 
on the metal center and ortho-metalation to form a bridged intermediate and successive 
olefin coordination and insertion. Murai reported a direct, site-selective alkylation of arenes 
using a ketone directing group.8 Catalyst insertion takes place exclusively at the ortho C–
H bond of the benzene ring in 1.12. The coordination of the substrate’s carbonyl oxygen to 
the ruthenium metal center enforces the proximity of the catalyst to the ortho C–H bond, 
subsequently leading to formation of a metallacycle through oxidative insertion (Scheme 
1.5, eq. 2). 
 
 
 
 
 
 
 
 
                                                 
7 Moore, E.J.; Pretzer, W. R.; O'Connell, T. J.; Harris, J.; LaBounty, L.; Chou, L.; Grimmer, S. S. J. Am. 
Chem. Soc. 1992, 114, 5888–5980. 
8 Murai, S.; Kakiuchi, F.; Sekine, S.; Tanaka, Y.; Kamatani, A.; Sonoda, M.; Chatani, N. Nature 1993, 366, 
529–531. 
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Scheme 1.5 Directing groups in metal-catalyzed selective C–H activation 
 
 
1.2.2 Site-Selective Functionalization of Complex Molecules 
 Controlling selectivity in natural product synthesis and late-stage derivatization of 
complex molecules is crucial in terms of synthetic efficiency and biological application. 
The Miller group has demonstrated remarkable progress in catalyst-controlled 
functionalization of complex, multi-functional, natural products, most notably 
erythromycin A, vancomycin, and teicoplanin. 9  In 2006, using peptide-based chiral 
catalyst 1.15, they achieved selective acetylation of erythromycin A (1.14)’s C11-OH to 
                                                 
9 (a) Lewis, C. A.; Miller, S. J. Angew. Chem. Int. Ed. 2006, 45, 5616–5619. (b) Pathak, T. P.; Miller, S. J. J. 
Am. Chem. Soc. 2012, 134, 6120–6123. (c) Han, S.; Miller, S. J. J. Am. Chem. Soc. 2013, 135, 12414–12421. 
9 
 
afford 1.16 in 58% yield (Scheme 1.6, eq. 1).9a More recently, they demonstrated site-
selective phosphorylation of teicoplanin using three distinct peptide-based catalysts 
(1.17a–c) to target three different hydroxyl groups (Scheme 1.6, eq. 2).9c The key 
interaction in this example is mutiple hydrogen bonds between the substrate and the side 
chain from the peptide-based catalyst. Structural rigidity of the catalyst induced by internal 
hydrogen bonding also contributes to spatial control for selective functionalization. 
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Scheme 1.6 Catalyst-controlled site-selective derivatization of complex molecules 
 
 
 Late-stage functionalization of unactivated C–H bonds in complex molecules has been 
a rapidly growing research area in the last decade.10 The White group in 2007 demonstrated 
                                                 
10 For selected examples, see: (a) Godula, K.; Sames, D. Science 2006, 312, 67–72. (b) Yamaguchi, J.; 
Yamaguchi, A. D.; Itami, K. Angew. Chem. Int. Ed. 2012, 51, 8960–9009. (c) Y. Ishihara and P. S. Baran, 
Synlett, 2010, 12, 1733–1745. (d) McMurray, L.; O’Hara, F.; Gaunt, M. J. Chem. Soc. Rev. 2011, 40, 1885–
11 
 
that both steric and electronic factors contribute to predictable selectivity in iron-catalyzed 
aliphatic C–H oxidation of complex molecules.11 The authors anticipated site-selective 
oxidation of (+)-artemisinin (1.21) would occur at the C10 position, which is electron-rich 
and less sterically hindered compared to other tertiary C–H bonds in the molecule. As 
predicted, reaction with hydrogen peroxide (H2O2) in the presence of electrophilic iron 
catalyst (1.22) afforded (+)-10β-hydroxyartemisinin (1.23) (Scheme 1.7, eq. 1). In contrast, 
when they subjected (–)-α-dihydropicrotoxinin (1.24) to the same oxidation conditions, 92% 
of the starting material was recovered, which can be rationalized by deactivation of the 
isopropyl tertiary C–H bond due to both electronic and steric factors (Scheme 1.7, eq. 2).  
 
 
 
 
 
 
 
 
                                                 
1898. (e) Wencel-Delord, J.; Glorius, F. Nature. Chem. 2013, 5, 369–375. (f) Davies, H. M. L.; Denton, J. R. 
Chem. Soc. Rev. 2009, 38, 3061–3071. (g) Gutekunst, W. R.; Baran, P. S. Chem. Soc. Rev. 2011, 40, 1976–
1991. (h) Dai, H.-X.; Stepan, A. F.; Plummer, M. S.; Zhang, Y.-H.; Yu, J.-Q. J. Am. Chem. Soc. 2011, 133, 
7222–7228. (i) Gormisky, P. E.; White, M. C. J. Am. Chem. Soc. 2013, 135, 14052–14055. (j) Larsen, M. A.; 
Hartwig, J. F. J. Am. Chem. Soc. 2014, 136, 4287–4299. (k) White, K. L; Movassaghi, M. J. Am. Chem. Soc. 
2016, 138, 11383–11389. (l) He, J.; Hamann, L.G.; Davies, H. M. L.; Beckwith, R. E. J. Nat. Commun. 2015, 
6, 5943. 
11 Chen, M. S.; White, M. C. Science 2007, 318, 783–787. 
12 
 
Scheme 1.7 Selective aliphatic C–H bond oxidations with 1.22 of natural products 
 
 In 2009, the Baran group reported a highly efficient site-selective oxidation of primary 
and secondary C–H bonds to synthesize a series of eudesmane terpenes.12 Inspired by 
terpene biosynthesis, they designed and succesfully demonstrated site-selective oxidation 
by innate and guided C–H functionalization logic. 13  Installation of the trifluoroethyl 
carbamate directing group on the C3–OH of dihydrojunenol (1.25) afforded a common 
precursor (Scheme 1.8, 1.26). Site-specific C1–H oxidation was achieved to afford the 
corresponding oxidized product 1.27 by reaction with methyl(trifluoromethyl)dioxirane 
(TFDO). The origin of site-selectivity was later experimentally explained by strain release 
effects due to the presence of a 1,3-diaxial interaction.14 Basic hydrolysis led to the final 
desired product, 4-epiajanol (1.28). Dihydroxyeudesmane (1.30) was accessed by site-
selective halogenation at C5 position, followed by cyclization and hydrolysis of the 
                                                 
12 Chen, K.; Baran, P. S. Nature 2009, 459, 824–828. 
13 Brückl, T.; Baxter, R. D.; Ishihara, Y.; Baran, P. S. Acc. Chem. Res. 2012, 45, 826–839. 
14 Chen, K.; Eschenmoser, A.; Baran, P. S. Angew. Chem. Int. Ed. 2009, 48, 9705–9708. 
13 
 
brominated intermediate (1.29). Site-selective bromination occurs at C5 position because 
geometric constraints prevents the directing group from reaching C1 position (Scheme 1.8). 
 
Scheme 1.8 Total syntheses of 4-epiajanol and dihydroxyeudesmane via site-specific C–H oxidations 
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1.2.3 Catalyst-Controlled Selective Functionalization of Carbohydrates 
1.2.3.1 Metal-Catalyzed Reactions 
 Selective functionalization or temporary protection of carbohydrates can be achieved 
via complexation of a diol unit within the substrate to a metal species. It typically proceeds 
through selective activation of one of the hydroxyl groups coordinated to the metal center. 
This strategy has been found most commonly effective using tin reagents.15  In 2000, 
Matsumura demonstrated regioselective monobenzoylation of the C2-hydroxyl group of 
glucose derivative 1.31 using a catalytic amount of Me2SnCl2 (Scheme 1.9, eq. 1).16 Tin 
coordination to the cis-1,2-diol motif comprising C1-OMe and C2-OH leads to 
benzoylation at the equatorial C2 position. More recently, Muramatsu reported chemo- and 
regioselective functionalization of unprotected carbohydrates also using tin-based 
catalysts. 17  An anomeric mixture of methyl D-glucoside (1.33 and 1.34) underwent 
benzoylation with high chemo- and regioselectivity to produce either C2- or C6-
functionalized products depending on the alkyl substituents on the tin catalyst (Scheme 1.9, 
eq. 2). The reaction was found to proceed well with various acylating and sulfonylating 
electrophiles. When Bu2SnCl2 is used as catalyst, formation of intermediate 1.37 from 
methyl α-D-glucoside 1.33 is kinetically favored (Figure 1.1a); which undergoes 
functionalization at the C2-OH to form the desired product 1.35. The other possible 
intermediates 1.38 and 1.39 are destabilized by 1,3-diaxial interactions between the Sn-Bu 
                                                 
15 (a) Wagner, D.; Verheyden, J. P. H.; Moffatt, J. G. J. Org. Chem. 1974, 39, 24–30. (b) Munavu, R. M.; 
Szmant, H. H. J. Org. Chem. 1976, 41, 1832–1836. (c) Nashed, M. A.; Anderson, L. Tetrahedron Lett. 1976, 
17, 3503–3506. (d) Tsuda, Y.; Haque, M. E.; Yoshimoto, K. Chem. Pharm. Bull. 1983, 31, 1612–1624. (e) 
Nicolaou, K. C.; van Delft, F. L.; Conley, S. R.; Mitchell, H. J.; Jin, Z.; Rodrı´guez, R. M. J. Am. Chem. Soc. 
1997, 119, 9057–9058. 
16 Iwasaki, F.; Maki, T.; Onomura, O,; Nakashima, W.; Matsumura, W. J. Org. Chem. 2000, 65, 996–1002. 
17 Muramatsu, W.; Takemoto, Y. J. Org. Chem. 2013, 78, 2336–2345. 
15 
 
group and the axial C4 and C6 protons (Figure 1.1b). The reaction with Me2SnCl2 occurs 
selectively at the sterically less hindered hydroxyl group at C6 of methyl β-D-glucoside 
1.34 through the intermediate 1.38. The origin of the selectivity was explained by anomeric 
effect as depicted in Figure 1.1c. They rationalized that nucleophilicity of C6-OH in the 
minor isomer 1.39 is weakened by anomeric effect compared to the case in the major 
isomer 1.38 (Figure 1.1c). This chemistry is one of the very few examples wherein catalyst 
control affords reactivity at the more sterically hindered secondary alcohol in the presence 
of primary alcohol. 
 
Scheme 1.9 Chemo- and regioselective functionalization of carbohydrates using tin reagents 
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Figure 1.1 Rationale for chemo- and regioselectivity 
 
 
1.2.3.2 Organocatalyst-Controlled Reactions 
 Regioselective functionalization of carbohydrates has also been accomplished using 
organocatalysts. The Taylor group employed diarylborinic acid derivatives to selectively 
control the reactivity of carbohydrate secondary hydroxyl groups through specific catalyst 
binding of substrate cis-1,2-diol units. 18  Specifically, they reported selective 
transformation with a variety of electrophiles to afford C3-functionalized methyl α-L-
fucopyranosides (Scheme 1.10). 19  Diphenylborinic acid 1.41 forms tetra-coordinated 
organoboron complex 1.42 with the substrate C3 and C4-OH groups; of these two activated 
hydroxyls, the equatorial C3-OH is more reactive and therefore undergoes subsequent 
                                                 
18 (a) Chan, L.; Taylor, M. S. Org. Lett., 2011, 13, 3090–3093. (b) Dimitrijevic, E; Taylor, M. S. ACS Catal. 
2013, 3, 945–. (c) Taylor, M. S. Acc. Chem. Res. 2015, 48, 295–305. (d) Tanveer, K.; Jarrah, K.; Taylor, M. 
S. Org. Lett. 2015, 17, 3482–3485. (e) Mancini, R. S.; Lee, J. B.; Taylor, M. S. Org. Biomol. Chem. 2017, 15, 
132–143.  
19 (a) Lee, D.; Taylor, M. S.  J. Am. Chem. Soc. 2011, 133, 3724–3727. (b) Lee, D.; Williamson, C. L.; Chan, 
L.; Taylor, M. S. J. Am. Chem. Soc. 2012, 134, 8260–8267. 
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functionalization. This chemistry was further developed to achieve glycosylation of 
carbohydrates for efficient oligosaccharide synthesis and derivatization of complex 
molecules.20 
 
Scheme 1.10 Regioselective functionalization of carbohydrates using a diarylborinic acid-derived catalyst 
 
 
 Inspired by enzyme-catalyzed reactions, the Miller group developed peptide-based 
catalysts for use in various asymmetric chemical transformations including site-selective 
functionalization of diols and carbohydrates. 21  The catalyst’s peptide residues form 
                                                 
20 (a) Gouliaras, C.; Lee, D.; Chan, L.; Taylor, M. S. J. Am. Chem. Soc. 2011, 133, 13926–13929. (b) Beale, 
T. M.; Taylor, M. S. Org. Lett. 2013, 15, 1358–1361. (c) McClary, C. A.; Taylor, M. S. Carbohydrate Res. 
2013, 381,112–122. (d) Beale, T. M.; Moon, P. J.; Taylor, M. S. Org. Lett. 2014, 16, 3604–3607. (e) Mancini, 
R. S.; McClary, C. A.; Anthonipillai, S.; Taylor, M. S. J. Org. Chem. 2015, 80, 8501–8510. (f) D'Angelo, K. 
A.; Taylor, M. S. J. Am. Chem. Soc. 2016, 138, 11058–11066. 
21 For selected examples, see: (a) Jarvo, E. R.; Miller, S. J. Tetrahedron 2002, 58, 2481–2495. (b) Colby 
Davie, E.; Mennen, S. M.; Xu, Y.; Miller, S. J. Chem. Rev. 2007, 107, 5759–5812. (c) Giuliano, M. W.; 
Miller, S. J. Top. Curr. Chem. 2016, 372, 157–201. (d) Miller, S. J.; Copeland, G. T.; Papaioannou, N.; 
Horstmann, T. E.; Ruel, E. M. J. Am. Chem. Soc. 1998, 120, 1629–1630. (e) Lewis, C. A.; Sculimbrene, B. 
R.; Xu, Y.; Miller, S. J. Org. Lett. 2005, 7, 3021–3023. 
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multiple hydrogen bonds with the substrate of interest to achieve a specific reaction 
geometry that selectively brings one substrate functional unit into proximity of the catalysts’ 
activating group. C3-acetylation of glucosamine analog 1.46 was achieved using penta-
peptide 1.47 with good conversion and excellent selectivity (Scheme 1.11).22 Variation of 
the peptide sequence facilitated expansion of the substrate scope to include molecules 
bearing polyol functionality as discussed in section 1.2.2.9 
 
Scheme 1.11 Miller’s peptide-based catalyst in controlling site-selectivity of acetylation 
 
 
 Kawabata’s C2-symmetric DMAP catalyst provides another example of an 
organocatalyst-controlled reaction. 23  Specifically, chiral catalyst 1.50 afforded site-
selective acylation at C4-OH of octyl β-D-glucopyranoside (1.49) (Scheme 1.12). They 
achieved high regioselectivity for this position (C2:C3:C4:C6= 0:<1:>99:0) even in the 
presence of the more reactive primary hydroxyl group at C6. The authors’ rationale for this 
selectivity involves a hydrogen bond between the primary C6 hydroxyl group and the 
catalyst’s amide carbonyl group. This molecular interaction consequently brings C4 
                                                 
22 Griswold, K.S.; Miller, S. J. Tetrahedron 2003, 59, 8869–8875. 
23 (a) Kawabata, T.; Muramatsu, W.; Nishio, T.; Shibata, T.; Schedel, H. J. Am. Chem. Soc. 2007, 129, 
12890–12895. (b) Yoshida, K.; Furuta, T.; Kawabata, T. Tetrahedron Lett. 2010, 51, 4830–4832. 
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hydroxyl into close proximity to the acyl pyridinium catalytic site. Additional hydrogen 
bonding of substrate C3-OH with the NH group of the catalyst indole moiety also 
contributes to the regioselectivity by further constraining the catalyst-bound substrate to a 
specific orientation (Figure 1.2).  
 
Scheme 1.12 Kawabata’s C2-symmetric DMAP-derived catalyst in regioselective C4-functionalization 
 
 
Figure 1.2 Transition state that rationalizes the C4 regioselectivity 
 
 
1.2.4 Scaffolding Catalysis 
1.2.4.1 Catalyst Mode of Action 
 To address similar synthetic problems, the Tan group developed catalysts to control 
reaction selectivity through reversible, covalent substrate binding. The general proposed 
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cycle for these catalysts is shown in Figure 1.3.24 Well-defined, rigid catalyst-substrate 
interactions via a single binding point induces a state of temporary intramolecularity 
between the substrate molecule and an activating residue on the catalyst. This proximity in 
turn accelerates a specific chemical transformation to lead to the product of interest. 
Dissociation of the converted product regenerates the catalyst, thus rendering the directing 
group catalytic. 
 
Figure 1.3 Proposed catalytic cycle for a scaffolding catalyst 
 
  
1.2.4.2 Desymmetrization of meso-1,2 -Diols 
 One of the Tan group’s initial applications of scaffolding catalysis featured the 
desymmetrization of meso-1,2-diols. Enantioselective desymmetrization of meso-1,2-diols 
has previously been reported by other groups using various catalytic functionalizations 
                                                 
24 (a) Tan, K. L. ACS Catal. 2011, 1, 877–886. (b) Tan, K. L.; Sun, X.; Worthy, A. D. Synlett 2012, 23, 321–
325. 
21 
 
including acylation, sulfonylation, phosphorylation, and silylation.25 In 2001, Ishikawa 
reported the first example of asymmetric silylation of secondary alcohols by using chiral 
guanidine derivatives.25f Kinetic resolution of indanol 1.52 was achieved by silyl transfer 
with a stoichiometric amount of the chiral base 1.53 to yield 79% silylated (R)-indanol 1.54 
in 58% ee (Scheme 1.13).  
 
Scheme 1.13 Asymmetric silylation of indanol using a chiral guanidine 
 
 
 In 2006, Hoveyda and Snapper demonstrated effective enantioselective silylation of 
1,2- and 1,3-diols using peptide-based catalysts, with enantioselectivities up to 96% ee 
(Scheme 1.14).25h They proposed that hydrogen bonding interactions between the diol 
substrate and the side chains of the catalyst leads to one enantiotopic diol substrate 
selectively undergoing silylation (Figure 1.4). In their initial mechanistic model, the role 
                                                 
25 (a) Oriyama, T.; Imai, K.; Sano, T.; Hosoya, T. Tet. Lett. 1998, 39, 3529–3532. (b) Spivey, A. C.; 
Arseniyadis, S. Top. Curr. Chem. 2010, 291, 233–280. (c) Sculimbrene, B.; Morgan, A.; Miller, S. J. Am. 
Chem. Soc. 2002, 124, 11653–11656. (d) Jordan, P. A.;Kayser-Bricker, K. J.; Miller, S. J. Proc. Natl. Acad. 
Sci. U. S. A. 2010, 107, 20620–20624. (e) Fiori, K. W.; Puchlopek, A. L. A.; Miller, S. J. Nat. Chem. 2009, 
1, 630–634. (f) Isobe, T.; Fukuda, K.; Araki, Y.; Ishikawa, T. Chem. Commun. 2001, 243–244. (g) Zhao, Y.; 
Mitra, A. W.; Hoveyda, A. H.; Snapper, M. L. Angew. Chem. Int. Ed. 2007, 46, 8471–8474. (h) Zhao, Y.; 
Rodrigo, J.; Hoveyda, A. H.; Snapper, M. L. Nature 2006, 443, 67–70. (i) You, Z.; Hoveyda, A. H.; Snapper, 
M. L. Angew. Chem., Int. Ed. 2009, 48, 547–550. (j) Rodrigo, J. M.; Zhao, Y.; Hoveyda, A. H.; Snapper, M. 
L. Org. Lett. 2011, 13, 3778–3781. (k) Mannville, N.; Alite, H.; Haeffner, F.; Hoveyda, A. H.; Snapper, M. 
L. Nature Chem. 2013, 5, 768–774. (l) Weickgenannt, A.; Mewald, M.; Oestreich, M. Org. Biomol. Chem. 
2010, 8, 1497–1504. 
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of the N-methylimidazole group was hypothesized to consist mainly of activating the silyl 
chloride. Based on their observation of the original reaction to be second-order in peptide 
catalyst, the catalytic system was further developed to enhance reaction efficiency by the 
aid of an achiral co-catalyst, 2-ethylthiotetrazole.25k In this example of dual catalysis, 
computational study suggested that deprotonated tetrazole serves as a nucleophilic co-
catalyst to activate silyl chloride while the imidazole unit of the chiral catalyst is involved 
in deprotonation of alcohol substrate acting as a Brønsted base (Figure 1.5). 
 
Scheme 1.14 Hoveyda-Snapper’s peptide-based chiral catalyst in desymmetrization of alcohols 
 
 
Figure 1.4 Initially proposed transition state model for enantioselective silylation using a peptide-based 
catalyst 
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Figure 1.5 Proposed transition state model for enantioselective silylation in dual catalysis 
 
 
 In 2011, we reported desymmetrization of cis-1,2-diols using scaffolding catalysts.26 
The catalyst was designed to benefit from induced temporal intramolecularity as discussed 
in section 1.2.4.1. It contains three main features: 1) oxazoline-based N,O-acetal substrate 
binding site to exchange with alcohol, 2) N-methylimidazole as a catalytic site, 3) amino 
alcohol-based chiral backbone to control stereoselectivity (Figure 1.6). We envisioned that 
inducing temporary intramolecularity during a reaction through a reversible covalent bond 
would result in both rate acceleration and high enantioselectivity. 
 
Figure 1.6 Key features of scaffolding catalyst 
 
 
                                                 
26 Sun, X.; Worthy, A. D.; Tan, K. L. Angew. Chem. Int. Ed. 2011, 50, 8167–8171. 
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 The chiral catalyst (–)-1.56 successfully afforded desymmetrization of various meso-
1,2-diols via silyl transfer with high yields and enantioselectivities under mild conditions 
(Table 1.1). We proposed that a reversible covalent bond between the chiral catalyst and 
the diol substrate is essential for high enantioselectivity. To rule out the possibility of the 
catalyst operating by alternative mechanisms involving non-covalent interactions with 
substrate, we attempted silylation of 1,2-cyclopentane diol with control catalyst 1.68 which 
lacks the ability to covalently bind substrates (Scheme 1.15). Both reaction yield and 
enantioselectivity suffered with 1.68 as compared to results with catalyst (–)-1.56, 
consistent with our hypothesis that covalent catalyst-substrate bonding plays a major role 
in achieving high reactivity and stereoselectivity. 
 
Table 1.1 Desymmetrization of meso-1,2-diols using scaffolding catalysts 
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Scheme 1.15 Silyl transfer reaction of 1,2-cyclopentane diol using a control catalyst 
 
  
1.3 Site-Selective Functionalization of 1,2-Diols of Carbohydrates27 
1.3.1 Importance of Polyhydroxylated Molecules 
 Polyhydroxylated moieties are conspicuously prevalent molecules that participate in 
critical biological processes (Figure 1.7). More specifically, species featuring carbohydrate 
groups in particular have been found to frequently play significant roles in the processes 
associated with cell growth, intercellular communication, and immune responses. 28 
Carbohydrates also notably compose the core structures of numerous antimicrobial and 
anticancer agents. 
 
 
 
 
 
                                                 
27 Sun, X.; Lee, H.; Lee, S.; Tan, K. L. Nature Chem. 2013, 5, 790–795. 
28 (a) van Kooyk, Y.; Rabinovich, G. A. Nature Immunol. 2008, 9, 593–601. (b) Feizi, T. Nature 1985, 314, 
53–57. (c) Crocker, P. R.; Feizi, T. Curr. Opin. Struct. Biol. 1996, 6, 679–691. (d) Liedtke, S.; Geyer, H.; 
Wuhrer, M.; Geyer, R.; Frank, G.; Gerardy-Schahn, R.; Zahringer, U.; Schachner, M. Glycobiology 2001, 
11, 373–384. (e) Almkvist, J.; Karlsson, A. Glycoconjugate J. 2004, 19, 575–581. 
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Figure 1.7 Polyhydroxylated molecules found in nature 
 
 
1.3.2 Motivation for Study 
 To expand the scope and solve unmet problems, we decided to examine our catalytic 
system in more complex substrates such as carbohydrates and natural products. An 
unsolved site-selective functionalization of carbohydrate is the reaction at axial hydroxyl 
groups. This challenging issue has been addressed by enzymatic systems. Kre2p/Mnt1p, a 
Golgi α-1,2-mannosyltransferase, catalyzes transfer of mannose from GDP-mannose to an 
α-mannoside.29 During the transfer, surrounding protein residues are engaged in multiple 
hydrogen bonds and van der Waals interactions for pre-organization of substrate in the 
active site (Figure 1.8). Through this mode of activation, the axial C2 hydroxyl group of 
methyl α-D-mannose is selectively functionalized. 
                                                 
29 Lobsanov, Y. D.; Romero, P. A.; Sleno, B.; Yu, B.; Yip, P.; Herscovics, A.; Howell, P. L. J. Biol. Chem. 
2004, 279, 17921–17931. 
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Figure 1.8 Schematic representation of the interactions in the active site of Kre2p/Mnt1p and methyl α-D-
mannose 
 
 
 We envisioned that with our catalytic system the number of interactions required for 
effective localization of substrate can be minimized through a single reversible covalent 
bond. In addition, as described in 1.2.4.2, our scaffolding catalysts have unique recognition 
of cis-1,2-diols. By employing this feature, site-selective functionalization of 
polyhydroxylated molecules is achievable, in which display cis-1,2-diol moiety within the 
structure. During the activation of mannose derivative, the chiral catalyst recognizes cis-
1,2-diol of C2 and C3 positions in the matched case and functionalization occurs at the C2-
axial hydroxyl group (Figure 1.9). It resembles pre-organization of substrate by the 
surrounding chiral information as we observe in the enzymatic system shown in Figure 1.8. 
However, our catalyst is not limited to a specific substrate but rather applicable in a wide 
range of polyols in selective functionalization due to its unique recognition ability of cis-
1,2-diol motif.   
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Figure 1.9 Proposed mode of activation of mannose derivative catalyzed by scaffolding catalyst 
 
 
1.3.3 Synthesis of Catalysts 
 The required catalysts can be synthesized in two steps from readily available materials. 
Imine formation between valinol and isopropyl aldehyde, followed by reaction with in situ-
generated 2-lithiated N-methylimidazole afforded intermediate 1.71 with good 
diastereoselectivity. Oxazoline ring formation was achieved by cyclization with 
DMF·DMA; the desired catalysts could be obtained as a single isomer after 
recrystallization. The use of simple amino alcohols and aldehydes as starting materials 
affords significant modularity with respect to the substituents of the catalysts’ chiral 
backbone. With different alkyl groups, one can access derivatives of chiral catalysts 
(Scheme 1.16).30 
  
 
 
 
                                                 
30 Worthy, A. D.; Sun, X.; Tan, K. L. J. Am. Chem. Soc. 2012, 134, 7321–7324. 
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Scheme 1.16 Synthesis of scaffolding catalysts 
 
 
1.3.4 Substrate Scope 
  With an array of catalysts in hand, we first examined site-selective functionalization of 
a C6-OH silyl-protected methyl α-D-mannose derivative (1.73). A control reaction using 
20 mol% N-methylimidazole as a catalyst revealed the C3-OH to possess the highest innate 
reactivity (C2:C3:C4= 5:78:17 in Table 1.2, entry 1). In a reaction with 20 mol% 
scaffolding catalyst (+)-1.56, however, the reaction selectivity was reversed to give C2-
OH functionalized mannose as the major product (Table 1.2, entry 2). This result 
demonstrates that the scaffolding catalyst’s ability to override the substrate’s inherent 
reactivity bias. When (–)-1.72 was used as catalyst, the reaction exclusively gave C3-OH 
silylated product in quantitative yield, reflecting an enhancement of the inherent reactivity 
of the C3-OH (Table 1.2, entry 3). As in previous work,26 reaction with a control catalyst 
(i.e. 1.68), which lacks a covalent substrate binding site, gave poor yields and similar 
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selectivities to those of the NMI-catalyzed reaction. This supports again our hypothesis 
that a covalent bond between catalyst and substrate has a critical role in both reactivity and 
selectivity. Depending on the choice of catalyst, selective acylation or sulfonylation can 
also be achieved for either the C2 or C3 hydroxyl group (Table 1.2, entries 4-9). 
  
Table 1.2 Site-selective functionalization of methyl α-D-mannose derivative 
 
 
 The catalysts are also applicable to site-selective functionalization of a variety of other 
monosaccharides. Methyl α-L-rhamnose bears a cis-1,2-diol motif between C2 and C3 
positions with the opposite absolute stereochemistry of D-mannose. Therefore, for axial 
C2-OH functionalization, the enantiomer of catalyst (–)-1.72 was required (Table 1.3, 
entries 2,5, and 8). Silylation, acylation, and sulfonylation occurred in overall good yield 
and high site-selectivity. For functionalization at the equatorial C3-OH position, catalyst 
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loading can be reduced to 5 mol% probably due to the pre-existing inherent bias being the 
most reactive site (Table 1.3, entries 3,6, and 9).  
 
Table 1.3 Site-selective functionalization of methyl α-L-rhamnose 
 
 
 The catalytic system could be further adopted to methyl β-L-arabinose, in which cis-
1,2-diol is located at C3 and C4 positions. With (–)-1.56 functionalization occurred 
selectively at the axial C4 hydroxyl group, whereas with the enantiomeric catalyst (+)-1.56 
reversed selectivity was observed to yield the C3-OH functionalized product as the major 
isomer (Table 1.4). Notably, during C4 modification higher selectivity was obtained when 
the catalyst (–)-1.56 was used instead of (–)-1.72. This might be ascribed to slight 
differences in sterics around substrate. Therefore it was necessary to have different alkyl 
groups on the catalyst to achieve high level of site-selectivity depending on substrate. 
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Table 1.4 Site-selective functionalization of methyl β-L-arabinose 
 
 
 Methyl α-D-galactose derivative (1.85) was also efficiently functionalized at the C3 
equatorial position with all three electrophiles (TESCl, AcCl, and MsCl) using the catalyst 
(+)-1.56 (Table 1.5). Unfortunately, attempts to functionalize the C4 axial position gave 
poor results, possibly due to added congestion around the C4-OH resulting from the 
adjacent C6-OTBS group. Functionalization at the C4 position of galactose could still be 
achieved, however, by reaction of conformationally constrained 1,6-anhydro-β-D-
galactose (1.89), in which the C4-OH is in an equatorial position instead (Table 1.6).  
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Table 1.5 Site-selective functionalization of methyl α-D-galactose derivative 
 
 
Table 1.6 Site-selective functionalization of 1,6-anhydro-β-D-galactose 
 
 
1.3.5 Origin of Axial Functionalization 
 One of the main advantages of our catalytic system is that it overturns inherent substrate 
reactivity favoring functionalization at the equatorial position and furnishes the axially 
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derivatized product instead. We investigated the origin of this preference for axial 
functionalization by studying the reaction of the C3-OH in 1,6-anhydro-β-D-galactose. 
With 20 mol% (+)-1.72, acetylation proceeded with good site-selectivity (Figure 1.10). 
Since the substrate is conformationally locked, catalyst-bound intermediate 1.93a cannot 
undergo chair-flip to form the less stable conformer 1.93b wherein the C3-OH is in an 
equatorial position. Therefore, the axially acetylated product 1.91b is believed to derive 
directly from the intermediate 1.93a. 
  
Figure 1.10 Fixed chair conformation in 1,6-anhydro-β-D-galactose 
 
 
 The above results do not rule out the possibility of chair-flipped intermediates being 
relevant to the reaction of unconstrained carbohydrates. Figure 1.11 shows potential chair-
flip mechanism in acetylation of the axial C2 position of methyl α-D-mannose derivative. 
The reaction can be initiated by the formation of the catalyst-bound intermediate, in which 
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the catalyst binding site is covalently bonded to the equatorial C3-OH group. The 
intermediate can undergo ring-flip to form a less stable axially bound intermediate 1.94b. 
After acyl transfer followed by dissociation of catalyst, equatorially functionalized product 
1.74b’ can proceed through a second ring-flip to generate the observed thermodynamically 
more stable product 1.74b. 
 
Figure 1.11 Potential chair-flip mechanism in unconstrained carbohydrates 
 
 
1.3.6 Application to Complex Molecules 
 The scaffolding catalysts’ ability to specifically recognize cis-1,2-diol units was also 
tested in other complex systems. Selective protection of one of the secondary hydroxyl 
groups on ribonucleosides would be advantageous to overcome limitation of low yielding 
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automated RNA synthesis. 31  As an example, 4,4’-dimethoxytrityl (DMTr)-protected 
uridine 1.95 underwent selective silyl protection at the C3-OH using the scaffolding 
catalyst (+)-1.56, leaving C2-OH available for elongation of the RNA strand. By switching 
the catalyst to (–)-1.72, protection occurred at C2-OH exclusively to give the desired silyl 
protected product 1.97 (Scheme 1.17).32 
 
Scheme 1.17 Selective silyl protection of ribonucleoside, uridine derivative 
 
 
 Mupirocin (an antibiotic for skin infections) and digoxin (a treatment for cardiovascular 
disease) both display multiple hydroxyl groups at disparate sites within their molecular 
frameworks. Site-selective derivatization of such complex molecules would be useful 
towards the preparation of structurally diversified analogs for use in medicinal chemistry 
or biochemical assays. Using scaffolding catalysis, we were able to selectively activate 
both the C6 and C7 hydroxyl groups of mupirocin methyl ester (1.98) (Scheme 1.18, eq. 
1). Digoxin has four other hydroxyl groups besides those at α and β positions. The 
                                                 
31 Somoza, A. Chem. Soc. Rev. 2008, 37, 2668–2675. 
32 Blaisdell, T. P.; Lee, S.; Kasaplar, P.; Sun, X.; Tan, K. L. Org. Lett., 2013, 15, 4710–4713. 
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acetylated products (1.102 and 1.103 in Scheme 1.18, eq. 2) are also used to treat heart 
failure. Site-selective acetylation with enantiomers of catalyst provided each of these target 
molecules in good yield (Scheme 1.18, eq. 2).  
 
Scheme 1.18 Selective functionalization of mupirocin methyl ester and digoxin using scaffolding catalysis 
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1.4 Si-Based Scaffold Enabling meta-Selective C–H Activation33 
1.4.1 Importance of Functionalized Arenes 
 Arenes are a prevalent motif in therapeutically important molecules. As shown in 
Figure 1.12, all the current best-selling drugs feature at least one (hetero) aryl unit. This 
can be partially explained by its readily functionalizable characteristics for further 
derivatization to build structural complexity found in drugs.34                   
                        
Figure 1.12 Arenes as a phamacophore 
 
 
                                                 
33 Lee, S.; Lee, H.; Tan, K. L. J. Am. Chem. Soc. 2013, 135, 18778–18781. 
34 Roughley, S. D.; Jordan, A. M. J. Med. Chem. 2011, 54, 3451–3479. 
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1.4.2 Template-Assisted Remote C–H Activation of Arenes 
 Enormous progress in site-selective C–H activation of arenes has been made in the last 
several decades. 35  Due to the advantageous features that ortho position has, such as 
propensity to form 6- or 7-membered metallocycle with a neighboring ortho substituent, 
proximity-driven C–H activation at this position is well developed.36 In sharp contrast, 
reports of remote C–H activation at the meta or para positions have been limited until very 
recently.37  
 In 2012, the Yu group used metal coordination by nitrile group to direct palladium-
catalyzed meta-selective olefination of toluene and hydrocinnamic acid derivatives.38 They 
initially proposed that end-on palladium coordination by the nitrile group of a template 
leads to a macrocyclic cyclophane-like pre-transition state. Later in 2014, however, a 
                                                 
35 For selected reviews, see: (a) Ryabov, A. D. Chem. Rev. 1990, 90, 403–424. (b) Arndtsen, B. A.; Bergman, 
R. G.; Mobley, T. A.; Peterson, T. H. Acc. Chem. Res. 1995, 28, 154–162. (c) Kakiuchi, F.; Murai, S. Acc. 
Chem. Res. 2002, 35, 826–834. (d) Ritleng, V.; Sirlin, C.; Pfeffer, M. Chem. Rev. 2002, 102, 1731–1770. (e) 
Labinger, J. A.; Bercaw, J. E. Nature 2002, 417, 507–514. (f) Dupont, J.; Consorti, C. S.; Spencer, J. Chem. 
Rev. 2005, 105, 2527–2571. (g) Alberico, D.; Scott, M. E.; Lautens, M. Chem. Rev. 2007, 107, 174–238. (h) 
Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. Angew. Chem. Int. Ed. 2009, 48, 5094–5115. 
36 For selected examples, see: (a) Miura, M.; Tsuda, T.; Satoh, T.; Pivsa-Art, S.; Nomura, M. J. Org. Chem. 
1998, 63, 5211–5215. (b) Boele, M. D. K.; van Strijdonck, G. T. P. F.; de Vries, A. H. M.; Kamer, P. C. J.; 
de Vries, J. G.; van Leeuwen, P. W. N. M. J. Am. Chem. Soc. 2002, 124, 1586–1587. (c) Zaitsev, V. G.; 
Daugulis, O. J. Am. Chem. Soc. 2005, 127, 4156–4157. (d) Cai, G.; Fu, Y.; Li, Y.; Wan, X.; Shi, Z. J. Am. 
Chem. Soc. 2007, 129, 7666–7673. (e) Wang, J.-R.; Yang, C.-T.; Liu, L.; Guo, Q.-X. Tetrahedron Lett. 2007, 
48, 5449–5453. (f) Li, J.-J.; Mei, T.-S.; Yu, J.-Q. Angew. Chem., Int. Ed. 2008, 47, 6452–6455. (g) Houlden, 
C. E.; Bailey, C. D.; Ford, J. G.; Gagne´, M. R.; Lloyd-Jones, G. C.; Booker-Milburn, K. I. J. Am. Chem. Soc. 
2008, 130, 10066–10067. (h) Cho, S. H.; Hwang, S. J.; Chang, S. J. Am. Chem. Soc. 2008, 130, 9254–9256. 
37 For recent developments on remote C–H functionalizations, see: (a) Topczewski, J. J.; Cabrera, P. J.; Saper, 
N. I.; Sanford, M. S. Nature 2016, 531, 220–224. (b) Patra, T.; Watile, R.; Agasti, S.; Naveen, T.; Maiti, D. 
Chem. Commun. 2016, 52, 2027–2030. (c) Shen, P.-X.; Wang, X.-C.; Wang, P.; Zhu, R.-Y.; Yu, J.-Q. J. Am. 
Chem. Soc. 2015, 137, 11574–11577. (d) Wang, X.-C.; Gong, W.; Fang, L.-Z.; Zhu, R.-Y.; Li, S.; Engle, K. 
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computational study examining the origin of the observed meta-selectivity indicated that 
the reaction occurs via Pd−Ag heterodimeric transition states (1.105) (Scheme 1.19).39 
Olefination of template-tethered benzyl alcohol 1.104 afforded meta-functionalized 
products (1.106 and 1.107) in high selectivity. 
 
Scheme 1.19 Template-directed meta-selective olefination of toluene 
 
  
 A modified nitrile-based template was developed and applied to meta-selective 
olefination of phenols (Scheme 1.20).40 This method was applied to functionalization of 
drug molecules containing an α-phenoxyacetic acid motif. The nitrile directing group can 
be removed by hydrolysis to afford meta-substituted α-phenoxyacetic acids. In addition, 
removal of acetic acid moiety can be achieved by treatment with diphenylphosphoryl azide 
(DPPA) to give functionalized phenols. A similar strategy was also employed in the meta-
                                                 
39 Yang, Y.-F.; Cheng, G.-J.; Liu, P.; Leow, D.; Sun, T.-Y.; Chen, P.; Zhang, X.; Yu, J.-Q.; Wu, Y.-D.; Houk, 
K. N. J. Am. Chem. Soc. 2014, 136, 344–355. 
40 Dai, H.-X.; Li, G.; Zhang, X.-G.; Stepan, A. F.; Yu, J.-Q. J. Am. Chem. Soc. 2013, 135, 7567–7571. 
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selective olefination and acetoxylation of tetrahydroquinolines and N-methylanilines.41 
Recent developments in meta-selective functionalization by other groups have also 
expanded the reaction scope beyond olefination and acetoxylation to include hydroxylation, 
arylation, alkylation, and halogenation.42 
 
Scheme 1.20 meta-Olefination of phenol derivative 1.108 
 
   
1.4.3 Silicon-Tethered Template Design and Optimization 
 As an extension of our scaffolding catalysis concept, we investigated controlling site-
selectivity in C–H activation of arenes. Removal of the Yu group’s nitrile template 
(Scheme 1.19) by hydrogenolysis ultimately results in formation of methyl substituted 
products wherein the initial olefin substituent has also been reduced (Scheme 1.21). Thus, 
                                                 
41 Tang, R.-Y.; Li, G.; Yu, J.-Q. Nature 2014, 507, 215–220. 
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Singha, S.; Sunoj, R. B.; Maiti, D. Chem. Sci. 2016, 7, 3147–3153. (c) Phipps, R. J.; Gaunt, M. J. Science 
2009, 323, 1593–1597. (d) Cornella, J.; Righi, M.; Larrosa, I. Angew. Chem. Int. Ed. 2011, 50, 9429–9432. 
(e) Wan, L.; Dastbaravardeh, N.; Li, G.; Yu, J.-Q. J. Am. Chem. Soc. 2013, 135, 18056–18059. (f) Luo, J.; 
Preciado, S.; Larrosa, I. J. Am. Chem. Soc. 2014, 136, 4109–4112. (g) Luo, J.; Preciado, S.; Larrosa, I. Chem. 
Commun. 2015, 51, 3127–3130. (h) Luo, J.; Preciado, S.; Araromi, S. O.; Larrosa, I. Chem. Asian J. 2016, 
11, 347–350. (i) Teskey, C. J.; Lui, A. Y. W.; Greaney, M. F. Angew. Chem., Int. Ed. 2015, 54, 11677–11680. 
(j) Chu, L.; Shang, M.; Tanaka, K.; Chen, O.; Pissarnitski, N.; Streckfuss, E.; Yu, J.-Q. ACS Cent. Sci. 2015, 
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we considered the possibility to obtain olefinated benzyl alcohols instead as final products, 
by designing a directing group which would be readily cleavable under mild conditions so 
as to avoid cleavage of the O–Cbenzyl bond (Scheme 1.21). 
 
Scheme 1.21 Products after removal of directing group of functionalized arene 
 
 
 We initially designed a template which could be rendered catalytic through reversible 
formation of a Si–O bond. Therefore, we introduced a silicon atom as an alcohol exchange 
site.  Exchange at the silicon center of a template prototype (1.110) between the starting 
ethoxy substituent and the benzyl alcohol substrate was observed under acidic conditions 
using either p-toluenesulfonic acid (PTSA) or pyridinium p-toluenesulfonate (PPTS) 
(Scheme 1.22). Unfortunately, however, under the actual oxidative conditions of C–H 
olefination of 1.112, we observed oxidation of the free alcohols to give benzaldehyde 
(Scheme 1.23). 
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Scheme 1.22 Alcohol exchange experiments with Si-containing template 
 
  
Scheme 1.23 Initial attempt at C–H olefination of 1.112 
 
  
 We then turned our attention to design a directing group-bearing template using a 
silicon tether (Figure 1.13, 1.114). We hypothesized that the silicon tether could be easily 
removed after the reaction through standard silyl deprotection methods. Similar to our 
organocatalysts, the template incorporates three interconnected: a substrate binding site, a 
catalytically active site and a rigid scaffold in between (Figure 1.13).  
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Figure 1.13 Template design 
  
 
 Several structural refinements of our initial template design were required in order to 
achieve the desired meta-selectivity, as summarized in Table 1.7. Indeed, the initial 
template 1.114 itself showed preference for ortho functionalization (o:m:p=56:29:14). By 
adjusting the bond angle (α) between the phenyl ring and nitrile, we expected that it will 
affect site-selectivity by changing the distance between catalytic site and functionalization 
position on the substrate. When the chelating nitrile unit was moved to the para-position 
relative to the silicon substituent, meta-selective functionalization became slightly 
preferred (1.115). With a 1,3 relationship between the two groups, however, we observed 
higher than 80% meta-selectivity (1.116). We finally discovered the s-butyl substituted 
optimized template (1.119 giving o:m:p=4:92:4 selectivity) upon further modification on 
the alkyl group between the nitrile and phenyl ring. 
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Table 1.7 Template optimization for meta-selective olefination  
 
 
1.4.4 Preparation of Template-Bound Substrates 
 The optimized template can be synthesized starting from commercially available 2-(3-
bromophenyl)-acetonitrile (1.124). Deprotonation with potassium t-butoxide and 
subsequent dialkylation with s-butyl iodide, followed by lithium-halogen exchange and 
subsequent quenching with diisopropylchlorosilane affords arylsilane 1.126. Chlorination 
using trichloroisocyanuric acid provided the optimized template 1.127 in good yield. 
Installation of template was achieved by silylation of various benzyl alcohols to give 
desired template-bound substrates (Scheme 1.24). 
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Scheme 1.24 Synthesis of template-bound substrates 
 
 
1.4.5 Substrate Scope 
 Under the optimized conditions, we investigated scope of benzyl alcohols, amenable to 
meta-olefination (Table 1.8). Mono- or bis-functionalization (at the two available meta 
positions) of benzyl alcohols afforded products with high meta-selectivity. Subsequent 
deprotection to remove the Si-containing directing group afforded free olefinated benzyl 
alcohols. C–H activation of benzyl alcohols with a wide range of substitution patterns at 
the ortho- (1.128a-c), meta- (1.128d-k), or para-positions (1.128l-n) resulted in desired 
meta-selectivity regardless of the electronic nature of the substituents. An ester group at 
the meta position did not negatively impact selectivity (1.129k, m:others= 91:9), whereas 
an acetyl group diminished meta-selectivity presumably due to the acetyl group’s ortho-
directing ability (1.129j, m:others= 78:22). Reaction of a naphthyl group occurred at the 
C3 position selectively (1.129o’). Similar reaction selectivity and yield were achieved 
when used secondary benzyl alcohols (1.128p-r) as substrates. 
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Table 1.8 Olefination with various benzyl alcohol-bound templates 
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 We then examined C–H activation of template-bound substrate 1.129d with various 
olefins besides ethyl acrylate under the optimized conditions (Table 1.9). C–H 
functionalization with a diverse array of olefins terminally substituted with amide, ketone, 
sulfone groups, as well as a 1,2-disubstituted alkene, gave high meta-selectivity. 
 
Table 1.9 Reaction with various olefins 
 
 
1.4.6 Kinetic Isotope Effect 
 An intermolecular competition experiment was performed to probe the reaction 
mechanism. A 1:1 mixture of hydrogenated and deuterated template-bound starting 
material was subjected to the standard reaction conditions. Removal of the silicon tether 
allowed for determination of a kinetic isotope effect of 2.5 (Scheme 1.25). The result is 
consistent with Yu’s mechanistic study on nitrile directed meta C–H activation, which 
suggests that C–H bond activation is the rate determining step.38 
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Scheme 1.25 Intermolecular competition experiment 
 
 
1.4.7 Recyclability of Template 
 One of the benefits of our strategy is that the template is recyclable after removal. 
Acidic hydrolysis of the template-bound functionalized product 1.129d afforded the 
directing group-free benzyl alcohol 1.129d’ and cleaved silanol directing group 1.132 in 
83% yield (Scheme 1.26). The resulting silanol can be reused to form the corresponding 
template-bound substrate 1.128d in moderate yield. 
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Scheme 1.26 Reusable directing group 
 
 
1.5 Conclusions 
 In the Tan laboratory, we developed scaffolding catalysts to control reaction selectivity 
(regio-, stereo-, and site-selectivity). This strategy utilizes directing groups that induce 
intramolecularity before the key reaction step. This was achieved through the formation of 
a labile covalent bond between the substrate and a binding site in a catalytic system. By 
this approach, we were able to develop 1) highly site-selective functionalization of 
polyhydroxylated molecules using a chiral organic scaffold, and 2) meta-selective C–H 
functionalization using a nitrile-based cleavable silyl tether.  
 In the first part, we demonstrated the catalyst’s recognition of cis-1,2-diol motif, within 
complex polyol frameworks and functionalization of a single hydroxyl group therein in a 
predictable manner. The reaction was controlled by chiral catalysts which are similar to 
enzymatic systems in terms of preorganization of substrate. However, our catalytic system 
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has broader substrate scope due to the catalysts’ ability to specifically recognize cis-1,2-
diol. 
 In the second part, we introduced a removable silicon tether for meta-selective 
olefination of benzyl alcohols. The reaction was compatible with various substituents on 
the aryl portion of the substrate, including both electron-deficient and electron-rich groups, 
to give high meta-selectivity. Several different olefins also efficiently afforded the desired 
functionalized products. The key features of this work are easy removal of the directing 
group by standard silyl deprotection methods and recyclability of template. 
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1.6 Experimental 
1.6.1 Site-Selective Functionalization of 1,2-Diols of Carbohydrates 
1.6.1.1 General Information 
 Unless otherwise noted, all reagents were obtained from commercial suppliers and used 
without further purification. N,N-Diisopropylethylamine, chlorotriethylsilane, acetyl 
chloride, and methanesulfonyl chloride were purchased from Sigma Aldrich and distilled 
over CaH2 before use. Flash column chromatography was performed using EMD Silica 
Gel 60 (230-400 mesh) and ACS grade solvents as received from Fisher Scientific. All 
experiments were performed in oven or flame dried glassware under an atmosphere of 
nitrogen or argon using standard syringe techniques, except where otherwise noted. All 
reactions were run with dry, degassed solvents dispensed from a Glass Contour Solvent 
Purification System (SG Water, USA LLC).   
 1H, 13C, and gCOSY NMR were performed on a Varian Gemini 400 MHz, Varian 
Gemini 500 MHz or a Varian Unity Inova 500 MHz spectrometer. Deuterated solvents 
were purchased from Cambridge Isotope Labs and stored over 3Å molecular sieves. All 
NMR chemical shifts are reported in ppm relative to residual solvent for 1H and 13C NMR.  
Signals are quoted as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), and broad 
singlet (br s). Coupling constants are reported in Hz. All IR spectra were gathered on a 
Bruker Alpha FT-IR equipped with a single crystal diamond ATR module and values are 
reported in cm1. All GC analyses were performed on an SHIMADZU GC-2014 System. 
HRMS data were generated in Boston College facilities.  
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 Methyl -L-rhamnose, methyl -L-arabinose, and 1,6-anhydro--D-galactose were 
purchased from Carbosynth and used as received. Digoxin was purchased from Carbosynth 
and dried under vacuum at 100 °C overnight before use. The following compounds were 
prepared following the previously reported procedures: Methyl-6-(tert-
butyldimethylsilyloxy)--D-mannose 43 , methyl-6-(tert-butyldimethylsilyloxy)--D-
galactose434343, 5-dimethoxytrityloxy-uridine44 and mupirocin methyl ester45. 
 
1.6.1.2 Experimental Procedures and Characterization 
Catalyst Synthesis: 
To a stirring solution of L-valinol (25.3 g, 250 mmol) in anhydrous THF 
(188 mL) under nitrogen atmosphere was added a solution of 
isobutyraldehyde (18.1 g, 250 mmol). MgSO4 (15.1 g, 125 mmol) was 
added, and the reaction was stirred at room temperature for 3 hours (1H 
NMR analysis showed oxazolidine formed). In another oven-dried glass reaction flask, to 
the solution of N-methylimidazole (45.2 g, 550 mmol) in anhydrous THF (250 mL) under 
nitrogen atmosphere was added butyllithium (55 mL of 10 M in hexanes, 550 mmol) slowly 
at –78 °C. The solution was stirred at –78 °C for 30 minutes, and the formed oxazolidine 
solution was slowly cannula transferred into the N-methylimidazolium lithium solution at 
–78 °C. The resulting mixture was stirred overnight and gradually warmed to room 
                                                 
43 Lee, D.; Taylor, M. S J. Am. Chem. Soc. 2011, 133, 3724–3727. 
44 Xu, Y.; Ishizuka, T.; Kimura, T.; Komiyama, M. J. Am. Chem. Soc. 2010, 132, 7231–7233. 
45 Scott, R. W.; Murphy, A. C.; Wu, J.; Hothersall, J.; Cox, R. J.; Simpson, T. J.; Thomas, C. M.; Willis, C. 
L. Tetrahedron 2011, 67, 5098–5106. 
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temperature. Aqueous NH4Cl (50 mL) was added slowly to quench the reaction at 0 °C. 
MgSO4 (15 g) was added. The mixture was stirred at room temperature for 15 minutes, 
filtered and concentrated. Excess N-methylimidazole was distilled off (150 °C at 1.0 
mmHg). Flash column chromatography (Hex/EtOAc = 2:1 to pure EtOAc) afforded the 
pure product 1.71 as colorless oil (32.8 g, 55 %). 1H NMR (CDCl3, 500 MHz)  6.93 (d, 
1H, J = 1.2), 6.78 (d, 1H, J = 1.2), 3.568-3.560 (m, 4H), 3.35 (d, 1H, J = 1.2), 3.35 (d, 1H, 
J = 3.9), 2.17-2.13 (m, 1H), 1.93-1.86 (m, 1H), 1.68-1.61 (m, 1H), 0.98 (d, 3H, J = 6.8), 
0.93 (d, 3H, J = 6.8), 0.89 (d, 3H, J = 2.9), 0.87 (d, 3H, J = 2.9); 13C NMR (CDCl3, 125 
MHz)  151.7, 127.0, 121.3, 64.2, 62.9, 60.4, 34.0, 32.9, 31.7, 20.2, 19.5, 19.4, 17.7; IR: 
2956, 2871, 1488, 1468, 1280, 1045, 725 cm–1; HRMS (DART-TOF) calcd. for C13H26N3O 
[M+H]+: 240.20759, found: 240.20870. Optical rotation: [a]25D 40 (c = 1.0, CH2Cl2).  To a 
solution of 1.71 (8.4 g, 35 mmol) in anhydrous methanol (70 mL) under nitrogen 
atmosphere was added N,N-dimethylformamide dimethyl acetal (24 mL, 70 mmol). The 
reaction was stirred at 50 °C overnight (1H NMR analysis showed all substrate consumed 
and product formed). Solvent was removed under vacuum, and the residue was redissolved 
in anhydrous methanol (70 mL). The reaction was stirred at 50 °C for 2 hours, and solvent 
was removed under vacuum. Impurities were distilled off (100 °C at 0.05 mmHg). 
Kugelrohr distillation (130 °C at 0.05 mmHg), followed by recrystallization with pentane 
(20 mL, 3 mL/g) at -40 °C overnight afforded the pure product (–)-1.56 as a white solid 
(5.6 g, 57 %). 1H NMR (C6D6, 500 MHz)  7.12 (d, 1H, J =1.2), 6.80 (s, 1H), 6.20 (d, 1H, 
J =1.2), 3.72 (dd, 1H, J =9.0, 8.1), 3.53 (dd, 1H, J =7.8, 7.1), 3.29 (s, 3H), 3.22 (d, 1H, J = 
10.8), 2.78 (s, 3H), 2.64-2.55 (m, 2H), 1.72-1.63 (m, 1H), 1.34 (d, 3H, J =6.4), 0.86 (d, 3H, 
J = 6.8), 0.67 (d, 3H, J = 6.8), 0.63 (d, 3H, J = 6.6); 13C NMR (C6D6, 125 MHz)  148.8, 
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128.7, 120.1, 112.4, 66.1, 65.8, 60.5, 52.7, 33.7, 32.2, 29.5, 21.6, 21.0, 20.2, 16.9; IR: 2956, 
1470, 1281, 1052, 964 cm–1; HRMS (DART-TOF) calcd. for C14H24N3O [M−OMe]
+: 
250.19194, found: 250.19264. Optical rotation: [a]26D -57 (c = 1.0, CH2Cl2). 
Catalysts (+)-1.56 was prepared following the same procedures to 
synthesize (–)-1.50. D-valinol and isobutraldehyde were used.  
 
Catalysts (–)-1.72 was prepared according to literature procedures30 
from L-valinol and cyclopentene. 
 
Catalysts (+)-1.72 was prepared according to literature procedures30 
from D-valinol and cyclopentene.  
 
 
 
Site-Selective Functionalization of Mannose (Table 1.2): 
General Procedure A (Table 1.2, Entry1): 
In a dry box, a solution of 1.73 (62 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous tert-amyl alcohol (1.0 mL) was prepared in an oven-dried 
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glass reaction vial. The solution was brought out of the dry box, N,N-diisopropylethylamine 
(42 L, 0.24 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The 
reaction was stirred at 4 °C for 10 minutes, followed by dropwise addition of 
chlorotriethylsilane (40 L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C for 2 hours. 
MeOH (50 L) was added to quench the reaction. The mixture was filtered through a 
Pasteur pipette packed with silica gel, followed by flush with EtOAc (15 mL). The solvent 
was removed under reduced pressure. Column chromatography (Hexane/EtOAc = 20:1 to 
5:1) afforded a mixture of mono-functionalized products (65 mg, 77%). 1H NMR of the 
mixture afforded the selectivity (C2:C3:C4 = 5:78:17). 
Table 1.2, Entry 2. 
The general procedure A was followed using (+)-1.56 (11 mg, 0.040 
mmol, 20 mol %) as the catalyst. Column chromatography 
(Hexane/EtOAc = 20:1 to 1:1) afforded the bis-silylated product (10 
mg, 9%), the substrate 3 (3 mg, 5%), and a mixture of mono-
functionalized products (71 mg, 84%). 1H NMR of the mixture afforded the selectivity 
(C2:C3:C4 = 90:10:-). A second column chromatography was performed to isolate the pure 
product 1.74a (64 mg, 76%). 1H NMR (CDCl3, 500 MHz)  4.57 (d, 1H, J = 1.5), 3.90 (dd, 
1H, J = 2.9, 1.7), 3.88 (dd, 1H, J = 10.5, 5.1), 3.85 (dd, 1H, J = 9.0, 3.2), 3.72-3.69 (m, 
2H), 3.53-3.50 (m, 1H), 3.43 (s, 3H), 2.88 (br s, 1H), 2.11 (br s, 1H), 0.96 (t, 9H, J = 8.1), 
0.90 (s, 9H), 0.63 (q, 6H, J = 7.8), 0.089 (s, 3H), 0.086 (s, 3H). 13C NMR (CDCl3, 125 
MHz)  106.9, 83.0, 82.7, 82.4, 75.8, 69.9, 60.4, 31.5, 23.9, 12.4, 10.6, 0.3, 0.2. IR: 3428, 
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2953, 2927, 2878, 1251, 1139, 1110, 1048, 1005, 833, 776, 728 cm–1. HRMS (DART-TOF) 
calcd. for C19H42O6Si2: [M+H]+: 423.2598, found: 423.2591. 
Table 1.2, Entry 3. 
The general procedure A was followed using (–)-1.72 (3.1 mg, 0.010 
mmol, 5 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
the selectivity (C2:C3:C4 = -:100:-). Column chromatography 
afforded the pure product 1.75a (84 mg, >98%). 1H NMR (CDCl3, 500 
MHz)  4.71 (d, 1H, J = 1.5), 3.87 (d, 1H, J = 1.0), 3.86 (d, 1H, J = 0.5), 3.84 (dd, 1H, J = 
8.8, 3.7), 3.75-3.73 (m, 1H), 3.70 (td, 1H, J = 9.5, 2.0), 3.58-3.54 (m, 1H), 3.56 (s, 3H), 
2.69 (d, 1H, J = 2.0), 2.57 (d, 1H, J = 1.5), 0.98 (t, 9H, J = 8.1), 0.90 (s, 9H), 0.67 (qd, 6H, 
J = 7.3, 2.5), 0.089 (s, 3H), 0.087 (s, 3H). 13C NMR (CDCl3, 125 MHz)  106.7, 83.9, 83.6, 
83.2, 79.4, 71.4, 61.3, 32.4, 24.8, 13.3, 11.4, 1.1, 1.0. IR: 3506, 2953, 2929, 2878, 1252, 
1137, 1106, 1054, 977, 834, 778, 742, 729 cm–1. HRMS (DART-TOF) calcd. for 
C19H42O6Si2: [M+NH4]+: 440.2864, found: 440.2874. 
General Procedure B (Table 1.2, Entry 4): 
In a dry box, a solution of 1.73 (62 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (3.0 mL) was prepared in an oven-dried glass reaction 
vial. The solution was brought out of the dry box, N,N-diisopropylethylamine (42 L, 0.24 
mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction was 
stirred at 4 °C for 10 minutes, followed by dropwise addition of acetyl chloride (17 L, 
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0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C for 4 hours. MeOH (50 L) was added 
to quench the reaction. The mixture was filtered through a Pasteur pipette packed with 
silica gel, followed by flush with EtOAc (15 mL). The solvent was removed under reduced 
pressure. 1,3,5-trimethoxybenzene (50 L of 0.40 M in CDCl3, 0.020 mmol, 10 mol %) 
was added as standard. 1H NMR of the crude mixture afforded yield (39%) and selectivity 
(C2:C3:C4 = 9:84:7). 
Table 1.2, Entry 5. 
The general procedure B was followed using (+)-1.56 (11 mg, 0.040 
mmol, 20 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
selectivity (C2:C3:C4 = 84:15:1). Column chromatography 
(Hexane/EtOAc = 5:1 to 2:1) afforded the mixture of mono-
functionalized products with 1.74b as the major product (52 mg, 74%, C2:C3:C4 = 
84:15:1). 1H NMR (CDCl3, 500 MHz)  5.07 (dd, 1H, J = 3.4, 1.5), 4.68 (d, 1H, J = 1.5), 
3.99 (d, 1H, J = 9.0), 3.92 (dd, 1H, J = 10.8, 4.9), 3.85 (dd, 1H, J = 10.5, 5.4), 3.81 (t, 1H, 
J = 9.5), 3.60-3.56 (m, 1H), 3.36 (s, 3H), 3.15 (br s, 1H), 2.44 (br s, 1H), 2.11 (s, 3H), 0.91 
(s, 9H), 0.11 (s, 3H), 0.10 (s, 3H). 13C NMR (CDCl3, 125 MHz)  171.0, 87.8, 72.0, 71.0, 
70.5, 70.2, 64.5, 55.2, 26.0, 21.1, 18.4, -5.23, -5.25. IR: 3412, 2952, 2929, 2856, 1748, 
1725, 1375, 1251, 1237, 1139, 1078, 1048, 836, 777 cm–1. HRMS (DART-TOF) calcd. for 
C15H30O7Si: [M−OH]+: 333.1733, found: 333.1743. 
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Table 1.2, Entry 6. 
The general procedure B was followed using (–)-1.72 (3.1 mg, 0.010 
mmol, 5 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
the selectivity (C2:C3:C4 = -:100:-). Column chromatography 
(Hexane/EtOAc = 5:1 to 2:1) afforded the pure product 1.75b (67 mg, 
96%). 1H NMR (CDCl3, 500 MHz)  5.08 (dd, 1H, J = 9.8, 3.2), 4.68 (d, 1H, J = 1.7), 4.00-
3.98 (m, 1H), 3.96 (t, 1H, J = 9.5), 3.91 (dd, 1H, J = 10.5, 4.9), 3.86 (dd, 1H, J = 10.5, 5.6), 
3.67-3.63 (m, 1H), 3.38 (s, 3H), 3.07 (br s, 1H), 2.18 (br s, 1H), 2.15 (s, 3H), 0.89 (s, 9H), 
0.090 (s, 3H), 0.088 (s, 3H). 13C NMR (CDCl3, 125 MHz)  171.2, 100.8, 74.6, 71.5, 69.3, 
68.2, 64.7, 55.2, 26.0, 21.3, 18.4, -5.3. IR: 3438, 2953, 2929, 1716, 1369, 1249, 1107, 1048, 
969, 833, 776, 732 cm–1. HRMS (DART-TOF) calcd. for C15H30O7Si: [M+H]+: 351.1839, 
found: 351.1844. 
General Procedure C (Table 1.2, Entry 7): 
In a dry box, a solution of 1.73 (62 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (1.0 mL) was prepared in an oven-dried glass reaction 
vial. The solution was brought out of the dry box, N,N-diisopropylethylamine (42 L, 0.24 
mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction was 
stirred at -15 °C for 10 minutes, followed by dropwise addition of methanesulfonyl chloride 
(19 L, 0.24 mmol, 1.2 eq). The reaction was stirred at -15 °C for 4 hours. MeOH (50 L) 
was added to quench the reaction. The mixture was filtered through a Pasteur pipette 
packed with silica gel, followed by flush with EtOAc (15 mL). The solvent was removed 
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under reduced pressure. Column chromatography (Hexane/EtOAc = 5:1 to 2:1) afforded a 
mixture of mono-functionalized products (53 mg, 68%). GC Analysis (Shimazu SHRXI-
5MS 15 m, 150 °C for 3 min, 10 °C/min to 200 °C, 200°C for 6 min, 15 psi., tC2 = 10.50 
min, tC3 = 11.04 min, tC4 = 9.50 min) of the mixture afforded selectivity (C2:C3:C4 = 
22:56:22). 
Table 1.2, Entry 8. 
The general procedure C was followed using (+)-1.56 (11 mg, 0.040 
mmol, 20 mol %) as the catalyst. GC Analysis of the crude mixture 
afforded selectivity (C2:C3:C4 = 91:8:1). Column chromatography 
(Hexane/EtOAc = 5:1 to 2:1) afforded the pure product 1.74c (62 mg, 
80%). 1H NMR (CDCl3, 500 MHz)  4.81 (d, 1H, J = 1.7), 4.78 (dd, 1H, J = 3.2, 1.7), 4.00 
(dd, 1H, J = 9.5, 3.2), 3.91 (dd, 1H, J = 10.3, 4.9), 3.83 (dd, 1H, J = 10.5, 6.4), 3.78 (t, 1H, 
9.3), 3.60-3.56 (m, 1H), 3.38 (s, 3H), 3.13 (s, 3H), 0.90 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H). 
13C NMR (CDCl3, 125 MHz)  99.2, 7.5, 71.0, 70.6, 69.6, 65.0, 55.4, 38.6, 26.0, 18.4, -
5.3. IR: 3457, 2928, 2856, 1352, 1175, 1138, 1069, 962, 907, 833, 777, 523 cm–1. HRMS 
(DART-TOF) calcd. for C14H30O8SSi: [M+H]+: 387.1509, found: 387.1510. 
Table 1.2, Entry 9. 
The general procedure C was followed using (–)-1.72 (3.1 mg, 0.010 
mmol, 5 mol %) as the catalyst. GC Analysis of the crude mixture 
afforded selectivity (C2:C3:C4 = -:100:-). Column chromatography 
(Hexane/EtOAc = 5:1 to 2:1) afforded the pure product 1.75c (75 mg, 
97%). 1H NMR (CDCl3, 500 MHz)  4.79 (dd, 1H, J = 9.5, 3.2), 4.72 (d, 1H, J = 1.7), 4.14-
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4.12 (m, 1H), 4.07 (td, 1H, J = 9.5, 2.0), 3.95 (dd, 1H, J = 10.3, 4.9), 3.85 (dd, 1H, J = 10.0, 
7.1), 3.68-3.63 (m, 1H), 3.49 (d, 1H, J = 2.2), 3.38 (s, 3H), 3.18 (s, 3H), 2.57 (d, 1H, J = 
4.7), 0.90 (s, 9H), 0.111 (s, 3H), 0.107 (s, 3H). 13C NMR (CDCl3, 125 MHz)  100.7, 82.7, 
70.5, 10.1, 68.9, 65.5, 55.3, 38.6, 26.0, 18.4, -5.3, -5.4. IR: 3497, 2930, 2857, 1350, 1253, 
1175, 1135, 1109, 1058, 963, 837, 779 cm–1. HRMS (DART-TOF) calcd. for C14H30O8SSi: 
[M+H]+: 387.1509, found: 387.1500. 
 
Site-Selective Functionalization of Rhamnose (Table 1.3): 
General Procedure D (Table 1.3, Entry 1): 
In a dry box, a solution of 1.77 (36 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous tert-amyl alcohol (1.0 mL) was prepared in an oven-dried 
glass reaction vial. The solution was brought out of the dry box, and N,N-
diisopropylethylamine (42 L, 0.24 mmol, 1.2 eq) was added to the stirring reaction at 
room temperature. The reaction was stirred at 4 °C for 10 minutes, followed by dropwise 
addition of chlorotriethylsilane (40 L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C 
for 4 hours. MeOH (50 L) was added to quench the reaction. The mixture was filtered 
through a Pasteur pipette packed with silica gel, followed by flushing with EtOAc (15 mL). 
The solvent was removed under reduced pressure. Column chromatography 
(Hexane/EtOAc = 10:1 to 3:1) afforded a mixture of mono-functionalized products (46 mg, 
78%). Selectivity of the mixture was determined by 1H NMR (C2:C3:C4 = 7:79:14). 
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Table 1.3, Entry 2. 
The general procedure D was followed using (–)-1.72  (12 mg, 0.040 
mmol, 20 mol %) as the catalyst. Column chromatography 
(Hexane/EtOAc = 10:1 to 3:1) afforded a mixture of mono-
functionalized products with 1.78a as the major product (52 mg, 88%). 
1H NMR of the mixture afforded the selectivity (C2:C3:C4 = 89:11:-). A second column 
chromatography was performed for characterization of the pure product. 1H NMR (CDCl3, 
500 MHz)  4.54 (d, 1H, J = 1.5), 3.91 (dd, 1H, J = 3.7, 1.7), 3.62-3.58 (m, 2H), 3.38 (t, 
1H, J = 9.3), 3.34 (s, 3H), 2.29 (br s, 1H), 2.03 (d, 1H, J = 10.5), 1.31 (d, 3H, J = 6.4), 0.97 
(t, 9H, J = 6.0), 0.64 (q, 6H, J = 8.1). 13C NMR (CDCl3, 125 MHz)  101.4, 74.0, 72.2, 
72.1, 67.9, 55.0, 17.8, 6.9, 5.1. IR: 3416, 2953, 2877, 2831, 1458, 1239, 1052, 1005, 829, 
727, 630 cm–1. HRMS (DART-TOF) calcd. for C13H28O5Si: [M+NH4]+: 310.2050, found: 
310.2049. 
Table 1.3, Entry 3. 
The general procedure D was followed using (+)-1.56 (2.8 mg, 0.010 
mmol, 5 mol %) as the catalyst. The reaction was stirred at 4 °C for 20 
hours. Selectivity was determined by 1H NMR of the crude reaction 
mixture (C2:C3:C4 = -:100:-). Column chromatography (Hexane/EtOAc = 10:1 to 3:1) 
afforded the pure product 1.79a (59 mg, >98%). 1H NMR (CDCl3, 500 MHz)  4.68 (d, 
1H, J = 1.2), 3.80 (dd, 1H, J = 8.8, 3.7), 3.78 (dd, 1H, J = 3.7, 1.5), 3.65-3.62 (m, 1H), 3.46 
(td, 1H, J = 9.1, 2.9), 3.36 (s, 3H), 2.54 (d, 1H, J = 1.5), 2.04 (d, 1H, J = 3.4), 1.32 (d, 3H, 
J = 6.4), 0.98 (t, 9H, J = 8.1), 0.67 (q, 6H, J = 8.1). 13C NMR (CDCl3, 125 MHz)  100.4, 
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73.4, 73.3, 71.8, 67.5, 55.0, 17.8, 6.9, 5.1. IR: 3477, 2954, 2911, 2833, 1458, 1238, 1107, 
972, 852, 727, 616 cm–1. HRMS (DART-TOF) calcd. for C13H28O5Si: [M+ H]+: 293.1784, 
found: 293.1780. 
 
General Procedure E (Table 1.3, Entry 4): 
In a dry box, a solution of 1.77 (36 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (1.0 mL) was prepared in an oven-dried glass reaction 
vial. The solution was brought out of the dry box, and N,N-diisopropylethylamine (42 L, 
0.24 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction 
was stirred at 4 °C for 10 minutes, followed by dropwise addition of acetyl chloride (17 
L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C for 4 hours. MeOH (50 L) was 
added to quench the reaction. The mixture was filtered through a Pasteur pipette packed 
with silica gel, followed by flushing with EtOAc (15 mL). The solvent was removed under 
reduced pressure. Column chromatography (Hexane/EtOAc = 5:1 to 1:1) afforded a 
mixture of mono-functionalized products (37 mg, 83%). Selectivity of the mixture was 
determined by 1H NMR (C2:C3:C4 = 12:79:9). 
Table 1.3, Entry 5. 
The general procedure E was followed using (–)-1.72 (12 mg, 0.040 
mmol, 20 mol %) as the catalyst in anhydrous THF (3.0 mL). Column 
chromatography (Hexane/EtOAc = 5:1 to 1:1) afforded the mixture of 
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mono-functionalized products (32 mg, 73%) with 1.78b as the major product. Selectivity 
was determined by 1H NMR of the isolated mixture (C2:C3:C4 = 84:14:2). 1H NMR 
(CDCl3, 500 MHz)  5.08 (dd, 1H, J = 3.4, 1.5), 4.63 (d, 1H, J = 1.5), 3.92 (dd, 1H, J = 
9.5, 3.4), 3.67-3.63 (m, 1H), 3.45 (t, 1H, J = 9.5), 3.37 (s, 3H), 3.16 (br s, 2H), 2.14 (s, 3H), 
1.34 (d, 3H, J = 6.1). 13C NMR (CDCl3, 125 MHz)  171.3, 98.7, 73.3, 72.6, 70.3, 68.1, 
55.2, 21.2, 17.7. IR: 3409, 2934, 2837, 1747, 1726, 1376, 1237, 1135, 1076, 1054, 973, 
838, 803 cm–1. HRMS (DART-TOF) calcd. for C9H16O6: [M+NH4]+: 238.1291, found: 
238.1294. 
Table 1.3, Entry 6. 
The general procedure E was followed using (+)-1.56 (2.8 mg, 0.010 
mmol, 5 mol %) as the catalyst in anhydrous THF (3.0 mL). 1H NMR of 
the crude reaction mixture afforded the selectivity (C2:C3:C4 = 1:99:-). 
Column chromatography (Hexane/EtOAc = 5:1 to 1:1) afforded the pure product 1.79b (43 
mg, 98%). 1H NMR (CDCl3, 500 MHz)  5.04 (dd, 1H, J = 9.8, 3.2), 4.68 (d, 1H, J = 1.7), 
4.05-4.03 (m, 1H), 3.74-3.71 (m, 1H), 3.64 (td, 1H, J = 9.5, 5.4), 3.41 (s, 3H), 2.21 (d, 1H, 
J = 5.6), 2.19 (s, 3H), 2.04 (d, 1H, J = 5.1), 1.37 (d, 3H, J = 6.1). 13C NMR (CDCl3, 125 
MHz)  171.6, 100.6, 75.2, 71.7, 69.9, 68.6, 55.2, 21.4, 17.8. IR: 3437, 2922, 2837, 1717, 
1450, 1372, 1249, 1132, 1056, 987, 973, 805 cm–1. HRMS (DART-TOF) calcd. for 
C9H16O6: [M+NH4]+: 238.1291, found: 238.1283. 
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General Procedure F (Table 1.3, Entry 7): 
In a dry box, a solution of 1.77 (36 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (1.0 mL) was prepared in an oven-dried glass reaction 
vial. The solution was brought out of the dry box, and N,N-diisopropylethylamine (42 L, 
0.24 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction 
was stirred at 4 °C for 10 minutes, followed by dropwise addition of methanesulfonyl 
chloride (19 L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C for 4 hours. MeOH 
(50 L) was added to quench the reaction. The mixture was filtered through a Pasteur 
pipette packed with silica gel, followed by flushing with EtOAc (15 mL). The solvent was 
removed under reduced pressure. Column chromatography (Hexane/EtOAc = 5:1 to 1:1) 
afforded a mixture of mono-functionalized products (37 mg, 72%). Selectivity of the 
mixture was determined by GC analysis (Shimazu SHRXI-5MS 15 m, 120 °C for 2 min, 
1 °C/min to 140 °C, 10 °C/min to 200 °C, 200°C for 2 min, 15 psi., tC2 = 15.07 min, tC3 = 
16.30 min, tC4 = 14.46 min) (C2:C3:C4 = 24:57:19). 
Table 1.3, Entry 8. 
The general procedure F was followed using (–)-1.72 (11 mg, 0.040 
mmol, 20 mol %) as the catalyst. The reaction was stirred at -15 °C for 
4 hours. Selectivity was determined by GC analysis of the crude reaction 
mixture (C2:C3:C4 = 92:8:-). Column chromatography (Hexane/EtOAc 
= 5:1 to 1:1) afforded the pure product 1.78c (42 mg, 82%). 1H NMR (CDCl3, 500 MHz) 
 4.82 (dd, 1H, J = 3.2, 1.7), 4.79 (d, 1H, J = 1.7), 3.93 (d, 1H, J = 9.5), 3.68-3.62 (m, 1H), 
66 
 
3.44 (t, 1H, J = 9.5), 3.38 (s, 3H), 3.15 (s, 3H), 3.03 (br s, 1H), 2.74 (br s, 1H), 1.33 (d, 3H, 
J = 6.4). 13C NMR (CDCl3, 125 MHz)  99.0, 79.0, 73.2, 69.8, 68.3, 55.3, 38.7, 17.6. IR: 
3454, 2935, 2842, 1451, 1346, 1173, 1133, 1051, 963, 907, 855, 637, 529 cm–1. HRMS 
(DART-TOF) calcd. for C8H16O7S: [M+NH4]+: 274.0961, found: 274.0974. 
Table 1.3, Entry 9. 
The general procedure F was followed using (+)-1.56 (2.8 mg, 0.010 
mmol, 5 mol %) as the catalyst. Selectivity was determined by GC 
analysis of the crude reaction mixture (C2:C3:C4 = 1:99:-). Column 
chromatography (Hexane/EtOAc = 5:1 to 1:1) afforded the pure product 1.79c (51 mg, 
>98%). 1H NMR (CDCl3, 500 MHz)  4.76 (dd, 1H, J = 9.1, 3.2), 4.70 (d, 1H, J = 1.7), 
4.19 (br s, 1H), 3.77-3.70 (m, 2H), 3.40 (s, 3H), 3.18 (s, 3H), 2.73 (br s, 1H), 2.71 (br s, 
1H), 1.38 (d, 3H, J = 5.9). 13C NMR (CDCl3, 125 MHz)  100.6, 82.8, 70.8, 70.5, 68.4, 
55.2, 38.6, 17.8. IR: 3462, 2936, 2839, 1452, 1348, 1198, 1150, 1055, 959, 860, 799, 530, 
513 cm–1. HRMS (DART-TOF) calcd. for C8H16O7S: [M+NH4]+: 274.0961, found: 
274.0964. 
 
Site-Selective Functionalization of Arabinose (Table 1.4): 
General Procedure G (Table 1.4, Entry 1): 
In a dry box, a solution of 1.81 (33 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous tert-amyl alcohol (1.0 mL) was prepared in an oven-dried 
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glass reaction vial. The solution was brought out of the dry box, and N,N-
diisopropylethylamine (42 L, 0.24 mmol, 1.2 eq) was added to the stirring reaction at 
room temperature. The reaction was stirred at 4 °C for 10 minutes, followed by dropwise 
addition of chlorotriethylsilane (40 L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C 
for 4 hours. MeOH (50 L) was added to quench the reaction. The mixture was filtered 
through a Pasteur pipette packed with silica gel, followed by flush with EtOAc (15 mL). 
The solvent was removed under reduced pressure. 1,3,5-trimethoxybenzene (50 L of 0.40 
M in CDCl3, 0.020 mmol, 10 mol %) was added as standard. 1H NMR of the crude mixture 
afforded the yield (39%) and selectivity (C2:C3:C4 = 27:14:59). 
Table 1.4, Entry 2. 
The general procedure G was followed using (–)-1.72 (11 mg, 0.040 
mmol, 20 mol %) as the catalyst. Reaction was performed in anhydrous 
tert-amyl alcohol (3.0 mL). 1H NMR of the crude mixture afforded the 
selectivity (C2:C3:C4 = -:3:97). Column chromatography (Hexane/EtOAc = 4:1 to 3:1) 
afforded the pure product 1.84a (51 mg, 92%). 1H NMR (CDCl3, 500 MHz)  4.75 (d, 1H, 
J = 3.2), 4.00 (dd, 1H, J = 5.6, 3.4), 3.79-3.78 (m, 1H), 3.74-3.72 (m, 2H), 3.57 (dd, 1H, J 
= 12.2, 3.4), 3.42 (s, 3H), 2.27 (d, 1H, J = 6.1), 2.23 (br s, 1H), 0.97 (t, 9H, J = 8.1), 0.63 
(q, 6H, J = 7.8). 13C NMR (CDCl3, 125 MHz)  100.0, 70.8, 70.3, 69.8, 63.6, 55.9, 6.9, 5.1. 
IR: 3422, 2952, 2911, 2875, 1070, 1045, 1002, 890, 877, 798, 725 cm–1. HRMS (DART-
TOF) calcd. for C12H26O5Si: [M+H]+: 279.1628, found: 279.1625. 
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Table 1.4, Entry 3. 
The general procedure G was followed using (+)-1.56 (2.8 mg, 0.010 
mmol, 5mol %) as the catalyst. 1H NMR of the crude mixture afforded 
the selectivity (C2:C3:C4 = -:98:2).Column chromatography 
(Hexane/EtOAc = 4:1 to 3:1) afforded the pure product 1.83a (54 mg, 97%). 1H NMR 
(CDCl3, 500 MHz)  4.75 (d, 1H, J = 3.7), 3.82 (dd, 1H, J = 8.8, 3.7), 3.79 (t, 1H, J = 1.5), 
3.75 (td, 1H, J = 8.6, 3.4), 3.72 (d, 2H, J = 1.7), 3.41 (s, 3H), 2.65 (s, 1H), 1.93 (d, 1H, J = 
8.3), 0.98-0.95 (m, 9H), 0.68-0.63 (m, 6H). 13C NMR (CDCl3, 125 MHz)  100.2, 71.9, 
70.0, 69.9, 61.7, 55.7, 6.9, 5.1. IR: 3458, 2952, 2911, 2875, 1062, 998, 848, 742 cm–1. 
HRMS (DART-TOF) calcd. for C12H26O5Si: [M+H]+: 279.1628, found: 279.1624. 
 
General Procedure H (Table 1.4, Entry 4): 
In a dry box, a solution of 1.81 (33 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (3.0 mL) was prepared in an oven-dried glass reaction 
vial. The solution was brought out of the dry box, and N,N-diisopropylethylamine (42 L, 
0.24 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction 
was stirred at 4 °C for 10 minutes, followed by dropwise addition of acetyl chloride (17 
L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C for 4 hours. MeOH (50 L) was 
added to quench the reaction. The mixture was filtered through a Pasteur pipette packed 
with silica gel, followed by flush with EtOAc (15 mL). The solvent was removed under 
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reduced pressure. 1,3,5-trimethoxybenzene (50 L of 0.40 M in CDCl3, 0.020 mmol, 10 
mol %) was added as standard. 1H NMR of the crude mixture afforded the yield (6%) and 
selectivity (C2:C3:C4 = 22:72:6). 
Table 1.4, Entry 5. 
The general procedure H was followed using (–)-1.72 (11 mg, 0.040 
mmol, 20 mol %) as the catalyst. Reaction was stirred for 8 hours. 1H 
NMR of the crude mixture afforded the selectivity (C2:C3:C4 = 
5:9:86).Column chromatography (CH2Cl2/MeOH = 100:1 to 20:1) 
afforded the mixture of mono-functionalized products with 1.84b as the major product (25 
mg, 61%). 1H NMR (acetone-d6, 500 MHz)  5.08-5.07 (m, 1H), 4.69 (d, 1H, J = 3.4), 
3.88 (dd, 1H, J = 9.8, 3.4), 3.80 (dd, 1H, J = 12.7, 1.5), 3.72 (dd, 1H, J = 9.8, 2.9), 3.57 
(dd, 1H, J = 12.7, 2.4), 3.35 (s, 3H), 2.04 (s, 3H). 13C NMR (acetone-d6, 125 MHz)  170.9, 
101.6, 72.7, 70.8, 69.1, 61.4, 55.8, 21.1. IR: 3429, 2937, 1734, 1241, 1077, 1038, 997 cm–
1. HRMS (DART-TOF) calcd. for C8H14O6: [M+H]+: 207.0869, found: 207.0861. 
Table 1.4, Entry 6. 
The general procedure H was followed using (+)-1.56 (2.8 mg, 0.010 
mmol, 5 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
the selectivity (C2:C3:C4 = 3:96:1). Column chromatography 
(Hex/EtOAc = 2:1 to 1:2) afforded the pure product 1.83b (34 mg, 83%). 1H NMR 
(acetone-d6, 500 MHz)  4.96 (dd, 1H, J = 10.3, 3.4), 4.70 (d, 1H, J = 3.7), 4.12 (d, 1H, J 
= 3.2), 4.00 (s, 1H), 3.98-3.96 (m, 1H), 3.79 (dd, 1H, J = 12.5, 1.5), 3.56 (dd, 1H, J = 12.2, 
2.4), 3.52 (d, 1H, J = 8.8), 3.37 (s, 3H), 2.02 (s, 3H). 13C NMR (acetone-d6, 125 MHz)  
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171.1, 101.8, 74.0, 68.2, 67.6, 63.7, 55.6, 21.1. IR: 3436, 2927, 1737, 1716, 1240, 1141, 
1057, 997cm–1. HRMS (DART-TOF) calcd. for C8H14O6: [M+H]+: 207.0869, found: 
207.0878. 
General Procedure I (Table 1.4, Entry 7): 
In a dry box, a solution of 1.81 (33 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (1.0 mL) was prepared in an oven-dried glass reaction 
vial. The solution was brought out of the dry box, and N,N-diisopropylethylamine (42 L, 
0.24 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction 
was stirred at 4 °C for 10 minutes, followed by dropwise addition of methanesulfonyl 
chloride (19 L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C for 4 hours. MeOH 
(50 L) was added to quench the reaction. The mixture was filtered through a Pasteur 
pipette packed with silica gel, followed by flush with EtOAc (15 mL). The solvent was 
removed under reduced pressure. Column chromatography (Hex/EtOAc = 1:1 to 1:3) 
afforded the mixture of mono-functionalized products (13 mg, 27%). 1H NMR of the 
mixture afforded the selectivity (C2:C3:C4 = 68:23:9). 
Table 1.4, Entry 8. 
The general procedure I was followed using (–)-1.72 (11 mg, 0.040 mmol, 
20 mol %) as the catalyst. Column chromatography (Hex/EtOAc = 1:1 to 
1:3) afforded the mixture of mono-functionalized products (45 mg, 93%). 
1H NMR of the mixture afforded the selectivity (C2:C3:C4 = 3:10:87). A 
second column chromatography (Hex/EtOAc = 1:1 to 1:3) afforded 1.84c for 
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characterizations. 1H NMR (acetone-d6, 500 MHz)  4.88-4.87 (m, 1H), 4.71 (d, 1H, J = 
3.4), 3.96 (dd, 1H, J = 10.0, 3.4), 3.91 (dd, 1H, J = 13.0, 1.0), 3.74 (dd, 1H, J = 13.0, 2.2), 
3.69 (dd, 1H, J = 10.0, 3.7), 3.36 (s, 3H), 3.15 (s, 3H). 13C NMR (acetone-d6, 125 MHz)  
101.5, 81.5, 70.3, 69.0, 62.2, 55.9, 38.6. IR: 3439, 2939, 1337, 1173, 1076, 975, 925, 895 
cm–1. HRMS (DART-TOF) calcd. for C7H14O7S: [M+NH4]+: 260.0804, found: 260.0809. 
Table 1.4, Entry 9. 
The general procedure I was followed using (+)-1.56 (2.8 mg, 0.010 
mmol, 5 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
the selectivity (C2:C3:C4 = 1:92:7). Column chromatography 
(Hex/EtOAc = 1:1 to 1:3) afforded the pure product 1.83c (44 mg, 91%). 
1H NMR (acetone-d6, 500 MHz)  4.75 (d, 1H, J = 3.2), 4.66 (dd, 1H, J = 9.0, 3.2), 4.47 
(d, 1H, J = 2.7), 4.13 (s, 1H), 4.04-4.02 (m, 2H), 3.82 (dd, 1H, J = 12.2, 1.2), 3.61 (dd, 1H, 
J = 12.5, 2.2), 3.38 (s, 3H), 3.14 (s, 3H). 13C NMR (acetone-d6, 125 MHz)  72.1, 52.8, 
39.8, 38.0, 34.1, 26.0, 9.0. IR: 3460, 1334, 1171, 1140, 1061, 1018, 972, 860 cm–1. HRMS 
(DART-TOF) calcd. for C7H14O7S: [M+NH4]+: 260.0804, found: 260.0802. 
 
Site-Selective Functionalization of Galactose (Table 1.5): 
General Procedure J (Table 1.5, Entry 1): 
In a dry box, a solution of 1.85 (62 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous tert-amyl alcohol (1.0 mL) was prepared in an oven-dried 
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glass reaction vial. The solution was brought out of the dry box, and N,N-
diisopropylethylamine (42 L, 0.24 mmol, 1.2 eq) was added to the stirring reaction at 
room temperature. The reaction was stirred at 4 °C for 10 minutes, followed by dropwise 
addition of chlorotriethylsilane (40 L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C 
for 4 hours. MeOH (50 L) was added to quench the reaction. The mixture was filtered 
through a Pasteur pipette packed with silica gel, followed by flush with EtOAc (15 mL). 
The solvent was removed under reduced pressure. 1,3,5-trimethoxybenzene (50 L of 0.40 
M in CDCl3, 0.020 mmol, 10 mol %) was added as standard. 1H NMR of the crude mixture 
afforded yield (77%) and selectivity (C2:C3:C4 = 86:14:-). 
Table 1.5, Entry 2. 
The general procedure J was followed using (+)-1.56 (11 mg, 0.040 
mmol, 20 mol %) as the catalyst. 1H NMR of the crude mixture 
afforded selectivity (C2:C3:C4 = 6:94:-). Column chromatography 
(Hexane/EtOAc = 20:1 to 5:1) afforded the pure product 1.87a (80 mg, 
95%). 1H NMR (CDCl3, 500 MHz)  4.78 (d, 1H, J = 3.2), 3.88-3.84 (m, 2H), 3.80-3.74 
(m, 3H), 3.41 (s, 3H), 2.58 (s, 1H), 1.87 (dd, 1H, J = 5.1, 3.7), 0.97 (t, 9H, J = 8.1), 0.89 
(s, 9H), 0.66 (qd, 6H, J = 7.6, 3.4), 0.08 (s, 6H). 13C NMR (CDCl3, 125 MHz)  99.8, 72.7, 
70.4, 70.0, 69.9, 62.5, 55.4, 26.0, 18.5, 7.0, 5.1, -5.1, -5.3. IR: 3566, 2953, 2930, 2877, 
1250, 1086, 1053, 835, 744 cm–1. HRMS (DART-TOF) calcd. for C19H42O6Si2: [M+H]+: 
423.2598, found: 423.2612. 
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General Procedure K (Table 1.5, Entry 3): 
In a dry box, a solution of 1.85 (62 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (3.0 mL) was prepared in an oven-dried glass reaction 
vial. The solution was brought out of the dry box, and N,N-diisopropylethylamine (42 L, 
0.24 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction 
was stirred at 4 °C for 10 minutes, followed by dropwise addition of acetyl chloride (17 
L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C for 4 hours. MeOH (50 L) was 
added to quench the reaction. The mixture was filtered through a Pasteur pipette packed 
with silica gel, followed by flush with EtOAc (15 mL). The solvent was removed under 
reduced pressure. 1,3,5-trimethoxybenzene (50 L of 0.40 M in CDCl3, 0.020 mmol, 10 
mol %) was added as standard. 1H NMR of the crude mixture afforded yield (26%) and 
selectivity (C2:C3:C4 = 42:58:-). 
Table 1.5, Entry 4. 
The general procedure K was followed using (+)-1.56 (11 mg, 0.040 
mmol, 20 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
selectivity (C2:C3:C4 = 19:81:-). Column chromatography 
(Hexane/EtOAc = 5:1 to 2:1) afforded the mixture of mono-functionalized products with 
1.87b as the major product (67 mg, 96%). 1H NMR (CDCl3, 500 MHz)  5.03 (dd, 1H, J 
= 10.0, 2.9), 4.84 (d, 1H, J = 3.9), 4.18 (s, 1H), 4.06 (td, 1H, J = 10.8, 3.9), 3.91 (dd, 1H, 
J = 10.8, 4.9), 3.87 (dd, 1H, J = 10.8, 4.2), 3.76 (t, 1H, J = 4.6), 3.43 (s, 3H), 3.25 (d, 1H, 
J = 2.0), 2.16 (s, 1H), 1.99 (d, 1H, J = 11.0), 0.89 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H). 13C 
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NMR (CDCl3, 125 MHz)  171.3, 100.0, 73.7, 69.6, 69.3, 67.5, 64.0, 55.6, 26.0, 21.4, 18.4, 
-5.3, -5.4. IR: 3428, 2953, 2929, 2856, 1739, 1721, 1248, 1146, 1083, 1050, 836, 776 cm–
1. HRMS (DART-TOF) calcd. for C15H30O7Si: [M−OH]+: 333.1733, found: 333.1743. 
 
General Procedure L (Table 1.5, Entry 5): 
In a dry box, a solution of 1.85 (62 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (1.0 mL) was prepared in an oven-dried glass reaction 
vial. The solution was brought out of the dry box, and N,N-diisopropylethylamine (42 L, 
0.24 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction 
was stirred at -15 °C for 10 minutes, followed by dropwise addition of methanesulfonyl 
chloride (19 L, 0.24 mmol, 1.2 eq). The reaction was stirred at -15 °C for 4 hours. MeOH 
(50 L) was added to quench the reaction. The mixture was filtered through a Pasteur 
pipette packed with silica gel, followed by flush with EtOAc (15 mL). The solvent was 
removed under reduced pressure. Column chromatography (Hexane/EtOAc = 5:1 to 2:1) 
afforded the mixture of mono-functionalized products (48 mg, 62%). 1H NMR of the 
mixture afforded the selectivity (C2:C3:C4 = 76:24:-). 
Table 1.5, Entry 6. 
The general procedure L was followed using (+)-1.56 (11 mg, 0.040 
mmol, 20 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
selectivity (C2:C3:C4 = -:100:-). Column chromatography 
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(Hexane/EtOAc = 5:1 to 2:1) afforded the pure product 1.87c (57 mg, 74%). 1H NMR 
(CDCl3, 500 MHz)  4.85 (d, 1H, J = 4.2), 4.73 (dd, 1H, J = 10.0, 2.9), 4.30 (s, 1H), 4.12 
(td, 1H, J = 10.0, 4.2), 3.89 (dd, 1H, J = 10.8, 5.4), 3.85 (dd, 1H, J = 10.8, 4.9), 3.76 (t, 1H, 
J = 5.1), 3.43 (s, 3H), 3.25 (d, 1H, J = 2.4), 3.18 (s, 3H), 2.39 (d, 1H, J = 10.3), 0.88 (s, 
9H), 0.08 (s, 6H). 13C NMR (CDCl3, 125 MHz)  99.8, 82.3, 70.0, 69.7, 67.3, 63.3, 55.6, 
39.0, 26.0, 18.4, -5.31, -5.32. IR: 3468, 2952, 2929, 2856, 1350, 1172, 1084, 1047, 961, 
834, 776, 731, 526, 489 cm–1. HRMS (DART-TOF) calcd. for C14H30O8SSi: [M+H]+: 
387.1509, found: 387.1505. 
 
Site-Selective Functionalization of 1,6-Anhydro-Galactose (Table 1.6): 
General Procedure M (Table 1.6, Entry 1): 
In a dry box, a solution of 1.89 (32 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous tert-amyl alcohol (1.0 mL) was prepared in an oven-dried 
glass reaction vial. The solution was brought out of the dry box, and N,N-
diisopropylethylamine (42 L, 0.24 mmol, 1.2 eq) was added to the stirring reaction at 
room temperature. The reaction was stirred at 4 °C for 10 minutes, followed by dropwise 
addition of chlorotriethylsilane (40 L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C 
for 4 hours. MeOH (50 L) was added to quench the reaction. The mixture was filtered 
through a Pasteur pipette packed with silica gel, followed by flush with EtOAc (15 mL). 
The solvent was removed under reduced pressure. 1,3,5-trimethoxybenzene (50 L of 0.40 
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M in CDCl3, 0.020 mmol, 10 mol %) was added as standard. 1H NMR of the crude mixture 
afforded the yield (51%) and selectivity (C2:C3:C4 = 91:-:9). 
Table 1.6, Entry 2. 
The general procedure M was followed using (–)-1.72 (3.1 mg, 0.010 
mmol, 5 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
the selectivity (C2:C3:C4 = 1:-:99). Column chromatography 
(Hexane/EtOAc = 3:1) afforded the pure product 1.92a (54 mg, 98%). 1H NMR (CDCl3, 
500 MHz)  5.36 (t, 1H, J = 1.5), 4.24 (d, 2H, J = 7.1), 4.06 (t, 1H, J = 4.7), 3.86-3.85 (m, 
1H), 3.83 (d, 1H, J = 8.3), 3.63 (dd, 1H, J = 6.4, 5.9), 2.88 (s, 1H), 2.32 (d, 1H, J = 8.6), 
0.96 (t, 9H, J = 8.1), 0.65 (q, 6H, J = 7.7). 13C NMR (CDCl3, 125 MHz)  101.6, 74.7, 71.6, 
71.2, 65.8, 63.9, 6.8, 4.9. IR: 3430, 2956, 2878, 1240, 1136, 1099, 1051, 1011, 938, 847, 
809, 765, 744, 456 cm–1. HRMS (DART-TOF) calcd. for C12H24O5Si: [M+H]+: 277.1471, 
found: 277.1474. 
 
General Procedure N (Table 1.6, Entry 3): 
In a dry box, a solution of 1.89 (32 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (3.0 mL) was prepared in an oven-dried glass reaction 
vial. The solution was brought out of the dry box, and N,N-diisopropylethylamine (42 L, 
0.24 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction 
was stirred at 4 °C for 10 minutes, followed by dropwise addition of acetyl chloride (17 
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L, 0.24 mmol, 1.2 eq). The reaction was stirred at 4 °C for 4 hours. MeOH (50 L) was 
added to quench the reaction. The mixture was filtered through a Pasteur pipette packed 
with silica gel, followed by flush with EtOAc (15 mL). The solvent was removed under 
reduced pressure. 1,3,5-trimethoxybenzene (50 L of 0.40 M in CDCl3, 0.020 mmol, 10 
mol %) was added as standard. 1H NMR of the crude mixture afforded the yield (53%) and 
selectivity (C2:C3:C4 = 75:8:17). 
Table 1.6, Entry 4. 
The general procedure N was followed using (–)-1.72 (3.1 mg, 0.010 
mmol, 5 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
the selectivity (C2:C3:C4 = -:3:97). Column chromatography 
(Hexane/EtOAc = 1:1 to 1:2) afforded the pure product 1.92b (38 mg, 93%). 1H NMR 
(acetone-d6, 500 MHz)  5.26 (s, 1H), 5.00 (br s, 1H), 4.41 (dd, 2H, J = 6.9, 3.2), 4.25 (d, 
1H, J = 6.9), 4.07 (t, 2H, J = 1.0), 3.68 (d, 1H, J = 6.9), 3.54 (t, 1H, J = 5.9), 2.04 (s, 3H). 
13C NMR (acetone-d6, 125 MHz)  170.4, 103.1, 73.9, 73.1, 70.8, 68.9, 64.8, 20.9. IR: 
3432, 2961, 2905, 1727, 1432, 1373, 1238, 1132, 1050, 975, 928, 852, 700, 463 cm–1. 
HRMS (DART-TOF) calcd. for C8H12O6: [M+H]+: 205.0712, found: 205.0717. 
 
General Procedure O (Table 1.6, Entry 5): 
In a dry box, a solution of 1.89 (32 mg, 0.20 mmol), catalyst (N-methylimidazole, 3.2 L, 
0.040 mmol, 20 mol %), and N,N-diisopropylethylamine hydrochloride (1.0 mg, 0.0060 
mmol, 3 mol %) in anhydrous THF (3.0 mL) was prepared in an oven-dried glass reaction 
78 
 
vial. The solution was brought out of the dry box, and N,N-diisopropylethylamine (42 L, 
0.24 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction 
was stirred at -15 °C for 10 minutes, followed by dropwise addition of methanesulfonyl 
chloride (19 L, 0.24 mmol, 1.2 eq). The reaction was stirred at -15 °C for 4 hours. MeOH 
(50 L) was added to quench the reaction. The mixture was filtered through a Pasteur 
pipette packed with silica gel, followed by flush with EtOAc (15 mL). The solvent was 
removed under reduced pressure. 1,3,5-trimethoxybenzene (50 L of 0.40 M in CDCl3, 
0.020 mmol, 10 mol %) was added as standard. 1H NMR of the crude mixture afforded the 
yield (50%) and selectivity (C2:C3:C4 = 75:6:19). 
Table 1.6, Entry 6. 
The general procedure O was followed using (–)-1.72 (3.1 mg, 0.010 
mmol, 5 mol %) as the catalyst. 1H NMR of the crude mixture afforded 
the selectivity (C2:C3:C4 = -:1:99). Column chromatography 
(Hexane/EtOAc = 1:1 to 1:2) afforded the pure product 1.92c (42 mg, 88%). 1H NMR 
(acetone-d6, 500 MHz)  5.28 (t, 1H, J = 1.5), 4.88 (t, 1H, J = 4.4), 4.56 (t, 1H, J = 4.2), 
4.44 (d, 1H, J = 7.1), 4.38-4.37 (m, 2H), 4.15 (br s, 1H), 3.75 (br s, 1H), 3.60 (td, 1H, J = 
5.1, 0.5), 3.22 (s, 3H). 13C NMR (acetone-d6, 125 MHz)  103.3, 75.0, 74.5, 74.0, 71.8, 
64.9, 38.8. IR: 3458, 2937, 1340, 1172, 1132, 1055, 1000, 970, 901, 818, 525, 459 cm–1. 
HRMS (DART-TOF) calcd. for C7H12O7S: [M+NH4]+: 258.0648, found: 258.0652. 
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Axial Hydroxyl Functionalization (Figure 1.10): 
The general procedure N was followed using (+)-1.72 (12 mg, 0.040 mmol, 
20 mol %) as the catalyst. 1H NMR of the crude mixture afforded the 
selectivity (C2:C3:C4 = 2:81:17). Column chromatography 
(Hexane/EtOAc = 1:1 to 1:2) afforded the mixture of mono-functionalized products with 
1.91b as the major product (30 mg, 73%, C2:C3:C4 = 2:81:7). 1H NMR (CDCl3, 500 MHz) 
 5.22 (t, 1H, J = 1.2), 5.03 (dq, 1H, J = 5.1, 1.2), 4.39 (d, 1H, J = 7.1), 4.32 (d, 2H, J = 
6.4), 4.24 (d, 1H, J = 7.1), 4.15-4.12 (m, 1H), 3.56-3.53 (m, 2H), 2.03 (s, 3H). 13C NMR 
(CDCl3, 125 MHz)  170.7, 102.2, 75.7, 73.4, 71.5, 64.8, 64.1, 21.1. IR: 3418, 2963, 2904, 
1723, 1435, 1240, 1137, 1066, 1040, 971, 852, 696, 438 cm–1. HRMS (DART-TOF) calcd. 
for C8H12O6: [M+H]+: 205.0712, found: 205.0721. 
 
Site-Selective Silylation of Uridine and Characterization of Products (Scheme 1.17): 
In a dry box, a mixture of 1.95 (112 mg, 0.20 mmol), (+)-1.56 (2.8 mg, 0.01 mmol, 5 
mol %), and N,N-diisopropylethylamine hydrochloride (1.5 mg, 0.006 mmol, 3 mol %) in 
anhydrous THF (1 mL) was prepared in an oven-dried round-bottom flask. The mixture 
was brought out of the dry box, and N,N-diisopropylethylamine (42 µL, 0.24 mmol, 1.2 eq) 
was added to the stirring reaction at room temperature, followed by dropwise addition of 
triethylsilyl chloride (40 µL, 0.24 mmol, 1.2 eq). The reaction was stirred at room 
temperature for 4 hours. MeOH (50 µL) was added to quench the reaction. The reaction 
mixture was put through a plug of silica gel and washed with 15 mL of EtOAc. The solvent 
was removed under reduced pressure. Column chromatography 
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(Dichloromethane/Methanol = 99.5:0.5 to 99:1) on silica gel 
afforded the desired product (1.96) as a white solid (106 mg, 80%, 
C3:C2 = 93:7). 1H NMR (CDCl3, 400 MHz)  8.36 (br s, 1H), 7.82 
(d, 1H, J = 10), 7.35–7.22 (m, 9H), 6.82 (dd, 4H, J = 2, 11), 5.96 (d, 
1H, J = 5.5), 5.36 (dd, 1H, J = 10, 3), 4.36–4.34 (m, 1H), 4.16–4.12 
(m, 1H), 4.05–4.03 (m, 1H), 3.78 (s, 6H), 3.58 (dd, J = 13.5, 3, 1H), 3.30 (dd, 1H, J = 13.5, 
3), 2.89 (d, 1H, J = 8), 0.87 (t, 9H, J = 10), 0.57–0.46 (m, 6H). 13C NMR (CDCl3, 100 
MHz)  163.3, 159.0, 150.6, 144.2, 140.4, 135.3, 135.2, 130.3, 128.4, 128.2, 127.4, 113.5, 
113.4, 102.7, 89.5, 87.3, 84.2, 75.4, 71.2, 62.4, 55.4, 6.8, 4.8. IR: 3441, 3170, 3058, 2954, 
2911, 2875, 2836, 1692, 1608 1581, 1508, 1459, 1415, 1389, 1300, 1250, 1176, 1150, 1112, 
1066, 1035, 1002, 910, 829, 729, 704, 676, 648, 633, 585, 427 cm–1. HRMS (DART-ESI+) 
calcd. for C36H44N2O8NaSi: [M+Na]+ : 683.27710, found: 683.275914. 
In a dry box, a mixture of 1.95 (112 mg, 0.20 mmol), (–)-1.72 (3.1 mg, 0.01 mmol, 5 
mol %), and N,N-diisopropylethylamine hydrochloride (1.5 mg, 0.006 mmol, 3 mol %) in 
anhydrous THF (1 mL) was prepared in an oven-dried round-bottom flask. The mixture 
was brought out of the dry box, and N,N-diisopropylethylamine (42 µL, 0.24 mmol, 1.2 eq) 
was added to the stirring reaction at room temperature, followed by dropwise addition of 
triethylsilyl chloride (40 µL, 0.24 mmol, 1.2 eq). The reaction was stirred at room 
temperature for 4 hours. MeOH (50 µL) was added to quench the reaction. The reaction 
mixture was put through a plug of silica gel and washed with 15 mL of EtOAc. The solvent 
was removed under reduced pressure. Column chromatography 
(Dichloromethane/Methanol = 99.5:0.5 to 99:1) on silica gel afforded the desired product 
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(1.97) as a white solid (114 mg, 86%, 2’:3’ = >98:<2). 1H NMR 
(CDCl3, 500 MHz)  8.67 (br s, 1H), 7.94 (d, 1H, J = 8), 7.37 (m, 
2H), 7.27 (m, 7H), 6.84 (d, 4H, J = 9), 5.94 (d, 1H, J = 3), 5.29 (dd, 
1H, J = 8.3, 2.3), 4.37–4.33(m, 2H), 4.13–4.10 (m, 1H), 3.80 (s, 6H), 
3.53–3.46 (m, 2H), 2.66–2.64 (m, 1H), 0.98 (t, 9H, J = 8), 0.70 (q, 
6H, J = 8). 13C NMR (CDCl3, 100 MHz)  163.5, 158.9, 158.9, 150.5, 144.5, 140.5, 135.4, 
135.2, 130.4, 130.3, 128.3, 128.2, 127.4, 113.5,113.5, 102.5, 88.9, 87.4, 83.7, 76.2, 70.6, 
62.5, 55.4, 6.7, 4.7 IR: 3197, 3058, 2955, 2912, 2876, 2836, 1680, 1607, 1582, 1508, 1458, 
1413, 1381, 1332, 1299, 1249, 1175, 1114, 1087, 1062, 1033, 1005, 912, 876, 827, 791, 
729, 701, 583, 557, 419 cm–1. HRMS (DART-ESI+) calcd. For C36H44N2O8NaSi: [M+Na]+: 
683.27700, found: 683.275914. 
 
Site-Selective Mesylation of Mupirocin and Characterization of Products (Scheme 1.18, 
eq. 1): 
A modified method was adopted from the 
previously reported procedure.45 To a 
solution of mupirocin (2.0 g, 4.0 mmol) in 
anhydrous toluene (16 mL) and anhydrous 
MeOH (4.0 mL) was added trimethylsilyldiazomethane (2.0 M in Et2O, 2.4 mL, 4.8 mmol) 
dropwise at room temperature. After stirring for 1 h, the reaction mixture was diluted with 
EtOAc (15 mL) and AcOH (10% aqueous, 10 mL) was added. The aqueous phase was 
extracted with EtOAc (3x15 mL) and the organic layers were combined, washed with brine 
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(25 mL), dried with MgSO4, filtered and the solvent was removed under reduced pressure. 
The resulting crude product (colorless oil) was dissolved in a mixture of hexane (10 mL) 
and Et2O (20 mL) and crystallized out in an ice bath as a white solid (1.84 g, 92%). Note: 
Trimethylsilyldiazomethane is highly toxic and potentially fatal if inhaled. 1H NMR 
(CDCl3, 500 MHz)  5.75 (s, 1H), 4.07 (t, 2H, J = 6.6), 3.92 (d, 1H, J = 2.9), 3.87 (dd, 1H, 
J = 12, 3.2), 3.82 (t, 1H, J = 6.6), 3.75 (td, 1H, J = 8.6, 3.2), 3.67 (s, 3H), 3.55 (dd, 1H, J = 
12, 2.7), 3.47 (td, 1H, J = 7.8, 2.9), 2.80 (td, 1H, J = 6.8, 2.2), 2.69 (dd, 1H, J = 8.1, 2.2), 
2.58 (dd, 1H, J = 14, 2.7), 2.43 (d, 1H, J = 3.2), 2.32-2.27 (m, 5H), 2.21 (s, 3H), 2.02-1.99 
(m, 1H), 1.78-1.68 (m, 2H), 1.66-1.60 (m, 4H), 1.36-1.31 (m, 9H), 1.22 (d, 3H, J = 6.4), 
0.94 (d, 3H, J = 7.1). 13C NMR (CDCl3, 125 MHz)  211.9, 198.8, 174.6, 166.9, 156.8, 
117.9, 75.0, 71.6, 70.7, 69.3, 65.5, 64.0, 61.6, 55.8, 51.7, 43.1, 39.7, 34.3, 31.8, 29.3, 29.2, 
28.9, 26.2, 25.1, 21.0, 19.3, 13.0. IR: 3444, 2931, 2859, 1736, 1714, 1647, 1437, 1346, 
1224, 1150, 1109, 1053, 943, 869 cm–1. HRMS (DART-TOF) calcd. for C27H46O9: [M+H]+: 
515.3220, found: 515.3229. 
In a dry box, a solution of mupirocin 
methyl ester (51 mg, 0.10 mmol), catalyst 
(–)-1.72 (6.1 mg, 0.020 mmol, 20 mol %), 
and N,N-diisopropylethylamine 
hydrochloride (0.5 mg, 0.0030 mmol, 3 mol %) in anhydrous THF (0.5 mL) was prepared 
in an oven-dried glass reaction vial. The solution was brought out of the dry box, and N,N-
diisopropylethylamine (21 L, 0.12 mmol, 1.2 eq) was added to the stirring reaction at 
room temperature. The reaction was stirred at -15 °C for 10 minutes, followed by dropwise 
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addition of methanesulfonyl chloride (9.3 L, 0.12 mmol, 1.2 eq). The reaction was stirred 
at -15 °C for 20 hours. MeOH (25 L) was added to quench the reaction. The mixture was 
filtered through a Pasteur pipette packed with silica gel, followed by flushing with EtOAc 
(8 mL). The solvent was removed under reduced pressure. Selectivity of the reaction was 
determined by 1H NMR in the crude reaction mixture (C6:C7 = >98:<2). Column 
chromatography (Hexane/EtOAc = 1:1 to 1/2) afforded the pure product 1.99 (49 mg, 82%). 
1H NMR  5.73 (s, 1H), 4.53 (dd, 1H, J = 7.8, 2.5), 4.23-4.22 (m, 1H), 4.09-4.03 (m, 3H), 
3.92 (dd, 1H, J = 12, 3.4), 3.84-3.81 (m, 1H), 3.67 (s, 3H), 3.59 (dd, 1H, J = 12, 3.4), 3.11 
(s, 3H), 2.80-2.78 (m, 1H), 2.72 (dd, 1H, J = 7.8, 2.0), 2.56 (d, 1H, J = 3.9), 2.44 (dd, 1H, 
J = 14, 3.4), 2.36-2.30 (m, 3H), 2.24 (d, 1H, J = 3.4), 2.20 (d, 3H, J = 1.0), 2.13-2.11 (m, 
1H), 1.85-1.80 (m, 1H), 1.69 (q, 1H, J = 7.4), 1.64-1.60 (m, 4H), 1.36-1.31 (m, 9H), 1.21 
(d, 3H, J = 6.4), 0.95 (d, 3H, J = 7.3). 13C NMR (CDCl3, 125 MHz)  174.5, 166.7, 154.9, 
118.6, 79.2, 72.4, 71.5, 69.3, 65.8, 64.1, 61.5, 55.7, 51.7, 43.1, 42.6, 39.8, 39.1, 34.3, 31.9, 
29.4, 29.3, 29.2, 28.9, 26.2, 25.1, 20.9, 19.0, 13.0. IR: 3500, 2933, 2858, 1714, 1649, 1455, 
1438, 1353, 1226, 1175, 1152, 1116, 965, 942, 856, 529 cm–1. HRMS (DART-TOF) calcd. 
for C28H48O11S: [M+H]+: 593.2996, found: 593.2977. 
In a dry box, a solution of mupirocin 
methyl ester (618 mg, 1.2 mmol), 
catalyst (+)-1.56 (68 mg, 0.24 mmol, 20 
mol %), and N,N-diisopropylethylamine 
hydrochloride (6.0 mg, 0.036 mmol, 3 mol %) in anhydrous THF (6.0 mL) was prepared 
in an oven-dried glass reaction vial. The solution was brought out of the dry box, and N,N-
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diisopropylethylamine (251 L, 1.44 mmol, 1.2 eq) was added to the stirring reaction at 
room temperature. The reaction was stirred at -15 °C for 10 minutes, followed by dropwise 
addition of methanesulfonyl chloride (111 L, 1.44 mmol, 1.2 eq). The reaction was stirred 
at -15 °C for 20 hours. MeOH (300 L) was added to quench the reaction. The mixture 
was filtered through a Pasteur pipette packed with silica gel, followed by flushing with 
EtOAc (90 mL). The solvent was removed under reduced pressure. Selectivity of the 
reaction was determined by 1H NMR in the crude reaction mixture (C6:C7 = 18:82). 
Column chromatography (Hexane/EtOAc = 1:1 to 2/5) afforded the pure product 1.100 
(403 mg, 57%). 1H NMR (CDCl3, 500 MHz)  5.75 (s, 1H), 5.04 (br s, 1H), 4.07 (t, 2H, J 
= 6.9), 3.86-3.82 (m, 2H), 3.70-3.3.65 (m, 5H), 3.61-3.59 (m, 1H), 3.15 (s, 3H), 2.81 (td, 
1H, J = 5.9, 2.0), 2.78 (dd, 1H, J = 7.3, 2.5), 2.65 (d, 1H, J = 14), 2.36 (d, 1H, J = 6.8), 
2.32-2.26 (m, 4H), 2.21 (s, 3H), 1.85-1.81 (m, 1H), 1.79-1.74 (m, 1H), 1.65-1.60 (m, 4H), 
1.45 (q, 1H, J = 6.8), 1.38-1.28 (m, 9H), 1.24 (d, 3H, J = 6.4), 0.93 (d, 3H, J = 6.9). 13C 
NMR (CDCl3, 125 MHz)  174.5, 166.8, 156.1, 118.1, 81.4, 75.4, 71.6, 67.6, 65.8, 64.1, 
61.0, 54.8, 51.7, 42.9, 42.6, 39.6, 38.8, 34.3, 32.0, 29.3, 29.2, 29.1, 29.0, 26.2, 25.1, 21.3, 
19.5, 12.6. IR: 3496, 2401, 2930, 2861, 1736, 1714, 1649, 1457, 1352, 1225, 1174, 1151, 
1112, 968, 874, 548 cm–1. HRMS (DART-TOF) calcd. for C28H48O11S: [M+H]+: 593.2996, 
found: 593.2980. 
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Site-Selective Acylation of Digoxin and Characterization of Products (Scheme 1.18, eq. 2): 
In a dry box, a 
suspension of 
digoxin (39 mg, 
0.050 mmol), 
catalyst (+)-1.72 
(4.6 mg, 0.015 
mmol, 30 mol %), and N,N-diisopropylethylamine hydrochloride (0.3 mg, 0.0015 mmol, 3 
mol %) in anhydrous THF (2.5 mL) was prepared in an oven-dried round-bottom flask. 
The suspension was brought out of the dry box, and N,N-diisopropylethylamine (11 L, 
0.060 mmol, 1.2 eq) was added to the stirring reaction at room temperature. The reaction 
was stirred at 4 °C for 10 minutes, followed by dropwise addition of acetyl chloride (4.3 
L, 0.060 mmol, 1.2 eq). The reaction was stirred at 4 °C for 16 hours. MeOH (12 L) was 
added to quench the reaction. The solvent was removed under reduced pressure. Column 
chromatography (CH2Cl2/MeOH = 50:1 to 30:1) afforded the pure product -acetyldigoxin 
1.102 (37 mg, 90%, no -acetyldigoxin observed). 1H NMR (CDCl3, 500 MHz)  5.95 (s, 
1H), 5.05-5.00 (m, 2H), 4.98-4.93 (m, 3H), 4.47 (dd, 1H, J = 9.8, 2.9), 4.31-4.28 (m, 3H), 
4.24-4.22 (m, 1H), 4.10-4.05 (m, 2H), 3.91-3.82 (m, 2H), 3.43 (dd, 1H, J = 12.0, 4.2), 3.38 
(d, 1H, J = 9.5, 6.1), 3.31 (dd, 1H, J = 9.5, 2.9), 3.27 (dd, 1H, J = 9.5, 2.9), 2.22-2.14 (m, 
1H), 2.13 (s, 3H), 2.09-1.61 (m, 19H), 1.56-1.48 (m, 4H), 1.27 (d, 3H, J = 6.1), 1.25 (d, 
3H, J = 6.4), 1.21 (d, 3H, J = 6.4), 1.00 (s, 3H), 0.83 (s, 3H). 13C NMR (CDCl3, 125 MHz) 
 178.6, 177.4, 172.2, 117.9, 100.8, 100.7, 97.1, 86.9, 83.9, 83.8, 76.8, 75.8, 75.6, 74.6, 
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69.6, 68.6, 68.5, 66.4, 57.4, 47.2, 42.4, 39.4, 39.1, 38.7, 38.1, 36.3, 33.8, 33.7, 31.6, 31.1, 
31.0, 28.5, 27.9, 27.6, 24.4, 22.9, 21.0, 18.63, 18.60, 18.4, 10.0 IR: 3433, 2932, 2880, 1734, 
1370, 1239, 1164, 1084, 1069, 1016, 866 cm–1. HRMS (DART-TOF) calcd. for C43H66O15: 
[M+Na]+: 845.4294, found: 845.4280. 
The same procedure 
to produce -
acetyldigoxin was 
followed using (–)-
1.56 (4.2 mg, 0.015 
mmol, 30 mol %) as 
the catalyst. Column chromatography (CH2Cl2/MeOH = 50:1 to 30:1) afforded the mixture 
of mono-acylated products with -acetyldigoxin 1.103 as the major product (23 mg, 56%, 
 = 91:9). 1H NMR (CDCl3, 500 MHz)  5.94 (s, 1H), 5.26 (d, 1H, J = 3.2), 5.03-4.89 
(m, 6H), 4.30-4.27 (m, 2H), 4.05 (d, 1H, J = 2.2), 3.90-3.80 (m, 3H), 3.42 (dd, 1H, J = 11.7, 
4.2), 3.37 (dd, 1H, J = 9.0, 5.6), 3.31 (dd, 1H, J = 9.5, 2.9), 3.26 (dd, 1H, J = 9.5, 2.9), 
2.19-2.15 (m, 1H), 2.12-1.63 (m, 20H), 1.52-1.50 (m, 3H), 1.34-1.32 (m, 2H), 1.30 (d, 3H, 
J = 6.4), 1.29-1.27 (m, 2H), 1.24 (d, 3H, J = 1.7), 1.23 (d, 3H, J = 1.5), 0.99 (s, 3H), 0.82 
(s, 3H). 13C NMR (CDCl3, 125 MHz)  179.2, 178.0, 173.0, 118.4, 101.3, 101.2, 97.6, 87.5, 
84.5, 84.2, 76.4, 76.2, 75.2, 73.4, 72.9, 72.3, 70.2, 69.2, 69.0, 58.0, 47.8, 42.9, 39.6, 39.2, 
38.7, 37.8, 36.9, 34.3, 34.2, 32.1, 31.7, 31.6, 29.1, 28.5, 28.2, 24.9, 23.5, 21.8, 19.3, 19.2, 
10.6. IR: 3412, 2931, 2882, 1736, 1371, 1241, 1163, 1068, 1017m 866 cm–1. HRMS 
(DART-TOF) calcd. for C43H66O15: [M+Na]+: 845.4294, found: 845.4303. 
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1.6.2 Template-Assisted Meta-Selective C–H Activation 
1.6.2.1 General Information 
 Unless otherwise noted, all reagents were obtained from commercial suppliers and used 
without further purification. Flash column chromatography was performed using EMD 
Silica Gel 60 (230-400 mesh) and ACS grade solvents as received from Fisher Scientific. 
All experiments were performed in oven or flame dried glassware under an atmosphere of 
nitrogen or argon using standard syringe techniques, except where otherwise noted. All 
reactions were run with dry, degassed solvents dispensed from a Glass Contour Solvent 
Purification System (SG Water, USA LLC).   
 1H, 13C, and NOE NMR were performed on a Varian Gemini 400 MHz, Varian Gemini 
500 MHz, Varian Gemini 600 MHz or a Varian Unity Inova 500 MHz spectrometer. 
Deuterated solvents were purchased from Cambridge Isotope Labs and stored over 3Å 
molecular sieves. All NMR chemical shifts are reported in ppm relative to residual solvent 
for 1H and 13C NMR. Signals are quoted as singlet (s), doublet (d), triplet (t), quartet (q), 
multiplet (m), and broad singlet (br s). Coupling constants are reported in Hz. All IR spectra 
were gathered on a Bruker Alpha FT-IR equipped with a single crystal diamond ATR 
module and values are reported in cm-1. HRMS data were generated in Boston College 
facilities. 
 
1.6.2.2 Experimental Procedures and Characterization 
Procedure for preparation of substrate: 
General procedure A (Scheme 1.24): 
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To a stirred solution of 2-(3-bromophenyl)-acetonitrile (1.0 eq) was 
added potassium tert-butoxide (2.2 eq) portionwise at –40 oC under 
nitrogen atmosphere. After being stirred for 15 min at –40 oC, alkyl iodide (2.45 eq) was 
added. The mixture was warmed to room temperature and stirred further for 1h. The white 
solid was filtered off though a short pad of Celite and filtrate was concentrated under 
reduced pressure. A column chromatography on silica gel gave the product as colorless oil. 
To a stirred solution of arylbromide (1.0 eq) in tetrahydrofuran (0.3 
M) was added n-BuLi (1.0 eq) at –100 oC in liquid nitrogen/acetone 
bath. After being stirred for 30min at the same temperature, chlorodiisopropylsilane (1.0 
eq) was added. The mixture was allowed to warm room temperature without more liquid 
nitrogen. With further 2 h of stirring, silica gel was added to quench the reaction and 
column chromatography afforded the product as colorless oil.  
To a suspension of trichloroisocyanuric acid (0.33 eq) in 
dichloromethane (0.3 M) was added previously synthesized silane 
in dichloromethane (0.5 M) at 0 oC under nitrogen atmosphere. After being stirred for 1h 
at room temperature, white solid was filtered off through a short pad of Celite and the 
filtrate was concentrated under reduced pressure. Short path distillation gave the product 
as colorless oil (when R= sBu, bp=220 oC at 0.05 mmHg). 
To a mixture of corresponding alcohol (1.0 eq) and imidazole (1.2 
eq) in dichloromethane (0.3 M) was added a solution of 
chlorosilane (1.1 eq) in dichloromethane (0.5 M) at 0 oC under N2 atmosphere. The mixture 
was warmed to room temperature and stirred for 1 h. After filtering off the white solid, the 
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filtrate was concentrated and purified using flash column chromatography to give a product 
as colorless oil. 
 
General procedure B (Scheme 1.27): 
Scheme 1.27 General procedure B for preparation of substrate 
 
 
 Chlorodiisopropylsilane (1.7 mL, 10.0 mmol, 1.0 eq) was added to a mixture 
of benzyl alcohol (1.0 mL, 10.0 mml, 1.0 eq) and DMAP (122 mg, 1.0 mmol, 
0.1 eq) in tetrahydrofuran (0.3 M) at 0 oC under nitrogen atmosphere. 
Triethylamine (2.8 mL, 20.0 mmol, 2.0 eq) was added dropwise and the reaction mixture 
was stirred for overnight at room temperature. White solid was filtered off and the filtrate 
was concentrated under reduced pressure. Column chromatography on silica gel 
(EA/Hx=1/20) gave the product as a colorless liquid (1.7 g, 76%) 1H NMR (CDCl3, 500 
MHz) 7.29-7.41 (m, 4H), 7.21-7.29 (m, 1H), 4.81 (s, 2H), 4.25 (s, 1H), 0.98-1.12 (m, 14H). 
13C NMR (CDCl3, 125 MHz)  141.1, 128.5, 127.3, 126.6, 67.6, 17.7, 17.6, 12.7 IR: 2942, 
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2864, 2091, 1461, 1094, 1064, 880, 837, 817, 800, 729, 694, 667 cm–1. HRMS (DART-
ESI+) calcd. for C13H23O1Si1: [M+H]+: 221.1362, found: 221.1363. 
To a suspension of trichloroisocyanuric acid (640 mg, 2.75 mmol, 0.33 eq) 
in dichloromethane (0.3 M) was added previously synthesized silane (1.7 g, 
7.6 mmol, 1.0 eq) in dichloromethane (0.5 M) at 0 oC under nitrogen 
atmosphere. After being stirred for 1h at room temperature, precipitated white solid was 
filtered off through short pad of Celite and the filtrate was concentrated under reduced 
pressure. Short path distillation gave the product as colorless oil (1.82 g, 93%, 150 oC at 
0.3 mmHg). 1H NMR (CDCl3, 500 MHz)  7.31-7.43 (m, 4H), 7.21-7.31 (m, 1H), 4.90 (s, 
2H), 1.16-1.30 (m, 2H), 1.12 (d, J=8.1 Hz, 6H), 1.11 (d, J=8.1 Hz, 6H). 13C NMR (CDCl3, 
125 MHz)  (ppm) 140.2, 128.5, 127.5, 126.6, 65.8, 17.1, 16.9, 15.3. IR: 2948, 2868, 1463, 
1093, 1062, 1027, 1001, 883, 827, 730, 694, 620 cm–1. LRMS (EI) calcd. for 
C13H22Cl1O1Si1: 256.11, found: 256.10. 
To a stirred solution of arylbromide (1.0 eq) in tetrahydrofuran (0.3 
M) was added n-BuLi (1.0 eq) at –100 oC in liquid nitrogen/acetone 
bath. After being stirred for 30 min at the same temperature, 
(benzyloxy)chlorodiisopropylsilane (1.0 eq) was added. The mixture was allowed to warm 
to room temperature. With additional 2 h stirring, silica gel was added to quench the 
reaction and column chromatography gave a product as colorless oil.  
The general procedure A was followed for the dialkylation in 20 mmol 
scale using 2-(4-bromophenyl)-acetonitrile (3.4 g, 76%). 1H NMR 
(CDCl3, 500 MHz)  7.48-7.55 (m, 2H), 7.31-7.38 (m, 2H), 1.71 (s, 6H). 13C NMR (CDCl3, 
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125 MHz)  140.7, 132.2, 127.1, 124.2, 122.0, 37.1, 29.2. IR: 2982, 1489, 1398, 1101, 
1074, 1008, 820, 714, 579, 520. cm–1. HRMS (DART-ESI+) calcd. for C10H11Br1N1: 
[M+H]+: 224.0075, found: 224.0066. 
The general procedure A was followed for silyl group introduction 
in 7.0 mmol scale (1.56 g, 86%). 1H NMR (CDCl3, 500 MHz)  
7.50-7.55 (m, 2H), 7.41-7.47 (m, 2H), 3.95 (t, J=3.2 Hz, 1H), 1.73 
(s, 6H), 1.19-1.28 (m, 2H), 1.07 (d, J=7.3 Hz, 6H), 0.99 (d, J=7.3 Hz, 6H). 13C NMR 
(CDCl3, 125 MHz)  142.3, 136.3, 134.1, 124.7, 124.5, 37.4, 29.3, 18.8, 18.7, 10.9. IR: 
2941, 2863, 2099, 1461, 1086, 1001, 880, 798, 660, 536 cm–1. HRMS (DART-ESI+) calcd. 
for C16H26N1Si1: [M+H]+: 260.1835, found: 260.1841. 
The general procedure A was followed for chlorination in 6.0 
mmol scale (1.43 g, 81%). 1H NMR (CDCl3, 500 MHz)  7.62 (m, 
2H), 7.50 (m, 2H), 1.74 (s, 6H), 1.39-1.45 (m, 2H), 1.09 (d, J=7.3 
Hz, 6H), 1.01 (d, J=7.3 Hz, 6H). 13C NMR (CDCl3, 125 MHz)  143.3, 135.2, 132.3, 124.8, 
124.5, 37.4, 29.2, 17.2, 16.9, 14.0. IR: 2948, 2868, 1463, 1396, 1086, 994, 882, 822, 733, 
673, 649, 550 cm–1. HRMS (DART-ESI+) calcd. for C16H25Cl1N1Si1: [M+H]+: 294.1445, 
found: 294.1456. 
The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using benzyl alcohol (547 mg, 100 %). 
1H NMR (CDCl3, 500 MHz)  7.55-7.63 (m, 2H), 7.42-7.50 (m, 
2H), 7.32-7.42 (m, 4H), 7.24-7.30 (m, 1H), 4.90 (s, 2H), 1.74 (s, 
6H), 1.36 (sept, J=7.4 Hz, 2H), 1.10 (d, J=7.3 Hz, 6H), 1.05 (d, 
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J=7.3 Hz, 6H). 13C NMR (CDCl3, 125 MHz)  142.5, 141.3, 135.5, 134.2, 128.5, 127.2, 
126.1, 124.7, 124.5, 65.7, 37.4, 29.2, 17.7, 17.5, 12.4. IR: 2942, 2864, 1460, 1377, 1206, 
1085, 993, 881, 820, 730, 695, 669, 631, 583, 537 cm–1. HRMS (DART-ESI+) calcd. for 
C23H32N1O1Si1: [M+H]+: 366.2253, found: 366.2248. 
The general procedure A was followed for the dialkylation in 20 mmol 
scale (4.0 g, 90 %). 1H NMR (CDCl3, 500 MHz)  7.60 (t, J=2.0 Hz, 1H), 
7.40-7.48 (m, 2H), 7.27 (t, J=8.0 Hz, 1H), 1.72 (s, 6H). 13C NMR (CDCl3, 125 MHz)  
143.9, 131.2, 130.7, 128.5, 124.1, 124.0, 123.2, 37.2, 29.2. IR: 2983, 2937, 2237, 1594, 
1567, 1476, 1418, 1369, 1239, 1091, 785, 693 cm–1. HRMS (DART-ESI+) calcd. for 
C10H10Br1N1Na1: [M+Na]+: 245.9889, found: 245.9883. 
The general procedure A was followed for silyl group introduction 
in 20 mmol scale (1.46 g, 80 %). 1H NMR (CDCl3, 500 MHz)  7.60 
(d, J=2.0 Hz, 1H), 7.44-7.50 (m, 2H), 7.37 (t, J=7.3 Hz, 1H), 3.97 (t, J=3.2 Hz, 1H), 1.74 
(s, 6H), 1.20-1.30 (m, 2H), 1.08 (d, J=7.3 Hz, 6H), 1.00 (d, J=7.3 Hz, 6H). 13C NMR 
(CDCl3, 125 MHz)  140.8, 135.6, 135.0, 132.1, 128.3, 126.0, 124.8, 37.4, 29.4, 18.8, 18.7, 
10.8. IR: 2940, 2863, 2102, 1461, 1397, 1127, 880, 783, 705, cm–1. HRMS (DART-ESI+) 
calcd. for C16H25N1Si1Na1: [M+Na]+: 282.1649, found: 282.1649. 
The general procedure A was followed for chlorination in 5.4 mmol 
scale (1.3 g, 82 %). 1H NMR (CDCl3, 500 MHz)  7.65-7.71 (m, 1H), 
7.55 (dd, J=7.8, 1.5 Hz, 2H), 7.43 (t, J=7.8 Hz, 1H), 1.74 (s, 6H), 1.43 (sept, J= 7.3 Hz, 
2H), 1.09 (d, J=7.3 Hz, 3H), 1.01 (d, J=7.3 Hz, 3H). 13C NMR (CDCl3, 125 MHz)  141.1, 
133.9, 133.7, 130.9, 128.6, 127.0, 124.6, 37.4, 29.4, 17.2, 16.9, 14.0. IR: 2948, 2868, 1463, 
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1398, 1128, 994, 882, 794, 750, 674, 639, 526 cm–1. HRMS (DART-ESI+) calcd. for 
C16H25Cl1N1Si1: [M+H]+: 294.1445, found: 294.1451. 
The general procedure A was followed for introduction of alcohol 
in 1.0 mmol scale (321 mg, 88 %). 1H NMR (CDCl3, 500 MHz)  
7.60-7.64 (m, 1H), 7.51 (dd, J=7.3, 1.5 Hz, 2H), 7.33-7.42 (m, 5H), 
7.24-7.29 (m, 1H), 4.90 (s, 2H), 1.65 (s, 6H), 1.40-1.34 (m, 2H), 
1.11 (d, J=7.3 Hz, 3H), 1.05 (d, J=7.3 Hz, 3H). 13C NMR (CDCl3, 125 MHz)  141.3, 
140.8, 135.6, 134.2, 131.1, 128.5, 128.4, 127.2, 126.4, 126.0, 124.8, 65.7, 37.4, 29.3, 17.7, 
17.5, 12.4. IR: 2942, 2865, 1462, 1397, 1205, 1097, 1068, 993, 882, 795, 732, 707, 676, 
617, 491 cm–1. HRMS (DART-ESI+) calcd. for C23H32N1O1Si1: [M+H]+: 388.2067, found: 
388.2076. 
The general procedure A was followed for the dialkylation in 10.0 
mmol scale (2.47 g, 98 %). 1H NMR (CDCl3, 500 MHz)  7.51 (t, J=1.7 
Hz, 1H), 7.45 (d, J=7.8 Hz, 1H), 7.34 (d, J=7.8 Hz, 1H), 7.26 (t, J=8.3 Hz, 1H), 1.99-2.10 
(m, 2H), 1.85-1.92 (m, 2H), 0.91 (t, J=7.3 Hz, 6H). 13C NMR (CDCl3, 125 MHz)  140.8, 
131.1, 130.5, 129.3, 125.2, 123.3, 121.9, 49.9, 34.0, 9.9. IR: 2971, 2937, 1594, 1567, 1475, 
1419, 1383, 1075, 997, 879, 778, 715, 694 cm–1. HRMS (DART-ESI+) calcd. for 
C12H15Br1N1Na1: [M+H]+: 274.0202, found: 274.0205. 
The general procedure B was followed for the introduction of 
silyl group in 1.5 mmol scale (506 mg, 86 %). 1H NMR (CDCl3, 
500 MHz)  7.47-7.54 (m, 2H), 7.42-7.45 (m, 1H), 7.33-7.41 (m, 
5H), 7.24-7.29 (m, 1H), 4.90 (s, 2H), 1.92-2.00 (m, 2H), 1.74-
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1.84 (m, 2H), 1.31-1.41 (m, 2H), 1.10 (d, J=7.3 Hz, 6H), 1.04 (d, J=7.3 Hz, 6H), 0.86 (t, 
J=7.3 Hz, 6H). 13C NMR (CDCl3, 125 MHz)  141.4, 137.4, 135.2, 134.0, 132.0, 128.5, 
128.3, 127.7, 127.2, 125.9, 122.5, 65.7, 49.9, 33.9, 17.7, 17.5, 12.4, 9.9. IR: 2940, 2865, 
1462, 1381, 1097, 1068, 993, 882, 797, 732, 708, 672, 492 cm–1. HRMS (DART-ESI+) 
calcd. for C25H35N1O1Si1Na1: [M+Na]+: 416.2380, found: 416.2385. 
The general procedure A was followed for the dialkylation (2.67 g, 
95 %). 1H NMR (CDCl3, 500 MHz)  7.52 (br. s., 1H), 7.46 (d, J=7.8 
Hz, 1H), 7.30-7.36 (m, 1H), 7.21-7.27 (m, 1H), 2.41-2.49 (m, 2H), 1.03 (d, J=6.8 Hz, 6H), 
0.88 (d, J=6.8 Hz, 6H). 13C NMR (CDCl3, 125 MHz)  (ppm) 137.4, 131.1, 131.0, 129.8, 
127.1, 122.7, 121.5, 58.0, 32.8, 19.0, 17.8. IR: 2970, 2837, 1593, 1562, 1472, 1416, 1390, 
1374, 1173, 1096, 1077, 996, 782, 719, 699 cm–1. HRMS (DART-ESI+) calcd. for 
C12H19Br1N1: [M+H]+: 280.0701, found: 280.0698. 
The general procedure B was followed for the introduction of 
silyl group in 1.5 mmol scale (414 mg, 65%). 1H NMR (CDCl3, 
500 MHz)  7.50-7.52 (m, 1H), 7.49 (br. s, 1H), 7.45 (d, J=7.8 
Hz, 1H), 7.39-7.42 (m, 2H), 7.33-7.39 (m, 3H), 7.24-7.29 (m, 1H), 
4.92 (s, 2H), 2.36 (sept, J= 6.8 Hz, 2H), 1.37 (sept, J= 7.4 Hz, 2H), 1.10 (d, J=7.3 Hz, 6H), 
1.04 (d, J=7.3 Hz, 6H), 0.99 (d, J=6.8 Hz, 6H), 0.80 (d, J=6.8 Hz, 6H). 13C NMR (CDCl3, 
125 MHz)  141.4, 134.2, 134.0, 133.9, 133.7, 129.9, 128.5, 127.7, 127.1, 125.8, 122.1, 
65.6, 58.1, 32.6, 19.0, 17.8, 17.7, 17.5, 12.4. IR: 2966, 2865, 1463, 1389, 1098, 1068, 993, 
882, 791, 731, 712, 695, 671 cm–1. HRMS (DART-ESI+) calcd. for C27H40N1O1Si1: 
[M+H]+: 422.2879, found: 422.2887. 
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The general procedure A was followed for the dialkylation in 20 mmol 
scale (6.54 g, 70 %). 1H NMR (CDCl3, 500 MHz)  7.51 (br. s., 1H), 
7.41-7.46 (m, 1H), 7.31 (d, J=6.8 Hz, 1H), 7.22 (t, J=7.8 Hz, 1H), 
2.06-2.22 (m, 2H), 1.69-1.83 (m, 1H), 1.31-1.45 (m, 1H), 0.70-1.08 (m, 14H). 13C NMR 
(CDCl3, 125 MHz)  138.4, 138.3, 138.2, 131.0, 131.0, 130.9, 130.8, 129.8, 126.8, 122.7, 
122.7, 122.1, 122.0, 121.8, 58.4, 58.1, 57.9, 39.9, 39.8, 39.5, 39.4, 25.9, 25.6, 24.8, 24.4, 
15.1, 14.8, 13.9, 13.3, 12.5, 12.3, 12.3 IR: 2968, 2936, 2877, 1593, 1563, 1475, 1384, 1077, 
996, 785, 727, 700. cm–1. HRMS (DART-ESI+) calcd. for C16H23Br1N1: [M+H]+: 308.1014, 
found: 308.1016. 
The general procedure A was followed for silyl group 
introduction in 32.0 mmol scale (8.76 g, 85 %). 1H NMR (CDCl3, 
500 MHz)  7.47 (br. s., 1H), 7.44 (d, J=7.3 Hz, 1H), 7.35-7.42 
(m, 1H), 7.32 (t, J=7.3 Hz, 1H), 3.95 (t, J=2.9 Hz, 1H), 2.08-2.27 (m, 2H), 1.82-1.76 (m, 
0.5H), 1.30-1.48 (m, 0.5H), 1.17-1.29 (m, 2H), 0.74-1.10 (m, 27H). 13C NMR (CDCl3, 125 
MHz)  134.9, 134.9, 134.8, 134.7, 134.6, 134.5, 134.3, 129.1, 127.6, 127.6, 122.7, 122.6, 
122.4, 58.5, 58.2, 58.0, 40.0, 39.7, 39.4, 39.3, 26.1, 25.7, 25.0, 24.4, 18.8, 18.8, 18.6, 18.6, 
15.1, 14.7, 13.8, 13.1, 12.6, 12.6, 12.4, 12.4, 10.9, 10.8. IR: 2962, 2939, 2863, 2102, 1461, 
1396, 1384, 1003, 880, 804, 783, 711, 657 cm–1. HRMS (DART-ESI+) calcd. for 
C22H38N1Si1: [M+H]+: 344.2774, found: 344.2768. 
The general procedure A was followed for chlorination in 25.4 
mmol scale (8.5 g, 89%). 1H NMR (CDCl3, 500 MHz)  7.50-
7.57 (m, 2H), 7.42-7.50 (m, 1H), 7.39 (t, J=7.8 Hz, 1H), 2.05-
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2.29 (m, 2H), 1.72-1.87 (m, 1H), 1.25-1.49 (m, 3H), 0.68-1.11 (m, 26H). 13C NMR (CDCl3, 
125 MHz)  135.2, 135.0, 135.0, 133.8, 133.8, 133.8, 133.4, 132.4, 130.1, 127.9, 127.9, 
122.4, 122.2, 58.5, 58.3, 58.1, 40.0, 39.7, 39.4, 39.3, 26.2, 25.7, 25.1, 24.4, 17.2, 17.1, 16.9, 
15.1, 14.7, 14.0, 13.9, 13.8, 13.1, 12.6, 12.5, 12.4, 12.4. IR: 2962, 2868, 1463, 1384, 1123, 
994, 882, 794, 751, 711, 672, 636, 529 cm–1. HRMS (DART-ESI+) calcd. for 
C22H40Cl1N2Si1: [M+NH4]+: 395.2649, found: 395.2654. 
The general procedure A was followed for an introduction of 
alcohol in 5.0 mmol scale (2.0 g, 89%). 1H NMR (CDCl3, 500 
MHz)  7.48-7.53 (m, 2H), 7.45 (d, J=7.3 Hz, 1H), 7.38-7.42 (m, 
2H), 7.33-7.38 (m, 3H), 7.24-7.29 (m, 1H), 4.92 (s, 2H), 2.01-
2.21 (m, 2H), 1.69-1.82 (m, 1H), 1.21-1.43 (m, 3H), 0.68-1.12 (m, 26H). 13C NMR (CDCl3, 
125 MHz)  141.3, 134.9, 134.7, 134.7, 134.2, 134.0, 133.9, 133.6, 129.6, 128.5, 128.5, 
128.3, 127.7, 127.2, 127.1, 125.9, 125.9, 125.8, 122.7, 122.6, 122.4, 65.6, 65.6, 58.5, 58.3, 
58.1, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 25.0, 24.4, 17.7, 17.7, 17.5, 17.5, 15.1, 14.7, 13.8, 
13.1, 12.5, 12.5, 12.4, 12.4, 12.4, 12.4. IR: 2962, 2940, 2865, 1461, 1382, 1205, 1097, 
1068, 1027, 993, 881, 809, 795, 749, 730, 713, 695, 680, 669, 496 cm–1. HRMS (DART-
ESI+) calcd. for C29H44N1O1Si1: [M+H]+: 450.3192, found: 450.3200. 
The general procedure A was followed for the dialkylation in 10.0 
mmol scale (955 mg, 27%). 1H NMR (CDCl3, 500 MHz)  7.49 (br. 
s, 1H), 7.41-7.46 (m, 1H), 7.27-7.31 (m, 1H), 7.22 (t, J=7.8 Hz, 1H), 
2.07 (tt, J=11.9, 3.0 Hz, 2H), 1.92 (d, J=12.7 Hz, 2H), 1.76-1.86 (m, 2H), 1.69-1.76 (m, 
2H), 1.64 (d, J=13.2 Hz, 2H), 1.54 (d, J=12.2 Hz, 2H), 1.25-1.35 (m, 2H), 1.14-1.25 (m, 
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2H), 0.98-1.12 (m, 4H), 0.88-0.98 (m, 2H). 13C NMR (CDCl3, 100 MHz)  138.1, 131.0, 
130.9, 129.8, 126.8, 122.7, 122.1, 57.4, 41.9, 29.2, 27.9, 26.6, 26.3. IR: 2930, 2853, 1592, 
1564, 1476, 1447, 1414, 1313, 1078, 996, 889, 800, 780, 743, 714, 695, 667 cm–1. HRMS 
(DART-ESI+) calcd. for C20H27Br1N1: [M+H]+: 360.1327, found: 360.1336. 
The general procedure B was followed for the introduction of 
silyl group in 1.5 mmol scale (650 mg, 86%). 1H NMR (CDCl3, 
400 MHz)  7.45-7.51 (m, 2H), 7.43 (d, J=7.8 Hz, 1H), 7.37-
7.41 (m, 2H), 7.31-7.37 (m, 3H), 7.22-7.28 (m, 1H), 4.91 (s, 
2H), 1.96-2.06 (m, 2H), 1.88 (d, J=12.5 Hz, 2H), 1.75 (d, 
J=13.3 Hz, 2H), 1.62 (t, J=15.7 Hz, 4H), 1.45 (d, J=12.5 Hz, 2H), 1.36 (sept, J=7.3 Hz, 
2H), 1.18-1.31 (m, 2H), 0.85-1.13 (m, 20H). 13C NMR (CDCl3, 100 MHz)  141.4, 134.7, 
134.0, 133.9, 133.4, 129.8, 128.5, 127.7, 127.2, 125.8, 122.6, 65.6, 57.4, 41.8, 29.2, 27.9, 
26.6, 26.4, 17.7, 17.5, 12.4. IR: 2930, 2855, 1450, 1098, 1067, 993, 882, 805, 785, 730, 
714, 694, 667, 493 cm–1. HRMS (DART-ESI+) calcd. for C33H48N1O1Si1: [M+H]+: 
502.3505, found: 502.3510. 
The biphasic mixture of 2-(3-bromophenyl)-acetonitrile (1.0 eq., 10 
mmol, 1.96 g) and 1,2-dibromoethane (1.5 eq., 1.3 mL) in toluene/water 
(0.5 M) was vigorously stirred for 4 h at room temperature. After dilution with water, the 
mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. A flash chromatography on 
silica gel gave the product as yellowish oil (959 mg, 43%). 1H NMR (CDCl3, 500 MHz)  
7.36-7.48 (m, 2H), 7.17-7.31 (m, 2H), 1.70-1.78 (m, 2H), 1.38-1.44 (m, 2H). 13C NMR 
98 
 
(CDCl3, 125 MHz)  138.5, 131.0, 130.6, 129.0, 124.8, 123.2, 122.1, 18.6, 13.8. IR: 2958, 
2236, 1596, 1566, 1478, 1424, 1073, 949, 876, 780, 718, 687 cm–1. HRMS (DART-ESI+) 
calcd. for C10H9Br1N1: [M+H]+: 221.9918, found: 221.9921. 
The general procedure B was followed for the introduction of silyl group in 1.5 mmol scale 
(478 mg, 88%). 1H NMR (CDCl3, 500 MHz)  7.44-7.51 (m, 1H), 7.31-7.43 (m, 7H), 7.24-
7.31 (m, 1H), 4.89 (s, 2H), 1.64 - 1.70 (m, 2H), 1.31-1.41 (m, 2H), 1.24-1.31 (m, 2H), 1.10 
(dd, J=7.3, 1.5 Hz, 6H), 1.04 (dd, J=7.6, 1.7 Hz, 6H). 13C NMR 
(CDCl3, 125 MHz)  141.3, 135.6, 135.4, 134.0, 131.5, 128.5, 
128.4, 127.3, 127.2, 126.0, 122.8, 65.7, 18.3, 17.7, 17.5, 14.0, 12.4. 
IR: 2944, 2865, 2236, 1462, 1377, 1097, 1068, 993, 882, 789, 733, 
703, 672, 578, 491 cm–1. HRMS (DART-ESI+) calcd. for C23H30N1O1Si1: [M+H]+: 
364.2097, found: 364.2104. 
The same procedure was followed with 1-(3-
bromophenyl)cyclopropane-1-carbonitrile except using 1,4-
dibromobutane. Product as yellowish oil (1.98 mg, 79%). 1H NMR (CDCl3, 500 MHz)  
7.54-7.62 (m, 1H), 7.45 (dd, J=7.8, 1.0 Hz, 1H), 7.40 (dd, J=7.8, 1.0 Hz, 1H), 7.25 (t, J=7.8 
Hz, 1H), 2.40-2.55 (m, 2H), 2.00-2.11 (m, 4H), 1.84-2.00 (m, 2H). 13C NMR (CDCl3, 125 
MHz)  142.3, 131.2, 130.6, 129.4, 125.0, 124.0, 123.2, 47.7, 40.7, 24.4. IR: 2965, 2876, 
2233, 1592, 1566, 1476, 1418, 1078, 996, 878, 782, 691 cm–1. HRMS (DART-ESI+) calcd. 
for C12H13Br1N1: [M+H]+: 250.0231, found: 250.0228. 
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The general procedure B was followed for the introduction of 
silyl group in 1.5 mmol scale (512 mg, 87 %). 1H NMR (CDCl3, 
500 MHz)  7.55-7.58 (m, 1H), 7.47-7.52 (m, 2H), 7.33-7.42 (m, 
5H), 7.24-7.29 (m, 1H), 4.90 (s, 2H), 2.35-2.45 (m, 2H), 1.89-
2.03 (m, 4H), 1.79-1.89 (m, 2H), 1.36 (sept, J= 7.5 Hz, 2H), 1.10 (d, J= 7.5 Hz, 6H), 1.05 
(d, J= 7.5 Hz, 6H). 13C NMR (CDCl3, 100 MHz)  141.4, 139.2, 135.4, 134.1, 132.0, 128.5, 
128.3, 127.4, 127.2, 126.0, 124.7, 65.7, 47.9, 40.6, 24.4, 17.7, 17.5, 12.4. IR: 2945, 2865, 
1453, 1378, 1096, 1068, 993, 882, 794, 732, 707, 492 cm–1. HRMS (DART-ESI+) calcd. 
for C25H34N1O1Si1: [M+H]+: 392.2410, found: 392.2402. 
The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using 2-methylbenzyl alcohol (461 
mg, 99 %). 1H NMR (CDCl3, 500 MHz)  7.55-7.65 (m, 1H), 
7.40-7.55 (m, 3H), 7.36 (t, J= 7.8 Hz, 1H), 7.26 (t, J= 7.3 Hz, 
1H), 7.20 (t, J= 7.1 Hz, 1H), 7.15 (d, J=7.3 Hz, 1H), 4.88 (s, 2H), 2.20-2.27 (m, 3H), 1.99-
2.17 (m, 2H), 1.67-1.80 (m, 1H), 1.22-1.46 (m, 3H), 0.73-1.14 (m, 26H). 13C NMR (CDCl3, 
125 MHz)  139.1, 134.9, 134.7, 134.7, 134.3, 133.9, 133.8, 133.5, 130.0, 129.6, 127.7, 
127.7, 127.1, 127.1, 127.0, 126.1, 126.1, 126.0, 125.9, 125.8, 122.7, 122.5, 122.4, 63.9, 
58.5, 58.3, 58.0, 39.8, 39.6, 39.2, 39.2, 26.1, 25.6, 24.9, 24.3, 18.7, 18.6, 18.6, 17.7, 17.7, 
17.6, 17.6, 15.1, 14.7, 13.7, 13.1, 12.5, 12.5, 12.4, 12.3, 12.3. IR: 2939, 2865, 1462, 1383, 
1122, 1083, 993, 881, 812, 745, 712, 669, 594, 494 cm–1. HRMS (DART- ESI+) calcd. for 
C30H46N1O1Si1: [M+H]+: 464.3349, found: 464.3332. 
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 The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using 2-bromobenzyl alcohol (484 
mg, 92%). 1H NMR (CDCl3, 500 MHz)  7.76 (d, J=8.3 Hz, 
1H), 7.42-7.53 (m, 4H), 7.34-7.42 (m, 2H), 7.15 (td, J=7.3, 
1.0 Hz, 1H), 4.89 (s, 1H), 2.00-2.16 (m, 2H), 1.70-1.77 (m, 1H), 1.21-1.46 (m, 3H), 1.72-
1.15 (m, 26H). 13C NMR (CDCl3, 125 MHz)  140.2, 135.0, 134.8, 134.8, 133.9, 133.9, 
133.8, 133.8, 133.8, 133.5, 132.3, 129.8, 128.5, 128.5, 128.5, 127.8, 127.8, 127.7, 127.5, 
127.4, 122.6, 122.5, 122.4, 121.1, 65.5, 58.5, 58.3, 58.0, 39.8, 39.6, 39.3, 39.2, 26.0, 25.6, 
24.9, 24.3, 17.7, 17.7, 17.5, 17.5, 15.1, 14.7, 13.7, 13.2, 12.5, 12.5, 12.5, 12.4, 12.4, 12.4, 
12.3. IR: 2963, 2865, 1463, 1383, 1203, 1120, 1097, 1026, 993, 881, 813, 749, 712, 669, 
620, 449 cm–1. HRMS (DART- ESI+) calcd. for C29H43Br1N1O1Si1: [M+H]+: 528.2297, 
found: 528.2292. 
 The general procedure A was followed for an introduction 
of alcohol in 1.0 mmol scale using 2-methoxybenzyl 
alcohol (478 mg, 99 %). 1H NMR (CDCl3, 500 MHz)  7.68 
(d, J=6.8 Hz, 1H), 7.42-7.54 (m, 3H), 7.35 (t, J=7.3 Hz, 1H), 
7.25 (td, J=7.7, 1.7 Hz, 1H), 7.03 (t, J=7.3 Hz, 1H), 6.84 (d, J=7.8 Hz, 1H), 4.90-4.95 (m, 
2H), 3.76-3.81 (m, 3H), 1.99-2.16 (m, 2H), 1.71-1.78 (m, 1H), 1.21-1.45 (m, 3H), 0.71-
1.14 (m, 26H). 13C NMR (CDCl3, 100 MHz)  156.0, 134.7, 134.6, 134.6, 134.4, 134.4, 
134.3, 133.9, 133.9, 133.4, 129.9, 129.8, 129.8, 127.8, 127.7, 127.7, 127.7, 126.4, 126.3, 
126.2, 122.7, 122.6, 122.4, 120.7, 109.6, 61.1, 61.0, 58.5, 58.2, 58.0, 55.2, 39.8, 39.6, 39.2, 
39.1, 26.1, 25.6, 24.9, 24.3, 17.7, 17.7, 17.6, 17.5, 15.1, 14.7, 13.7, 13.0, 12.5, 12.4, 12.4. 
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IR: 2940, 2865, 1491, 1462, 1382, 1239, 1122, 1085, 882, 752, 712, 669, 494 cm–1. HRMS 
(DART- ESI+) calcd. for C30H46N1O2Si1: [M+H]+: 480.3298, found: 480.3278. 
The general procedure A was followed for an introduction of 
alcohol in 3.0 mmol scale using 3-methylbenzyl alcohol (1.32 
g, 95%). 1H NMR (CDCl3, 500 MHz)  7.48-7.53 (m, 2H), 
7.43-7.48 (m, 1H), 7.36 (t, J=7.8 Hz, 1H), 7.25 (t, J=7.8 Hz, 
1H), 7.17-7.23 (m, 2H), 7.08 (d, J=7.3 Hz, 1H), 4.88 (s, 2H), 2.37 (s, 3H), 2.02-2.18 (m, 
2H), 1.68-1.83 (m, 1H), 1.24-1.48 (m, 3H), 0.79-1.12 (m, 26H). 13C NMR (CDCl3, 125 
MHz)  141.3, 138.0, 134.8, 134.7, 134.7, 134.3, 134.0, 133.9, 133.5, 129.7, 128.5, 128.4, 
128.4, 127.9, 127.7, 126.6, 126.5, 123.0, 123.0, 122.9, 122.7, 122.6, 122.4, 65.6, 65.6, 58.5, 
58.3, 58.1, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 25.0, 24.4, 21.7, 17.7, 17.7, 17.5, 17.5, 15.1, 
14.7, 13.8, 13.1, 12.5, 12.5, 12.4, 12.4, 12.3. IR: 2964, 2866, 1462, 1383, 1157, 1104, 993, 
882, 815, 771, 713, 669, 495 cm–1. HRMS (DART-ESI+) calcd. for C30H46N1O1Si1: 
[M+H]+: 464.3349, found: 464.3363. 
 The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using 3-fluorobenzyl alcohol (462 
mg, 99%). 1H NMR (CDCl3, 500 MHz)  7.40-7.53 (m, 3H), 
7.36 (t, J=7.3 Hz, 1H), 7.28-7.33 (m, 1H), 7.10-7.17 (m, 2H), 
6.95 (td, J=8.6, 2.4 Hz, 1H), 4.89 (s, 2H), 2.03-2.18 (m, 2H), 1.70-1.77 (m, 1H), 1.24-1.43 
(m, 3H), 0.71-1.12 (m, 26H). 13C NMR (CDCl3, 100 MHz)  164.5, 162.1, 144.2, 144.1, 
135.0, 134.8, 134.8, 133.9, 133.9, 133.8, 133.5, 130.0, 129.9, 129.8, 127.8, 122.6, 122.5, 
122.4, 121.2, 121.2, 121.2, 121.1, 121.1, 114.0, 113.8, 112.9, 112.8, 112.6, 112.6, 65.0, 
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64.9, 64.9, 58.5, 58.3, 58.0, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 24.9, 24.4, 17.7, 17.6, 17.5, 
17.5, 15.1, 14.7, 13.7, 13.1, 12.5, 12.5, 12.4, 12.3, 12.3. IR: 2963, 2866, 1592, 1462, 1383, 
1253, 1136, 1101, 1065, 993, 924, 881, 779, 713, 682, 496 cm–1. HRMS (DART-ESI+) 
calcd. for C29H43F1N1O1Si1: [M+H]+: 468.3098, found: 468.3094. 
 The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using 3-chlorobenzyl alcohol (475 
mg, 98%). 1H NMR (CDCl3, 500 MHz)  7.43-7.65 (m, 3H), 
7.40 (s, 1H), 7.36 (t, J = 7.0, 1H), 7.22-7.32 (m, 3H), 4.88 (s, 
2H), 1.98-2.20 (m, 2H), 1.69-1.82 (m, 1H), 1.24-1.44(m, 3H), 0.68-1.12 (m, 26H). 13C 
NMR (CDCl3, 125 MHz)  143.5, 143.5, 135.0, 134.9, 134.8, 134.5, 133.9, 133.9, 133.5, 
129.8, 129.8, 127.8, 127.3, 126.0, 125.9, 123.9, 123.9, 123.8, 122.5, 122.4, 64.9, 64.9, 58.5, 
58.3, 58.1, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 25.0, 24.4, 17.7, 17.6, 17.5, 17.5, 15.1, 14.7, 
13.8, 13.1, 12.5, 12.5, 12.4, 12.3. IR: 2963, 2940, 2866, 1600, 1462, 1384, 1200, 1108, 994, 
882, 810, 775, 681, 496 cm–1. HRMS (DART-ESI+) calcd. for C29H43Cl1N1O1Si1: [M+H]+: 
484.2802, found: 484.2791. 
 The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using 3-bromobenzyl alcohol (464 
mg, 88 %). 1H NMR (CDCl3, 500 MHz)  7.56 (s, 1H), 7.42-
7.53 (m, 3H), 7.40 (d, J=8.3 Hz, 1H), 7.36 (t, J=7.8 Hz, 1H), 
7.31 (d, J=7.8 Hz, 1H), 7.22 (t, J=7.8 Hz, 1H), 4.87 (s, 2H), 2.00-2.23 (m, 2H), 1.70-1.77 
(m, 1H), 1.24-1.44 (m, 3H), 0.73-1.12 (m, 26H). 13C NMR (CDCl3, 125 MHz)  143.7, 
143.7, 135.0, 134.9, 134.8, 133.9, 133.8, 133.5, 130.2, 130.1, 129.9, 128.9, 128.8, 127.8, 
103 
 
124.4, 124.4, 124.3, 122.7, 122.6, 122.5, 122.4, 64.8, 64.8, 58.5, 58.3, 58.1, 39.9, 39.7, 
39.3, 39.2, 26.1, 25.7, 25.0, 24.4, 17.7, 17.6, 17.5, 17.5, 15.1, 14.7, 13.8, 13.1, 12.5, 12.5, 
12.4, 12.3, 12.3. IR: 2963, 2865, 1571, 1461, 1383, 1197, 1107, 993, 881, 810, 772, 712, 
681, 495 cm–1. HRMS (DART-ESI+) calcd. for C29H43Br1N1O1Si1: [M+H]+: 528.2297, 
found: 528.2296. 
 The general procedure A was followed for an introduction 
of alcohol in 1.0 mmol scale using 3-trifluoromethylbenzyl 
alcohol (508 mg, 98 %). 1H NMR (CDCl3, 500 MHz)  7.66 
(s, 1H), 7.58 (d, J = 7.8, 1H), 7.53 (d, J =7.8, 1H), 7.42-7.51 
(m, 4H), 7.36 (t, J = 7.8, 1H), 4.95 (s, 2H), 2.02-2.18 (m, 2H), 1.70 - 1.80 (m, 1H), 1.24-
1.44 (m, 3H), 1.68-1.13 (m, 26H). 13C NMR (CDCl3, 125 MHz)  142.3, 135.0, 134.9, 
134.8, 133.9, 133.8, 133.5, 131.0, 130.7, 129.8, 129.1, 129.0, 127.8, 125.8, 124.0, 124.0, 
123.1, 122.6, 122.6, 122.4, 65.0, 65.0, 58.5, 58.3, 58.1, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 
25.0, 24.4, 17.7, 17.6, 17.5, 17.5, 15.1, 14.7, 13.7, 13.0, 12.5, 12.5, 12.4, 12.3. IR: 2965, 
2942, 2867, 1463, 1330, 1164, 1126, 1073, 882, 793, 702, 495 cm–1. HRMS (DART-ESI+) 
calcd. for C30H43F3N1O1Si1: [M+H]+: 518.3066, found: 518.3087. 
The general procedure A was followed for an introduction 
of alcohol in 1.0 mmol scale using 3-methoxybenzyl 
alcohol (400 mg, 83%). 1H NMR (CDCl3, 500 MHz)  
7.40-7.59 (m, 3H), 7.35 (t, J = 7.8, 1H), 7.26 (t, J = 7.8, 1H), 
7.00 (s, 1H), 6.95 (d, J = 7.8, 1H), 6.81 (dd, J = 7.8, 2.9, 1H), 4.89 (s, 2H), 3.82 (s, 3H), 
1.99-2.23 (m, 2H), 1.65-1.80 (m, 1H), 1.22-1.44 (m, 3H), 1.69-1.12 (m, 26H). 13C NMR 
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(CDCl3, 125 MHz)  160.1, 143.1, 134.9, 134.8, 134.7, 134.2, 134.0, 133.9, 133.5, 129.8, 
129.5, 127.7, 122.6, 122.4, 118.1, 118.1, 117.9, 112.6, 112.6, 112.5, 111.5, 111.4, 111.2, 
65.5, 65.4, 58.5, 58.3, 58.1, 55.4, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 24.9, 24.4, 17.7, 17.7, 
17.5, 17.5, 15.1, 14.7, 13.7, 13.1, 12.5, 12.5, 12.4, 12.4, 12.3. IR: 2962, 2940, 2866, 1603, 
1462, 1383, 1283, 1152, 1105, 882, 795, 713, 690, 496 cm–1. HRMS (DART-ESI+) calcd. 
for C30H46N1O2Si1: [M+H]+: 480.3298, found: 480.3296. 
 The general procedure A was followed for an introduction 
of alcohol in 1.0 mmol scale using 3-
(hydroxymethyl)phenyl acetate (339 mg, 67%).1H NMR 
(CDCl3, 500 MHz)  7.46-7.54 (m, 2H), 7.44 (d, J=5.9 Hz, 
1H), 7.32-7.39 (m, 2H), 7.25 (d, J=7.8 Hz, 1H), 7.13 (s, 1H), 6.99 (d, J=8.3 Hz, 1H), 4.90 
(s, 2H), 2.30 (s, 3H), 2.05-2.19 (m, 2H), 1.69-1.82 (m, 1H), 1.23-1.44 (m, 4H), 0.79-1.11 
(m, 26H). 13C NMR (CDCl3, 100 MHz)  169.6, 151.0, 143.2, 143.2, 134.9, 134.8, 134.7, 
134.0, 133.9, 133.9, 133.6, 129.7, 129.4, 127.8, 123.2, 123.1, 122.6, 122.5, 122.4, 120.3, 
119.0, 118.9, 65.1, 58.5, 58.2, 58.0, 39.9, 39.6, 39.3, 39.2, 26.1, 25.6, 25.0, 24.3, 21.4, 17.6, 
17.6, 17.5, 17.5, 15.1, 14.7, 13.7, 13.0, 12.5, 12.5, 12.3, 12.3. IR: 2963, 2940, 2866, 1768, 
1462, 1369, 1204, 1139, 1102, 1072, 881 cm–1. HRMS (DART- ESI+) calcd. for 
C31H46N1O3Si1: [M+H]+: 508.3247, found: 508.3245. 
The general procedure A was followed for an 
introduction of alcohol in 1.0 mmol scale using methyl 
3-(hydroxymethyl)benzoate (476 mg, 94%). 1H NMR 
(CDCl3, 500 MHz)  8.04 (s, 1H), 7.95 (d, J = 7.3, 1H), 
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7.64 (d, J =7.3, 1H), 7.41-7.54 (m, 4H), 7.35 (t, J = 8.3, 1H), 4.94 (s, 2H), 3.92 (s, 3H), 
2.01-2.16 (m, 2H), 1.70-1.79 (m, 1H), 1.24-1.42 (m, 3H), 0.68-1.13 (m, 26H). 13C NMR 
(CDCl3, 125 MHz)  167.3, 141.8, 141.8, 134.9, 134.8, 134.8, 134.0, 133.9, 133.6, 130.5, 
130.5, 130.4, 129.8, 128.7, 128.5, 127.8, 127.1, 127.0, 122.6, 122.5, 122.4, 65.2, 65.2, 58.5, 
58.3, 58.0, 52.3, 39.9, 39.7, 39.3, 39.2, 26.1, 26.7, 25.0, 24.6, 17.7, 17.6, 17.5, 17.5, 15.1, 
14.7, 13.7, 13.1, 12.5, 12.5, 12.4, 12.3. IR: 2963, 2942, 2866, 1725, 1462, 1287, 1200, 
1106, 882, 747, 496 cm–1. HRMS (DART-ESI+) calcd. for C31H46N1O3Si1: [M+H]+: 
508.3247 found: 508.3253. 
The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using 4-methylbenzyl alcohol (350 mg, 
76%). 1H NMR (CDCl3, 500 MHz)  7.48-7.56 (m, 2H), 7.46 (d, 
J=7.3 Hz, 1H), 7.36 (t, J=7.3 Hz, 1H), 7.30 (d, J=7.8 Hz, 2H), 
7.17 (d, J=7.8 Hz, 2H), 4.88 (s, 2H), 2.36 (s, 3H), 2.04-2.19 (m, 
2H), 1.75-1.81 (m, 1H), 1.24-1.45 (m, 3H), 0.73-1.12 (m, 26H). 13C NMR (CDCl3, 125 
MHz)  138.3, 136.7, 136.6, 134.8, 134.7, 134.7, 134.3, 134.3, 134.0, 133.9, 133.6, 129.6, 
129.2, 129.1, 127.7, 127.7, 126.0, 126.0, 125.8, 122.7, 122.6, 122.4, 65.5, 65.5, 58.5, 58.3, 
58.0, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 24.9, 24.4, 21.3, 17.7, 17.7, 17.5, 17.5, 15.1, 14.7, 
13.8, 13.1, 12.5, 12.5, 12.4, 12.4, 12.3. IR: 2940, 2865, 1462, 1383, 1092, 993, 881, 793, 
749, 713, 669, 615, 479 cm–1. HRMS (DART-ESI+) calcd. for C30H46N1O1Si1: [M+H]+: 
464.3349, found: 464.3343. 
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The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using 4-bromolbenzyl alcohol (526 
mg, 99%). 1H NMR (CDCl3, 500 MHz)  7.46-7.55 (m, 4H), 
7.44 (d, J= 7.3 Hz, 1H), 7.35 (t, J= 7.3 Hz, 1H), 7.28 (d, J= 8.8 
Hz, 2H), 4.85 (s, 2H), 2.05-2.17 (m, 2H), 1.70-1.77 (m, 1H), 
1.25-1.44 (m, 3H), 0.70-1.11 (m, 26H). 13C NMR (CDCl3, 125 MHz)  140.4, 140.3, 134.9, 
134.8, 134.8, 134.0, 133.9, 133.8, 133.7, 131.6, 129.6, 127.8, 127.7, 127.7, 127.6, 127.5, 
122.6, 122.5, 122.3, 120.9, 65.0, 65.0, 58.5, 58.3, 58.0, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 
24.9, 24.4, 17.7, 17.6, 17.5, 17.5, 15.1, 14.7, 13.8, 13.1, 12.5, 12.5, 12.4, 12.3. IR: 2962, 
2865, 1486, 1462, 1383, 1098, 1010, 881, 795, 712, 670, 606, 505 cm–1. HRMS (DART- 
ESI+) calcd. for C29H43Br1N1O1Si1: [M+H]+: 528.2297, found: 528.2292. 
The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using 4-methoxybenzyl alcohol (431 
mg, 90%). 1H NMR (CDCl3, 500 MHz)  7.47 - 7.54 (m, 2H), 
7.45 (d, J=6.8 Hz, 1H), 7.35 (t, J=7.3 Hz, 1H), 7.32 (d, J=8.8 Hz, 
2H), 6.90 (d, J=8.8 Hz, 2H), 4.85 (s, 2H), 3.82 (s, 3H), 2.03 - 
2.19 (m, 2H), 1.71 - 1.84 (m, 1H), 1.24 - 1.47 (m, 3H), 0.71 - 1.11 (m, 26H). 13C NMR 
(CDCl3, 100 MHz)  158.9, 134.8, 134.7, 134.6, 134.4, 134.3, 134.3, 134.0, 133.9, 133.6, 
133.5, 129.6, 127.7, 127.4, 127.3, 127.2, 122.7, 122.6, 122.4, 113.9, 65.3, 65.3, 58.5, 58.2, 
58.0, 55.5, 55.4, 39.9, 39.7, 39.3, 39.2, 26.1, 25.6, 24.9, 24.4, 17.7, 17.6, 17.5, 17.5, 15.1, 
14.7, 13.8, 13.1, 12.5, 12.5, 12.4, 12.3. IR: 2940, 2865, 1613, 1512, 1462, 1382, 1300, 
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1246, 1169, 1091, 1037, 881, 820, 745, 713, 669, 500 cm–1. HRMS (DART- ESI+) calcd. 
for C30H46N1O2Si1: [M+H]+: 480.3298, found: 480.3291. 
The general procedure A was followed for an introduction 
of alcohol in 1.0 mmol scale using 1-naphthylmethanol (478 
mg, 96 %). 1H NMR (CDCl3, 500 MHz)  7.86-7.96 (m, 2H), 
7.80 (d, J = 8.3, 1H), 7.76 (d, J = 6.8, 1H), 7.41-7.56 (m, 6H), 
7.35 (t, J = 6.8, 1H), 5.38 (s, 2H), 1.95-2.10 (m, 2H), 1.65-1.75 (m, 1H), 1.36-1.49 (m, 2H), 
1.18-1.32 (m, 1H), 0.63-1.17 (m, 26H). 13C NMR (CDCl3, 125 MHz)  136.6, 134.9, 134.8, 
134.7, 134.2, 134.0, 133.9, 133.9, 133.7, 133.5, 130.7, 130.6, 129.8, 128.9, 128.9, 127.8, 
127.8, 127.7, 127.7, 126.2, 126.1, 125.8, 125.7, 125.7, 123.5, 123.3, 123.1, 123.1, 123.0, 
122.7, 122.6, 122.4, 64.1, 64.0, 58.5, 58.2, 58.0, 39.8, 39.6, 39.2, 39.1, 26.0, 25.6, 24.9, 
24.3, 17.8, 17.7, 17.6, 17.6, 15.0, 14.7, 13.6, 13.0, 12.5, 12.5, 12.4, 12.3. IR: 3051, 2962, 
2940, 2865, 1462, 1384, 1167, 920, 792, 713, 670, 488 cm–1. HRMS (DART-ESI+) calcd. 
for C33H46N1O1Si1: [M+H]+: 500.3349, found: 500.3356. 
The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using α-methyl-3-methylbenzyl 
alcohol (437 mg, 92%). 1H NMR (CDCl3, 500 MHz)  7.37-
7.52 (m, 3H), 7.31 (t, J = 7.3 Hz, 1H), 7.15-7.23 (m, 3H), 7.05 
(d, J = 7.3 Hz, 1H), 4.98 (q, J=6.0 Hz, 1H), 2.35 (s, 3H), 1.98-2.17 (m, 2H), 1.70-1.81 (m, 
1H), 1.49 (d, J=6.4 Hz, 3H), 1.21-1.43 (m, 3H), 0.68-1.08 (m, 26H). 13C NMR (CDCl3, 
100Hz)  159.8, 159.8, 159.8, 148.8, 148.7, 134.9, 134.8, 134.7, 134.6, 134.5, 133.9, 133.9, 
133.6, 129.6, 129.4, 129.4, 127.5, 127.5, 122.7, 122.6, 122.5, 117.9, 117.8, 117.8, 112.5, 
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112.4, 112.4, 112.3, 111.1, 111.0, 111.0, 110.8, 71.7, 71.6, 71.6, 58.5, 58.3, 58.3, 58.1, 
55.3, 40.0, 39.9, 39.7, 39.6, 39.3, 39.2, 39.2, 39.1, 28.0, 26.2, 26.1, 25.7, 25.6, 25.0, 25.0, 
24.4, 17.6, 17.6, 17.5, 17.4, 17.4, 15.1, 15.1, 14.7, 14.7, 13.8, 13.7, 13.1, 12.6, 12.5, 12.5, 
12.5, 12.5, 12.5, 12.4, 12.4, 12.3. IR: 2965, 2865, 1462, 1383, 1161, 1092, 1037, 994, 882, 
703, 667, 598, 504 cm–1. HRMS (DART- ESI+) calcd. for C31H48N1O1Si1: [M+H]+: 
478.3505, found: 478.3513. 
The general procedure A was followed for an introduction of 
alcohol in 1.0 mmol scale using α-methyl-3-bromobenzyl 
alcohol (541 mg, 99%). 1H NMR (CDCl3, 500 MHz)  7.53 
(s, 1H), 7.39-7.50 (m, 3H), 7.37 (d, J = 7.8 Hz, 1H), 7.27-7.35 
(m, 2H), 7.16-7.22 (m, 1H), 4.97 (m, 1H), 1.97-2.21 (m, 2H), 1.68-1.85 (m, 1H), 1.48 (d, 
J = 6.4 Hz, 3H), 1.24-1.45 (m, 3H), 0.67 1.08 (m, 26H). 13C NMR (CDCl3, 100 MHz)  
149.4, 149.3, 134.8, 134.7, 134.6, 134.6, 134.5, 134.5, 133.9, 133.8, 133.7, 130.2, 130.1, 
129.5, 128.6, 128.6, 128.6, 127.6, 124.1, 124.0, 124.0, 122.7, 122.6, 122.4, 71.2, 71.1, 71.1, 
58.5, 58.3, 58.3, 58.1, 40.0, 39.9, 39.7, 39.7, 39.4, 39.2, 39.2, 39.2, 27.9, 26.2, 26.1, 25.7, 
25.6, 25.0, 25.0, 24.4, 17.5, 17.5, 17.5, 17.5, 17.4, 17.4, 17.4, 15.1, 14.7, 14.7, 13.8, 13.7, 
13.1, 12.6, 12.6, 12.5, 12.5, 12.5, 12.4, 12.4, 12.4, 12.4, 12.4. IR: 2965, 2866, 1570, 1463, 
1383, 1200, 1117, 1094, 1034, 994, 960, 882, 818, 786, 712, 695, 667, 504 cm–1. HRMS 
(DART-ESI+) calcd. for C30H45Br1N1O1Si1: [M+H]+: 542.2454, found: 542.2471. 
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The general procedure A was followed for an introduction 
of alcohol in 1.0 mmol scale using α-methyl-3-
methoxybenzyl alcohol (492 mg, 99%). 1H NMR (CDCl3, 
500 MHz)  7.37-7.51 (m, 3H), 7.31 (t, J = 7.3 Hz, 1H), 
7.23 (td, J = 7.8, 1.5 Hz, 1H), 6.98 (s, 1H), 6.90-6.96 (m, 1H), 6.78 (dd, J = 7.8, 2.4 Hz, 
1H), 5.00 (q, J = 6.4 Hz, 1H), 3.80 (s, 3H), 1.99-2.19 (m, 2H), 1.69-1.82 (m, 1H), 1.50 (d, 
J = 6.4 Hz, 3H), 1.20-1.44 (m, 3H), 0.77-1.07 (m, 26H). 13C NMR (CDCl3, 100Hz)  146.9, 
137.9, 137.8, 135.0, 134.9, 134.7, 134.5, 134.5, 133.9, 133.9, 133.6, 129.5, 128.3, 127.8, 
127.8, 127.5, 127.5, 126.1, 126.1, 126.1, 122.7, 122.6, 122.5, 122.5, 122.5, 122.4, 71.8, 
71.8, 71.7, 58.5, 58.3, 58.3, 58.1, 40.0, 39.9, 39.6, 39.4, 39.2, 39.2, 39.2, 28.0, 26.2, 26.2, 
25.7, 25.6, 25.1, 25.0, 24.4, 24.4, 21.7, 17.6, 17.5, 17.5, 17.5, 17.4, 17.4, 15.1, 14.7, 14.7, 
13.8, 13.7, 13.1, 12.6, 12.5, 12.5, 12.5, 12.5, 12.5, 12.4, 12.4, 12.4. IR: 2964, 2866, 1602, 
1462, 1383, 1256, 1157, 1092, 1036, 994, 968, 881, 782, 713, 698, 667, 504 cm–1. HRMS 
(DART-ESI+) calcd. for C31H48N1O2Si1: [M+H]+: 494.3454, found: 494.3464. 
 
C-H Activation: 
General procedure for C-H activation reaction ( 
Table 1.7): 
To a 4 mL vial, substrate (0.1 mmol), 2.2 mg Pd(OAc)2 (0.1 eq., 0.01 mmol), 2.3 mg acetyl 
glycine (0.2 eq., 0.02 mmol), 36.0 mg AgOAc (2.0 eq., 0.2 mmol) were measured in glove 
box. The reaction vial was taken out from glove box and 16 μL olefin (1.5 eq., 0.15 mmol), 
1.0 mL 1,2-dichloroethane were added. The reaction mixture was heated at 90 oC for 24 h 
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with a screw cap. The silver and palladium precipitates were removed by filtering through 
a short pad of celite and washed with ethyl acetate. The solvent was evaporated under 
reduced pressure and column chromatography on silica gel gave the product as sticky oil. 
Determination of regioselectivity: 
Regioselectivity was determined by 1H NMR experiment based on known chemical shifts 
for 2-, 3-, and 4- substituted free benzyl alcohol.46 
 16.8 mg, 36%, o:m:p=7:81:12. 1H NMR (CDCl3, 500 
MHz)  7.72 (d, J = 16.1 Hz, 1H), 7.63-7.66 (m, 1H), 
7.58 (s, 1H), 7.51-7.55 (m, 2H), 7.38-7.48 (m, 4H), 6.46 
(d, J = 16.1 Hz, 1H), 4.93 (s, 2H), 4.30 (q, J = 7.2 Hz, 
2H), 1.68 (s, 6H), 1.37-1.43 (m, 2H), 1.37 (t, J = 7.1 Hz, 3H), 1.13 (d, J = 7.3 Hz, 6H), 
1.08 (d, J = 7.3 Hz, 6H). 13C NMR (CDCl3, 100 MHz)  167.2, 144.9, 142.1, 140.9, 135.4, 
134.7, 134.2, 131.1, 129.1, 128.5, 128.0, 126.9, 126.5, 125.6, 124.7, 118.6, 65.4, 60.7, 37.4, 
29.3, 17.7, 17.5, 14.6, 12.3. IR: 2942, 2865, 1711, 1637, 1462, 1367, 1308, 1265, 1160, 
1103, 991, 882, 792, 707, 678, 490 cm–1. HRMS (DART-ESI+) calcd. for 
C28H37N1O3Na1Si1: [M+H]+: 486.2435, found: 486.2438. 
18.4 mg, 38%, o:m:p=6:88:6. 1H NMR (CDCl3, 500 
MHz)  7.73 (d, J=16.1 Hz, 1H), 7.57 (s, 1H), 7.50 - 
7.54 (m, 2H), 7.38 - 7.48 (m, 5H), 6.47 (d, J=16.1 Hz, 
                                                 
46 Ortho: Xia, W., Shao, Y., Gui, W. & Yang, C. Chem. Commun. 2011, 11098–11100. Meta: Kurita, T.; 
Aoki, F.; Mizumoto, T.; Maejima, T.; Esaki, H.; Maegawa, T.; Monguchi, Y.; Sajiki, H. Chem. Eur. J. 2008, 
14, 3371–3379. Para: Hirono, Shuichi; Shiozawa, Shunichi. EP1445249 A1, 2004 
111 
 
1H), 4.93 (s, 2H), 4.30 (q, J=7.2 Hz, 2H), 1.94 - 2.04 (m, 2H), 1.79 - 1.86 (m, 2H), 1.34 - 
1.44 (m, 2H), 1.37 (t, J=7.1 Hz, 3H), 1.13 (d, J=7.3 Hz, 6H), 1.07 (d, J=7.3 Hz, 6H), 0.89 
(t, J=7.6 Hz, 6H). 13C NMR (CDCl3, 125 MHz)  167.2, 144.8, 142.1, 137.4, 134.9, 134.7, 
134.0, 132.0, 129.1, 128.4, 127.9, 127.8, 126.9, 125.6, 122.5, 118.6, 65.3, 60.7, 49.9, 33.9, 
17.7, 17.5, 14.5, 12.3, 9.8. IR: 2938, 2864, 1711, 1637, 1461, 1308, 1264, 1176, 1159, 
1129, 1103, 1081, 1041, 991, 882, 786, 708, 674 cm–1. HRMS (DART-ESI+) calcd. for 
C30H41N1O3Si1: [M+H]+: 514.2748, found: 514.2754. 
20.1 mg, 39%, o:m:p=4:90:6. 1H NMR (CDCl3, 500 
MHz)  7.70 (d, J = 15.7 Hz, 1H), 7.56 (s, 1H), 7.46-
7.51 (m, 2H), 7.41-7.46 (m, 2H), 7.41 (s, 1H), 7.34-
7.40 (m, 2H), 6.44 (d, J = 15.7 Hz, 1H), 4.91 (s, 2H), 
4.27 (q, J = 7.2 Hz, 2H), 2.34 (sept, J = 6.7 Hz, 2H), 1.30-1.43 (m, 5H), 1.10 (d, J = 7.3 
Hz, 6H), 1.04 (d, J = 7.3 Hz, 6H), 0.97 (d, J = 6.8 Hz, 6H), 0.78 (d, J = 6.8 Hz, 6H). 13C 
NMR (CDCl3, 125 MHz)  167.2, 144.8, 142.2, 134.7, 134.0, 133.9, 133.8, 133.7, 130.0, 
129.1, 127.8, 127.8, 126.9, 125.5, 122.1, 118.5, 65.2, 60.7, 58.1, 32.6, 19.0, 17.8, 17.7, 
17.6, 14.6, 12.4. IR: 2966, 2941, 2865, 1713, 1638, 1463, 1369, 1308, 1264, 1176, 1160, 
1102, 1082, 882, 810, 789, 712 cm–1. HRMS (DART-ESI+) calcd. for C32H46N1O3Si1: 
[M+H]+: 520.3247, found: 520.3246. 
29.6 mg, 54%, o:m:p=2:96:2. 1H NMR (CDCl3, 500 
MHz)  7.70 (d, J = 16.1 Hz, 1H), 7.55 (s, 1H), 7.47-
7.51 (m, 2H), 7.42-7.47 (m, 2H), 7.41 (s, 1H), 7.32-
7.40 (m, 2H), 6.44 (d, J = 16.1 Hz, 1H), 4.91 (s, 2H), 
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4.27 (q, J = 7.3 Hz, 2H), 1.98-2.19 (m, 2H), 1.65-1.82 (m, 1H), 1.19-1.43 (m, 6H), 069-
1.12 (m, 26H). 13C NMR (CDCl3, 100 MHz)  167.2, 144.8, 142.2, 142.1, 134.9, 134.8, 
134.8, 134.7, 134.0, 134.0, 133.9, 133.9, 133.5, 129.8, 129.1, 127.9, 127.8, 127.8, 127.8, 
127.8, 126.9, 126.9, 126.9, 125.6, 125.5, 125.4, 122.6, 122.5, 122.4, 118.5, 65.3, 60.7, 58.5, 
58.3, 58.0, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 25.0, 24.4, 17.7, 17.7, 17.5, 17.5, 15.1, 14.7, 
14.6, 13.8, 13.1, 12.5, 12.5, 12.4, 12.4, 12.4. IR: 2963, 2866, 1713, 1638, 1462, 1383, 1308, 
1264, 1159, 1103, 992, 882, 792, 713, 681, 496 cm–1. HRMS (DART-ESI+) calcd. for 
C34H50N1O3Si1: [M+H]+: 548.3560, found: 548.3567. 
20.3 mg, 31%, mm:others=85:15 (structure and 
regioselectivity were confirmed after deprotection). 1H 
NMR (CDCl3, 500 MHz)  7.67 (d, J = 16.1 Hz, 2H), 
7.56 (s, 1H), 7.54 (s, 2H), 6.48 (d, J = 16.1 Hz, 2H), 4.75 (d, J = 4.9 Hz, 2H), 4.27 (q, J = 
7.0 Hz, 4H), 1.84 (t, J = 5.9 Hz, 1H), 1.34 (t, J = 7.1 Hz, 6H). 13C NMR (CDCl3, 125 MHz) 
 166.9, 143.7, 142.6, 135.7, 127.8, 127.1, 119.8, 64.7, 60.9, 14.5. IR: 3454, 2924, 1708, 
1637, 1463, 1443, 1391, 1367, 1306, 1286, 1267, 1177, 1164, 1095, 1036, 981, 852 cm–1. 
HRMS (DART-ESI+) calcd. for C17H21O5: [M+H]+: 305.1389, found: 305.1396. 
25.1 mg, 42 %, o:m:p=6:90:4. 1H NMR (CDCl3, 
500 MHz)  7.70 (d, J = 16.1 Hz, 1H), 7.56 (s, 1H), 
7.49 (d, J = 7.3 Hz, 1H), 7.33-7.46 (m, 6H), 6.44 
(d, J = 16.1 Hz, 1H), 4.91 (s, 2H), 4.27 (q, J = 6.8 
Hz, 2H), 1.96-2.04 (m, 2H), 1.88 (d, J = 12.7 Hz, 
2H), 1.75 (d, J = 12.2 Hz, 2H), 1.56-1.68 (m, 4H), 1.45 (d, J = 12.2 Hz, 2H), 1.30-1.42 (m, 
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5H), 1.15-1.30 (m, 2H), 0.83-1.13 (m, 20H). 13C NMR (CDCl3, 100 MHz)  167.2, 144.8, 
142.2, 134.8, 134.7, 133.9, 133.7, 133.4, 129.8, 129.1, 127.8, 127.7, 126.9, 125.4, 122.6, 
118.6, 65.2, 60.7, 57.4, 41.9, 29.2, 27.9, 26.6, 26.3, 17.7, 17.5, 14.6, 12.4. IR: 2931, 2857, 
1714, 1462, 1450, 1307, 1264, 1176, 1159, 1100, 1069, 992, 882, 806, 786, 730, 715, 667, 
493 cm–1. HRMS (DART-ESI+) calcd. for C38H54N1O3Si1: [M+H]+: 600.3873, found: 
600.3858. 
20.0 mg, 43%, o:m:p=6:81:13. 1H NMR (CDCl3, 500 
MHz)  7.70 (d, J = 16.1 Hz, 1H), 7.54 (s, 1H), 7.43-
7.49 (m, 2H), 7.32-7.43 (m, 5H), 6.44 (d, J = 16.1 Hz, 
1H), 4.89 (s, 2H), 4.27 (q, J = 7.2 Hz, 2H), 1.65-1.70 
(m, 2H), 1.31-1.41 (m, 5H), 1.27-1.31 (m, 2H), 1.10 (d, J = 7.8 Hz, 6H), 1.04 (d, J = 7.8 
Hz, 6H). 13C NMR (CDCl3, 125 MHz)  167.2, 144.8, 142.1, 135.4, 134.8, 134.0, 131.6, 
129.1, 128.5, 128.3, 128.0, 127.2, 127.0, 125.6, 122.8, 118.6, 65.4, 60.7, 18.4, 17.7, 17.5, 
14.6, 14.1, 12.3. IR: 2942, 2865, 1712, 1637, 1637, 1462, 1367, 1308, 1265, 1177, 1103, 
882, 787, 704 cm–1. HRMS (DART-ESI+) calcd. for C28H36N1O3Si1: [M+H]+: 462.2464, 
found: 462.2454. 
17.1 mg, 35 %, o:m:p=5:86:9. 1H NMR (CDCl3, 500 
MHz)  7.70 (d, J = 16.1 Hz, 1H), 7.56 (d, J = 2.0 Hz, 
1H), 7.55 (s, 1H), 7.45-7.52 (m, 2H), 7.41-7.45 (m, 
1H), 7.35-7.41 (m, 3H), 6.44 (d, J = 16.1 Hz, 1H), 
4.90 (s, 2H), 4.27 (q, J = 7.0 Hz, 2H), 2.33-2.46 (m, 2H), 1.90-2.06 (m, 4H), 1.79-1.90 (m, 
2H), 1.29-1.42 (m, 5H), 1.11 (d, J = 7.3 Hz, 6H), 1.05 (d, J = 7.3 Hz, 6H). 13C NMR (CDCl3, 
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100 MHz)  167.2, 144.8, 142.1, 139.3, 135.2, 134.7, 134.1, 131.9, 129.1, 128.4, 127.9, 
127.5, 126.9, 125.6, 124.6, 118.6, 65.3, 60.7, 47.9, 40.7, 24.4, 17.7, 17.5, 14.6, 12.4. IR: 
2943, 2865, 1710, 1637, 1461, 1366, 1307, 1174, 1157, 1097, 1080, 886, 788, 681, 490 
cm–1. HRMS (DART-ESI+) calcd. for C30H40N1O3Si1: [M+H]+: 490.2777, found: 
490.2800. 
 
General procedure for C-H activation reaction (Table 1.8 and Table 1.9): 
To a 4 mL vial, substrate (0.1 mmol), 2.2 mg Pd(OAc)2 (0.1 eq., 0.01 mmol), 2.3 mg acetyl 
glycine (0.2 eq., 0.02 mmol), 50.0 mg AgOAc (3.0 eq., 0.3 mmol) were measured in glove 
box. The reaction vial was taken out from glove box and 16 μL olefin (1.5 eq., 0.15 mmol), 
50 μL 1,1,1,3,3,3-hexafluoro-2-propanol, and 1.0 mL 1,2-dichloroethane were added. The 
reaction mixture was heated at 90 oC for 24 h with a screw cap. The silver and palladium 
precipitates were removed by filtering through a short pad of Celite and washed with ethyl 
acetate. The solvent was evaporated under reduced pressure and column chromatography 
on silica gel gave the product as sticky oil.  
Deprotection procedure: 
After filter off solid residues, the reaction mixture was concentrated and re-dissolved in 3.0 
mL tetrahydrofuran. 0.2 mL of 1.0 M tetrabutylammonium fluoride in THF was subjected 
and the reaction mixture was stirred for 1h at room temperature. The solvent was 
evaporated and purification using column chromatography on silica gel gave the product. 
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Determination of regioselectivity: 
Structure of 1.129a′ to 1.129c′ and 1.129l′ to 1.129n′ was confirmed by 1D NOE 
experiments. 
Structure of 1.129d to 1.129k, 1.129p to 1.129r, 1.130a to 1.130d, was confirmed by 
observation of at least 2 singlets in aromatic region (if necessary, after deprotection). 
Structure of 1.129o was determined by observation of 2 singlets in aromatic region after 
deprotection. 
Stereochemistry of 1.130d was confirmed by 2D NOESY experiment. 
11.3 mg, 51 %, m:others=95:5 (structure and regioselectivity were 
confirmed after deprotection). 1H NMR (CDCl3, 500 MHz)  7.66 
(d, J = 16.1 Hz, 1H), 7.55 (s, 1H), 7.36 (dd, J = 7.8, 2.0 Hz, 1H), 
7.18 (d, J = 7.8 Hz, 1H), 6.42 (d, J = 16.1 Hz, 1H), 4.71 (s, 2H), 4.25 (q, J = 7.0 Hz, 2H), 
2.36 (s, 3H), 1.45 (br. s, 1H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  167.4, 
144.7, 139.5, 138.8, 132.6, 131.1, 127.6, 127.1, 117.7, 63.4, 60.7, 18.9, 14.5. IR: 3412, 
2979, 1707, 1634, 1415, 1391, 1367, 1317, 1270, 1228, 1201, 1177, 1160, 1123, 1095, 
1037, 983, 819 cm–1. HRMS (DART-ESI+) calcd. for C13H17O3: [M+H]+: 221.1178, found: 
221.1178. 
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9.0 mg, 28%, mm:others=92:8 (structure and 
regioselectivity were confirmed after deprotection). 1H 
NMR (acetone-d6, 500 MHz)  8.01 (d, J = 15.7 Hz, 1H), 
7.65 (d, J = 16.1 Hz, 1H), 7.60 (s, 2H), 6.46 (d, J = 15.7 
Hz, 1H), 6.35 (d, J = 15.7 Hz, 1H), 4.75 (s, 2H), 4.21-4.32 (m, 4H), 2.40 (s, 3H), 1.79 (br. 
s, 1H), 1.31-1.38 (m, 6H). 13C NMR (CDCl3, 100 MHz)  167.1, 166.9, 143.9, 142.2, 140.4, 
137.9, 135.3, 132.6, 128.3, 126.1, 121.3, 118.7, 63.7, 60.9, 60.8, 15.0, 14.5. IR: 3445, 2925, 
1709, 1635, 1464, 1367, 1268, 1177, 1135, 1094, 1036, 981, 856 cm–1. HRMS (DART-
ESI+) calcd. for C18H23O5: [M+H]+: 319.1546, found: 319.1545. 
13.0 mg, 46%, m:others=97:3 (structure and regioselectivity 
were confirmed after deprotection). 1H NMR (CDCl3, 500 MHz) 
 7.67 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 16.1 Hz, 1H), 7.55 (d, J = 
8.3 Hz, 1H), 7.30 (dd, J = 8.3, 2.4 Hz, 1H), 6.46 (d, J = 16.1 Hz, 
1H), 4.77 (s, 2H), 4.26 (q, J = 7.3 Hz, 2H), 2.04 (br. s, 1H), 1.34 (t, J = 7.1 Hz, 3H). 13C 
NMR (CDCl3, 125 MHz)  166.9, 143.4, 140.6, 134.3, 133.3, 128.4, 128.1, 124.3, 119.5, 
64.9, 60.9, 14.5. IR: 3410, 2927, 1710, 1637, 1467, 1406, 1315, 1268, 1215, 1179, 1021, 
982, 864 cm–1. HRMS (DART-ESI+) calcd. for C12H14Br1O3: [M+H]+: 285.0126, found: 
285.0133. 
10.0 mg, 26%, mm:others=80:20 (structure and 
regioselectivity were confirmed after deprotection). 1H 
NMR (CDCl3, 500 MHz)  8.08 (d, J = 16.1 Hz, 1H), 
7.71 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 16.1 Hz, 1H), 7.61-
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7.63 (m, 1H), 6.51 (d, J = 16.1 Hz, 1H), 6.40 (d, J = 16.1 Hz, 1H), 4.80 (d, J = 4.9 Hz, 2H), 
4.24-4.33 (m, 4H), 2.11 (t, J = 6.1 Hz, 1H), 1.32-1.37 (m, 6H). 13C NMR (CDCl3, 100 
MHz)  166.7, 166.4, 142.9, 142.7, 142.0, 136.1, 134.3, 128.4, 126.4, 126.3, 122.5, 120.2, 
65.1, 61.1, 61.0, 14.5. IR: 3446, 2925, 1711, 1637, 1268, 1179, 1094, 1072, 1035, 980, 860 
cm–1. HRMS (DART-ESI+) calcd. for C17H20Br1O5: [M+H]+: 383.0494, found: 383.0496. 
13.5 mg, 57%, m:others=94:6 (structure and regioselectivity 
were confirmed after deprotection). 1H NMR (CDCl3, 500 MHz) 
 7.63 (d, J = 15.7 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.43 (dd, 
J  = 8.6, 2.2 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 6.32 (d, J = 15.7 
Hz, 1H), 4.69 (s, 2H), 4.24 (q, J = 7.3 Hz, 2H), 3.89 (s, 3H), 2.24 (br. s, 1H), 1.32 (t, J = 
7.1 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  167.5, 159.2, 144.3, 129.9, 129.7, 128.2, 127.4, 
116.3, 110.6, 61.8, 60.6, 55.8, 14.5. IR: 3435, 2933, 1702, 1631, 1604, 1499, 1463, 1442, 
1423, 1392, 1368, 1301, 1250, 1210, 1177, 1160, 1124, 1095, 982, 859, 813, cm–1. HRMS 
(DART-ESI+) calcd. for C13H17O4: [M+H]+: 237.1127, found: 237.1131. 
29.5 mg, 54%, m:others=95:5. 1H NMR (CDCl3, 600 
MHz)  7.67 (d, J = 15.8 Hz, 1H), 7.41-7.52 (m, 3H), 
7.36 (t, J = 7.6 Hz, 2H), 7.25 (s, 1H), 7.22 (s, 1H), 
6.42 (d, J = 15.8 Hz, 1H), 4.87 (s, 2H), 4.26 (q, J = 
7.0 Hz, 2H), 2.38 (s, 3H), 1.99-2.15 (m, 2H), 1.68-1.83 (m, 1H), 1.33 (t, J = 7.0 Hz, 3H), 
1.21-1.41 (m, 3H), 0.69-1.12 (m, 26H). 13C NMR (CD3OD, 125 MHz)  168.7, 146.4, 
146.4, 143.5, 140.2, 136.2, 136.0, 136.0, 136.0, 135.9, 135.9, 135.3, 135.1, 134.9, 130.9, 
129.9, 129.9, 129.8, 128.9, 128.9, 128.9, 128.8, 128.8, 128.7, 123.9, 123.8, 123.7, 123.4, 
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123.3, 119.1, 119.1, 66.3, 61.8, 59.8, 59.5, 59.3, 41.0, 40.8, 40.4, 40.3, 27.3, 26.9, 26.1, 
25.6, 21.6, 18.1, 18.1, 18.1, 18.1, 17.9, 15.5, 15.2, 14.8, 14.3, 13.7, 13.5, 13.5, 13.5, 12.8, 
12.7, 12.5. IR: 2939, 2865, 1713, 1638, 1462, 1383, 1264, 1158, 1101, 983, 881, 848, 795, 
713, 680, 495 cm–1. HRMS (DART-ESI+) calcd. for C35H52N1O3Si1: [M+H]+: 562.3716, 
found: 562.3692. 
16.5 mg, 75%, m:others=95:5. 1H NMR (CDCl3, 500 MHz)  7.65 
(d, J = 16.1 Hz, 1H), 7.33 (s, 1H), 7.26 (s, 1H), 7.20 (s, 1H), 6.43 
(d, J = 15.7 Hz, 1H), 4.68 (s, 2H), 4.25 (q, J = 7.3 Hz, 2H), 2.37 (s, 
3H), 1.80 (br s. 1H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3, 
125 MHz)  167.2, 144.7, 141.7, 139.1, 134.9, 129.8, 128.3, 123.9, 118.6, 65.2, 60.7, 21.5, 
14.5. IR: 3401, 2923, 1707, 1636, 1446, 1392, 1367, 1325, 1305, 1257, 1177, 1163, 1095, 
1039, 981, 848 cm–1. HRMS (DART-ESI+) calcd. for C13H17O3: [M+H]+: 221.1178, found: 
221.1179. 
40.9 mg, 72%, mm:others=86:14. 1H NMR (CDCl3, 
500 MHz)  7.63 (d, J = 16.1 Hz, 1H), 7.42-7.51 (m, 
3H), 7.36 (t, J = 7.8 Hz, 1H), 7.28 (s, 1H), 7.16 (d, 
J = 9.3 Hz, 1H), 7.12 (d, J = 9.3 Hz, 1H), 6.42 (d, J 
= 16.1 Hz, 1H), 4.89 (s, 2H), 4.27 (q, J = 7.3 Hz, 1H), 2.01-2.19 (m, 2H), 1.70-1.77 (m, 
1H), 1.21-1.44 (m, 3H), 1.34 (t, J = 7.3 Hz, 3H), 0.75 (m, 26H). 13C NMR (CDCl3, 100 
MHz)  166.8, 164.7, 162.2, 144.8, 144.8, 143.5, 143.5, 136.8, 136.7, 135.0, 134.9, 134.9, 
133.9, 133.8, 133.7, 133.6, 129.8, 127.9, 122.6, 122.5, 122.3, 121.3, 121.3, 121.3, 121.2, 
121.2, 120.0, 119.9, 114.7, 114.6, 114.5, 114.4, 113.0, 113.0, 112.8, 64.7, 64.7, 60.9, 58.5, 
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58.3, 39.9, 39.7, 39.3, 39.3, 26.1, 25.7, 25.0, 24.4, 17.6, 17.5, 17.5, 17.5, 14.7, 15.1, 14.5, 
13.8, 13.1, 12.5, 12.5, 12.4, 12.3. IR: 2940, 2866, 1715, 1641, 1592, 1462, 1368, 1272, 
1177, 1099, 981, 881, 852, 795, 713, 671 cm–1. HRMS (DART-ESI+) calcd. for 
C34H49F1N1O3Si1: [M+H]+: 566.3466, found: 566.3438. 
45.2 mg, 78%, mm:others=91:9. 1H NMR (CDCl3, 
500 MHz)  7.61 (d, J =15.7, 1H), 7.34-7.51 (m, 
7H), 6.43 (d, J = 15.7, 1H), 4.87 (s, 2H), 4.27 (q, J 
= 7.3, 2H), 2.03-2.19 (m, 2H), 1.70-1.80 (m, 1H), 
1.25-1.42 (m, 3H), 1.34 (t, J = 7.1, 3H), 0.68-1.13 (m, 26H). 13C NMR (CDCl3, 125 MHz) 
 166.8, 144.1, 144.1, 143.2, 136.4, 135.2, 135.0, 134.9, 134.9, 133.9, 133.6, 133.6, 129.9, 
128.0, 128.0, 127.5, 127.4, 126.5, 126.4, 123.7, 123.6, 122.6, 122.5, 122.3, 120.0, 64.7, 
64.6, 60.9, 58.5, 58.3, 58.0, 39.9, 39.7, 39.3, 39.2, 26.1, 25.7, 25.0, 24.4, 17.7, 17.6, 17.6, 
17.5, 17.5, 14.7, 15.1, 14.5, 13.8, 13.0, 12.5, 12.5, 12.3, 12.3. IR: 2962, 2940, 2866, 1714, 
1640, 1575, 1462, 1367, 1267, 1176, 1096, 881, 851, 713, 671, 495 cm–1. HRMS (DART-
ESI+) calcd. for C34H48NO3NaSiCl: [M+Na]+: 604.2984, found: 604.2984. 
The structure of regioisomer was confirmed after deprotection. 
1H NMR (CD3OD, 500 MHz)  7.65 (d, J = 16.1, 1H), 7.54 (s, 
1H), 7.52 (s, 1H), 7.43 (s, 1H), 6.58 (d, J = 16.1, 1H), 4.64 (s, 
2H), 4.27 (q, J = 7.2, 2H), 1.35 (t, J = 7.3, 3H). 13C NMR (CD3OD, 
125 MHz)  168.4, 146.3, 144.5, 137.9, 136.1, 129.5, 127.7, 125.8, 120.9, 64.2, 61.9, 14.7. 
IR: 3411, 2981, 2932, 2872, 1706, 1639, 1574, 1435, 1368, 1316, 1178, 1036, 979, 850, 
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672, 639, 593 cm–1. HRMS (DART-ESI+) calcd. for C12H13O3Na1Cl1: [M+Na]+: 263.0445, 
found: 263.0454. 
39.2 mg, 63%, m:others=91:9. 1H NMR (CDCl3, 
500 MHz)  7.60 (d, J=15.7Hz, 1H), 7.57 (s, 1H), 
7.55 (s, 1H), 7.41 - 7.50 (m, 4H), 7.37 (t, J=7.3 Hz, 
1H), 6.42 (d, J=16.1 Hz, 1H), 4.87 (s, 2H), 4.27 (q, 
J=7.3 Hz, 2H), 2.01 - 2.17 (m, 2H), 1.67 - 1.80 (m, 1H), 1.34 (t, J=7.3 Hz, 3H), 1.26 - 1.43 
(m, 3H), 0.72 - 1.12 (m, 26H). 13C NMR (CDCl3, 100 MHz)  166.7, 144.3, 143.1, 136.7, 
135.0, 134.9, 134.9, 133.9, 133.6, 133.5, 130.4, 130.4, 130.2, 130.0, 129.4, 129.4, 129.4, 
127.9, 124.1, 124.1, 124.0, 123.2, 122.6, 122.5, 122.3, 120.0, 64.6, 58.5, 58.3, 58.0, 39.9, 
39.7, 39.3, 39.2, 17.6, 17.6, 17.5, 17.5, 14.5, 15.1, 14.7, 13.8, 13.1, 12.6, 12.5, 12.3, 12.3). . 
IR: 2963, 2939, 2866, 1715, 1639, 1461, 1383, 1367, 1312, 1267, 1177, 1113, 1096, 1040, 
992, 980, 881, 796, 712, 670 cm–1. HRMS (DART-ESI+) calcd. for C34H49Br1N1O3Si1: 
[M+H]+: 626.2665, found: 626.2679. 
30.9 mg, 50%, m:others=97:3. 1H NMR (CD3OD, 
500 MHz)  7.90 (s, 1H), 7.84 (s, 1H), 7.81 (s, 1H), 
7.77 (d, J =16.1, 1H), 7.56 (d, J = 6.8, 2H), 7.49 (br 
s, 1H), 7.45 (t, J = 6.8, 1H), 6.64 (dt, J = 15.8, 1.7, 
1H), 5.05 (s, 2H), 4.28 (q, J = 6.8, 2H), 2.02-2.22 (m, 2H), 1.68-1.80 (m, 1H), 1.25-1.50 
(m, 3H), 1.35 (t, J = 6.8, 3H), 0.64-1.20 (m, 26H). 13C NMR (CDCl3, 125 MHz)  166.6, 
143.3, 143.0, 135.6, 135.0, 134.9, 133.9, 133.6, 131.9, 131.6, 129.9, 128.4, 128.3, 127.9, 
125.1, 124.1, 124.0, 123.4, 123.3, 123.0, 122.4, 122.3, 120.5, 64.7, 61.0, 58.5, 58.3, 58.0, 
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56.7, 39.9, 39.7, 39.3, 39.2, 26.1, 25.6, 25.0, 24.4, 17.6, 17.6, 17.6, 17.5, 17.5, 14.7, 15.1, 
14.5, 13.7, 13.0, 12.5, 12.5, 12.4, 12.3. IR: 2963, 2941, 2867, 1715, 1643, 1463, 1368, 
1216, 1156, 1127, 882, 795, 696, 496 cm–1. HRMS (DART-ESI+) calcd. for 
C35H48N1O3F3Na1Si1: [M+Na]+: 638.3248, found: 638.3252. 
41.1 mg, 71 %, m:others=87:13. 1H NMR (CDCl3, 
500 MHz)  7.65 (d, J = 16.1, 1H), 7.41-7.52 (m, 
3H), 7.36 (t, J = 7.3, 1H), 7.12 (s, 1H), 7.02 (s, 1H), 
6.95 (s, 1H), 6.42 (d, J = 16.1, 1H), 4.88 (s, 2H), 
4.26 (q, J = 7.3, 2H), 3.84 (s, 3H), 2.00-2.17 (m, 2H), 1.69-1.79 (m, 1H), 1.20-1.42 (m, 
3H), 1.34 (t, J = 7.1, 3H), 0.67-1.15 (m, 26H). 13C NMR (CDCl3, 125 MHz)  167.2, 160.3, 
144.8, 143.7, 135.9, 134.9, 134.8, 134.8, 133.9, 133.5, 129.8, 127.8, 122.6, 122.5, 122.4, 
118.8, 118.2, 118.2, 118.1, 113.7, 113.6, 113.5, 111.7, 111.6, 111.5, 65.2, 65.1, 60.7, 58.5, 
58.3, 58.0, 55.5, 39.9, 39.7, 39.3, 39.2, 26.1, 25.6, 24.9, 24.4, 17.7, 17.7, 17.5, 17.5, 14.7, 
15.1, 14.5, 13.7, 13.1, 12.5, 12.5, 12.4, 12.4, 12.3. IR: 2962, 2939, 2866, 1712, 1593, 1461, 
1278, 1163, 1103, 882, 810, 713, 495 cm–1. HRMS (DART-ESI+) calcd. for 
C35H51N1O4Na1Si1: [M+Na]+: 600.3480 found: 600.3481. 
44.5 mg, 73%, m:others=78:22. 1H NMR (CDCl3, 
500 MHz)  7.65 (d, J = 16.1 Hz, 1H), 7.40 - 7.51 
(m, 3H), 7.39 (s, 1H), 7.36 (t, J = 7.8 Hz, 1H), 7.16 
(s, 2H), 6.42 (d, J = 16.1 Hz, 1H), 4.89 (s, 2H), 4.26 
(q, J = 7.3 Hz, 2H), 2.31 (s, 3H), 2.01-2.18 (m, 2H), 1.72-1.77 (m, 1H), 1.34 (t, J = 7.3 Hz, 
3H), 1.27-1.44 (m, 3H), 0.76-1.14 (m, 26H). 13C NMR (CDCl3, 100 MHz)  169.4, 166.9, 
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151.4, 143.8, 143.8, 138.1, 135.0, 134.9, 134.8, 133.9, 133.8, 133.3, 129.8, 127.8, 123.0, 
122.9, 122.6, 122.5, 122.4, 120.8, 120.8, 119.6, 119.5, 64.8, 60.8, 58.5, 58.3, 58.1, 39.9, 
39.7, 39.3, 39.2, 26.2, 25.7, 25.0, 24.4, 21.4, 17.6, 17.6, 17.5, 17.5, 14.5, 15.1, 14.7, 13.8, 
13.1, 12.5, 12.5, 12.4, 12.3. IR: 2962, 2940, 2866, 1770, 1714, 1639, 1462, 1368, 1269, 
1200, 1177, 1139, 1101, 1037, 993, 881, 713 cm–1. HRMS (DART-ESI+) calcd. for 
C36H52N1O5Si1: [M+H]+: 606.3615, found: 606.3614. 
45.5 mg, 75%, m:others=91:9. 1H NMR (CDCl3, 
500 MHz)  8.12 (s, 1H), 8.04 (s, 1H), 7.76 (s, 1H), 
7.72 (d, J =16.1, 1H), 7.41-7.52 (m, 3H), 7.36 (t, J 
= 7.8, 1H), 6.52 (d, J = 16.1, 1H), 4.94 (s, 2H), 4.28 
(q, J = 6.8, 2H), 3.94 (s, 3H), 2.01-2.18 (m, 2H), 1.69-1.80 (m, 1H), 1.20-1.42 (m, 3H), 
1.34 (t, J = 7.1, 3H), 0.66 - 1.16 (m, 26H). 13C NMR (CDCl3, 125 MHz)  166.9, 166.7, 
143.7, 142.7, 142.7, 135.2, 135.0, 134.9, 134.9, 133.9, 133.7, 131.2, 129.7, 129.6, 128.6, 
128.5, 127.9, 127.8, 122.6, 122.5, 122.3, 119.9, 64.9, 60.9, 58.5, 58.3, 58.0, 52.5, 39.9, 
39.7, 39.3, 39.2, 26.1, 25.7, 25.0, 24.4, 17.7, 17.7, 17.5, 17.5, 14.7, 15.1, 14.5, 13.7, 13.1, 
12.5, 12.5, 12.4, 12.3. IR: 2961, 2941, 2866, 1716, 1641, 1461, 1266, 1212, 1160, 1097, 
982, 795, 713, 671, 497 cm–1. HRMS (DART-ESI+) calcd. for C36H51N1O5Na1Si1: 
[M+Na]+: 628.3429, found: 628.3434. 
10.1 mg, 46 %, m:others=91:9 (structure and regioselectivity were 
confirmed after deprotection). 1H NMR (CDCl3, 500 MHz)  7.96 
(d, J = 16.1 Hz, 1H), 7.56 (d, J = 1.5 Hz, 1H), 7.28 (dd, J=7.6, 1.7 
Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 6.39 (d, J = 15.7 Hz, 1H), 4.68 
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(s, 2H), 4.27 (q, J = 7.0 Hz, 2H), 2.43 (s, 3H), 1.69 (br. s, 1H), 1.34 (m, J = 14.7 Hz, 3H). 
13C NMR (CDCl3, 100 MHz)  167.2, 142.3, 139.1, 137.2, 133.8, 131.2, 128.8, 125.2, 
119.8, 65.1, 60.7, 19.7, 14.5. IR: 3431, 2926, 1708, 1632, 1611, 1495, 1446, 1391, 1367, 
1313, 1269, 1230, 1176, 1104, 1034, 980, 863, 822 cm–1. HRMS (DART-ESI+) calcd. for 
C13H17O3: [M+H]+: 221.1178, found: 221.1177. 
8.3 mg, 26 %, mm:others=91:9 (structure and 
regioselectivity were confirmed after deprotection). 1H 
NMR (CDCl3, 500 MHz)  8.03 (d, J = 16.1 Hz, 2H), 
7.54 (s, 2H), 6.34 (d, J = 16.1 Hz, 2H), 4.70 (s, 2H), 4.27 
(q, J = 7.3 Hz, 4H), 2.45 (s, 3H), 1.77 (br. s, 1H), 1.34 (t, J = 7.3 Hz, 6H). 13C NMR (CDCl3, 
125 MHz)  166.9, 142.5, 139.1, 136.0, 135.3, 126.9, 121.3, 64.8, 60.9, 14.5. IR: 3469, 
2924, 1709, 1629, 1449, 1391, 1367, 1311, 1264, 1174, 1095, 1068, 1031, 978, 929, 860 
cm–1. HRMS (DART-ESI+) calcd. for C18H23O5: [M+H]+: 319.1546, found: 319.1545. 
10.5 mg, 37%, m:others=84:16 (structure and regioselectivity were 
confirmed after deprotection). 1H NMR (CDCl3, 500 MHz)  8.03 
(d, J = 16.1 Hz, 1H), 7.61 (d, J = 2.4 Hz, 1H), 7.59 (d, J = 8.3 Hz, 
1H), 7.22 (dd, J = 8.3, 2.4 Hz, 1H), 6.41 (d, J = 16.1 Hz, 1H), 4.68 
(s, 2H), 4.28 (q, J = 7.2 Hz, 2H), 1.87 (br. s, 1H), 1.34 (t, J = 7.2 Hz, 1H). 13C NMR (CDCl3, 
100 MHz)  166.6, 143.0, 140.8, 134.8, 133.7, 129.8, 126.2, 124.4, 121.6, 64.5, 61.0, 14.5. 
IR: 3432, 2926, 1711, 1635, 1465, 1315, 1270, 1180, 1025, 980, 820 cm–1. HRMS (DART-
ESI+) calcd. for C12H14Br1O3: [M+H]+: 285.0126, found: 285.0127. 
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12.0 mg, 51%, m:others=98:2 (structure and regioselectivity were 
confirmed after deprotection). 1H NMR (CDCl3, 500 MHz)  7.96 
(d, J = 16.1 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.34 (dd, J = 8.3, 2.0 
Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 6.53 (d, J = 16.1 Hz, 1H), 4.63 (s, 
2H), 4.25 (q, J = 7.6 Hz, 2H), 3.88 (s, 3H), 1.79 (br. s, 1H), 1.33 (t, J = 7.6 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz)  167.7, 158.1, 139.9, 133.3, 130.5, 128.0, 123.6, 119.3, 111.5, 
64.9, 60.6, 55.9, 14.6. IR: 3399, 2932, 1701, 1628, 1497, 1463, 1367, 1310, 1269, 1247, 
1159, 1115, 1095, 1026, 985, 862, 813 cm–1. HRMS (DART-ESI+) calcd. for C13H17O4: 
[M+H]+: 237.1127, found: 237.1131. 
2.0 mg, 9%, mm:others=78:22 (structure and 
regioselectivity were confirmed after deprotection). 1H 
NMR (CDCl3, 500 MHz)  8.02 (d, J = 16.1 Hz, 2H), 7.54 
(s, 2H), 6.35 (d, J = 16.1 Hz, 2H), 4.70 (s, 2H), 4.28 (q, J  
= 7.3 Hz, 4H), 2.45 (s, 3H), 1.77 (br. s, 1H), 1.34 (t, J = 7.3 Hz, 6H). 13C NMR (CDCl3, 
125 MHz)  167.1, 157.7, 138.7, 137.4, 129.2, 128.2, 120.8, 64.6, 63.4, 60.9, 29.9, 14.5. 
IR: 3434, 2924, 2852, 1712, 1633, 1466, 1426, 1391, 1368, 1312, 1261, 1219, 1176, 1096, 
1038, 996, 863 cm–1. HRMS (DART-ESI+) calcd. for C18H23O6: [M+H]+: 335.1495, found: 
335.1496. 
(structure and regioselectivity were confirmed after 
deprotection). 1H NMR (CDCl3, 500 MHz)  7.82-
8.01 (m, 5H), 7.41-7.57 (m, 5H), 7.36 (t, J = 7.3, 
1H), 6.56 (dd, J = 16.1, 1.5, 1H), 5.35 (s, 2H), 4.30 
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(q, J = 7.2, 2H), 1.90-2.09 (m, 2H), 1.64-1.74 (m, 1H), 1.39-1.49 (m, 2H), 1.36 (t, J = 6.8, 
3H), 0.60-1.20 (m, 26H). 13C NMR (CDCl3, 125 MHz)  167.3, 145.0, 137.5, 135.0, 134.9, 
134.8, 133.9, 133.9, 133.8, 133.7, 133.7, 133.7, 133.4, 131.8, 131.6, 131.6, 131.5, 129.9, 
129.7, 129.7, 129.6, 127.9, 127.8, 127.5, 126.7, 123.2, 123.1, 123.0, 122.6, 122.5, 122.4, 
121.1, 121.0, 121.0, 118.6, 63.9, 63.8, 60.7, 58.5, 58.2, 58.0, 39.7, 39.6, 39.2, 39.2, 26.0, 
25.6, 24.8, 24.3, 17.8, 17.7, 17.7, 17.6, 17.6, 14.7, 15.0, 14.6, 13.6, 13.1, 12.5, 12.5, 12.5, 
12.4, 12.2. IR: 2962, 2939, 2866, 1711, 1635, 1462, 1306, 1265, 1174, 1114, 883, 750, 713, 
595, 497 cm–1. HRMS (DART-ESI+) calcd. for C38H51N1O3Na1Si1: [M+Na]+: 620.3530, 
found: 620.3536. 
13.7 mg, 53%, 3:others=96:4. 1H NMR (CDCl3, 500 MHz)  
8.06 (d, J = 8.3, 1H), 7.87 (d, J = 7.8, 1H), 7.85 (s, 1H), 7.81 (d, 
J = 16.1, 1H), 7.72 (s, 1H), 7.49-7.61 (m, 2H), 6.55 (d, J = 16.1, 
1H), 5.15 (s, 2H), 4.27 (q, J = 7.3, 2H), 2.08 (br s, 1H), 1.35 (t, 
J = 7.3, 3H). 13C NMR (CDCl3, 125 MHz)  167.3, 144.6, 137.4, 133.9, 132.2, 131.7, 130.5, 
129.6, 127.8, 126.9, 123.8, 122.7, 118.8, 63.7, 60.8, 14.6 IR: 3426, 2980, 2938, 1706, 1634, 
1368, 1308, 1268, 1177, 1038, 980, 853, 751, 617 cm–1. HRMS (DART-ESI+) calcd. for 
C16H16O3Na1: [M+Na]+: 279.0992, found: 279.0993. 
43.3 mg, 75%, m:others=97:3. 1H NMR (CDCl3, 500 
MHz)  7.66 (d, J = 16.1 Hz, 1H), 7.39-7.49 (m, 3H), 
7.34 (s, 1H), 7.32 (t, J = 7.8 Hz, 1H), 7.23 (s, 1H), 
7.20 (s, 1H), 6.42 (d, J = 16.1 Hz, 1H), 4.94-5.03 (m, 
1H), 4.26 (q, J = 7.2 Hz, 2H), 2.36 (s, 3H), 2.00-2.18 (m, 2H), 1.70-1.82 (m, 1H), 1.50 (d, 
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J = 6.4 Hz, 3H), 1.33 (t, J = 7.3 Hz, 3H), 1.22-1.42 (m, 3H), 0.76-1.07 (m, 26H). 13C NMR 
(CDCl3, 100 MHz)  167.3, 147.7, 145.1, 138.6, 138.6, 134.7, 134.7, 134.7, 134.6, 134.6, 
134.6, 134.5, 134.3, 133.9, 133.9, 133.9, 133.6, 129.5, 128.3, 128.3, 128.3, 127.8, 127.6, 
127.6, 127.6, 122.7, 122.6, 122.5, 122.4, 122.4, 118.2, 71.5, 71.5, 71.4, 60.6, 58.5, 58.3, 
58.2, 58.0, 40.0, 39.9, 39.7, 39.7, 39.4, 39.3, 39.2, 39.2, 28.0, 26.2, 26.2, 25.7, 25.6, 25.1, 
25.0, 24.4, 21.6, 17.6, 17.5, 17.5, 17.5, 17.4, 17.4, 17.4, 14.5, 15.1, 14.7, 13.8, 13.8, 13.0, 
12.6, 12.6, 12.5, 12.5, 12.4, 12.4, 12.4, 12.4, 12.4, 12.3. IR: 2964, 2939, 1713, 1462, 1265, 
1160, 1109, 1044, 981, 881, 853, 775, 712, 693, 679, 503 cm–1. HRMS (DART-ESI+) 
calcd. for C36H54N1O3Si1: [M+H]+: 576.3873, found: 576.3860. 
38.5 mg, 60%, m:others=92:8. 1H NMR (CDCl3, 500 
MHz)  7.59 (d, J = 15.7 Hz, 1H), 7.55 (s, 1H), 7.53 
(s, 1H), 7.37-7.49 (m, 4H), 7.33 (t, J = 7.3 Hz, 1H), 
6.42 (d, J = 16.1 Hz, 1H), 4.91-5.02 (m, 1H), 4.26 (q, 
J = 6.8 Hz, 2H), 2.00-2.21 (m, 2H), 1.68-1.83 (m, 1H), 1.49 (d, J = 6.4 Hz, 3H), 1.22-1.45 
(m, 6H), 0.74 (m, 26H). 13C NMR (CDCl3, 100 MHz)  166.7, 149.9, 143.2, 136.7, 136.7, 
134.9, 134.8, 134.7, 134.3, 134.3, 134.3, 133.9, 133.9, 133.9, 133.6, 130.2, 130.1, 129.6, 
129.4, 129.4, 127.7, 123.9, 123.8, 123.8, 123.1, 122.6, 122.5, 122.4, 120.0, 71.0, 70.9, 70.9, 
60.9, 58.5, 58.3, 58.3, 58.1, 40.0, 39.9, 39.7, 39.7, 39.4, 39.3, 39.2, 39.2, 27.8, 26.2, 26.2, 
25.7, 25.7, 25.1, 25.0, 24.4, 17.6, 17.6, 17.5, 17.4, 17.4, 17.4, 14.5, 15.2, 14.7, 13.8, 13.8, 
13.1, 13.1, 12.6, 12.6, 12.5, 12.5, 12.5, 12.4, 12.4. IR: 2964, 2939, 2866, 1715, 1462, 1311, 
1266, 1225, 1176, 1163, 1120, 1094, 1038, 993, 980, 881, 712, 684 cm–1. HRMS (DART-
ESI+) calcd. for C35H51Br1N1O3Si1: [M+H]+: 640.2822, found: 640.2790. 
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45.4 mg, 77%, m:others=91:9. 1H NMR (CDCl3, 
500 MHz)  7.64 (d, J=16.1 Hz, 1H), 7.36 - 7.52 (m, 
3H), 7.32 (t, J=7.3 Hz, 1H), 7.10 (s, 1H), 6.98 - 7.03 
(m, 1H), 6.92 - 6.95 (m, 1H), 6.38 - 6.44 (m, 1H), 
4.94 - 5.04 (m, 1H), 4.26 (q, J=7.3 Hz, 2H), 3.83 (s, 3H), 1.99 - 2.17 (m, 2H), 1.70 - 1.77 
(m, 1H), 1.50 (d, J=6.4 Hz, 3H), 1.20 - 1.43 (m, 6H), 0.72 - 1.07 (m, 26H). 13C NMR 
(CDCl3, 100 MHz)  167.1, 160.2, 160.2, 160.2, 149.4, 149.4, 144.8, 135.8, 135.8, 134.8, 
134.7, 134.6, 134.6, 134.6, 133.9, 133.9, 133.6, 129.6, 127.6, 127.6, 122.7, 122.6, 122.4, 
118.7, 118.1, 118.0, 117.9, 113.5, 113.4, 113.4, 113.2, 111.6, 111.5, 111.5, 111.4, 71.4, 
71.4, 71.3, 60.7, 58.5, 58.2, 58.1, 55.5, 40.0, 39.9, 39.7, 39.7, 39.3, 39.2, 39.2, 27.9, 26.2, 
26.1, 25.7, 25.6, 25.0, 25.0, 24.4, 24.4, 17.6, 17.6, 17.5, 17.4, 17.4, 17.4, 15.1, 15.1, 14.7, 
14.5, 13.8, 13.1, 13.0, 12.6, 12.5, 12.5, 12.5, 12.5, 12.4, 12.4, 12.4, 12.4, 12.3. IR: 2964, 
2939, 2866, 1715, 1592, 1461, 1276, 1162, 1108, 1093, 1061, 1040, 992, 982 cm–1. HRMS 
(DART-ESI+) calcd. for C36H54N1O4Si1: [M+H]+: 592.3822, found: 592.3795. 
33.3 mg, 62%, mm:others=98:2. 1H NMR (CDCl3, 
500 MHz)  7.65 (d, J=15.7 Hz, 1H), 7.41 - 7.51 
(m, 3H), 7.38 (s, 1H), 7.35 (t, J=7.8 Hz, 1H), 7.24 
(s, 1H), 7.17 (s, 1H), 6.89 (d, J=15.7 Hz, 1H), 4.88 
(s, 2H), 3.16 (s, 3H), 3.06 (s, 3H), 2.37 (s, 3H), 
1.97 - 2.17 (m, 2H), 1.62 - 1.82 (m, 1H), 1.19 - 1.43 (m, 3H), 0.75 - 1.14 (m, 26H). 13C 
NMR (CDCl3, 125 MHz)  166.9, 142.7, 141.9, 138.6, 135.6, 134.8, 134.7, 134.0, 133.9, 
133.9, 133.6, 129.7, 127.9, 127.8, 127.8, 127.5, 127.4, 127.4, 122.6, 122.5, 122.4, 122.4, 
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122.2, 117.4, 117.4, 65.3, 65.3, 65.2, 58.5, 58.2, 58.0, 39.9, 39.7, 39.3, 39.2, 37.6, 36.1, 
26.1, 25.6, 25.0, 24.4, 21.6, 17.7, 17.7, 17.5, 17.5, 15.1, 14.7, 13.8, 13.1, 12.5, 12.5, 12.4, 
12.4, 12.4, 12.3. IR: 2938, 2865, 1653, 1613, 1462, 1392, 1261, 1104, 980, 882, 841, 796, 
713, 679, 605 cm–1. HRMS (DART-ESI+) calcd. for C35H53N2O2Si1: [M+H]+: 561.3871, 
found: 561.3863. 
33.7 mg, 63%, m:others=92:8. 1H NMR (CDCl3, 500 
MHz)  7.46-7.55 (m, 3H), 7.43 (br. s, 1H), 7.39 (s, 1H), 
7.36 (t, J = 7.3. Hz, 1H), 7.27 (s, 1H), 7.23 (s, 1H), 6.71 
(d, J = 16.1 Hz, 1H), 4.88 (s, 2H), 2.39 (s, 3H), 2.38 (s, 
3H), 1.98-2.17 (m, 2H), 1.70-1.78 (m, 1H), 1.24-1.44 
(m, 4H), 0.76-1.14 (m, 25H). 13C NMR (CDCl3, 125 MHz)  198.6, 143.9, 142.2, 142.2, 
138.9, 134.9, 134.8, 134.8, 134.7, 134.0, 134.0, 133.9, 133.9, 133.7, 129.7, 129.0, 128.9, 
127.8, 127.8, 127.8, 127.7, 127.2, 123.2, 123.1, 123.0, 122.6, 122.5, 122.4, 65.3, 65.2, 58.5, 
58.3, 58.0, 39.9, 39.7, 39.3, 39.2, 27.7, 26.1, 25.7, 25.0, 24.4, 21.6, 17.7, 17.7, 17.5, 17.5, 
15.1, 14.7, 13.8, 13.1, 12.6, 12.5, 12.4, 12.4. IR: 2939, 2865, 1669, 1613, 1461, 1382, 1254, 
1156, 1103, 992, 882, 795, 713, 681, 597, 496 cm–1. HRMS (DART-ESI+) calcd. for 
C34H50N1O2Si1: [M+H]+: 532.3611, found: 532.3610. 
33.2 mg, 58%, m:others=94:6. 1H NMR (CDCl3, 
500 MHz)  7.61 (d, J = 15.2 Hz, 1H), 7.53 (br. s, 
1H), 7.48 (d, J = 6.8 Hz, 1H), 7.42 (d, J=6.4 Hz, 
1H), 7.32-7.39 (m, 2H), 7.27 (s, 1H), 7.23 (s, 1H), 
6.91 (d, J = 15.2 Hz, 1H), 4.87 (s, 2H), 3.03 (s, 3H), 2.39 (s, 3H), 2.00-2.19 (m, 2H), 1.57-
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1.80 (m, 1H), 1.20-1.43 (m, 3H), 0.77-1.12 (m, 26H). 13C NMR (CDCl3, 125 MHz)  144.4, 
142.4, 139.1, 134.9, 134.8, 134.8, 133.9, 133.9, 133.9, 133.8, 132.4, 129.8, 129.8, 129.7, 
129.5, 128.1, 128.1, 128.1, 127.8, 126.2, 123.4, 123.3, 123.2, 122.5, 122.3, 65.1, 65.1, 58.5, 
58.2, 58.0, 43.5, 39.9, 39.7, 39.3, 39.2, 26.1, 25.6, 25.0, 24.4, 21.5, 17.7, 17.7, 17.5, 17.5, 
15.1, 14.7, 13.8, 13.1, 12.5, 12.5, 12.4, 12.3. IR: 2938, 1462, 1310, 1134, 966, 882, 798, 
713, 501 cm–1. HRMS (DART-ESI+) calcd. for C33H50N1O3S1Si1: [M+H]+: 568.3281, 
found: 568.3275. 
36.4 mg, 65%, m:others=97:3. 1H NMR (CDCl3, 
500 MHz)  7.48-7.56 (m, 2H), 7.46 (d, J = 6.8 Hz, 
1H), 7.36 (t, J = 7.3 Hz, 1H), 7.31 (s, 1H), 7.21 (s, 
1H), 7.19 (s, 1H), 6.14 (s, 1H), 4.89 (s, 2H), 3.75 (s, 
3H), 2.58 (s, 3H), 2.39 (s, 3H), 2.01-2.18 (m, 2H), 
1.69-1.79 (m, 1H), 1.26-1.45 (m, 3H), 0.77-1.13 (m, 26H). 13C NMR (CDCl3, 125 MHz)  
167.5, 156.4, 156.3, 156.3, 142.5, 142.4, 142.4, 141.6, 141.6, 138.4, 138.4, 134.9, 134.8, 
134.7, 134.0, 134.0, 133.9, 133.4, 129.7, 127.8, 127.8, 127.4, 127.3, 125.9, 122.6, 122.5, 
122.3, 121.1, 121.0, 116.7, 116.7, 65.4, 65.4, 58.5, 58.3, 58.0, 51.3, 39.9, 39.7, 39.3, 39.2, 
26.1, 25.7, 25.0, 24.4, 21.7, 21.7, 18.3, 18.2, 17.7, 17.7, 17.5, 17.5, 15.1, 14.7, 13.8, 13.1, 
12.5, 12.5, 12.4, 12.4, 12.4, 12.3. IR: 2941, 2865, 1717, 1628, 1462, 1382, 1214, 1161, 
1109, 881, 796, 713 cm–1. HRMS (DART-ESI+) calcd. for C35H52N1O3Si1: [M+H]+: 
562.3716, found: 562.3729. 
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Hydrolytic deprotection of directing group: 
To a stirred mixture of 1.129d (28 mg, 0.05 mmol) in 2 mL of wet ethanol 
(ethanol:water=3:1) was added 0.1 equiv para-toluenesulfonic acid at room temperature. 
After heating at 90 oC for 12 h, the mixture was diluted with ethyl acetate and dried over 
anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure and 
column chromatography on silica gel gave the alcohol 1.129d′ (9.2 mg, 83%) and silanol 
1.132 (15.0 mg, 83%). 
15.0 mg, 83%. 1H NMR (CDCl3, 500 MHz)  7.44-7.56 (m, 2H), 
7.37-7.44 (m, 1H), 7.34 (t, J = 7.3 Hz, 1H), 2.06-2.27 (m, 2H), 
2.03 (s, 1H), 1.71-1.85 (m, 1H), 1.29-1.51 (m, 1H), 1.13-1.28 
(m, 2H), 0.74-1.09 (m, 26H). 13C NMR (CDCl3, 125 MHz)  135.4, 134.5, 134.4, 134.3, 
133.3, 133.3, 133.2, 133.1, 129.1, 127.4, 127.4, 122.5, 122.4, 122.2, 58.3, 58.1, 57.8, 39.8, 
39.5, 39.2, 39.1, 25.9, 25.5, 24.8, 24.2, 17.1, 16.9, 14.9, 14.5, 13.6, 12.9, 12.4, 12.4, 12.4, 
12.3. IR: 3482, 2939, 2864, 1462, 1384, 1123, 993, 882, 838, 793, 747, 712, 667, 613, 494 
cm–1. HRMS (DART-ESI+) calcd. for C22H38N1O1Si1: [M+H]+: 360.2723, found: 
360.2739. 
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1.6.3 Spectral Data 
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2. Chapter 2: Investigation of the Interactions of 1,2-Azaborines with 
Biomacromolecules: Hydrogen Bonding 
2.1 Introduction 
2.1.1 Arenes as a Pharmacophore 
 Aromatic rings are ubiquitous in nature, and arene-containing compounds prevail 
among clinically important small-molecule drugs (Figure 1.2). 1  This reflects the 
importance of aromatics to the fundamental key interactions involved in various molecular 
recognition. Because of their polarizability, aromatic molecules engage in many of non-
covalent interactions, including cation–π, π–π stacking, and hydrophobic interaction.2 Such 
interactions are prominent in the functional elements of receptor-type drug targets, and thus 
are frequently considered in rational drug designs. 
 
2.1.2 BN/CC Isosterism 
 Creating structural diversity is one of the main goals for synthetic chemists, especially 
during the process of lead optimization efforts in medicinal chemistry.3 In this regards, 
BN/CC isosterism4  (i.e. the replacement of a carbon-carbon (CC) unit with a boron-
                                                 
1 (a) Roughley, S. D.; Jordan, A. M. J. Med. Chem. 2011, 54, 3451–3479. (b) McGrath, N. A.; Brichacek, 
M.; Njardarson, J. T. J. Chem. Ed. 2010, 87, 1348–1349. 
2 (a) Tewari, A. K.; Srivastava, P.; Singh, V. P.; Singh, P.; Khanna, R. S. Res. Chem. Intermed. 2013, 39, 
2925–2944. (b) Tewari, A. K.; Dubey, R. Bioorg. Med. Chem. 2008, 16, 126–143. (c) Johnson, D. W.; Hof, 
F. Aromatic Interactions: Frontiers in Knowledge and Application 2016. 
3 Bleicher, K. H.; Böhm, H.-J.; Müller, K.; Alanine, A. I. Nat. Rev. Drug Discov. 2003, 2, 369–378. (b) 
Keserü, G. M.; Makara, G. M. Drug Discov Today 2006, 11, 741–748. 
4 For selected reviews, see: (a) Liu, Z.; Marder, T. B. Angew. Chem., Int. Ed. 2008, 47, 242–244. (b) Bosdet, 
M. J. D.; Piers, W. E. Can. J. Chem. 2009, 87, 8–29. (3) Campbell, P. G.; Marwitz, A. J. V.; Liu, S.-Y. Angew. 
Chem., Int. Ed. 2012, 51, 6074–6092. (d) Scriven, E.; Ramsden, C. A. Advances in Heterocyclic Chemistry 
Volume 118, Academic Press, 2016. 
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nitrogen (BN) unit) has recently emerged as a strategy to increase the accessible chemical 
space of compounds relevant to biomedical research.5 1,2-Dihydro-1,2-azaborine (2.1) is 
the BN isostere of benzene.6 It has the same number of valence electrons as benzene but 
its electronic structure significantly differs due to the presence of the unsymmetrical BN 
unit (Figure 2.1). Based on DFT calculations, the dipole moment of 1,2-dihydro-1,2-
azaborine is ~ 2.2 D whereas benzene has dipole moment of 0 D.7 We anticipated these 
differences in polarization would lead to 1,2-azaborines exhibiting chemical and physical 
properties distinct from all-carbon arenes.  Specifically, we anticipate to take advantage of 
two unique features of 1,2-azaborine in the context of medicinal chemistry: 1) The NH 
group in 1,2-azaborine should serve as a hydrogen bond donor that can potentially improve 
binding to its macromolecular target. 2) The dipolar nature of 1,2-azaborines should 
improve solubility and thus positively impact pharmacokinetic behavior.8 
 
Figure 2.1 Electronic structure differences between benzene and 1,2-azaborine 
 
                                                 
5 (a) Zhou, H.-B.; Nettles, K. W.; Bruning, J. B.; Kim, Y.; Joachimiak, A.; Sharma, S.; Carlson, K. E.; Stossi, 
F.; Katzenellenbogen, B. S.; Greene, G. L.; Katzenellenbogen, J. A. Chem. Biol. 2007, 14, 659–669. (b) Ito, 
H.; Yumura, K.; Saigo, K. Org. Lett. 2010, 12, 3386–3389. 
6 (a) Marwitz, A. J. V.; Matus, M. H.; Zakharov, L. N.; Dixon, D. A.; Liu, S.-Y. Angew. Chem. Int. Ed. 2009, 
48, 973–977. (b) Abbey, E. R.; Lamm, A. N.; Baggett, A. W.; Zakharov, L. N.; Liu, S.-Y. J. Am. Chem. Soc. 
2013, 135, 12908–12913. 
7 Chrostowska, A.; Xu, S.; Lamm, A. N.; Mazière, A.; Weber, C. D.; Dargelos, A.; Baylère, P.; Graciaa, A.; 
Liu, S-Y. J. Am. Chem. Soc. 2012, 134, 10279–10285. 
8 Waring, M. J. Expert Opin Drug Discov. 2010, 5, 235–248. 
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 Azaborines have a potential to expand exponentially the chemical space of arenes when 
they are substituted. For example, the low symmetry of the 1,2-azaborine core results in 
the possibility of twelve ortho di-substituted regioisomers. In contrast, one structural 
arrangement is possible for an ortho di-substituted benzene (Figure 2.2). 
 
Figure 2.2 Structural diversification of an arene through BN/CC isosterism 
 
 
2.2 Background 
2.2.1 1,2-Azaborines in Biological Systems 
 While recent development of synthetic methods have broadened access to structurally 
diversified 1,2-azaborines,9 very little remains known about the biological behavior of 
these molecules. In 2013, the Liu group reported that the BN isosteres of ethylbenzene, N- 
                                                 
9 For selected examples, see: (a) Marwitz, A. J. V.; Abbey, E. R.; Jenkins, J. T.; Zakharov, L. N.; Liu, S.-Y. 
Org. Lett. 2007, 9, 4905–4908. (b) Lamm, A. N.; Garner, E. B.; Dixon, D. A.; Liu, S.-Y. Angew. Chem. Int. 
Ed. 2011, 50, 8157–8160. (c) Rudebusch, G. E.; Zakharov, L. N.; Liu, S.-Y. Angew. Chem., Int. Ed. 2013, 
52, 9316–9319. (d) Baggett, A. W.; Vasiliu, M.; Li, B.; Dixon, D. A.; Liu, S.-Y. J. Am. Chem. Soc. 2015, 
137, 5536–5541. (e) Brown, A. N.; Li, B.; Liu, S.-Y. J. Am. Chem. Soc. 2015, 137, 8932–8935. (f) Amani, 
J.; Molander, G. A. Org. Lett. 2015, 17, 3624–3627. (g) Wisniewski, S. R.; Guenther, C. L.; Argintaru, O. 
A.; Molander, G. A. J. Org. Chem. 2014, 79, 365–378. (h) Braunschweig, H.; Geetharani, K.; Oscar, J.; 
Jimenez-Halla, C.; Schäfer, M. Angew. Chem. Int. Ed. 2014, 53, 3500–3504. (i) Couchman, S. A.; Thompson, 
T. K.; Wilson, D. J. D.; Duttona, J. L.; Martin, C. D. Chem. Commun. 2014, 50, 11724–11726. 
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and B-ethyl-1,2-azaborine, inhibit ethylbenzene dehydrogenase (EbDH).10  EbDH is an 
oxygen-independent enzyme that catalyzes hydroxylation of alkyl-substituted aromatics 
(i.e. ethylbenzene) via the formation of radical and cationic intermediates.11 Both N- and 
B-ethyl-1,2-azaborine (2.2 and 2.3 in Table 2.1, respectively) showed inhibitory activity 
with IC50 values of 2.8 μM and 100 μM, respectively. Relative calculated ∆∆G values for 
formation of potential radical and carbocation intermediates from both BN isosteres of 
ethylbenzene are substantially higher than those for ethylbenzene (Table 2.1). Therefore, 
it is plausible that the energy barriers for oxidation of the azaborine compounds cannot be 
overcome by the enzyme, resulting in inhibition. This study clearly shows that electronic 
differences between the azaborine analogs and ethylbenzene can affect enzymatic activity. 
 
 
 
 
 
 
 
                                                 
10 Knack, D. H.; Marshall, J. L.; Harlow, G. P.; Dudzik, A.; Szaleniec, M.; Liu, S.-Y.; Heider, J. Angew. 
Chem., Int. Ed. 2013, 52, 2599–2601. 
11 (a) Kniemeyer, O.; Heider, J. J. Biol. Chem. 2001, 276, 21381–21386. (b) Szaleniec, M.; Hagel, C.; Menke, 
M.; Nowak, P.; Witko, M.; Heider, J. Biochemistry 2007, 46, 7637–7646. (c) Knack, D. H.; Hagel, C.; 
Szaleniec, M.; Dudzik, A.; Salwinski, A.;.Heider, J. Appl. Environ. Microbiol. 2012, 78, 6475–6482. (d) 
Szaleniec, M.; Borowski, T.; Schuhle, K.; Witko, M.; Heider, J. J.Am. Chem. Soc. 2010, 132, 6014–6024. (e) 
Szaleniec, M.; Witko, M.; Heider, J. J. Mol. Catal. A 2008, 286,128–136. (f) Szaleniec, M.; Witko, M.; 
Tadeusiewicz, R.; Goclon, J. J. Comput.-Aided Mol. Des. 2006, 20, 145–157. 
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Table 2.1 Relative calculated energy levels for the formation of radical and carbocation intermediates 
 
 
2.2.2 BN Isosteres in Medicinal Chemistry 
 Bioisosterism has been applied in the area of medicinal chemistry as a strategy to 
improve drug properties and discover new biological activities against target proteins.12 
However, there are few examples of BN isosteres being examined in drug discovery efforts. 
As an initial attempt, Dewar in 1964 synthesized BN isosteres of phenanthrene and 
naphthalene as potential agents for neutron capture therapy and as antibacterial agents.13 
Even though they exhibited improved aqueous solubility compared to their carbonaceous 
analogs, preliminary antibacterial activity tests showed unpromising results, with little to 
no increase in inhibitory effect against various bacterial strains. An in vivo study of 
potential application as boron neutron capture therapy agents also revealed that both 
                                                 
12 (a) Burger, A. Prog. Drug Res. 1991, 37, 287−371. (b) Patani, G. A.; LaVoie, E. J. Chem. Rev. 1996, 96, 
3147−3176. (c) Lima, L. M.; Barreiro, E. J. Curr. Med. Chem. 2005, 12, 23−49. (d) Brown, N. Bioisosteres 
in Medicinal Chemistry Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2012. 
13 Dewar, M. J. S.; Hashmall, J.; Kubba, V. P. J. Org. Chem. 1964, 29, 1755–1757. 
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intravenous (9 μg B/g) and intraperitoneal (17.5 μg B/g) injections induced instant death 
in mice (Figure 2.3). 
 
Figure 2.3 BN isosteres of phenanthrene and naphthalene tested in in vivo studies of neutron capture therapy 
 
 
 Since Dewar’s early experiments, efforts towards the application of 1,2-azaborines in 
biomedical research have resumed only recently. In 2015, Kilburn reported ADME 
(absorption, distribution, metabolism, and excretion) profiling of borazaronaphthalenes as 
phosphodiesterase 10A (PDE10A) inhibitors.14 PDE10A is a potential target enzyme for 
the treatments of mental disorders such as Parkinson’s disease, Huntington’s disease, 
schizophrenia, and obsessive compulsive disorder (OCD). Compound 2.9a (MP10, Table 
2.2) was found to exhibit subnanomolar PDE10A inhibition with >1000-fold selectivity 
over other PDE’s. The co-crystal structure of the active site of PDE10A, combined with 
structure activity relationship (SAR) analysis, revealed that one of the key binding 
                                                 
14 Vlasceanu, A.; Jessing, M.; Kilburn, J. P. Bioorg. Med. Chem. 2015, 23, 4453−4461. 
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interactions was a hydrogen bond between the hydroxyl group of tyrosine residue (TYR693) 
and the nitrogen of quinoline moiety of MP10 (Figure 2.4).  
 
Figure 2.4 Binding mode of MP10 in the active site of PDE10A 
 
 
 In the report, the authors described a correlation between the physical properties of the 
bicyclic rings (quinoline, naphthalene, and BN naphthalene) and the compounds’ ability to 
inhibit PDE10A. Direct comparisons of IC50 values, lipophilicities, and clearance rates of 
the analogs were made (Table 2.2). The presence of the more polarized B–N bond in the 
BN naphthalenes (2.10a–d) resulted in higher inhibitory activity compared to the 
carbonaceous naphthalene analogs (2.11a–d); this activity was, however, still substantially 
lower than the quinoline-based compounds (2.9a–d). Systematic trends between 
lipophilicity and metabolic stability could not be identified for the compounds tested in the 
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study, thus highlighting the need for further refinement of structure-clearance relationship 
models. 
 
Table 2.2 Potency, lipophilicity and metabolic stability of quinolinyl-, borazaronaphthyl-, and naphthyl-
analogs 
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 Another report in 2015 also examined the potential application of BN/CC isosterism to 
drug discovery. Two BN analogues of propranolol were synthesized and examined in both 
in vitro ADME profiles and in vivo pharmacokinetic studies.15 Propranolol is an adrenergic 
β-receptor antagonist, used for the treatment of cardiovascular and psychiatric diseases.16 
Comparable inhibitory potency against 26 receptors was observed between the two BN-
containing compounds (2.13 and 2.14) and propranolol (2.12) (Table 2.3, entries 1–4). 
Interestingly, both BN analogues showed improved metabolic stability in human liver 
microsomes (Table 2.3, entry 5).  
 
Table 2.3 Physicochemical and in vitro ADME properties of 2.13 and 2.14 versus propranolol 
  
                                                 
15 Rombouts, F. J.; Tovar, F.; Austin, N.; Tresadern, G.; Trabanco, A. A. J. Med. Chem. 2015, 58, 9287–
9295. 
16 Black, J. W.; Crowther, A. F.; Shanks, R. G.; Smith, L. H.; Dornhorst, A. C. Lancet 1964, 283, 1080−1081. 
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 Cytotoxicity tests showed that 2.13 and 2.14 display higher toxicity compared to 
propranolol (Table 2.4). This might originate from the formation of reactive species during 
the metabolic process due to the reduced aromaticity of the BN-ring system. The Ames II 
mutagenicity assay for all three compounds are negative, indicating low mutagenic 
potential for these compounds.   
 
Table 2.4 Cytotoxicity and mutagenicity of 2.13 and 2.14 versus propranolol 
 
 
 Table 2.5 shows a pharmacokinetic study in rats of bioavailability (Cmax values in brain) 
via subcutaneous administration and brain penetration (brain/plasma AUC ratio (Kp)). 
Both BN-containing compounds were bioavailable (Cmax of 7 μM and 62 μM for 2.13 and 
2.14, respectively) and readily crossed the blood-brain barrier (Kp of 13 and 19 for 2.13 
and 2.14, respectively). 
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Table 2.5 Pharmacokinetic profile of 2.13 and 2.14 versus propranolol 
 
 
 In their stability tests, the BN isosteres were found to be chemically stable under neutral 
pH, but sensitive to acidic conditions. This issue can be potentially addressed, however, 
with formulation technologies for oral delivery. 
 
2.2.3 Hydrogen Bonding as a Major Contributor in Molecular Recognition 
 Hydrogen bonding is among the most prevalent of non-covalent interactions in 
chemical and biological systems, and plays a key role in molecular recognition. Hydrogen 
bonds provide directionality and specificity in both protein folding and protein-ligand 
interactions, and thus are often responsible for protein stability, functions and drug potency, 
respectively.17 
 
2.2.3.1 Determination of Hydrogen Bond Strengths 
 Insight into the energy of hydrogen bonds can provide a better understanding of 
fundamental biological processes, and by extension, lead to more effective drug design. 
                                                 
17 (a) Liu, Z.; Wang, G.; Li, Z.; Wang, R. J. Chem. Theory Comput. 2008, 4, 1959–1973. (b) Fersht, A. R.; 
Shi, J.-P.; Knill-Jones, J.; Lowe, D. M.; Wilkinson, A. J.; Blow, D. M.; Brick, P.; Carter, P.; Waye, M. M. 
Y.; Winter, G. Nature 1985, 314, 235–238. 
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There have been extensive studies to predict the strength of hydrogen bonds using 
theoretical energy calculations and molecular modeling docking experiments.18 However, 
experimental determinations of hydrogen bond strengths are still limited, especially in the 
aqueous environment typical for drug-receptor binding interactions. This scarcity is 
attributed to the difficulty of dissecting the respective contributions to binding free energy 
of different factors (i.e. hydrophobic effect, hydrogen bonds, electrostatic interactions, 
lipophilicity, shape complementarity, and bulk solvent effect).19 
 Representative experimental approaches to quantify hydrogen bond strength in 
biological system can be found in the reports by Fersht17b and Williams.20 In 1985, the 
Fersht group examined the contribution of hydrogen bonding to drug-receptor binding 
interactions using a site-directed mutagenesis strategy. They employed protein engineering 
of the tyrosyl-tRNA synthetase, which catalyzes the aminoacylation of tRNA when 
triggered by the formation of the enzyme-bound tyrosyl adenylate complex. As shown in 
Figure 2.5, multiple hydrogen bonding interactions between the protein side chains and 
tyrosyl adenylate are involved in this process.  
 
                                                 
18 For selected examples, see: (a) Wendler, K.; Thar, J.; Zahn, S.; Kirchner, B. J. Phys. Chem. A 2010, 114, 
9529–9536. (b) Dong, H.; Hua, W.; Li, S. J. Phys. Chem. A 2007, 111, 2941–2945. (c) Gilli, P.; Pretto, L.; 
Bertolasi, V.; Gilli, G. Acc. Chem. Res. 2009, 42, 33–44. (d) Sheu, S. Y.; Yang, D. Y.; Selzle, H. L.; Schlag, 
E. W. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 12683–12687. (e) Schwöbel, J. A. H.; Ebert, R.-U.; Kühne, 
R.; Schüürmann, G. J. Phys. Org. Chem. 2011, 24 1072–1080. (f) Schwöbel, J. A. H.; Ebert, R.-U.; Kühne, 
R.; Schüürmann, G. J. Comput. Chem. 2009, 30,1454–1464. (g) . Kollman, P. A.; Massova, I.; Reyes, C.; 
Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W. Acc. Chem. Res. 2000, 33, 889–897. 
19 (a) Bronowska, A. K. Thermodynamics of Ligand-Protein Interactions: Implications for Molecular Design, 
Thermodynamics - Interaction Studies - Solids, Liquids and Gases. ISBN: 978-953-307-563-1, InTech, 2011. 
(b) Tsai, C. J.; Norel, R.; Wolfson, H. J.; Maizel, J. V. Nussinov, R. Protein–Ligand Interactions: Energetic 
Contributions and Shape Complementarity eLS, 2001. 
20 Williams, D. H.; Searle, M. S.; Mackay, J. P.; Gerhard, U.; Maple-stone, R. A. Proc. Natl. Acad. Sci. U. S. 
A. 1993, 90, 1172–1178. 
502 
 
Figure 2.5 Schematic representation of hydrogen bonding between wild-type tyrosyl-tRNA synthetase and 
tyrosyl adenylate 
 
 
 By the experimental measurement of kinetic parameters for activation of substrates, 
(kcat/KM)mutant versus ((kcat/KM)wild-type, they systematically analyzed the effect of mutation 
on loss and gain in hydrogen bond energy (Table 2.6).  They classified the hydrogen bond 
interactions by two categories, hydrogen bonds with a neutral group and with a charged 
group. Based on their analysis, they found that a neutral-neutral hydrogen bond contributes 
about 0.5-1.5 kcal/mol in binding energy (equivalent to a 2- to 15-fold increase in affinity), 
but a hydrogen bond with a charged group contributes up to 4.5 kcal/mol (equivalent to a 
3000-fold increase in affinity). For example, deletion of the hydroxyl group from Tyr34 by 
mutation to Phe34 resulted in only 0.52 kcal/mol loss of energy, presumably due to the 
relatively poor hydrogen bonding ability of tyrosyl OH with uncharged species (Table 2.6, 
entry 1).  In contrast, mutation of Tyr169 to Phe169 resulted in loss of 3.72 kcal/mol 
binding energy (Table 2.6, entry 7). Deletion of the tyrosine side chain at this position 
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eliminates a strong hydrogen bond between the ammonium ion of the substrate and tyrosyl 
hydroxyl group. 
 
Table 2.6 Comparison of binding energies of wild-type and mutant enzymes with substrates 
 
 
  In 1993, the Williams group estimated hydrogen bond strengths by measuring the 
binding constants of organic molecules in aqueous media.20 In a series of NMR studies, 
they investigated changes in the binding of cell wall peptide analogues to vancomycin and 
ristocetin derivatives, following modification of the peptide structures. Two additional 
factors, the hydrophobic effect and entropic costs of rotor restrictions and bimolecular 
associations of the antibiotics, were considered to quantify the pure hydrogen bond energy. 
Based on ∆Gh (the favorable free energy change due to the hydrophobic effect) and ∆Gr 
(the entropic penalties incurred by rotational restriction upon association) values from a 
comparison of the binding of peptide ligands to ristocetin A, the average neutral amide-
amide hydrogen bond strengths were estimated to be –0.2 to –1.7 kcal/mol (Table 2.7). 
This result is in good agreement with the early works by Fersht. 
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Table 2.7 Estimates of amide-amide hydrogen bond strength (∆Gp) in the binding of peptides to ristocetin A 
 
 
2.2.3.2 Select Examples of Hydrogen Bond in Biology 
 One of the classic examples of hydrogen bonding in biological systems is base-pairing 
in DNA to form a stable double-helix. Hydrogen bonding also serves as the main 
organizing interaction for the assembly of α-helix and β-sheet, secondary protein structures. 
For instance, human myoglobin consists of eight α-helices that form a hydrophobic pocket 
around a heme molecule to enable oxygen transfer to muscle tissues. The structure of 
oxygenated human myoglobin is shown in Figure 2.6.21 The α-helical structure maximizes 
the number of hydrogen bonding interactions along the peptide backbone, thereby directing 
the orientation of the side chains to create the hydrophobic core.  
 
 
 
 
 
                                                 
21 Phillips, S. E. V. J. Mol. Biol. 1980, 142, 531–554. 
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Figure 2.6 α-Helical structure of oxymyoglobin (PDB: 1MBO) 
 
 
 Another prevalent motif in protein structures is the β-sheet, in which peptidic amide 
groups form hydrogen bonds in either parallel or antiparallel series. Thioredoxin comprises 
five β-sheets in the central core surrounded by four α-helices; the β-strands from the N-
terminus run parallel, and the β-strands from the C-terminus run antiparallel (Figure 2.7).22 
This characteristic tertiary structure of thioredoxin plays a key role in its folding and 
function during cellular redox processes.23 
 
 
                                                 
22 Weichsel, A.; Gasdaska, J. R.; Powis, G.; Montfort, W. R. Structure 1996, 4, 735–751. 
23 Collet, J. F.; Messens, J. Antioxid Redox Signal. 2010, 13, 1205–1216. 
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Figure 2.7 Structure of human thioredoxin composed of five central β-sheets (PDB: 1ERT) 
 
 
2.2.3.3 Select Examples of Hydrogen Bond in Pharmaceuticals 
 Hydrogen bonding interactions are often utilized in structure-activity relationship 
studies in drug discovery, and have been found to at times enhance the potency of drugs.24 
A well-studied example is imatinib, a strong inhibitor of the tyrosine kinase Abl. 25 
Imatinib’s specificity and potency are believed to arise from intermolecular hydrogen 
bonding interactions (as well as additional van der Waals interactions) between the 
                                                 
24 For selected examples, see: (a) Gonzalez, A. Z.; Li, Z.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; 
Duquette, J.; Eksterowicz, J.; Fox, B. M.; Fu, J.; Huang, X.; Houze, J.; Jin, L.; Li, Y.; Ling, Y.; Lo, M.-C.; 
Long, A. M.; McGee, L. R.; McIntosh, J.; Oliner, J. D.; Osgood, T.; Rew, Y.; Saiki, A. Y.; Shaffer, P.;  
Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Olson, S. H.; Sun, D.; Medina, J. C. 
J. Med. Chem. 2014, 57, 2963–2988. (b) Verner, E.; Katz, B. A.; Spencer, J. R.; Allen, D.; Hataye, J.; 
Hruzewicz, W.; Hui, H. C.; Kolesnikov, A.; Li, Y.; Luong, C.; Martelli, A.; Radika, K.; Rai, R.; She, M.; 
Shrader, W.; Sprengeler, P. A.; Trapp, S.; Wang, J.; Young, W. B.; Mackman, R. L. J. Med. Chem. 2001, 44, 
2753–2771. (c) Wang, Y.; Liu, Z.; Brunzelle, J. S.; Kovari, I. A.; Dewdney, T. G.; Reiter, S. J.; Kovari, L. 
C. Biochem. Biophys. Res. Commun. 2011, 412, 737–742. (d) Das, K.; Sarafianos, S. G.; Clark Jr, A. D.; 
Boyer, P. L; Hughes, S. H.; Arnold, E. J. Mol. Biol. 2007, 365, 77–89. 
25 Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Nat. Rev. Drug Discov. 2002, 1, 493–502. 
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molecule and the protein side chains of the kinase binding site.26 From the crystal structure 
of the imatinib-Abl complex, six hydrogen bonds are observed with interatomic distances 
of 2.7–3.2 Å (Figure 2.8).27 Imatinib’s piperazinyl group is most likely protonated, and 
therefore able to form hydrogen-bond contacts with the carbonyl oxygens of His361 and 
Ile360.26  
 
Figure 2.8 Schematic diagram of the H-bonding interactions between imatinib and Abl residues 
 
 
 Intermolecular formation of hydrogen bonds between drugs and receptors improve 
drug potency by enabling specificity through the selective favorability of these local 
binding interactions. Intramolecular hydrogen bonds within drugs, however, can also 
produce notable effects, particularly with respect to membrane permeability, water 
solubility, and lipophilicity. 28  A systematic analysis of intramolecular hydrogen bond 
                                                 
26 Lin, Y.-L.; Meng, Y.; Jiang, W.; Roux, B. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 1664–1669. 
27 Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; 
Kuriyan, J. Cancer Res. 2002, 62, 4236–4243. 
28 Alex, A.; Millan, D. S.; Perez, M.; Wakenhut, F.; Whitlock, G. A. Med. Chem. Commun. 2011, 2, 669–
674. 
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effects was conducted by the discovery chemistry group at Roche. 29  The authors 
hypothesized that the formation of intramolecular hydrogen bond within a molecule would 
effectively remove the availability of one donor and one acceptor unit to form 
intermolecular hydrogen bonds, resulting in increased lipophilicity and membrane 
permeability and decreased aqueous solubility. Indeed, they observed indicators of these 
very trends in several different model systems, two of which are presented in Table 2.8. 
Compound 2.16 has the ability to from an intramolecular hydrogen bond between the 
benzimidazole NH and the carbonyl oxygen of amide group. Both cell permeability 
(PAMPA Pe) and lipophilicity (logD) improved compared to those of 2.15 in which the 
benzimidazole nitrogen is methylated. Similar trends were observed for 2.17–2.20; 2.20 
showed a slight increase in cell permeability compared to analogs 2.18 and 2.19. Water 
solubility and logD values were comparable throughout the series, except for compound 
2.17, which was considerably less water soluble and more lipophilic. 
 
 
 
 
 
 
 
                                                 
29 Kuhn, B.; Mohr, P.; Stahl, M. J. Med. Chem. 2010, 53, 2601–2611. 
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Table 2.8 Molecular properties examined in the model ligand sets 
 
 
2.2.4 Cavity-Bearing T4 Lysozyme Mutants 
 The T4 lysozyme consists of 164 amino acids and works to hydrolyze the β-1,4 linkages 
between the N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) units of 
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bacterial cell walls. The enzyme has been extensively studied as a tool to gain 
understanding of the general factors that determine the structure and stability of proteins.30 
 
2.2.4.1 Origin of T4 Lysozyme Mutants 
 The first systematic mutation of bacteriophage T4 lysozyme was investigated by 
Poteete et al. in 1991.31 They introduced amber mutation using 13 different amino acids at 
every one of the 164 residues and measured the resulting enzymatic activity. Mutation at 
89 of the 164 sites (55%) was found to leave activity equivalent to that of the wild-type. 
Most of these tolerant sites are distributed on the surface of the protein, consistent with the 
principle of protein folding: residues on the surface are partially or fully solvated, and 
therefore have little impact on enzymatic activity. However, residues in or near the catalytic 
sites (Glu11, Asp20, Asp10, Arg145, Arg148) and a few others (Gly30, Trp 138, Tyr161) 
were notably sensitive to replacements. 
 Protein stability was also examined by monitoring changes in the melting temperature 
brought on by point mutations (Figure 2.9).30b Many point mutations decreased protein 
stability by more than 3 °C, which roughly corresponds to a change in the free energy of 
stabilization (∆∆G) of about 1 kcal/mol. The most destabilizing point mutants reduced the 
melting temperature by about 20 °C. These include mutation in the hydrophobic core of 
the protein: M102K, A98F, A98W, L99G, and R95A.  
                                                 
30 For selected reviews on T4 lysozyme mutants, see: (a) Matthews, B. W. Biochemistry 1987, 26, 6885–
6888. (b) Baase, W. A.; Liu, L.; Tronrud, D. E.; Matthews, B. W. Protein Sci. 2010, 19, 631–641. (c) 
Matthews, B. W.; Liu, L. Protein Sci. 2009, 18, 494–502. (d) Xu, J.; Baase, W. A.; Baldwin, E.; Matthews, 
B. W. Protein Sci. 1998, 7, 158–177. 
31 Rennell, D.; Bouvier, S. E.; Hardy L. W. ; Poteete, A. R. J. Mol. Biol. 1991, 222, 67–87. 
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Figure 2.9 Distribution of ∆Tm (°C) for 312 known point mutants (This figure has been reproduced from 
reference 30b) 
 
 
2.2.4.2 Discovery of Cavity-Bearing T4 Lysozyme Mutants 
 The interiors of proteins are usually tightly packed with little empty space remaining.32 
If a polar cavity exists, it is typically occupied by water molecules; this type of cavity can 
be up to about 150 Å3 in volume. Apolar cavities appear to be empty and generally have 
volumes up to about 50 Å3. An artificial cavity can be generated by replacement of a bulky 
residue (Phe, Leu, Ile, and Met) with a small residue (Ala) in a core of proteins. 
 In 1992, the Matthews group discovered that the replacement of Leu99 with Ala in T4 
lysozyme creates a structurally rigid apolar cavity inside the hydrophobic core of the 
protein’s C-domain.33 The L99A cavity is unusually large (150 Å3) and well-concealed 
                                                 
32 Hubbard, S. J.; Gross, K-H.; Argos, P. Protein Eng. 1994, 7, 613–626. 
33 (a) Eriksson, A. E.; Baase, W. A.; Wozniak, J. A.; Matthews, B. W. Nature 1992, 355, 371–373. (b) 
Eriksson, A. E.; Baase, W. A.; Zhang, X-J.; Heinz, D. W.; Blaber, M.; Baldwin, E. P.; Matthews, B. W. 
Science 1992, 255, 178–183. 
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from external solvent molecules. Through crystallographic and thermodynamic analyses, 
the authors found that the cavity is large enough to bind benzene; this binding notably 
increases the melting temperature of the protein by 6 °C at pH 3.0. 
 
2.2.4.3 Binding Studies of Cavity-Bearing T4 Lysozyme Mutants 
 Binding thermodynamics were systematically studied by examining the binding of 91 
compounds within the cavity of the L99A T4 lysozyme mutant.34 In an initial screen, a 
thermal upshift assay indicated no apparent binding by compounds presumably protonated 
at pH 3.0, such as aniline, pyridine, and quinoline. Neutral polar compounds including 
ethanol, furan, phenol, and benzyl alcohol also did not induce thermal upshift. Lastly, 
binding by sterically bulky ligands, i.e. t-butylbenzene, (±)-camphene, and (±)-camphor, 
was also not detected (Figure 2.10).  
 
Figure 2.10 Examples of compounds for which binding to L99A was not detected 
 
                                                 
34 Morton, A.; Baase, W. A.; Matthews, B. W. Biochemistry, 1995, 34, 8564–8575. 
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 Those ligands that did exhibit binding to the cavity residues were segregated into three 
separate categories: isophobic ligands of equivalent hydrophobicity to probe possible steric 
influences in the cavity wall (Class I); isosteric ligands of different hydrophobicities to 
evaluate hydrophobic contributions to the binding energy (Class II); and alkylbenzenes 
with different length of side-chains length to determine the effects of ligand size (Class III; 
Figure 2.11). 
 
Figure 2.11 Classification of ligands used for binding thermodynamic analysis    
 
 
 Table 2.9 lists the results of isothermal titration calorimetry (ITC) measurements of the 
binding thermodynamics of ligand classes I–III. Among the class I ligands, di-substituted 
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compounds show poorer binding compared to their mono-substituted counterparts (xylenes 
vs. ethylbenzene and ethyltoluenes vs. propylbenzene). These results indicate sterics 
strongly influence binding energetics. Later, crystallographic analysis revealed that there 
is a bulge region in the mutant cavity that can accommodate a single substituent on the 
aromatic ring. 35  The results for the class II ligands indicate only a rough correlation 
between hydrophobicitiy and binding free energy. Among the class III compounds, there 
is a good correlation between the length of the alkyl side-chain and binding strength, with 
longer chains equating to larger ∆G values. 
 
Table 2.9 Binding thermodynamics of aromatic compounds in L99A cavity 
 
 
                                                 
35 Morton, A.; Matthews, B. W. Biochemistry, 1995, 34, 8576–8588. 
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 Crystal structure analyses of the ligand-bound protein complexes indicated a 
substantial conformational rearrangement occurs during ligand binding.35 However, the 
binding cavity remains rigid upon ligand binding, as characterized by low temperature 
factors and strong protection from hydrogen exchange. Therefore, this part of the protein 
is mainly responsible for discrimination of ligand shapes. In contrast, significant 
conformational adjustments (large positional shifts of 1.5–2.5 Å) were found to occur in 
the flexible region, helix F (residues 108–113) (Figure 2.12). Temperature factors in helix 
F are significantly higher than those of other regions, which is indicative of great 
conformational destabilization upon ligand binding.  
   
Figure 2.12 Structure of benzene-bound complex of L99A mutant (PDB: 181L) 
 
 
 Since their initial discovery, T4 lysozyme mutants have been extensively studied as a 
model system to verify and test docking predictions generated by different calculation 
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approaches. The advantages of these systems in this regard include straightforward 
detection of ligand binding, measurement of affinity, and unambiguous determination of 
structure by X-ray crystallography.  
 In the course of developing a docking scoring function, Matthews and Shoichet 
introduced the T4 lysozyme double mutant L99A/M102Q, which bears a polar binding 
cavity.36 The methionine residue was replaced by a polar residue, glutamine. In the binding 
pocket, a water molecule and β-mercaptoethanol (from the crystallization buffer) were 
found in the crystal structure in the absence of an added organic compound. The docking 
calculation was repeated for representative polar organic molecules and verified by 
experimental results using circular dichroism (CD), ITC, and X-ray crystallography.  
 Generally, a good agreement was observed between the prediction model and 
experimental data. Ranking and scoring functions were verified by experimental 
measurement of thermal denaturation using CD in the binding of a series of polar molecules 
to the cavity of L99A/M102Q (Table 2.10). These ligands are known not to bind to the 
apolar binding pocket (L99A). In all cases, binding of the ligands resulted in an increase 
of protein melting temperature. 
 
 
 
 
                                                 
36 Wei, B. Q.; Baase, W. A.; Weaver, L. H.; Matthews, B. W.; Schoichet, B. K. J. Mol. Biol. 2002, 322, 
339−355. 
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Table 2.10 Representative ligands predicted to bind preferentially to the polar L99A/M102Q cavity 
 
 
 Four polar ligands were further examined in calorimetric experiments to determine the 
binding affinity of each complex with the protein. Among those tested, 3-chlorophenol 
shows the highest binding affinity (Ka = 18 x 103 M-1; Table 2.11, entry 2). An apolar ligand, 
toluene, was also found to bind to the L99A/M102Q cavity (Ka = 6.4 x 103 M-1), but with 
lesser affinity than for L99A (Ka = 9.8 x 103 M-1).  
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Table 2.11 ITC results of ligand binding to L99A/M102Q 
 
 
 The binding geometry predicted by the authors’ AMSOL charge prediction model was 
also well-aligned with the actual crystallographic data of the binding of five polar ligands 
to L99A/M102Q (Figure 2.13). Based on the crystal structures, hydrogen bonds formed 
between the polar substituents of the ligands and the carbonyl oxygen of Gln102 with the 
lengths of 2.7–3.3 Å. 
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Figure 2.13 Comparison of the geometries of binding predicted using the AMSOL charges (carbons in cyan) 
and the experimentally observed modes (carbons in grey) (This figure has been reproduced from reference 
36) 
 
 
 L99A and L99A/M102Q have been repeatedly used in further development of 
molecular docking prediction methods including testing a flexible-receptor docking 
algorithm, 37  assembling decoy databases, 38  predicting absolute ligand binding free 
energy,39 rescoring docking hit lists,40 and constructing alchemical free energy methods.41 
 To better understand the effects of protein residues in ligand binding and enzyme 
activity, Matthews developed another T4 lysozyme double mutant: L99A/M102E. A 
                                                 
37 Wei, B. Q.; Weaver, L. H.; Ferrari, A. M.; Matthews, B. W.; Shoichet, B. K. J. Mol. Biol. 2004, 337, 1161–
1182. 
38 Graves, A. P.; Brenk, R.; Shoichet, B. K. J. Med. Chem. 2005, 48, 3714–3728. 
39 Mobley, D. L.; Graves, A. P.; Chodera, J. D.; McReynolds, A. C.; Shoichet, B. K.; Dill, K. A. J. Mol. Biol. 
2007, 371, 1118–1134. 
40 Graves, A. P.; Shivakumar, D. M.; Boyce, S. E.; Jacobson, M. P.; Case, D. A.; Shoichet, B. K. J. Mol. Biol. 
2008, 377, 914–934. 
41 Boyce, S. E.; Mobley, D. L.; Rocklin, G. J.; Graves, A. P.; Dill, K. A.; Shoichet, B. K. J. Mol. Biol. 2009, 
394, 747–763. 
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negatively charged glutamic acid residue was introduced at the 102 methionine position of 
the L99A mutant to generate a more polar environment in the binding cavity.42 The shape 
of the cavity was found to be essentially the same as in L99A. However, three water 
molecules were identified in the binding pocket at positions that indicated formation of 
hydrogen bond network among themselves and with the peptide residues. In addition, 
binding of both polar and nonpolar benzene analogs was observed in this cavity by 
crystallographic analysis.  
 Shoichet also mutated the 102 methionine residue, this time to introduce a positively 
charged histidine group into the binding pocket.43 Isolation of the L99A/M102H protein 
required additional mutations at the residues remote from the binding site to counteract 
stability issues. Various mutations were introduced and a series of these mutants were used 
to explore catalysis of Kemp elimination.4343a Notably, certain polar molecules such as 4-
nitrophenol that did not or poorly bind to the other mutants (L99A, L99A/M102Q, and 
L99A/M102E), were accommodated into the L99A/M102H cavity.43b  
 
                                                 
42 Liu, L.; Baase, W. A.; Matthews, B. W. Biochemistry, 2009, 48, 8842–8851. 
43 (a) Merski, M.; Shoichet, B. K. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 16179−16183. (b) Merski, M.; 
Shoichet, B. K. J. Med. Chem. 2013, 56, 2874−2884. 
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2.3 Hydrogen Bonding of 1,2-Azaborines in the Binding Cavity of T4 Lysozyme 
Mutants: Structures and Thermodynamics44 
2.3.1 Previous Evidence of Hydrogen Bonding of 1,2-Azaborines 
 One of the potential beneficial features of 1,2-azaborines in biological systems is their 
hydrogen bonding capability. We previously estimated by computation (B3LYP/DZVP2) 
the pKa value of the 1,2-azaborine NH to be around 24 (Figure 2.14), which is indicative 
of modestly protic character.9d The protic nature was also confirmed experimentally by 
deuterium exchange with CD3OD.6a Additionally, the crystal structure of compound 2.21 
showed an intramolecular hydrogen bond between the N–H and the carbonyl oxygen of the 
B-phenylacetate substituent (Figure 2.14).6b 
 
Figure 2.14 Hydrogen bonding capability of 1,2-azaborines 
 
 
 However, no evidence of hydrogen bonding of 1,2-azaborines had been ascertained in 
a biological context. Hydrogen bonding ability of 1,2-azaborines would have merits over 
                                                 
44 (a) Lee, H.; Fischer, M.; Shoichet, B. K.; Liu, S.-Y. J. Am. Chem. Soc. 2016, 138, 12021–12024. (b) Lee, 
H.; Liu, S.-Y. J. Vis. Exp. 2017, 121, e55154. 
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other 6-membered aromatic compounds, especially in the context of potential application 
in medicinal chemistry. Therefore, we sought to establish a fundamental understanding of 
the hydrogen bonding capability of 1,2-azaborines in a biological model system: the T4 
lysozyme mutant. 
 
2.3.2 Synthesis of 1,2-Azaborines 
 To prepare the NH-containing 1,2-azaborines required for our binding studies, we 
employed a modified version of previously reported synthetic routes.6,10 Triallylborane 
(2.22)45 was used as a substitute for allyltriphenyl tin or potassium allyltrifluoroborate to 
prepare the B-N adduct 2.23. This substitution notably renders the route more atom-
economical and environmentally friendly. Conproportionation of triallylborane with boron 
trichloride generates allylboron dichloride in situ, which then reacts with TBS-protected 
allylamine to afford 2.23. Subsequent ring closing metathesis, followed by oxidation 
furnishes the aromatic azaborine core to provide a versatile azaborine intermediate (2.24) 
in a one-pot, two-step sequence. Amide-assisted deprotection of TBS and displacement 
with the appropriate alcohol results in either precursor 2.25 or 2.26. Reduction of 2.25 with 
lithium aluminum hydride gave the unsubstituted azaborine ligand 2.1. Ethyl lithium was 
used to complete the synthesis of 2.3.  
 
 
                                                 
45 Brown, H. C.; Racherla, U. S. J. Org. Chem. 1986, 51, 427–432. 
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Scheme 2.1 Synthesis of NH containing 1,2-azaborines used in binding study 
 
 
2.3.3 Protein X-Ray Crystal Structures 
 We chose two engineered cavity-bearing T4 lysozyme mutants, L99A and 
L99A/M102Q, as a macromolecule binding model. L99A was used as a control protein as 
it has no residues capable of forming hydrogen bonds inside the binding pocket. A slightly 
more polar protein, L99A/M102Q was used to determine a potential hydrogen bond 
between 1,2-azaborines and a polar glutamine residue. Protein X-ray crystallography was 
utilized to examine this interaction. 
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 In the non-polar cavity (L99A), similar binding modes were observed for the 
carbonaceous arenes and their corresponding BN analogs, as observed previously.46 The 
ethyl group of both ethylbenzene and BN analog 2.3 is oriented towards the bulge region 
of the cavity, presumably due to shape complementarity. There are two alternative 
conformations in the binding of 2.1, ethylbenzene, and 2.3 (Figure 2.15). As expected, in 
all cases there is no evidence of hydrogen bond formation between the ligands and the 
surrounding protein residues in the cavity. In addition, the distances between the nitrogen 
of the azaborine ligands and the sulfur atom of Met102 are 4.0 and 4.5 Å in the 2.1-L99A 
complex and 5.9 and 6.2 Å in the 2.3-L99A complex, all too far to be a hydrogen bond 
(non-classical sulfur-containing hydrogen bond47). 
 
 
 
 
 
 
 
 
                                                 
46 Liu, L.; Marwitz, A. J. V.; Matthews, B. W.; Liu, S.-Y. Angew. Chem. Int. Ed. 2009, 48, 6817–6819. 
47 (a) Zhou, P.; Tian, F.; Lv, F.; Shang, Z. Proteins: Struct., Funct., Bioinf. 2009, 76, 151–163. (b) Gregoret, 
L. M.; Rader, S. D.; Fletterick, R. J.; Cohen, F. E. Proteins: Struct., Funct., Bioinf. 1991, 9, 99–107. 
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Figure 2.15 X-ray structures of ligand-bound L99A complexes 
 
 
 In the polar cavity (L99A/M102Q), a distinctly different interaction is observed 
between the aryl-bound complexes and the azaborine-bound complexes. In the benzene-
L99A/M102Q complex, benzene displaces 2-mercaptoethanol (observed in the previously 
reported crystal structure; PDB: 1 LGU36) to occupy the binding pocket (Figure 2.16, top 
left). A water molecule is still present in the cavity, forming a hydrogen bond with the 
carbonyl oxygen of Gln102 with distances of 2.5 and 2.7 Å in the two alternative 
conformations. In contrast, the crystal structure of the 2.1-L99A/M102Q complex shows a 
hydrogen bond between the NH of azaborine 2.1 and the C=O of Gln102 with distances of 
3.1 and 3.2 Å in the two alternative conformations of the residue (Figure 2.16, top right). 
This is the first example of unambiguous structural evidence of an azaborine forming a 
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hydrogen bond in a biological macromolecule. Similarly, a hydrogen bonding interaction 
is observed in the 2.3-L99A/M102Q complex. The distances between the nitrogen of 
azaborine 2.3 and the carbonyl oxygen of Gln102 are 3.2 and 3.6 Å in the two alternative 
conformations of the ligand (Figure 2.16, bottom right). The latter could be considered as 
a very weak hydrogen bond or a polar non-covalent interaction. There is no obvious 
hydrogen bonding interaction in the ethylbenzene-L99A/M102Q complex (Figure 2.16, 
bottom left). Additionally, we found a substantial positional change of the Gln102 side 
chain in the azaborine-bound complexes. Binding of the NH-containing azaborine led to 
movement of the glutamine residue, resulting in 0.4 and 1.1 Å difference in the position of 
the oxygen atom compared to the corresponding carbonaceous ligand-bound structures 
(benzene-L99A/M102Q vs. 2.1-L99A/M102Q and ethylbenzene-L99A/M102Q vs. 2.3-
L99A/M102Q, respectively). Thus, it appears that the Gln102 side chain undergoes 
considerable geometric changes upon binding of 1,2-azaborines to accommodate hydrogen 
bonding. 
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Figure 2.16 X-ray structures of ligand-bound L99A/M102Q complexes 
 
 
 A crystal structure of N-ethyl substituted azaborine (2.2)-bound L99A/M102Q 
complex was also obtained (Figure 2.17). Hydrogen bonding capability of this ligand is 
inhibited by the ethyl substituent, thus it serves as an internal control (binding 
thermodynamics using this compound as a reference will be discussed in 2.3.5). In the 
structure, a comparable binding mode was observed as seen in the ethylbenzene-bound 
complex, with two alternative conformations. There was no indication of hydrogen 
bonding interactions and we observed BH group of the ligand was positioned away from 
the carbonyl oxygen of Gln102 in both conformations. 
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Figure 2.17 X-ray structure of 2.2-bound L99A/M102Q 
 
 
2.3.4 Isothermal Titration Calorimetry Data 
 To better understand the energetics of the azaborine-protein hydrogen bonding 
interactions, we determined the binding free energies of each complex using isothermal 
titration calorimetry (ITC). As expected, in the non-polar cavity (L99A) azaborine ligands 
2.1 and 2.3 lost 0.5 and 0.4 kcal/mol, respectively, in binding free energy compared to their 
arene isosteres (Table 2.12, left column). This is consistent with azaborines having more 
polar character and thus incurring a higher desolvation penalty. 
 In contrast, binding of azaborines in the polar cavity (L99A/M102Q) showed 0.2–0.4 
kcal/mol stronger binding free energy relative to the carbonaceous analogs (Table 2.12, 
right column). As observed in the crystal structures, this is due to a hydrogen bonding 
interaction, which apparently is strong enough to overcome the azaborines’ desolvation 
penalty. We also observed lower binding affinity in the complexes of ethyl-substituted 
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ligand-bound L99A/M102Q compared to the unsubstituted ligand-bound cases, 
presumably due to the higher steric demand of the ethyl group.48 
 
Table 2.12 Binding free energy and affinity determined by ITC 
 
 
2.3.5 Thermodynamic Cycle Analysis 
 In the analysis of energetic contributions of protein-ligand interactions, we need to 
consider various factors, such as the hydrophobic effect, desolvation cost, hydrogen 
bonding, electrostatic interactions, etc., that attribute to the observed total energy.19b 
Therefore, it is difficult to determine the energetic contribution of hydrogen bonding by 
simply comparing a pair of free energy values; e.g. the binding free energies of benzene 
and 2.1 to the L99A/M102Q mutant. In this simple analysis, the binding free energy 
difference (ΔΔG = ΔG2.1-L99A/M102Q – ΔGbenzene-L99A/M102Q = –6.40 – (–5.96) = –0.44 
kcal/mol) represents the totality of electronic structure differences between benzene and 
2.1, not just hydrogen bonding. 
                                                 
48 Merski, M.; Fischer, M.; Balius, T. E.; Eidam, O.; Shoichet, B. K. Proc. Natl. Acad. Sci. U. S. A. 2015, 
112, 5039–5044. 
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 To quantify the stabilization energy gained from the hydrogen bonding interactions 
alone, we turned to double mutant thermodynamic cycle analysis. This method uses “wild-
type” and “mutant” versions of both the enzyme and ligand, with each “mutant” lacking 
the interacting groups of interest. The energetic cost, ΔΔG, of removing the ligand 
functional group both in the presence and the absence of the enzyme residue with which it 
interacts can be calculated, and the difference between these energies, ΔΔΔG, is the energy 
of the interaction. In our case, the wild-type enzyme is the L99A/M102Q T4 lysozyme and 
the mutant enzyme (lacking the hydrogen bonding interaction) is the L99A T4 lysozyme. 
The wild-type ligands are the NH-containing 1,2-azaborines, 2.1 and 2.3, and the mutant 
ligands are benzene and ethylbenzene. 
 Using this simple thermodynamic cycle analysis we estimated the free energy of 
hydrogen bonding between Gln102=O and the NH of 2.1 and 2.3 to be –0.94 and –0.64 
kcal/mol, respectively (Figure 2.18). The weaker hydrogen bond interaction for 2.3 
compared to 2.1 with the Gln102 residue may arise from a steric penalty induced by the 
ethyl substituent. This is consistent with the longer average hydrogen bond distance with 
Gln102 residue in the 2.3-L99A/M102Q structure compared to the 2.1-L99A/M102Q 
structure. The estimated hydrogen bond strengths between the azaborine NH and the 
glutamine carbonyl oxygen are within a typical range for neutral-neutral hydrogen bonds 
in an aqueous environment (0.5–1.5 kcal/mol).49 
  
 
                                                 
49 Davis, A. A.; Teague, S. J. Angew. Chem., Int. Ed. 1999, 38, 736–749. 
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Figure 2.18 Thermodynamic cycle analysis to estimate hydrogen bond strengths 
 
 
 These estimated energetic values may also contain an additional electrostatic 
contribution between dipolar azaborine molecules and protein binding sites. Therefore, we 
experimentally determined the binding free energies of N-ethyl substituted azaborine (2.2) 
with both L99A and L99A/M102Q to elucidate such interactions (Table 2.12). The 
resulting thermodynamic cycle analysis with this ligand compared to ethylbenzene is 
shown in Figure 2.19. The energy derived from the analysis is +0.21 kcal/mol, the energetic 
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contributions from other polar interactions beyond hydrogen bonding, which turns into 
rather a repulsive interaction. This may arise from unfavorable interaction between the BH 
group of the ligand and oxygen of Gln102 as seen in the crystal structure (Figure 2.17). 
Thus, to better estimate the hydrogen bond strength conferred by 2.3, we took this energy 
into account and performed another thermodynamic cycle analysis using 2.2 as the “mutant” 
ligand (Figure 2.20). The estimated energy from the analysis is –0.85 kcal/mol, slightly 
higher than the value estimated using ethylbenzene as a control (–0.64 kcal/mol). By the 
same analogy, the hydrogen bond strength for 2.1 with consideration of the repulsive 
dipolar interaction leads to –1.15 kcal/mol. Overall, in addition to structural evidences, we 
conclude that our estimation of hydrogen bond strengths for 2.1 and 2.3 accounts for 
hydrogen bond as a strong component of the total electrostatic interaction. 
 
Figure 2.19 Thermodynamic cycle analysis using 2.2 as the azaborine ligand 
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Figure 2.20 Thermodynamic cycle analysis between 2.2 and 2.3 
 
 
2.4 Conclusions 
 Aromatic rings are a ubiquitous structural motif in medicinal chemistry, and 
diversification of chemical structures is a routine practice for medicinal chemists as part of 
lead compound optimization efforts. Thus, as boron-nitrogen-containing isosteres of arenes, 
azaborine heterocycles have the potential to expand the chemical space of arenes and 
generate novel pharmacological activity.  
 We demonstrated that 1,2- azaborines can be readily accommodated in classic aryl 
recognition pockets and established one of 1,2- azaborine’s distinguishing features from 
arenes, i.e., its ability to serve as an NH hydrogen bond donor in a biological setting. 
Specifically, we directly compared NH-containing 1,2-azaborines and their carbonaceous 
arene analogs in binding to a biological model system, T4 lysozyme mutants-L99A and 
L99A/M102Q.  
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 We utilized high-resolution protein X-ray crystallography and ITC experiments to 
achieve a systematic quantitative analysis of hydrogen bonding interactions. A 
Gln102=O···H–N hydrogen bond was observed in the complexes of 1,2-azaborine in the 
polar binding pocket of L99A/M102Q. Using a simple thermodynamic cycle analysis with 
ethylbenzene as the “mutant” ligand lacking the hydrogen bond capability, the strengths of 
the hydrogen bond were estimated to be 0.94 and 0.64 kcal/mol for 2.1 and 2.3, respectively. 
The quantitative structural and thermodynamic binding data of this work will serve as a 
general reference in future applications of 1,2-azaborines as a pharmacophore. 
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2.5 Experimental 
2.5.1 General Information 
 All oxygen- and moisture-sensitive manipulations were carried out under an inert 
atmosphere (N2) using either standard Schlenk techniques or a glove box. THF, Et2O, 
CH2Cl2, toluene and pentane were purified by passing through a neutral alumina column 
under argon. Acetonitrile was dried over CaH2 and distilled under N2 prior to use. Pd/C 
was purchased from Strem and heated under high vacuum at 100°C for 12 hours prior to 
use. Silica gel (230-400 mesh) was dried for 12 hours at 180 oC under high vacuum. Flash 
chromatography was performed with this silica gel under an inert atmosphere. All other 
chemicals and solvents were purchased and used as received. 
 NMR spectra were recorded on a Varian VNMRS 600 MHz, VNMRS 500 MHz, 
INOVA 500 MHz, or VNMRS 400 MHz spectrometer. Deuterated solvents were 
purchased from Cambridge Isotope Labs. 11B NMR spectra were externally referenced to 
BF3•Et2O (δ 0). All NMR chemical shifts are reported in ppm relative to residual solvent 
for 1H and 13C NMR. Infrared spectroscopy was performed on a Bruker ALPHA-Platinum 
FT-IR Spectrometer with ATR-sampling module. High-resolution mass spectrometry 
analyses were performed by direct analysis in real time (DART) on a JEOL AccuTOF 
DART instrument. 
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2.5.2 Synthesis of 1,2-Azaborines 
To an oven-dried 1 L round bottom flask equipped with a stir bar was added 
triallylborane (6.70 g, 50.0 mmol) and 250 mL CH2Cl2. The reaction 
mixture was cooled to -78 °C. A solution of boron trichloride (100 mL, 100 
mmol, 1.0 M in hexane) was added to the reaction mixture via cannula transfer at –78 °C 
over 30 min, and the mixture was stirred for 3.5 h at this temperature. A solution of N-
TBS-allylamine (25.7 g, 150 mmol) in 20 mL CH2Cl2 was added to the reaction mixture at 
–78 °C, followed by triethylamine (21.0 mL, 150 mmol). The reaction mixture was slowly 
warmed to room temperature and stirred for 16 h. At the conclusion of the reaction, 
approximately two-third of the solvent was removed under vacuum. The reaction mixture 
was passed through a medium-porosity frit, and the filtrate was concentrated under reduced 
pressure. Vacuum distillation (50-60 °C, 350 mTorr) afforded the desired product 2.23 as 
a colorless liquid (32.3 g, 84%). Spectra of the isolated compound matched published 
values.6a 
In a glove box, Grubbs 1st generation catalyst (1.79 g, 2.17 mmol) was added 
in portion to a stirring solution of aminoborane 2.23 (56.0 g, 217 mmol) in 
500 mL toluene in an oven-dried 1 L round bottom flask. The solution was 
stirred at room temperature for 20 min. To this solution of the ring-closed product, Pd/C 
(14.0 g, 13.16 mmol, 10 wt. % on activated carbon) was added. The reaction mixture was 
refluxed at 135 °C for 16 h. The reaction was monitored by 11B NMR. Usually at this point 
11B NMR indicates the reaction is incomplete, with a minor starting material peak (ca. 42.9 
ppm) remaining. Additional Pd/C (3.00 g, 2.82 mmol, 10 wt. % on activated carbon) was 
added to the reaction mixture and refluxed for an additional 24 h. At the conclusion of the 
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reaction, the reaction mixture was passed through a disposable flash chromatography 
column packed with paper wipes. The solvent was removed under reduced pressure. 
Vacuum distillation (65-70 °C, 1000 mTorr) afforded the desired product 2.24 as a 
colorless liquid (25.8 g, 52% over two steps). Spectra of the isolated compound matched 
published values.6 
To an oven-dried 100 mL round bottom flask was added 2.24 (5.00 g, 22.0 
mmol), acetamide (1.30 g, 22.0 mmol), and 45 mL acetonitrile. The 
reaction mixture was refluxed at 85 oC and stirred for 15 h. After cooling 
to room temperature, the reaction mixture was concentrated under reduced pressure. The 
reaction mixture was redissolved in 23 mL THF and added dodecanol (4.09 g, 22.0 mmol). 
The reaction mixture was heated to 50 oC and stirred for 1.5 h. The solvent was removed 
under reduced pressure. Silica gel column chromatography in a glove box using Et2O as 
the eluent afforded the desired product 2.25 as a white solid (5.5 g, 95%). Spectra of the 
isolated compound matched published values.50 
An oven-dried 250 mL two-neck round bottom flask was charged with 2.25 (5.5 
g, 20.9 mmol) and 22 mL bis(2-butoxyethyl) ether. To the reaction flask, lithium 
aluminum hydride (1.45 g, 38.2 mmol) was added at 0 oC and the reaction 
mixture was stirred for 30 min. Decanoic acid (25.8 g, 150 mmol) was added to the reaction 
mixture to quench at 0 oC and the reaction mixture was stirred for 30 min. Vacuum transfer 
                                                 
50 Baggett, A. W. New Strategies Enabling Diverse Functionalization of Aromatic 1,2-Azaborine Motifs. 
PhD, Boston College, 2016. 
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afforded the desired product 2.1 as a colorless oil (1.07 g, 65%). Spectra of the isolated 
compound matched published values.6   
 To an oven-dried 100 mL round bottom flask was added 2.24 (2.27 g, 10.0 
mmol), acetamide (650 mg, 11.0 mmol), and 50 mL acetonitrile. The reaction 
mixture was refluxed at 85 oC and stirred for 15 h. After cooling to room 
temperature, the reaction mixture was concentrated under reduced pressure. The reaction 
mixture was redissolved in 10 mL THF and added n-butanol (1.83 mL, 20.0 mmol). The 
reaction mixture was stirred at room temperature for 1 h. The solvent was removed under 
reduced pressure. Silica gel column chromatography in a glove box using 10% 
Et2O/pentane as the eluent afforded the desired product 2.26 as a white solid (1.33 g, 88%). 
Spectra of the isolated compound matched published values.6b  
To an oven-dried 100 mL round bottom flask containing 2.26 (1.00 g, 6.62 
mmol) in Et2O (25 mL) a solution of ethyllithium in Et2O was added dropwise 
under nitrogen atmosphere at –30 oC (the ethyllithium solution was prepared 
from 26.50 mL of 0.5 M solution of EtLi in benzene/cyclohexane, 13.24 mmol, which was 
concentrated to dryness and then redissolved in 13 mL Et2O). The reaction mixture was 
stirred for 1 h as it was allowed to slowly warm up to room temperature. The reaction 
progress was monitored by 11B NMR until completion. At the end of the reaction, an HCl 
solution (6.62 mL of 2.0 M solution in Et2O, 13.2 mmol) was added at –30 oC, and the 
reaction mixture was allowed to warm to room temperature and stirred for 1h. The solvent 
was removed under vacuum, and the resulting crude residue was purified by column 
chromatography with isopentane as the eluent in a glove box. The desired product 2.3 was 
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isolated as a colorless oil (397 mg, 56%). Spectra of the isolated compound matched 
published values and are included in Chapter 3.10  
Synthetic procedures and characterization of compound 2.2 are described in Chapter 3. 
 
2.5.3 Protein Preparation and Crystallization 
 Escherichia coli strain RR1 (ATCC® 31343™) was transformed with the subcloned 
plasmids (Addgene plasmids # 18476 and 18477 from Brian Matthews lab, for T4 
lysozyme WT* (L99A) and T4L mutant (S38D L99A M102Q N144D), respectively. 
Ampicillin-resistant transformants were isolated and stored in 20% glycerol stock solution 
in LB (lysogeny broth) media. 
 The bacteria were grown in 200 mL LB media supplemented with 40 mg ampicillin at 
37 oC for 12 h. 160 mL of this culture was added to an Erlenmeyer flask containing 4 liters 
of LB media with 800 mg ampicillin. The resulting mixture was incubated at 37 oC at 240 
rpm shaking speed with filtered air supply. When the optical density reached 0.7 at 600 nm, 
the bacterial cultures were cooled to room temperature by removing them from the 
incubator. Once cooled to room temperature, isopropyl-β-D-1-thiogalactopyranoside 
(IPTG) was added (final concentration of 0.7 mM) to induce the protein expression. The 
cultures were incubated for the induction at 110 rpm shaking speed for 21 h at 25 oC. Then 
the cultures were centrifuged down at 5000 rpm for 30 min at 4 oC. The resulting pellet 
was resuspended in 300 mL of 0.1 M sodium phosphate (pH 6.6), 0.2 M NaCl and added 
30 mL of 0.5 M EDTA (pH 8.0) and the suspension was stirred for 17 h at 4 oC. To the 
suspension was then added 30 mL of 1.0 M MgCl2 and 0.5 mL of DNaseI, and the mixture 
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was stirred at room temperature for 8 h. After the lysis and centrifugation at 15000 rpm for 
30 min at 4 oC, the lysate was collected and dialyzed against 20 mM sodium phosphate 
(pH 6.5 for L99A and pH 6.3 for L99A/M102Q) at 4 oC overnight. The solution containing 
protein was then loaded onto a CM Sepharose Fast Flow (GE healthcare) column that was 
pre-equilibrated with equilibration buffer (50 mM Tris, 1 mM EDTA, pH 7.3). The column 
was washed with 100 mL of equilibration buffer and eluted with a 600 mL linear gradient 
of 300 mM NaCl within the equilibration buffer, and the fractions containing pure protein 
were collected. 
 For crystallization, the protein sample was dialyzed against 100 mM sodium phosphate, 
550 mM NaCl, 0.02% NaN3 (pH 6.5 for L99A and pH 6.3 for L99A/M102) at 4 oC 
overnight. 2- Mercaptoethanol (final concentration of 5 mM) was added to the dialyzed 
sample, and the protein solution was concentrated to 40 mg/mL using Vivaspin 20 (10,000 
mwco (molecular weight cutout)). Protein concentrations were determined by measuring 
absorption at 280 nm. Any precipitate was removed by spinning prior to crystallization. 
 The crystals were obtained by vapor-diffusion hanging-drop or sitting-drop method. 5 
μL of the 40 mg/mL protein solution was mixed with 5 μL of reservoir solution (2.0-2.2 M 
sodium/potassium phosphate, pH 6.7-7.1, 50 mM 2-mercaptoethanol, 50 mM 2-
hydroxyethyl disulfide), and equilibrated against 1.0 mL of the reservoir solution at 4 oC. 
Crystals normally grew within 1-2 weeks. 
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2.5.4 Complex Preparation 
 Suitable crystals were picked and transferred into a microcentrifuge tube and 
maintained in 50 μl of the mother liquor. Crystals were equilibrated with ligands at 4 oC 
for 2-7 days by vapor diffusion method by placing a droplet of each ligand inside of the 
snap-cap of the tube. The complexes were prepared in a glove box for azaborine ligands. 
 
2.5.5 ITC Experiments 
 Isothermal titration calorimetry (ITC) experiments were carried out with Nano ITC 
Low Volume calorimeter from TA instruments. Titrations were run by injection of ligand 
solution to protein solution at 10 oC and 310 rpm stirring rate with a data collection interval 
of 4 min/injection. A total of 40 injections of a total volume of 100 uL ligand solution 
(2.66-3.32 mM) were done with 320 uL protein solution (~0.2 mM). Both ligand and 
protein were in a degassed buffer solution of 5% PEG400, 0.5 M NaCl, 0.1 M sodium 
phosphate (pH 6.8). The protein solution was prepared by dialyzing against the degassed 
buffer and the concentrations were determined by molar absorptivity at 280 nm. Due to the 
limited solubility of the small molecule ligands in aqueous buffer, accurate concentrations 
of ligand solution were determined by GC against a calibrated internal standard. Baseline 
mixing heats were estimated by injection of ligand solution into the buffer and subtracted 
from individual titration curve. The resulting reaction heat profiles were fit to the 
independent binding model with the stoichiometry n fixed to 1.0. All data were analyzed 
using NanoAnalyze software. Experiments were repeated five times and averaged with 
standard deviation error of the mean. 
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* Representative ITC data 
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2.5.6 X-ray Structure Data Collection, Structure Determination, and Refinement 
 Prior to X-ray data collection the crystals were flash-frozen in liquid nitrogen with 
protection of N-paratone (Hampton Research). Data were collected from beamline 8.3.1. 
at the Advanced Light Source, Berkeley, CA. Reflection data were integrated and scaled 
with d*TREK.51 Molecular replacement was performed using PHASER-MR52 with the 
ligand-free T4 lysozyme L99A (PDB code: 3DMV53) and L99A/M102Q (PDB code: 
1LGU3636) as the starting models. Initial refinements were carried out with simulated 
annealing using PHENIX54 and COOT55. Ligand restraints of azaborines were generated 
by REEL based on knowledge of the crystal structures of the small molecules. All models 
were checked by MolProbity56 and the PDB validation tool prior to deposition. Figures 
were generated with PyMol (The PyMOL Molecular Graphics System, Schrödinger, LLC). 
The ethyl derivatives were solved to a resolution of 1.3, 1.47 and 1.65 Å for ethylbenzene-
L99A/M102Q, 2.3-L99A/M102Q, and 2.3-L99A, respectively, allowing alternative 
conformations, which are visible in the electron density maps, to be modeled explicitly. 
Their occupancies were refined automatically within phenix.refine using the 
“strategy=occupancies” flag. Hence occupancies were determined without manual 
intervention during the final cycles of the structural refinement. 
                                                 
51 Pflugrath, J. W. Acta Cryst. 1999, D55, 1718–1725. 
52 McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. J. Appl. 
Cryst. 2007, 40, 658–674. 
53 Liu, L.; Baase, W. A.; Matthews, B. W. J. Mol. Biol. 2009, 385, 595–605. 
54 Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-
W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; 
Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. Acta Cryst. 2010, D66, 213–221. 
55 Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Acta Cryst. 2010, D66, 486–501. 
56 Chen, V. B.; Arendall, W. B.; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; Murray, L. W.; 
Richardson, J. S.; Richardson, D. C. Acta Cryst. 2010, D66, 12–21. 
548 
 
2.5.7 Data Deposition 
 The coordinates and structure factors have been deposited in the RCSB Protein Data 
Bank with PDB ID’s 5JWS, 5JWT, 5JWU, 5JWV, and 5JWW for L99A with B-Et-1,2-
azaborine (2.3), L99A/M102Q with benzene, 1,2-dihydro-1,2-azaborine (2.1), 
ethylbenzene, B-Et-1,2-azaborine (2.3), respectively. 
* Overview of PBD codes for ligands in the two T4L cavities 
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* X-ray Data Collection and Structure Refinement Statistics 
Ligand 
B-Et-1,2-Azaborine 
(2.3) 
benzene 
Protein L99A L99A/M102Q 
PDB entry 5JWS 5JWT 
Data collection   
Space group P3221 P3221 
Cell dimensions   
a, b, c (Å) 60.13, 60.13, 95.61 60.23, 60.23, 96.87 
α, β, γ () 90, 90, 120 90, 90, 120 
Resolution (Å) 31.87-1.65 (1.71 - 1.65)a 45.93-1.41 (1.46-1.41) a 
Rmerge 0.118 (0.294) 0.058 (0.321) 
I/σ(I) 9.6 (3.3) 10.7 (2.9) 
Completeness (%) 96.0 (96.0) 99.6 (99.6) 
Redundancy 5.65 (5.54) 5.19 (4.98) 
   
Refinement   
Resolution (Å) 31.87-1.65 45.93-1.41 
No. reflections 23691 (2417) 39665 (3884) 
Rwork / Rfree 0.1944/ 0.2328 0.2201/ 0.2429 
No. atoms   
Protein 1402 1371 
Ligand/ion 18 6 
Water 321 299 
B factors   
Protein 15.65 16.40 
Ligand/ion 15.72 13.31 
Water 31.05 29.11 
R.m.s. deviations   
Bond lengths (Å) 0.006 0.005 
Bond angles () 0.83 0.79 
a Values in parentheses are for highest-resolution shell. 
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Ligand 
1,2-dihydro- 
1,2-azaborine (2.1) 
ethylbenzene 
Protein L99A/M102Q L99A/M102Q 
PDB entry 5JWU 5JWV 
Data collection   
Space group P3221 P3221 
Cell dimensions   
a, b, c (Å) 60.10, 60.10, 96.77 60.16, 60.16, 96.81 
α, β, γ () 90, 90, 120 90, 90, 120 
Resolution (Å) 45.84-1.70 (1.76-1.70)a 45.88-1.30 (1.35-1.30)a 
Rmerge 0.084 (0.438) 0.070 (0.327) 
I/σ(I) 8.6 (2.3) 11.0 (4.0) 
Completeness (%) 98.1 (98.1) 99.9 (99.9) 
Redundancy 5.63 (5.62) 5.72 (5.73) 
   
Refinement   
Resolution (Å) 45.84-1.70 45.88-1.30 
No. reflections 22407 (2239) 50443 (4979) 
Rwork / Rfree 0.2261/ 0.2509 0.1838/ 0.2035 
No. atoms   
Protein 1379 1336 
Ligand/ion 8 16 
Water 144 367 
B factors   
Protein 28.82 12.12 
Ligand/ion 30.17 10.61 
Water 39.74 25.54 
R.m.s. deviations   
Bond lengths (Å) 0.007 0.006 
Bond angles () 1.00 0.83 
a Values in parentheses are for highest-resolution shell. 
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Ligand 
B-Et-1,2-Azaborine 
(2.3) 
Protein L99A/M102Q 
PDB entry 5JWW 
Data collection  
Space group P3221 
Cell dimensions  
a, b, c (Å) 60.16, 60.16, 97.09 
α, β, γ () 90, 90, 120 
Resolution (Å) 22.95-1.47 (1.52-1.47)a 
Rmerge 0.107 (0.527) 
I/σ(I) 8.4 (1.6) 
Completeness (%) 98.2 (98.2) 
Redundancy 5.25 (5.40) 
  
Refinement  
Resolution (Å) 22.95-1.47 
No. reflections 34608 (3459) 
Rwork / Rfree 0.2139/ 0.2491 
No. atoms  
Protein 1370 
Ligand/ion 17 
Water 297 
B factors  
Protein 19.55 
Ligand/ion 21.62 
Water 34.00 
R.m.s. deviations  
Bond lengths (Å) 0.006 
Bond angles () 0.84 
a Values in parentheses are for highest-resolution shell. 
 
 
2.5.8 X-ray Structure Data Refinement Details 
2.5.8.1 Modeling of Alternative Positions 
 We modeled alternative positions in this work where present, based on difference 
features in the electron density maps. Figure 2.21 illustrates how alternative conformations 
are engulfed by “wider” electron densities, whereas the single conformation of Q102 in the 
ethylbenzene structure shows a more “tapered” profile. 
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Figure 2.21 2Fo-Fc electron density maps, rendered at 1 sigma, showing alternate Q102 conformers for 
different ligand complexes 
 
 
 We have re-refined the benzene-L99A/M102Q structure omitting conformers using the 
same refinement protocol. The resulting Fo-Fc maps show green difference density for the 
omitted residue in the presence of only one conformer. In addition Rfree values increase 
from 23.1% for both Q102 conformers to 23.3% for conformer A and 23.4% for conformer 
B, respectively (Figure 2.22). 
 
Figure 2.22 Positive Fo-Fc difference density (shown as green mesh at 3sigma) and increased Rfree values 
for structures containing only one conformer (2Fo-Fc maps are shown as blue mesh at 1sigma) 
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2.5.8.2 Determining the Position of N and B 
 We determined the positions of N vs. B based on three criteria. First, we inspected 
electron density maps for differential features, including Fo-Fc difference density in early 
refinement rounds. Additionally we utilized differences in the number of electrons between 
B, C and N to determine their relative positions. Figure 2.23 shows that the highest electron 
density peak (at 4.2 sigma) covers the most electron-rich atom, nitrogen. 
 
Figure 2.23 2Fo-Fc maps shown at 1 and 4.2 sigma to reveal the highest electron density peaks around the 
nitrogen atom of 2.1 
 
 
 Second, we monitored atomic B factor distribution upon refining different ligand 
orientations. This approach is based on the expectation that atomic B factors should be 
homogenously distributed within the ligand and discrepancies can indicate alternative 
conformations or ligand flips. Third, the hydrogen-bonding ability of N vs. B helps to 
disambiguate their relative position. 
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 To illustrate the second point, we re-refined the 2.1-L99A/M102Q structure with two 
different orientations of the 2.1 ligand using the identical refinement protocol (Figure 2.24). 
For the correct ligand orientation, no difference density is visible and the B-factors of N 
and B are of comparable magnitude. For the incorrect ligand orientation, with N and B 
being swapped, difference density appears and B-factors differ considerably (red box). 
Rfree values confirm this trend but are expectedly not significantly different. 
 
Figure 2.24 Ligand conformations determined by monitoring the appearance of Fo-Fc difference density 
(green mesh at 3 sigma on the right) and the B-factor distribution upon re-refinement of alternative ligand 
positions using an identical refinement protocol 
 
555 
 
3. Chapter 3: Binding Study of Ethylbenzene Analogs of 1,2-
Azaborines in T4 Lysozyme Mutant Cavity 
3.1 Introduction 
 1,2-Azaborines have unique electronic structures compared to carbon-based arenes due 
to the presence of a polar B–N bond. In addition, as discussed in 2.1.2, one of the beneficial 
features of 1,2-azaborines to carbonaceous counterparts is the multiplied number of 
constitutional isomers possible even when mono-substituted (Figure 2.2). Thus, in the 
context of our biomedical research efforts, we were interested to see how the binding of 
different ethyl-substituted 1,2-azaborines to proteins would all compare with that of all-
carbon ethylbenzene. For this study, we prepared five 1,2-azaborine regioisomers of 
ethylbenzene and used them in comparative binding studies to the L99A T4 lysozyme 
mutant. 
 
3.2 Background 
3.2.1 Previous Efforts towards Regio-Selective Functionalization of 1,2-Azaborines 
 Electronic differences of each position of 1,2-azaborine ring induced by the asymmetric 
nature of the heterocyclic core has allowed selective functionalization of all six positions. 
This chapter will treat only functionalization of 1,2-azaborines at C4 and C5; previous 
works on functionalization at N, B, C3, and C6 will be reviewed in detail in Chapter 4. 
 Efforts to synthesize C4- and C5-substituted 1,2-azaborines led to the discovery that 
Ir-catalyzed borylation of N-substituted 1,2-azaborines gives a mixture of C4- and C5-
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borylated products.1 The origin of the slight preference for C5 in most cases is unclear; this 
selectivity was observed regardless of the boron and nitrogen substituents of the substrates 
(Table 3.1), and the calculated pKa values 2  for C4–H and C5–H are 45.8 and 46.0, 
respectively. 
 
Table 3.1 Ir-catalyzed borylation of N-substituted 1,2-azaborines 
 
 
 Unfortunately, most of the mixtures of borylated products in Table 3.1 were not 
separable by column chromatography. Selective oxidation of C4-regioisomer in the 
mixture of C4- and C5-borylated compounds (3.2 a/3.2a’) was achieved using N-
methylmorpholine N-oxide (NMO) to afford the corresponding C4-OH product (3.3, 
                                                 
1 Baggett, A. W. New Strategies Enabling Diverse Functionalization of Aromatic 1,2-Azaborine Motifs. PhD, 
Boston College, 2016.   
2 Baggett, A. W.; Vasiliu, M.; Li, B.; Dixon, D. A.; Liu, S.-Y. J. Am. Chem. Soc. 2015, 137, 5536–5541.   
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Scheme 3.1). Using this method, the pure C5-Bpin compound (3.2a’) was recovered in 90% 
yield. 
 
Scheme 3.1 NMO oxidation of a mixture of C4- and C5-borylated 1,2-azaborines 
 
 
3.3 Syntheses of Ethylbenzene Analogs of 1,2-Azaborines and Their Binding Study in 
the Cavity of T4 Lysozyme Mutants 
3.3.1 Synthesis of Ethylbenzene Derivatives of 1,2-Azaborines 
3.3.1.1 Synthesis of N-Ethyl-1,2-Azaborine 
 To prepare N-ethyl-1,2-azaborine,  we followed the previously reported synthetic 
method with minor modifications.3  Addition of N-ethylallylamine to in situ-generated 
allylboron dichloride afforded diallyl species 3.5. Ring-closing metathesis using Grubbs 
1st generation catalyst, followed by Pd-mediated oxidation produced 1,2-azaborine 3.7. 
Reduction of 3.7 with lithium aluminium hydride (LiAlH4) furnished 3.8 (Scheme 3.2). 
 
 
 
                                                 
3 Marwitz, A. J. V.; Abbey, E. R.; Jenkins, J. T.; Zakharov, L. N.; Liu, S.-Y. Org. Lett. 2007, 9, 4905–4908. 
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Scheme 3.2 Synthesis of N-ethyl-1,2-azaborine 3.8 
 
 
3.3.1.2 Synthesis of B-Ethyl-1,2-Azaborine 
 Synthesis of B-ethyl-1,2-azaborine is described in section 2.3.2 (Scheme 2.1). 
 
3.3.1.3 Synthesis of C3-Ethyl-1,2-Azaborine 
 C3-Ethylated 1,2-azaborine can be accessed starting from C3-brominated compound 
3.9,4 which first undergoes a two-step boron-substitution/N-deprotection1,5 to give 3.10. 
Reaction with LiAlH4, followed by acidic quench results in formation of the 1,2-azaborine 
equivalent of bromobenzene (3.11). Negishi cross-coupling compatible with the BH group 
in 3.11 was employed to introduce the desired ethyl group in the final product (3.12) in 
moderate yield (Scheme 3.3). 
 
                                                 
4 Brown, A. N.; Li, B.; Liu, S.-Y. J. Am. Chem. Soc. 2015, 137, 8932–8935. 
5 Lamm, A. Fundamental Chemistry of 1,2-Dihydro-1,2-Azaborines. PhD, University of Oregon, 2012. 
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Scheme 3.3 Synthesis of C3-ethyl-1,2-azaborine 3.12 
 
 
3.3.1.4 Synthesis of C6-Ethyl-1,2-Azaborine 
 C6-Ethyl-1,2-azaborine was prepared by following the previously reported method.1 
Iridium catalyzed borylation of NH-containing azaborine 3.13 afforded C6-borylated 
product in good yield and regioselectivity. Suzuki cross coupling of 3.14 with 
vinylbromide installed a C6-vinyl group that was readily reduced through Pd-catalyzed 
hydrogenation. Utilizing Cu-catalyzed radical reaction,1 the benzyl protecting group on 
boron was transformed into an alkoxy group. Subsequent reduction with LiAlH4 furnished 
the desired product (3.18) in moderate yield (Scheme 3.4).  
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Scheme 3.4 Synthesis of C6-ethyl-1,2-azaborine 3.18 
 
 
3.3.1.5 Syntheses of C4- and C5-Ethyl-1,2-Azaborines 
 Synthesis of C4- and C5-substituted 1,2-azaborines is most challenging because those 
positions are distal from hetero atoms to take advantage of electronic nature for selective 
transformations to occur. Under conditions similar to those discussed in 3.2.1, Ir-catalyzed 
borylation of N-substituted starting material 3.20 allowed access to both C4- and C5-
borylated products in a 36:64 ratio. The steric bulk of the TBS group precludes C6-
functionalization. We found that the resulting regioisomers exhibit a key difference in 
solubility: the majority of C4-borylated product 3.21a can be precipitated out from the 
mixture using pentane, while the supernatant becomes correspondingly enriched with the 
other isomer (3.21b). The remaining residual C4-isomer can be separated from the C5-
isomer by column chromatography. With pure samples of both regioisomers in hand, we 
proceeded through a similar reaction sequence as that used in the preparation of C6-ethyl-
1,2-azaborine. Suzuki-Miyaura cross-coupling with vinyl bromide followed by 
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hydrogenation afforded C4- and C5-ethyl substituted products 3.23a and 3.23b, 
respectively.  Deprotection on both nitrogen and boron resulted in the requisite precursors 
(3.25a and 3.25b) to the final products. The final boron substitution reaction of 3.25b with 
LiAlH4 afforded the C5-ethyl-1,2-azaborine 3.27. The C4-isomer (3.26), however, proved 
to be far more susceptible to decomposition during the reaction workup and thus could not 
be isolated at present (Scheme 3.5). 
 
Scheme 3.5 Synthesis of C4- and C5-ethyl-1,2-azaborines, 3.26 and 3.27 
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3.3.2 Binding Studies of Ethylbenzene Derivatives in T4 Lysozyme Mutant L99A 
3.3.2.1 Isothermal Titration Calorimetry Data 
 To measure differences in the binding free energy of the regioisomers in the L99A T4 
lysozyme binding cavity, we performed ITC experiments. Surprisingly, the more polar N-
ethyl-1,2-azaborine (3.8) gained 0.6 kcal/mol binding free energy in the non-polar pocket 
of L99A relative to ethylbenzene (Table 3.2, –6.11 vs. –5.55 kcal/mol). The origin of this 
observation remains unclear at this point. B-Ethyl and C3-ethyl-1,2-azaborines (3.28 and 
3.12) showed relatively weaker binding affinities. However, the binding free energies for 
C5- and C6-ethyl derivatives (3.27 and 3.18) were also about 1.0 kcal/mol stronger in 
comparison with ethylbenzene. 
 
Table 3.2 Binding free energy and affinity determined by ITC 
 
 
 The position of the ethyl substituent of ligand may have influence on these empirical 
binding observation. Figure 3.1 (left) shows an electrostatic potential map of the 1,2-
azaborine core and the calculated dipole moment value (~ 2.2 D).6 The ethyl group of 
                                                 
6 Chrostowska, A.; Xu, S.; Lamm, A. N.; Mazière, A.; Weber, C. D.; Dargelos, A.; Baylère, P.; Graciaa, A.; 
Liu, S-Y. J. Am. Chem. Soc. 2012, 134, 10279–10285. 
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relatively stronger binders (C5, C6, and N-ethyl derivatives) is positioned comparatively 
on the opposite side of that of relatively weaker binders (C3 and B-ethyl isomers; Figure 
3.1). Thus, we speculate that the observed binding phenomena may originate from dipole 
interaction induced by dipole moment of ligand and electronic nature of the surrounding 
protein residue. 
 
Figure 3.1 Dipole moment of 1,2-azaborine and binding trend of BN-ethyl derivatives 
 
  
 In conclusion, more experimental data (eg. structural determination and binding 
thermodynamics of C4-ethyl-1,2-azaborine) and computational modeling will need to be 
performed to give a more in-depth understanding of the observed binding behavior.  
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3.4 Conclusions 
 Recent developments in synthetic methods to functionalize the carbon positions of 1,2-
azaborines allowed us to selectively substitute each of the six possible positions. Five ethyl-
substituted 1,2-azaborines were thereby successfully synthesized.  
 With these ethylbenzene derivatives in hand, we proceeded to measuring the 
thermodynamics of their binding to T4 lysozyme mutant L99A. Since the compounds 
examined here are isosteric, we predicted that the main factors that produce differences in 
binding energies would originate from electronic differences instead. Specifically, we 
initially hypothesized that the dipole moment existing in azaborine ring would play a role. 
This is consistent with our preliminary observation that C5, C6, and N-ethyl substituted 
1,2-azaborines are relatively stronger binders than the C3 and B-ethyl substituted isomers. 
However, dipole-dipole interactions, for example interactions with the helix macro-dipole, 
are largely dependent on the distance of the interacting components.7 As the binding cavity 
of L99A is relatively large (150 Å3), it may be difficult for dipole-dipole interactions 
between the bound ligand and the surrounding helix to span the distances involved.  
 It is also possible that the binding free energy differences observed for each ligand are 
induced by local dipolar interactions and possibly hydrogen or dihydrogen bonding. We 
are in the process of computationally calculating the binding energetics of each complex 
in an effort to develop a model that is consistent with the experimental results.   
 
                                                 
7 (a) Le Fèvre, R. J. W. Dipole moments; their measurement and application in chemistry. London, Methuen, 
1953. (b) Atkins, P. W. and Paula, J. D. Physical chemistry for the life sciences. New York, Oxford University 
Press; Freeman, 2006. (c) Bloomfield, M. M. Chemistry and the living organism. New York, Wiley, 1992. 
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3.5 Experimental 
3.5.1 General Information 
 All oxygen- and moisture-sensitive manipulations were carried out under an inert 
atmosphere (N2) using either standard Schlenk techniques or a glove box. THF, Et2O, 
CH2Cl2, and pentane were purified by passing through a neutral alumina column under 
argon. Acetonitrile and toluene were dried over CaH2 and distilled under N2 prior to use. 
Pd/C was purchased from Strem and heated under high vacuum at 100 °C for 12 hours 
prior to use. Silica gel (230-400 mesh) was dried for 12 hours at 180 oC under high vacuum. 
Flash chromatography was performed with this silica gel under an inert atmosphere. All 
other chemicals and solvents were purchased and used as received. 
 NMR spectra were recorded on a Varian VNMRS 600 MHz, VNMRS 500 MHz, 
INOVA 500 MHz, or VNMRS 400 MHz spectrometer. Deuterated solvents were 
purchased from Cambridge Isotope Labs. 11B NMR spectra were externally referenced to 
BF3•Et2O (δ 0). All NMR chemical shifts are reported in ppm relative to residual solvent 
for 1H and 13C NMR. Infrared spectroscopy was performed on a Bruker ALPHA-Platinum 
FT-IR Spectrometer with ATR-sampling module. High-resolution mass spectrometry 
analyses were performed by direct analysis in real time (DART) on a JEOL AccuTOF 
DART instrument or by Agilent 6220 TOF using APPI, and toluene as dopant. 
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3.5.2 Synthesis of 1,2-Azaborines 
N-Ethyl-1,2-Azaborine  Synthesis: 
Compound 3.8 was synthesized following previously reported methods.3 
Spectra of the isolated compound matched published values. 1H NMR (600 
MHz, CD2Cl2):  7.59 (t, J = 8.4 Hz, 1H), 7.31 (d, J = 6.0 Hz, 1H), 6.83 (d, J 
= 10.8 Hz, 1H), 6.40 (td, J = 6.6, 1.2 Hz, 1H), 4.95 (br q, J = 138 Hz, 1H), 3.86 (q, J = 7.2 
Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H). 11B NMR (192 MHz, CD2Cl2): δ 32.1 (d, J = 128 Hz). 
13C NMR (151 MHz, CD2Cl2): δ 142.8, 138.7, 131.4 (br), 112.3, 53.4, 19.3. FTIR (thin 
film): 3034, 2977, 2933, 2518, 2476, 1603, 1512, 1473, 1451, 1406, 1378, 1251, 1132, 
1008, 954, 879, 803, 741, 603 cm-1. HRMS (DART-TOF) calcd for C6H11BN ([M+H]+): 
108.09845, found: 108.09897. 
 
B-Ethyl-1,2-Azaborine Synthesis: 
Synthesis of compound 3.28 was described in Chapter 2. Spectra of the isolated 
compound matched published values.8 1H NMR (600 MHz, CD2Cl2):  7.86 
(br t, J = 48.0 Hz, 1H), 7.55 (dd, J = 10.5, 6.5 Hz, 1H), 7.25 (t, J = 7.5 Hz, 1H), 6.71 (d, J 
= 11.0 Hz, 1H), 6.20 (t, J = 6.0 Hz, 1H), 1.18-1.10 (m, 2H), 1.09-1.05 (m, 3H). 11B NMR 
(160 MHz, CD2Cl2): δ 37.5. 13C NMR (151 MHz, CD2Cl2): δ 143.8, 134.1, 129.6 (br), 
110.1, 26.3, 10.2. FTIR (thin film): 3383, 3022, 2954, 2931, 2870, 1615, 1539, 1507, 1461, 
                                                 
8 Knack, D. H.; Marshall, J. L.; Harlow, G. P.; Dudzik, A.; Szaleniec, M.; Liu, S.-Y.; Heider, J. Angew. 
Chem., Int. Ed. 2013, 52, 2599–2601.   
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1426, 1397, 1296, 1249, 1157, 1129, 1007, 836, 735 cm-1. HRMS (DART-TOF) calcd for 
C6H11BN ([M+H]+): 108.09845, found: 108.09903. 
 
C3-Ethyl-1,2-Azaborine  Synthesis: 
To a 100 mL round bottom flask containing compound 3.9 (5.70 g, 18.6 
mmol) in acetonitrile (40 mL) was added acetamide (1.21 g, 20.5 mmol) 
under nitrogen atmosphere. The reaction flask was equipped with a reflux 
condenser and heated to 85 oC and refluxed for 3 h. After the reaction is cooled to room 
temperature, the solvent was removed under vacuum. The reaction mixture was dissolved 
in THF (15 mL), and added n-butanol (2.04 mL, 22.3 mmol). The reaction mixture was 
then stirred at room temperature for 3 h. The solvent was removed under vacuum and the 
product was isolated by silica gel column chromatography with 5-15% Et2O/pentane as an 
eluent, affording the desired product 3.10 as colorless oil (3.93 g, 92%). 1H NMR (600 
MHz, CD2Cl2):  7.71 (d, J = 6.6 Hz, 1H),  7.05 (t, J = 6.0 Hz, 1H), 6.95 (br s, 1H), 5.81 
(td, J = 6.6, 1.8 Hz, 1H), 3.91 (t, J = 7.2 Hz, 2H), 1.71-1.66 (m, 2H), 1.48-1.42 (m, 2H), 
0.96 (t, J = 7.8 Hz, 3H). 11B NMR (192 MHz, CD2Cl2): δ 25.9. 13C NMR (151 MHz, 
CD2Cl2): δ 146.2, 132.8, 106.5, 64.4, 34.0, 19.6, 14.2 (The carbon adjacent to boron was 
not observed). FTIR (thin film): 3383, 2957, 2933, 2872, 1621, 1531, 1443, 1288, 968, 694, 
671 cm-1. HRMS (DART-TOF) calcd for C8H14BBrNO ([M+H]+): 230.03518, found: 
230.03539. 
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A 250 mL round bottom flask was charged with compound 3.10 (2.70 g, 11.7 
mmol) and Et2O (120 mL). Lithium aluminium hydride (178 mg, 4.70 mmol) 
was added in small portions at room temperature under nitrogen atmosphere. The 
reaction was monitored by 11B NMR and at the completion HCl solution (9.40 mL, 18.8 
mmol, 2.0 M in Et2O) was added dropwise at room temperature and stirred for 30 min. 
After removing the solvent, silica gel column chromatography using 30% Et2O/pentane as 
eluent afforded the desired product 3.11 as colorless oil (1.14g, 62%). 1H NMR (500 MHz, 
CD2Cl2):  8.42 (br t, J = 57 Hz, 1H),  7.91 (d, J = 6.5 Hz, 1H), 7.39 (t, J = 7.0 Hz, 1H), 
6.34 (t, J = 6.5 Hz, 1H), 5.02 (br q, J = 139 Hz, 1H). 11B NMR (192 MHz, CD2Cl2): δ 31.4 
(d, J =  143 Hz). 13C NMR (126 MHz, CD2Cl2): δ 145.4, 133.7, 129.2 (br), 112.2. FTIR 
(thin film): 3385, 25612, 1608, 1520, 1416, 1311, 1238, 988, 863, 734, 646, 593 cm-1. 
HRMS (DART-TOF) calcd for C4H6BBrN ([M+H]+): 157.97767, found: 157.97760. 
Compound 3.11 (1.14 g, 7.24 mmol) in THF (100 mL) in a 250 mL round bottom 
flask was added bis(tri-tert-butylphosphine)palladium (185 mg, 0.362 mmol) 
under nitrogen atmosphere. The reaction was cooled to 0 oC and diethylzinc 
solution (10.9 mL, 10.9 mmol, 1.0 M in hexane) was added dropwise. The reaction was 
slowly warmed to room temperature and stirred for 14 h under nitrogen. The solvent was 
removed under reduced pressure. Silica gel column chromatography using 100% 
isopentane afforded the desired product 3.12 as colorless oil (337 mg, 44%). 1H NMR (500 
MHz, CD2Cl2):  8.32 (br t, J = 57 Hz, 1H),  7.40 (d, J = 6.0 Hz, 1H), 7.22 (t, J = 7.0 Hz, 
1H), 6.33 (t, J = 6.5 Hz, 1H), 4.95 (br q, J = 128 Hz, 1H), 2.58 (q, J = 7.5 Hz, 2H), 1.18 (t, 
J = 7.5 Hz, 3H). 11B NMR (160 MHz, CD2Cl2): δ 31.6 (d, J = 127 Hz). 13C NMR (126 
MHz, CD2Cl2): δ 150.6 (br), 140.4, 131.7, 111.4, 30.3, 17.1. FTIR (thin film): 3389, 2960, 
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2927, 2869, 2516, 2487, 1611, 1542, 1433, 1209, 1055, 926, 868, 776, 732, 597, 537 cm-
1. HRMS (DART-TOF) calcd for C6H11BN ([M+H]+): 108.09845, found: 108.09897. 
 
C4-Ethyl-1,2-Azaborine  Synthesis: 
An oven-dried 250 mL round bottom flask was charged with 
magnesium turnings (2.40 g, 98.8 mmol) with a crystal of I2 and 
50 mL THF, and a solution of 4-methoxybenzyl chloride (12.0 g, 
76.6 mmol) in 100 mL THF was added to the flask. The mixture was allowed to stir at 
room temperature for 1 h during which time a gentle reflux was observed as the Grignard 
reagent was formed. This Grignard reagent solution was added in portions to a 250 mL 
round bottom flask containing 3.19 (15.0 g, 65.9 mmol) dissolved in 50 mL Et2O until the 
reaction was judged to be complete by 11B NMR. Pentane was added at this point to 
precipitate magnesium salts and the reaction mixture was filtered through Celite. The 
filtrate was concentrated under reduced pressure. The crude material was purified by silica 
gel column chromatography using 10-100% CH2Cl2 in pentane as an eluent to afford the 
desired product 3.20 as a colorless oil (17.0 g, 82%). 1H NMR (500 MHz, CD2Cl2):  7.37 
(dd, J = 11.5, 5.5 Hz, 1H),  7.32 (d, J = 7.0 Hz, 1H), 7.01 (d, J = 8.0 Hz, 2H), 6.79 (d, J = 
8.0 Hz, 2H), 6.28 (d, J = 11.5 Hz, 1H), 6.22 (t, J = 6.0 Hz, 1H), 3.76 (s, 3H), 2.70 (s, 2H), 
0.98 (s, 9H), 0.54 (s, 6H). 11B NMR (160 MHz, CD2Cl2): δ 40.9. 13C NMR (151 MHz, 
CD2Cl2): δ 157.3, 143.1, 138.8, 136.5, 131.2 (br), 130.6, 114.1, 111.3, 55.7, 29.6 (br), 27.0, 
19.7, –1.0. FTIR (thin film): 2954, 2931, 2858, 1608, 1507, 1391, 1243, 1146, 1039, 985, 
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842, 811, 711. 689, 571 cm-1. HRMS (DART-TOF) calcd for C18H29BNOSi ([M+H]+): 
314.2111, found: 314.2127. 
Under nitrogen atmosphere, a 150 mL pressure vessel 
was charged with 3.20 (15.73 g,  50.22 mmol), 
[Ir(OMe)(cod)]2 (499 mg, 0.753 mmol), 4,4’-di-tert-
butyl-2,2’-bipyridine (dtbpy) (404 mg, 1.51 mmol), and bis(pinacolato)diboron (B2pin2) 
(12.75 g, 50.22 mmol), and 67.0 mL methyl tert-butyl ether (MTBE). The reaction mixture 
was heated at 75 °C for 17 h. The solvent was removed under reduced pressure. The desired 
product 3.21a was precipitated in pentane and filtered off. The remaining mixture of 3.21a 
and 3.21b was purified by silica gel column chromatography using 10% CH2Cl2 in pentane 
as an eluent to afford 3.21a as a white solid (4.76 g, 22%). 1H NMR (500 MHz, CD2Cl2): 
 7.29 (d, J = 6.5 Hz, 1H),  7.02 (d, J = 8.0 Hz, 2H), 6.87 (s, 1H), 6.67 (d, J = 8.5 Hz, 2H), 
6.50 (d, J = 7.0 Hz, 1H), 3.79 (s, 3H), 2.71  (s, 2H), 1.26 (s, 12H), 0.97 (s, 9H), 0.53 (s, 
6H). 11B NMR (160 MHz, CD2Cl2): δ 40.4, 30.4. 13C NMR (151 MHz, CD2Cl2): δ 157.4, 
141.1 (br), 137.4, 136.2, 130.7, 129.6 (br), 114.7, 114.1, 84.3, 55.7, 29.4 (br), 26.9, 25.2, 
19.6, –1.0. FTIR (thin film): 2977, 2931, 2859, 1611, 1509, 1485, 1388, 1361, 1323, 1244, 
1145, 1066, 987, 964, 874, 841, 822, 809, 785, 693 cm-1. HRMS (APPI-TOF) for 
C24H40B2NO3Si ([M+H]+) found: 438.304199. 
Inside a drybox, a 250 mL pressure vessel was charged with 
3.21a (4.76 g, 10.8 mmol), Pd(dppf)Cl2·CH2Cl2 (266 mg, 
0.325 mmol), KOH (1.83 g, 32.5 mmol), and a solution of 
vinyl bromide (43.4 mL, 43.4 mmol, 1 M in THF) in MTBE (37 mL) and H2O (3.1 mL). 
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The reaction mixture was heated to 80 °C for 45 min. After cooling the reaction mixture to 
room temperature, the solvent was removed under reduced pressure. Silica gel column 
chromatography using 10-50% CH2Cl2 in pentane as an eluent afforded the desired product 
3.22a as a colorless liquid (2.49 g, 68%). 1H NMR (500 MHz, CD2Cl2):  7.31 (d, J = 7.5 
Hz, 1H), 7.02 (d, J = 8.5 Hz, 2H), 6.80 (d, J = 8.5 Hz, 2H), 6.46 (dd, J = 17.5, 10.5 Hz, 
1H), 6.39 (dd, J = 7.5, 2.5 Hz, 1H), 6.17 (d, J = 2.0 H, 2H),  5.66 (d, J = 17.5 H, 1H), 5.21 
(d, J = 10.5 Hz, 1H), 3.77 (s, 3H), 2.69 (s, 2H), 0.98 (s, 9H), 0.53 (s, 6H). 11B NMR (160 
MHz, CD2Cl2): δ 41.2. 13C NMR (151 MHz, CD2Cl2): δ 157.3, 150.2, 139.6, 139.3, 136.2, 
130.6, 129.3 (br), 116.1, 114.1, 108.0, 55.7, 29.5 (br), 26.9, 19.7, –1.2. FTIR (thin film): 
2954, 2930, 2858, 1630, 1604, 1509, 1494, 1298, 1243, 1131, 1039, 985, 913, 841, 822, 
786, 691, 420 cm-1. HRMS (APPI-TOF) for C20H31BNOSi ([M+H]+) found: 339.231598. 
Inside a drybox, a 250 mL round bottom flask was charged 
with 3.22a (2.76 g, 8.13 mmol), Pd/C (519 mg of 10 wt% Pd, 
0.489 mmol) in ethylacetate (70 mL). The reaction mixture 
was stirred at room temperature for 4 h under 1 atm H2 atmosphere. The solvent was 
removed under reduced pressure. Silica gel column chromatography using 15-40% CH2Cl2 
in pentane as an eluent afforded the desired product 3.23a as a colorless liquid (2.53 g, 
91%). 1H NMR (500 MHz, CD2Cl2):  7.25 (d, J = 6.5 Hz, 1H), 7.16 (d, J = 8.5 Hz, 2H), 
6.80 (d, J = 8.5 Hz, 2H), 6.11 (d, J = 7.0 Hz, 1H), 6.06 (s, 1H), 3.77 (s, 3H), 2.68 (s, 2H), 
2.36 (q, J = 8.0 Hz, 2H), 1.07 (t, J = 8.0 Hz, 3H), 0.98 (s, 9H), 0.52 (s, 6H). 11B NMR (160 
MHz, CD2Cl2): δ 40.6. 13C NMR (151 MHz, CD2Cl2): δ 159.4, 157.3, 138.8, 136.5, 130.6, 
127.2 (br), 114.0, 112.6, 55.7, 31.7, 29.5 (br), 27.0, 19.7, 14.5, –1.1. FTIR (thin film): 2956, 
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2931, 2858, 1617, 1508, 1464, 1279, 1243, 1178, 1063, 1039, 994, 866, 841, 808, 751, 693, 
485 cm-1. HRMS (APPI-TOF) for C20H33BNOSi ([M+H]+) found: 342.243286. 
To a solution of 3.23a (2.53 g, 7.42 mmol) in 74 mL THF was 
added a solution of tetrabutylammonium fluoride (7.42 mL, 
7.42 mmol, 1 M in THF) and the reaction mixture was stirred 
at room temperature for 30 min. The solvent was removed under reduced pressure. Silica 
gel column chromatography using 30-50% CH2Cl2 in pentane as an eluent afforded the 
desired product 3.24a as a colorless oil (1.60 g, 95%). 1H NMR (500 MHz, CD2Cl2):  7.46 
(br s, 1H), 7.12 (t, J = 7.0 Hz, 1H), 7.07 (d, J = 8.5 Hz, 2H), 6.70 (d, J = 8.5 Hz, 2H), 6.48 
(s, 1H), 6.11 (d, J = 6.5 Hz, 1H), 3.79 (s, 3H), 2.66 (s, 2H), 2.52 (q, J = 7.5 Hz, 2H), 1.20 
(t, J = 7.5 Hz, 3H). 11B NMR (160 MHz, CD2Cl2): δ 36.5. 13C NMR (151 MHz, CD2Cl2): 
δ 160.5, 157.5, 135.0, 134.1, 130.1, 125.9 (br), 114.5, 111.6, 55.7, 32.3, 26.6 (br), 14.9. 
FTIR (thin film): 3378, 2963, 2932, 2833, 1620, 1580, 1532, 1464, 1407, 1296, 1178, 1089, 
1037, 874, 834, 725, 532 cm-1. HRMS (APPI-TOF) for C14H19BNO ([M+H]+) found: 
227.160294. 
Inside a drybox, a 30 mL microwave vial was charged with 3.24a 
(1.42 g, 6.25 mmol), n-dodecanol (1.63 g, 8.75 mmol) CuBr (90 mg, 
0.63 mmol), pyridine (1.01 mL, 12.5 mmol), DTBP (1.38 mL, 7.50 
mmol), and 17 mL toluene. The reaction mixture was stirred at 90 °C for 45 min and 
immediately cooled with chilled water. The solvent was removed under reduced pressure. 
Silica gel column chromatography using 30-100% CH2Cl2 in pentane as an eluent afforded 
the desired product 3.25a as a colorless liquid (969 mg, 53% yield of 98% pure product). 
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Further purification using recycling HPLC with a GPC column afforded the pure desired 
product. 1H NMR (600 MHz, CD2Cl2):  6.96 (t, J = 7.2 Hz, 1H), 6.75 (br s, 1H), 5.98 (s, 
1H), 5.77 (d, J = 7.2 Hz, 1H), 3.89 (t, J = 7.8 Hz, 2H), 2.46 (q, J = 7.8 Hz, 2H), 1.63-1.58 
(m, 2H), 1.37-1.25 (m, 18H), 1.17 (t, J = 7.8 Hz, 3H), 0.90-0.86 (m, 3H). 11B NMR (160 
MHz, CD2Cl2): δ 29.0. 13C NMR (151 MHz, CD2Cl2): δ 162.9, 133.9, 114.2 (br), 107.7, 
65.2, 32.5, 32.4, 30.4, 30.3, 30.2, 30.1, 30.0, 29.9, 27.6, 26.5, 23.3, 14.7, 14.5. FTIR (thin 
film): 3324, 2958, 2922, 2853, 1623, 1533, 1430, 1387, 1345, 1316, 1266, 1247, 1138, 
1104, 944, 844, 768, 720, 689, 427 cm-1. HRMS (DART-TOF) calcd for C18H35BNO 
([M+H]+): 292.2812, found: 292.2823. 
 
C5-Ethyl-1,2-Azaborine  Synthesis: 
C5-borylated product 3.21b was prepared in the same 
reaction for the synthesis of 3.21a. The desired product 
3.21b was isolated as a white solid (8.14 g, 37%) by 
silica gel column chromatography using 10% CH2Cl2 in 
pentane as an eluent. 1H NMR (500 MHz, CD2Cl2):  7.86 (s, 1H),  7.62 (d, J = 11.0 Hz, 
1H), 7.00 (d, J = 8.0 Hz, 2H), 6.79 (d, J = 8.0 Hz, 2H), 6.26 (d, J = 10.5 Hz, H), 3.77 (s, 
3H), 2.70  (s, 2H), 1.27 (s, 12H), 0.99 (s, 9H), 0.56 (s, 6H). 11B NMR (160 MHz, CD2Cl2): 
δ 41.8, 30.9. 13C NMR (151 MHz, CD2Cl2): δ 157.4, 148.3, 147.0, 140.9 (br), 136.1, 130.6, 
130.3 (br), 114.1, 83.7, 55.7, 29.8 (br), 27.0, 25.2, 19.6, –1.0. FTIR (thin film): 2977, 2931, 
2859, 1604, 1509, 1499, 1402, 1373, 1259, 1243, 1145, 1091, 1040, 829, 807, 787, 691, 
672 cm-1. HRMS (APPI-TOF) for C24H40B2NO3Si ([M+H]+) found: 438.303894. 
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Inside a drybox, a 250 mL pressure vessel was charged with 
3.21b (4.31 g, 9.81 mmol), Pd(dppf)Cl2·CH2Cl2 (240 mg, 
0.294 mmol), KOH (1.65 g, 29.4 mmol), and a solution of 
vinyl bromide (39.3 mL, 39.3 mmol, 1 M in THF) in MTBE (33.5 mL) and H2O (2.8 mL). 
The reaction mixture was heated to 80 °C for 45 min. After cooling the reaction mixture to 
room temperature, the solvent was removed under reduced pressure. Silica gel column 
chromatography using 10-50% CH2Cl2 in pentane as an eluent afforded the desired product 
3.22b as a colorless liquid (1.91 g, 57%). 1H NMR (500 MHz, CD2Cl2):  7.69 (d, J = 11.5 
Hz, 1H), 7.26 (s, 1H), 7.00 (d, J = 8.0 Hz, 2H), 6.79 (d, J = 8.0 Hz, 2H), 6.51 (dd, J = 17.5, 
11.5 Hz, 1H), 6.33 (d, J = 11.5 Hz, 1H), 5.40 (d, J = 18.0 H, 1H),  4.95 (d, J = 11.5 H, 1H), 
3.77 (s, 3H), 2.70 (s, 2H), 0.99 (s, 9H), 0.55 (s, 6H). 11B NMR (160 MHz, CD2Cl2): δ 41.2. 
13C NMR (151 MHz, CD2Cl2): δ 157.4, 139.9, 139.6, 139.4, 136.1, 136.1, 131.7 (br), 130.6, 
122.1, 114.2, 109.0, 55.7, 29.4 (br), 27.0, 19.6, –1.0. FTIR (thin film): 2954, 2931, 2858, 
1632, 1609, 1508, 1463, 1418, 1367, 1283, 1267, 1244, 1174, 1073, 1038, 986, 881, 842, 
804, 691, 406 cm-1. HRMS (DART-TOF) calcd for C20H31BNOSi ([M+H]+): 340.2268, 
found: 340.2285. 
Inside a drybox, a 250 mL round bottom flask was charged 
with 3.22b (3.83 g, 11.3 mmol), Pd/C (720 mg of 10 wt% Pd, 
0.677 mmol) in ethylacetate (100 mL). The reaction mixture 
was stirred at room temperature for 4 h under 1 atm H2 atmosphere. The solvent was 
removed under reduced pressure. Silica gel column chromatography using 10-30% CH2Cl2 
in pentane as an eluent afforded the desired product 3.23b as a colorless liquid (3.54 g, 
92%). 1H NMR (500 MHz, CD2Cl2):  7.32 (d, J = 11.0 Hz, 1H), 7.10 (s, 1H), 7.00 (d, J = 
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6.5 Hz, 2H), 6.79 (d, J = 6.5 Hz, 2H), 6.25 (d, J = 11.0 Hz, 1H), 3.77 (s, 3H), 2.68 (s, 2H), 
2.38 (q, J = 8.0 Hz, 2H), 1.11 (t, J = 8.0 Hz, 3H), 0.98 (s, 9H), 0.54 (s, 6H). 11B NMR (160 
MHz, CD2Cl2): δ 39.9. 13C NMR (151 MHz, CD2Cl2): δ 157.3, 145.1, 136.7, 135.7, 131.9 
(br), 130.5, 125.5, 114.1, 55.7, 29.3 (br), 27.2, 26.9, 19.7, 16.3, –1.0. FTIR (thin film): 
2956, 2929, 2857, 1623, 1586, 1509, 1450, 1382, 1299, 1245, 1173, 1125, 1081, 1002, 938, 
827, 786, 691, 636, 575, 413 cm-1. HRMS (DART-TOF) calcd for C20H33BNOSi ([M+H]+): 
342.2424, found: 342.2413. 
To a solution of 3.23b (3.54 g, 10.4 mmol) in 100 mL THF 
was added a solution of tetrabutylammonium fluoride (10.4 
mL, 10.4 mmol, 1 M in THF) and the reaction mixture was 
stirred at room temperature for 30 min. The solvent was removed under reduced pressure. 
Silica gel column chromatography using 30-50% CH2Cl2 in pentane as an eluent afforded 
the desired product 3.24b as a colorless oil (2.33 g, 99%). 1H NMR (500 MHz, CD2Cl2):  
7.52 (d, J = 12.0 Hz, 1H), 7.50 (br s, 1H), 7.05 (d, J = 8.5 Hz, 2H), 6.99 (d, J = 7.5 Hz, 
1H), 6.83 (d, J = 8.5 Hz, 2H), 6.67 (d, J = 11.5 Hz, 1H), 3.78 (s, 3H), 2.64 (s, 2H), 2.40 (q, 
J = 7.5 Hz, 2H), 1.13 (t, J = 7.5 Hz, 3H). 11B NMR (160 MHz, CD2Cl2): δ 35.6. 13C NMR 
(151 MHz, CD2Cl2): δ 157.5, 146.0, 135.0, 131.2, 130.1, 129.8 (br), 125.2, 114.5, 55.7, 
26.7, 26.4 (br), 16.3. FTIR (thin film): 3381, 2998, 2961, 2871, 1626, 1610, 1536, 1509, 
1456, 1399, 1297, 1243, 1205, 1178, 1085, 1036, 846, 740, 619 cm-1. HRMS (DART-TOF) 
calcd for C14H19BNO ([M+H]+): 228.1560, found: 228.1568. 
Inside a drybox, a 30 mL microwave vial was charged with 3.24b 
(1.41 g, 6.20 mmol), n-dodecanol (1.62 g, 8.68 mmol) CuBr (89 mg, 
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0.62 mmol), pyridine (1.00 mL, 12.4 mmol), DTBP (1.37 mL, 7.44 mmol), and 17 mL 
toluene. The reaction mixture was stirred at 90 °C for 35 min and immediately cooled with 
chilled water. The solvent was removed under reduced pressure. Silica gel column 
chromatography using 30-100% CH2Cl2 in pentane as an eluent afforded the desired 
product 3.25b as a white solid (912 mg, 50% yield of 97% pure product). Further 
purification using recycling HPLC with a GPC column afforded the pure desired product. 
1H NMR (500 MHz, CD2Cl2):  7.46 (d, J = 12.0 Hz, 1H), 6.83 (d, J = 7.0 Hz, 1H), 6.75 
(br s, 1H), 6.22 (d, J = 12.0 Hz, 1H), 3.87 (t, J = 7.0 Hz, 2H), 2.32 (q, J = 7.5 Hz, 2H), 
1.63-1.57 (m, 2H), 1.40-1.21 (m, 18H), 1.10 (t, J = 7.5 Hz, 3H), 0.89-0.85 (m, 3H). 11B 
NMR (160 MHz, CD2Cl2): δ 28.5. 13C NMR (151 MHz, CD2Cl2): δ 148.5, 130.8, 120.7, 
118.6 (br), 65.4, 32.5, 32.4, 31.2, 30.8, 30.6, 30.3, 30.1, 30.0, 26.5, 26.4, 23.3, 16.3, 14.5. 
FTIR (thin film): 3321, 2958, 2924, 2853, 1632, 1538, 1462, 1409, 1383, 1363, 1274, 1207, 
1192, 1140, 1054, 795, 692, 499 cm-1. HRMS (DART-TOF) calcd for C18H35BNO 
([M+H]+): 292.2812, found: 292.2824. 
A 100 mL round bottom flask was charged with compound 3.25b (1.44 g, 
4.94 mmol) and Et2O (30 mL). Lithium aluminium hydride (195 mg, 5.13 
mmol) was added in small portions at –30 °C under nitrogen atmosphere. 
The reaction was monitored by 11B NMR and at the completion HCl solution (5.00 mL, 
10.0 mmol, 2.0 M in Et2O) was added dropwise at –30 °C and stirred for 30 min. The 
reaction mixture was filtered through a filter paper and filtrate was concentrated by 
removing solvent by distillation, silica gel column chromatography using 100% isopentane 
as eluent afforded the desired product 3.27 as a colorless oil (113 mg, 21%). 1H NMR (600 
MHz, CD2Cl2):  8.30 (br t, J = 50.4 Hz, 1H),  7.66 (d, J = 11.4 Hz, 1H), 7.21 (d, J = 7.2 
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Hz, 1H), 6.90 (d, J = 10.8 Hz, 1H), 4.80 (br q, J = 135 Hz, 1H), 2.47 (q, J = 7.2 Hz, 2H), 
1.17 (t, J = 7.2 Hz, 3H). 11B NMR (160 MHz, CD2Cl2): δ 30.1 (d, J = 125 Hz). 13C NMR 
(126 MHz, CD2Cl2): δ 146.4, 132.0, 131.1 (br), 127.0, 26.9, 16.2. FTIR (thin film): 3399, 
3024, 2962, 2870, 2528, 1622, 1454, 1308, 1260, 1136, 1094, 1019, 878, 800, 699, 586 
cm-1. HRMS (DART-TOF) calcd for C6H11BN ([M+H]+): 108.0985, found: 108.0988.  
 
C6-Ethyl-1,2-Azaborine  Synthesis:  
Compound 3.18 was synthesized following previously reported methods.1 
Spectra of the isolated compound matched published values. 1H NMR (500 MHz, 
CD2Cl2):  8.19 (br t, J = 54.0 Hz, 1H), 7.68-7.62 (m, 1H), 6.70 (d, J = 10.5 Hz, 
1H), 6.25 (d, J = 6.5 Hz, 1H), 4.84 (br q, J = 130 Hz, 1H), 2.61 (q, J = 7.5 Hz, 2H), 1.26 
(t, J = 7.5 Hz, 3H). 11B NMR (160 MHz, CD2Cl2): δ 31.3 (d, J = 141 Hz). 13C NMR (151 
MHz, CD2Cl2): δ 149.4, 145.3, 127.8 (br), 109.5, 29.5, 13.4. FTIR (thin film): 3371, 3023, 
2970, 2934, 2875, 2520, 2455, 1611, 1543, 1446, 1402, 1377, 1343, 1194, 1166, 1085, 891, 
853, 716, 686, 520, 452 cm-1. HRMS (DART-TOF) calcd for C6H11BN ([M+H]+): 
108.0985, found: 108.0990. 
 
3.5.3 ITC Experiments 
 Isothermal titration calorimetry (ITC) experiments were carried out with Nano ITC 
Low Volume calorimeter from TA instruments. Titrations were run by injection of ligand 
solution to protein solution at 10 oC and 310 rpm stirring rate with a data collection interval 
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of 4 min/injection. A total of 20–40 injections of a total volume of 50–100 uL ligand 
solution (2.66–4.75 mM) were done with 320 uL protein solution (~0.2 mM). Both ligand 
and protein were in a degassed buffer solution of 5% PEG400, 0.5 M NaCl, 0.1 M sodium 
phosphate (pH 6.8). The protein solution was prepared by dialyzing against the degassed 
buffer and the concentrations were determined by molar absorptivity at 280 nm. Due to the 
limited solubility of the small molecule ligands in aqueous buffer, accurate concentrations 
of ligand solution were determined by either GC against a calibrated internal standard or 
UV/VIS. Baseline mixing heats were estimated by injection of ligand solution into the 
buffer and subtracted from individual titration curve. The resulting reaction heat profiles 
were fit to the independent binding model with the stoichiometry n fixed to 1.0. All data 
were analyzed using NanoAnalyze software. Experiments were repeated five times and 
averaged with standard deviation error of the mean. 
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* Representative ITC data 
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3.5.4 Spectral Data 
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4. Chapter 4: Late-Stage N-Functionalization of 1,2-Azaborines 
4.1 Introduction 
 BN/CC isosterism has been demonstrated to lead to diversification of chemical 
structures and discovery of unique chemical/physical properties of organic compounds.1 
Late-stage functionalization of 1,2-azaborines, i.e., functionalization after assembly of the 
azaborine core, provides a general approach to access a library of structurally diversified 
molecules. However, implementing such a strategy has been challenging until recently due 
to the scarcity of methodologies that enable selective modification around the aromatic 
ring.  
 Recently, Liu and Ashe have demonstrated selective functionalization of monocyclic 
1,2-azaborines at the B2 and C3–C6 positions. Nucleophilic substitution, Rh-catalyzed B-
Cl arylation and B–H alkenylation were used to functionalize the boron position. 2 
Electrophilic aromatic substitution reactions at C3 and C5 were reported by Ashe in 2007, 
and the Liu group developed a Negishi cross-coupling procedure involving C3-halogenated 
1,2-azaborines in 2015.3 Ir-catalyzed C–H borylation, followed by Suzuki–Miyaura cross-
coupling afforded functionalization of the remaining carbonaceous positions C4, C5, or 
                                                 
1 (a) Liu, Z.; Marder, T. B. Angew. Chem., Int. Ed. 2008, 47, 242–244. (b) Bosdet, M. J. D.; Piers, W. E. 
Can. J. Chem. 2009, 87, 8–29. (c) Campbell, P. G.; Marwitz, A. J. V.; Liu, S.-Y. Angew. Chem., Int. Ed. 
2012, 51, 6074–6092. (d) Wang, X.-Y.; Wang, J.-Y.; Pei, J. Chem. Eur. J. 2014, 21, 3528–3539. 
2 (a) Marwitz, A. J. V.; Abbey, E. R.; Jenkins, J. T.; Zakharov, L. N.; Liu, S.-Y. Org. Lett. 2007, 9, 4905–
4908. (b) Lamm, A. N.; Garner, E. B.; Dixon, D. A.; Liu, S.-Y. Angew. Chem., Int. Ed. 2011, 50, 8157–8160. 
(c) Rudebusch, G. E.; Zakharov, L. N.; Liu, S.-Y. Angew. Chem., Int. Ed. 2013, 52, 9316–9319. (d) Brown, 
A. N.; Zakharov, L. N.; Mikulas, T.; Dixon, D. A.; Liu, S.-Y. Org. Lett. 2014, 16, 3340–3343. 
3 (a) Pan, J.; Kampf, J. W.; Ashe, A. J. Org. Lett. 2007, 9, 679–681. (b) Brown, A. N.; Li, B.; Liu, S.-Y. J. 
Am. Chem. Soc. 2015, 137, 8932–8935. 
638 
 
C6.4 To date, only limited examples can be found in literatures for N-functionalization of 
1,2-azaborines and these transformations generally do not allow for further derivatization 
because the electrophiles used in the reactions are silyl protecting groups or simple alkyl 
chains.5 
 
Figure 4.1 Late-stage functionalization of 1,2-azaborines 
 
 
                                                 
4 (a) Baggett, A. W.; Vasiliu, M.; Li, B.; Dixon, D. A.; Liu, S.-Y. J. Am. Chem. Soc. 2015, 137, 5536–5541. 
(b) Baggett, A. W.; Guo, F.; Liu, S.-Y.; Jäkle, F. Angew. Chem. Int. Ed. 2015, 54, 11191–11195. See Chapter 
3 for C4 and C5 borylation. 
5 (a) Pan, J.; Kampf, J. W.; Ashe, A. J. Organometallics 2004, 23, 5626–5629. (b) Pan, J.; Kampf, J. W.; 
Ashe, A. J. Organometallics 2008, 27, 1345–1347. (c) Abbey, E. R.; Lamm, A. N.; Baggett, A. W.; Zakharov, 
L. N.; Liu, S.-Y. J. Am. Chem. Soc. 2013, 135, 12908–12913. 
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4.2 Background 
4.2.1 Functionalization of Polycylic 1,2-Azaborines 
 While various methods are available to construct the 1,2-azaborine core, 6 , 7 
development of methodologies for functionalization of the resulting BN-heterocycles are 
still scarce. In Dewar’s initial studies of functionalization of 9,10-BN-phenanthrenes, he 
demonstrated nucleophilic substitution at boron, 8  halogenation, nitration, and Friedel-
Crafts acetylation at C6 and C8 through electrophilic aromatic substitution, 9  and N-
acylation via lithiation of NH-containing derivatives.10  
 Research on functionalization of both mono- and polycyclic BN-heterocycles then lay 
largely dormant until the late 2000s. In 2007, the Piers group utilized Pt-catalyzed alkyne 
                                                 
6 For examples of synthesis of polycyclic 1,2-azaborines, see: (a) Dewar, M. J. S.; Kubba, V. P.; Pettit, R. J. 
Chem. Soc. 1958, 3073–3076. (b) Dewar, M. J. S.; Dietz, R. J. Chem. Soc. 1959, 2728–2730. (c) Dewar, M. 
J. S.; Gleicher, G. J.; Robinson, B. P. J. Am. Chem. Soc. 1964, 86, 5698–5699. (d) Bosdet, M. J. D.; Piers, 
W. E.; Sorensen, T. S.; Parvez, M. Angew. Chem. Int. Ed. 2007, 46, 4940–4943. (e) Neue, B.; Araneda, J. F.; 
Piers, W. E.; Parvez, M. Angew. Chem. Int. Ed. 2013, 52, 9966–9969. (f) Bettinger, H. F.; Müller, M. J. Phys. 
Org. Chem. 2015, 28, 97–103. (g) Lu, J.-S.; Ko, S.-B.; Walters, N. R.; Kang, Y.; Sauriol, F.; Wang, S. Angew. 
Chem. Int. Ed. 2013, 52, 4544–4548. (h) Li, G.; Zhao, Y.; Li, J.; Cao, J.; Zhu, J.; Sun, X. W.; Zhang, Q. J. 
Org. Chem. 2015, 80, 196–203. (i) Wang, X.; Zhang, F.; Liu, J.; Tang, R.; Fu, Y.; Wu, D.; Xu, Q.; Zhuang, 
X.; He, G.; Feng, X. Org. Lett. 2013, 15, 5714–5717. (j) Hashimoto, S.; Ikuta, T.; Shiren, K.; Nakatsuka, S.; 
Ni, J.; Nakamura, M.; Hatakeyama, T. Chem. Mater. 2014, 26, 6265–6271. (k) Wang, X.-Y.; Zhuang, F.-D.; 
Wang, R.-B.; Wang, X.-C.; Cao, X.-Y.; Wang, J.-Y.; Pei, J. J. Am. Chem. Soc. 2014, 136, 3764–3767. (l) 
Wisniewski, S. R.; Guenther, C. L.; Argintaru, O. A.; Molander, G. A. J. Org. Chem., 2014, 79, 365–378. 
(m) Ishibashi, J. S. A.; Marshall, J. L.; Maziere, A.; Lovinger, G. J.; Li, B.; Zakharov, L. N.; Dargelos, A.; 
Graciaa, A.; Chrostowska, A.; Liu, S.-Y. J. Am. Chem. Soc. 2014, 136, 15414–15421. (n) Fang, X.; Yang, 
H.; Kampf, J. W.; Holl, M. M. B.; Ashe, A. J. Organometallics 2006, 25, 513–518.        
7 For examples of synthesis of monocyclic 1,2-azaborines, see: (a) Dewar, M. J. S.; Marr, P. A. J. Am. Chem. 
Soc. 1962, 84, 3782. (b) White, D. G. J. Am. Chem. Soc. 1963, 85, 3634–3636. (c) Ashe, A. J.; Fang. Org. 
Lett. 2000, 2, 2089–2091. (d) Ashe, A. J.; Fang, X.; Fang, X.; Kampf, J. W. Organometallics 2001, 20, 5413–
5418. (e) Marwitz, A. J. V.; Matus, M. H.; Zakharov, L. N.; Dixon, D. A.; Liu, S.-Y. Angew. Chem. Int. 
Ed. 2009, 48, 973–977. (f) Braunschweig, H.; Geetharani, K.; Jimenez-Halla, J. O. C.; Schäfer, M. Angew. 
Chem. Int. Ed. 2014, 53, 3500–3504. (g) Braunschweig, H.; Hörl, C.; Mailänder, L.; Radacki, K.; Wahler, J. 
Chem. Eur. J. 2014, 20, 9858–9861. (h) Couchman, S. A.; Thompson, T. K.; Wilson, D. J. D.; Dutton, J. L.; 
Martin, C. D. Chem. Commun. 2014, 50, 11724–11726.     
8 Dewar, M. J. S.; Maitlis, P. M. J. Am. Chem. Soc. 1961, 83, 187–193.   
9 (a) Dewar, M. J. S.; Kubba, V. P. Tetrahedron 1959, 7, 213–222. (b) Dewar, M. J. S.; Kubba, V. P. J. Org. 
Chem. 1960, 25, 1722–1724. (c) Dewar, M. J. S.; Kubba, V. P. J. Am. Chem. Soc. 1961, 83, 1757–1760.   
10 Dewar, M. J. S.; Maitlis, P. M. Tetrahedron 1961, 15, 35–45.   
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cyclization to furnish internally BN-pyrene analogs.11 B–N bond formation between bis-
alkynylated pyridine 4.1 and boracyclohexadienes 4.2 afforded intermediate 4.3, which 
underwent spontaneous cyclization to form BN-phenanthrene derivative 4.4. The second 
cyclization reaction to complete the formation of the pyrene core, however, required 
heating in the presence of 5 mol% PtCl2 (Scheme 4.1).  
 
Scheme 4.1 Synthesis of BN-pyrene analog using Pt-catalyzed cyclization 
 
 
 B-Phosphorylation of 9,10-BN-phenanthrene was demonstrated by Pringle in 2014.12 
BN analogues of monoarylphosphine ligands were synthesized by the reaction of the B–Cl 
                                                 
11 Bosdet, M. J. D.; Piers, W. E.; Sorensen, T. S.; Parvez, M. Angew. Chem. Int. Ed. 2007, 46, 4940–4943.   
12 Bailey, J. A.; Haddow, M. F.; Pringle, P. G. Chem. Commun. 2014, 50, 1432-1434.   
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bond in BN-phenanthrene 4.6 and silylphosphines R2PSiMe3 (Scheme 4.2). The 
resulting azaborinylphos-phines demonstrated higher turnover frequencies in Rh-catalyzed 
hydrogenation reactions of cyclohexene compared to arylphosphine analogs.   
 
Scheme 4.2 Synthesis of the azaborinylphosphines 
 
  
 The Molander group contributed to increasing the accessibility of 1,2-BN-naphthalene 
analogs introducing the use of potassium organotrifluoroborates (R-BF3K) for their 
synthesis.6l Notably, C3-selective bromination of BN-naphthalene 4.8, followed by 
Suzuki–Miyaura cross-coupling with (Het)Ar-BF3K salts produced derivatives of C3-
arylated BN-naphthalenes (Scheme 4.3, eq. 1).13 C3-Alkenylation was likewise achieved 
following some minor modifications to the reaction conditions (Scheme 4.3, eq. 2).14 
 
 
 
                                                 
13 Molander, G. A.; Wisniewski, S. R. J. Org. Chem. 2014, 79, 6663–6678.   
14 Molander, G. A.; Wisniewski, S. R.; Etemadi-Davan, E. J. Org. Chem. 2014, 79, 11199–11204.   
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Scheme 4.3 Syntheses of C3-functionalized BN-naphthalenes using potassium organotrifluoroborates 
 
 
 In the course of developing the above cross-coupling reactions of C3-brominated BN-
naphthalenes, the Molander group also discovered a unique reaction mode of N-substituted, 
B-aryl, C3-brominated substrates involving apparent self-arylation under Suzuki–Miyaura 
conditions. 15  Using (SPhos)-(aminobiphenyl) palladium chloride (SPhos-Pd-G2) as 
precatalyst and KOH as base, the self-arylation was found to proceed at ambient 
temperature to provide B-OH-3-aryl products (Scheme 4.4). A crossover experiment 
conducted as mechanistic probe revealed that the reaction is actually an intermolecular 
process (Scheme 4.5, eq. 1). Also of note, the free NH-containing substrate 4.9c did not 
undergo self-arylation (Scheme 4.5, eq. 2). Computational studies suggested that the 
presence of a nitrogen substituent forces the B-arly group out of plane relative to the BN-
                                                 
15 Molander, G. A.; Wisniewski, S. R. J. Org. Chem. 2014, 79, 8339–8347.   
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naphthalene ring, thereby weakening the B–Caryl bond and rendering transmetalation of the 
aryl group more facile than in NH-containing substrates. 
 
Scheme 4.4 Self-arylation of B-aryl, C3-brominated BN-naphthalenes 
 
 
Scheme 4.5 Probing the reaction mechanism of self-arylation  
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 In 2014, Molander also demonstrated alkylation of C3-brominated BN-naphthalenes 
using Ni-catalyzed reductive cross-coupling reactions. 16 Various primary and secondary 
alkyl iodides provided the desired sp2–sp3 coupling products in good yields (Scheme 4.6). 
 
Scheme 4.6 Ni-catalyzed reductive cross-coupling of BN-naphthalenes 
 
 
 In 2014, Fang demonstrated iodinated BN-fused naphthalenes can undergo Suzuki–
Miyaura, Sonogashira, and Heck cross-coupling reactions.17 To prepare the halogenated 
precursors 4.15–4.17, the authors employed Lewis acid-catalyzed electrophilic aromatic 
substitution reactions. (A second halogenation could also be performed at the α’-carbon 
adjacent to boron to afford bis-halogenated products 4.18–4.21 (Scheme 4.7, eq. 1).) The 
iodinated BN-naphthalene 4.17 was converted into the corresponding arylated, alkynylated, 
and alkenylated coupled products under Pd-catalyzed conditions shown in Scheme 4.7 (eq. 
2). 
 
 
                                                 
16 Molander, G. A.; Wisniewski, S. R.; Traister, K. M. Org. Lett. 2014, 16, 3692–3695.   
17 Sun, F.; Lv, L.; Huang, M.; Zhou, Z.; Fang, X. Org. Lett. 2014, 16, 5024–5027. 
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Scheme 4.7 Halogenation of 4.14 and Pd-catalyzed cross-coupling reactions of 4.17. 
 
 
4.2.2 Late-Stage Functionalization of Monocyclic 1,2-Azaborines 
4.2.2.1 Functionalization at Boron 
 The most straightforward derivatization of 1,2-azaborines is nucleophilic substitution 
at boron as demonstrated in 2007 by Liu.2a Direct displacement of the labile B-chloro group 
in 4.25 was successful with a variety of organolithiates and Grignard reagents (Table 4.1, 
entries 1–4). Heteroatom-based nucleophiles resulted in formation of 1,2-azaborines 
646 
 
bearing B–N, B–S, and B–O bonds (Table 4.1, entries 5–7). Nucleophilic substitution with 
LiBEt3H afforded a B–H containing molecule (Table 4.1, entry 8).  
 
Table 4.1 Nucleophilic substitution at the boron center of 1,2-azaborines 
 
 
 Isolation of parent 1,2-azaborine (4.27)7e allowed the group to examine the reactivity 
of the simplest BN isostere of the arene family. Nucleophilic aromatic substitution of 4.27 
was demonstrated; particularly, reactions with various nucleophiles and subsequent 
quenching with electrophiles generated mono- and bis-functionalized 1,2-azaborines 
(Table 4.2).2b Mechanistic studies revealed that the reaction to form 4.28h proceeds 
through the following sequence: 1) deprotonation of the azaborine NH, 2) formation of 
dianion species by attack of a second equivalent of nucleophile, 3) expulsion of H- to form 
anionic species 4.31, and 4) quenching with electrophile to generate the final product 4.28h 
(Scheme 4.8). 
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Table 4.2 Nucleophilic aromatic substitution of 4.27 
 
 
Scheme 4.8 Proposed reaction mechanism of SNAr of 4.27 
 
 
 In 2013, the Liu group reported Rh-catalyzed B-arylation to form BN-biphenyl 
compounds.2c B–Cl containing azaborine 4.25 underwent arylation at boron to form 
biphenyl products through Rh-catalyzed addition of arylstannanes (Table 4.3). A wide 
range of functional groups were tolerated under the reaction condition, in marked contrast 
to the earlier protocols that required organomagnesium and organolithium reagents. The 
authors demonstrated the utility of this method by synthesizing in just two steps from 
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azaborine 4.33 a BN-containing version of felbinac, a topical nonsteroidal anti-
inflammatory drug (Scheme 4.9). 
 
Table 4.3 Substrate scope of Rh-catalyzed arylation of 1,2-azaborines 
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Scheme 4.9 Synthesis of BN-felbinac using Rh-catalyzed arylation 
 
 
 Rh-catalyzed B-alkenylation was also reported using B–H containing 1,2-azaborines as 
starting materials.2d The reaction proceeds through B−H activation of the 1,2-azaborine 
substrate and dehydrogenative borylation of the styrene coupling partner. Using this 
method, BN-analogs of stilbene were synthesized (Scheme 4.10) and examined for unique 
photophysical properties in direct comparison with all-carbon analogs. 
 
Scheme 4.10 Synthesis of BN stilbenes by Rh-catalyzed dehydrogenative borylation 
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 In 2013, a protecting group-free synthesis of 1,2-azaborines was demonstrated. The 
resulting final product 4.40 served as a versatile synthon to access other 1,2-azaborine 
derivatives. Reaction of 4.40 with lithium aluminum hydride and subsequent acidic 
quenching allowed isolation of gram quantities of parent 1,2-azaborine 4.27 (Scheme 4.11, 
eq. 1). Nucleophilic substitution with two equivalents of either vinyl magnesium bromide 
or n-butyllithium produced 4.41 and 4.42, respectively (Scheme 4.11, eq. 2 and 3). Di-
substitution at both boron and nitrogen was also viable to afford 4.43 and 4.44 (Scheme 
4.11, eq. 4 and 5). 
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Scheme 4.11 Functionalization of versatile synthon 4.40 
 
 
 The more reactive azaborine 4.45 was generated in situ by the reaction of 4.40 with 
BCl3; the resulting B-chloro species then subsequently reacted with nucleophiles incapable 
of directly displacing the -On-Bu group in 4.40 (Scheme 4.12). 
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Scheme 4.12 Reactions of in situ-generated 4.45 
 
 
4.2.2.2 Functionalization at Carbon Positions 
 In 2007, Ashe group reported C3- and C5-selective electrophilic aromatic substitution 
reactions of monocyclic 1,2-azaborines to afford a variety of 3- and 5-substituted 
derivatives (Scheme 4.13).3a Acid-catalyzed proton-deuterium isotopic exchange afforded 
the C3-deuterated product. Bromination of 4.32a occurred at C3, and the resulting 
brominated product was converted to nitrile 4.51. Selective iodination of 4.32a at C3, 
followed by quenching with aqueous Na2S2O3 purportedly gave C3-OH derivative “4.52”18. 
Functionalization at C5 was also demonstrated: Friedel-Crafts acetylation of 4.32a 
afforded the corresponding C5-acetylated product, while a Mannich reaction with N,N-
dimethylmethyleneiminium chloride gave 4.54 in moderate yield. Molecular orbital 
calculations indicated that the greatest electron density is localized around C3 and C5, a 
                                                 
18 Based on our own characterization, the reported compound seems to be a B-OH, C3-Ph isomer. 
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prediction consistent with the experimental observation of these sites as the most 
nucleophilic. 
 
Scheme 4.13 Electrophilic aromatic substitution reactions of 1,2-azaborines 
 
 
 More recently, the Liu group developed a Negishi cross-coupling reaction of 1,2-
azaborines in order to introduce functionality at the C3 position.3b Bromination of 4.33 
occurs selectively at C3, similar to the reactivity observed by Ashe. Cross-coupling of the 
resulting Br-substituted azaborine is compatible in the presence of a reactive B–Cl bond. 
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The method was applied to synthesize previously unknown BN isosteres of indenyl and 
naphthalene; C3-brominated precursor 4.55 underwent regioselective Negishi cross-
coupling with vinylzinc bromide to yield 4.56, which was then utilized in syntheses of BN-
indenyl analog 4.57 and a new BN-naphthalene 4.58. 
 
Scheme 4.14 Negishi cross-coupling of 1,2-azaborine and its application to the synthesis of BN analogs of 
indenyl and naphthalene 
 
 
 In 2015, the first general method to functionalize C6–H of 1,2-azaborines was 
established by Ir-catalyzed borylation and subsequent Suzuki–Miyaura cross-coupling.4a 
Regioselective borylation of NH-containing 1,2-azaborines with a number of substituents 
on boron afforded C6-borylated products (Table 4.4). The observed regioselectivity was 
attributed primarily to the greater acidity of the C6 proton compared to that of the other 
carbon positions.  
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Table 4.4 Regioselective borylation of 1,2-azaborines 
 
 
 The resulting borylated products successfully underwent Suzuki–Miyaura cross-
coupling with various (hetero)aryl bromides to afford a library of C6-functionalized 1,2-
azaborines. By utilizing this transformation, the authors reported the synthesis of a new 
type of N,N-bidentate ligand (Scheme 4.15). This novel ligand after deprotonation forms 
κ2-N,N complex 4.62 with dimesitylboron, demonstrating a potential application of 1,2-
azaborines in coordination chemistry.    
 
Scheme 4.15 Synthesis of κ2-N,N-bidentate ligand 4.61 and its complex with dimesitylboron 
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 By combining regioselective bromination at C3 of 1,2-azaborines with Ir-catalyzed 
borylation at C6, the Liu group also demonstrated 1,2-azaborine-based oligomer and 
polymer syntheses.4b C3-brominated azaborine precursor 4.63 was cross-coupled with C6-
borylated azaborine 4.60c to provide dimer 4.64, which upon further borylation and cross-
coupling afforded the trimer 4.66 (Scheme 4.16, eq. 1). An X-ray crystal structure of 4.64 
showed a syn conformation with respect to B-mesityl groups favored by N–H···π 
interactions. Similarly, regioselective borylation of 4.63 afforded bis-functionalized 1,2-
azaborine 4.67, which served as a monomeric unit for Suzuki–Miyaura polycondensation 
(Scheme 4.16, eq. 2).  
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Scheme 4.16 Regioregular synthesis of azaborine oligomers and a polymer 
 
 
 The C4 and C5 positions of 1,2-azaborines remain challenging sites to selectively 
functionalize. A limited number of examples are discussed in the Chapter 3 for the 
synthesis of C4- and C5-borylated 1,2-azaborines. In these cases, steric effects play a more 
significant role compared to C6-borylation due to the presence of the bulky nitrogen TBS 
substituent (Scheme 4.17). 
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Scheme 4.17 Diversity-oriented borylation of 1,2-azaborine to functionalize C4 and C5 
 
 
4.3 Late-Stage N-Functionalization of 1,2-Azaborines and its Application to the 
Synthesis of BN Isosteres of trans-Stilbene and a Lisdexamfetamine Derivative 
4.3.1 Early Syntheses of N-Functionalized 1,2-Azaborines 
 The first example of a direct N-functionalization of 1,2-azaborines was demonstrated 
by the Ashe group during their efforts to synthesize π-coordinated metal complexes of 
azaborines.5a Deprotonation of 4.28e with potassium bis(trimethylsilyl)amide (KHMDS) 
afforded the corresponding NK salt 4.72. Upon treatment of 4.72 with an excess amount 
of MeI, the authors observed formation of methylated product 4.73, demonstrating the 
possibility to render the nitrogen of 1,2-azaborines nucleophilic (Scheme 4.18). In the 
report, the acid-base properties of the nitrogen atom in 4.28e and the ruthenium π complex 
4.74 were examined. Approximate pKa value for 4.28e was estimated to be ~26 whereas a 
reduced basicity was observed for 4.74 (pKa = ~9.2) presumably modulated by π-
complexation. 
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Scheme 4.18 Synthesis of 4.73 and azaborinyl π-complex 4.74  
 
 
 Similarly, in 2008, the Ashe group reported synthesis of an η1-N bis-(1,2-azaborine).5b 
Anionic azaborine 4.72 reacted with zirconocene dichloride (Cp2ZrCl2) to form σ-metal 
complex 4.76 (Scheme 4.19). To compare the bond lengths and angles from crystal 
structures, compound 4.75 was prepared by electrophilic substitution of 4.72 with 
trimethylsilyl chloride (TMSCl). 
  
Scheme 4.19 Synthesis of 4.75 and azaborinyl σ-complex 4.76   
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 Molander’s approach discussed in 4.2.1 enabled modular synthesis of complex BN 
isosteres of naphthalene with various substituents on nitrogen. However, these complex 
molecules were assembled from pre-functionalized 2-aminostyrenes. Thus, the scope of 
nitrogen substituents was limited to a handful of aryl and alkyl groups (Figure 4.2).6l,13-16,19 
  
Figure 4.2 Functional groups on nitrogen resulting from Molander’s approach to BN-naphthalenes 
 
 
   Previously in our laboratory, we have demonstrated a handful of examples of N-
functionalization of 1,2-azaborines. For example, sequential nucleophlic attack on boron 
followed by electrophilic quenching on nitrogen gave TMS protection and methylation 
(Table 4.2 and Scheme 4.11). To expand the scope of possible N-substituents, however, we 
decided to investigate late-stage functionalization of 1,2-azaborines specifically at the 
nitrogen position alone. 
                                                 
19 (a) Molander, G. A.; Wisniewski, S. R.; Amani, J. Org. Lett. 2014, 16, 5636–5639. (b) Davies, G. H. M.; 
Zhou, Z.-Z.; Jouffroy, M.; Molander, G. A. J. Org. Chem. 2017, 82, 549–555.  
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4.3.2 Electrophilic Substitution 
 First, we investigated electrophilic substitution reactions involving initial 
deprotonation of NH-containing azaborines followed by reaction with various electrophiles. 
N-H-B-phenyl-1,2-azaborine 4.28e was deprotonated with KHMDS to generate the 
corresponding NK salt 4.72, which reacted with numerous electrophiles to afford the 
desired products in good to excellent yields, including N-Boc, N-alkyl, and N-benzoyl 
azaborines (Table 4.5, entries 1–4, 6). Only moderate yield was achieved with propargyl 
bromide presumably due to competing protonation of the NK salt by the relatively acidic 
propargyl CHs to regenerate the NH azaborine (Table 4.5, entry 5). Electrophilic 
substitution with another azaborine molecule gave a dimeric species (4.77g) in 98% yield 
(Table 4.5, entry 7). 
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Table 4.5 Electrophilic substitution of 1,2-azaborines  
 
 
 Reactions with either epoxides or an aziridine successfully produced the corresponding 
ring-opened products under ambient temperature without the need for a Lewis acid additive 
(Table 4.5, entries 8–10).  
 
4.3.3 Synthesis of a BN-Analog of Lisdexamfetamine 
 To demonstrate the potential utility of the aziridine ring opening reaction in particular 
to medicinal chemistry, we aimed to synthesize a derivative of a biologically relevant 
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molecule. Scheme 4.20 illustrates the synthesis of a BN-analog of lisdexamfetamine. 
Starting with enantiomerically pure (S)-2-methylaziridine-1-carboxylic acid tert-butyl 
ester, aziridine ring opening occurred efficiently with NK salt 4.72 (80%) to form 4.77j’. 
Boc-deprotection under acidic conditions afforded a BN-analog of amphetamine (4.78). 
Amide coupling of 4.78 with lysine-derived hydroxysuccinimide ester furnished the Boc-
protected BN-lisdexamfetamine derivative 4.79 in excellent yield. 
 
Scheme 4.20 Synthesis of BN-lisdexamfetamine analog 
 
 
4.3.4 N–C(sp2) Bond Formation 
 We next pursued N–C(sp2) bond formation reactions based on standard Buchwald-
Hartwig protocols (see Experimental section 4.5 for ligand studies and optimization 
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details).20 The reaction proceeded successfully using a ferrocene-based ligand (QPhos) to 
generate N–C(sp2) coupling products (Table 4.6). The reaction with 1,4-dibromobenzene 
afforded an oligomeric species with five aryl units alternating between phenyl and 
azaborinyl (Table 4.6, entry 2). This compound in particular has potential applications in 
synthesis of BN-containing poly(o-phenylene) derivatives and extended triphenylene core. 
Effective N-vinylation21 was achieved using the same catalytic system by switching the 
base from NaOt-Bu to n-BuLi. 22  The reaction proved stereospecific to give the 
corresponding alkenylated products with retention of the configuration of the vinyl 
bromide starting materials (Table 4.6, entries 3 and 4). 
 
 
 
 
                                                 
20 For select examples, see: (a) Paul, F.; Patt, J.; Hartwig, J. F. J. Am. Chem. Soc. 1994, 116, 5969–5970. (b) 
Guram, A. S.; Buchwald, S. L. J. Am. Chem. Soc. 1994, 116, 7901–7902. (c) Guram, A. S.; Rennels, R. A.; 
Buchwald, S. L. Angew. Chem., Int. Ed. 1995, 34, 1348–1350. (d) Louie, J.; Hartwig, J. F. Tetrahedron Lett. 
1995, 36, 3609–3612. For selective reviews, see: (e) Muci, A. R.; Buchwald, S. L. Top. Curr. Chem. 2002, 
219, 131–209. (f) Hartwig, J. F. Angew. Chem. Int. Ed. 1998, 37, 2046–2067. (g) Hartwig, J. F. Acc. Chem. 
Res. 1998, 31, 852–860. (h) Wolfe, J. P.; Wagaw, S.; Marcoux, J.-F.; Buchwald, S. L. Acc. Chem. Res. 1998, 
31, 805–818. 
21 For select examples of palladium-catalyzed vinylation, see: (a) Lebedev, A. Y.; Izmer, V. V.; Kazyul’kin, 
D. N.; Beletskaya, I. P.; Voskoboynikov, A. Z. Org. Lett. 2002, 4, 623–626. (b) Barluenga, J.; Fernández, M. 
A.; Aznar, F.; Valdés, C. Chem. Commun. 2002, 2362–2363. (c) Kozawa, Y.; Mori, M. Tetrahedron Lett. 
2002, 43, 111–114. For select examples of copper-catalyzed vinylation, see: (d) Lam, P. Y. S.; Vincent, G.; 
Clark, C. G.; Deudon. S.; Jadhav, P. K. Tetrahedron Lett. 2001, 42, 3415–3418. (e) Lam, P. Y. S.; Vincent, 
G.; Bonne, D.; Clark, C. G. Tetrahedron Lett. 2003, 44, 4927–4931. (f) Jiang, L.; Job, G. E.; Klapars, A.; 
Buchwald, S. L. Org. Lett. 2003, 5, 3667–3669. (g) Pan, X.; Cai, Q.; Ma, D. Org. Lett. 2004, 6, 1809–1812. 
(h) Taillefer, M.; Ouali, A.; Renard, B.; Spindler, J.-F. Chem. Eur. J. 2006, 12, 5301–5313. (i) Liao, Q.; 
Wang, Y.; Zhang, L.; Xi, C. J. Org. Chem. 2009, 74, 6371–6373. 
22 Vinyl halides are known to undergo elimination by MOt-Bu to give the respective alkynes: Huntsman, W. 
D. In The Chemistry of the Carbon-Carbon Triple Bond; Patai, S., Ed.; Wiley: New York, 1978; pp 553–620. 
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Table 4.6 N–C(sp2) coupling of 1,2-azaborines 
 
 
4.3.5 Synthesis of a BN Isostere of trans-Stilbene 
 Through the method described above, we were able to synthesize a parental BN isostere 
of trans-stilbene (Scheme 4.21). A benzyl group was chosen to protect the boron to allow 
for removal through a novel three-step sequence after cross-coupling. Following 
deprotonation by n-BuLi, azaborine 4.81 coupled with β-bromostyrene to give the N-
alkenylated intermediate 4.82.23 Stereochemistry around the newly formed N–C (sp2) bond 
was unambiguously determined to be trans by an X-ray crystal structure (shown in Scheme 
4.21). Copper-mediated oxidation was utilized to remove the benzyl group on boron. 
Chromatographic purification of the crude materials afforded a mixture of BOR species 
(dimer and monomer R = n-C12H25 or R = H), which upon reduction with LiAlH4 furnished 
                                                 
23 Benzyl displacement by an n-butyl group was also observed, producing the corresponding B-butyl N-
alkenyl side product (9% isolated yield). 
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the desired BN-stilbene in moderate yield (38%) over three steps. The photoluminescence 
quantum yield of the resulting trans-BN-stilbene was determined to be ~4.4 times lower 
than that of the carbonaceous analog in cyclohexane (0.0388 and 0.179 for BN-stilbene 
and CC-stilbene, respectively). The solid state quantum yield were 0.127 and 0.324, 
respectively for BN-stilbene and CC-stilbene (BN-stilbene with ~2.6 times lower yield 
than that of CC-stilbene). Both absorption and emission peaks of the BN-stilbene are red-
shifted compared to carbonaceous stilbene (Figure 4.3).  
 
Scheme 4.21 Synthesis of unsubstituted BN isostere of trans-stilbene 
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Figure 4.3 Normalized absorption and emission spectra (in cyclohexane) of BN-stilbene in direct comparison 
with CC-stilbene 
 
 
4.3.6 N–C(sp) Bond Formation 
 To access N-alkynyl functionality, we chose copper-catalyzed alkynylation reactions 
with alkynyl bromides under non-oxidative conditions that have been previously applied 
to either amide, enamide, carbamate, or sulfoximine substrates.24,25 We hypothesized that 
reactivity of the azaborine nitrogen atom would be comparable to that of a nitrogen atom 
in resonance with a carbonyl, sulfonyl, or alkene. Avoidance of dioxygen in particular as a 
                                                 
24 For select examples of alkynylation with alkynyl bromides, see: (a) Frederick, M. O.; Mulder, J. A.; Tracey, 
M. R.; Hsung, R. P.; Huang, J.; Kurtz, K. C. M.; Shen, L.; Douglas, C. J. J. Am. Chem. Soc. 2003, 125, 2368–
2369. (b) Dunetz, J. R.; Danheiser, R. L. Org. Lett. 2003, 5, 4011–4014. (c) Zhang, Y.; Hsung, R. P.; Tracey, 
M. R.; Kurtz, K. C. M.; Vera, E. L. Org. Lett. 2004, 6, 1151–1154. (d) Hirano, S.; Tanaka, R.; Urabe, H.; 
Sato, F. Org. Lett. 2004, 6, 727–729. (e) Chen, W. Y.; Wang, L.; Frings, M.; Bolm, C. Org. Lett. 2014, 16, 
3796–3799. (f) Zhang, X.; Zhang, Y.; Huang, J.; Hsung, R. P.; Kurtz, K. C. M.; Oppenheimer, J.; Petersen, 
M. E.; Sagamanova, I. K.; Shen, L.; Tracey, M. R. J. Org. Chem. 2006, 71, 4170–4177. 
25 For select examples of oxidative cross-coupling reactions, see: (a) Hamada, T.; Ye, X.; Stahl, S. S. J. Am. 
Chem. Soc. 2008, 130, 833–835. (b) Jia, W.; Jiao, N. Org. Lett. 2010, 12, 2000–2003. (c) Laouiti, A.; 
Rammah, M. M.; Rammah, M. B.; Marrot, J.; Couty, F.; Evano, G. Org. Lett. 2012, 14, 6–9. 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
200 250 300 350 400 450 500 550
N
o
rm
al
iz
ed
 In
te
n
si
ty
Wavelength (nm)
BN-stilbene (emission)
CC-stilbene (emission)
BN-stilbene (absorption)
CC-stilbene (absorption)
668 
 
stoichiometric oxidant was also deemed necessary to prevent azaborine decomposition. 
However, when 4.28e was subjected to the copper-mediated N-alkynylation reaction, we 
observed only trace amounts of N-functionalized side product 4.86a (Scheme 4.22, in 
parentheses), with the alkyne homo-coupling product as the major species instead. The side 
product 4.86a was produced presumably via phenyl group displacement from boron by an 
excess amount of n-BuLi and subsequent N-coordination to the active copper complex to 
undergo alkynylation.  
 
Scheme 4.22 Unexpected results from N-alkynylation reaction 
 
 
 Thus, we decided to change the substituent on boron to more greatly favor the desired 
reaction path. Under the optimized catalytic condition, n-butyl or mesityl substituted 
azaborines underwent efficient N-alkylnylation to furnish the desired products in high 
yields (Table 4.7). 
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Table 4.7 N-Alkynylation of 1,2-azaborines 
 
 
4.3.7 Discovery of New Reactivity of 1,2-Azaborines 
 During the electrophilic substitution reactions with epoxides or aziridines before 
quenching with acid, we observed formation of tetra-coordinated boron species induced by 
intramolecular cyclization of heteroatom to boron (an example of reaction with ethylene 
oxide is shown in Scheme 4.23, eq. 1). The 11B NMR peak of the intermediate appeared at 
0.4–2.7 ppm, and 1H NMR peaks appeared relatively upfield: 4.4–4.5 ppm and 5.4-5.6 ppm, 
for C5-H and C3-H, respectively. This observation presents the opportunity to harness a 
new reaction mode of 1,2-azaborines through the enhanced activity of the boronate species 
4.88. For example, we recently published Diels–Alder reactions of 1,2-azaborines, and 
observed reversible cycloadduct formation, which limited the synthetic utility (Scheme 
4.23, eq. 2).26 We envision that the activated intermediates (such as 4.88) can potentially 
serve as electron-rich dienes to undergo Diels–Alder reactions without using Lewis acid 
catalysts under milder conditions. 
 
                                                 
26 Burford, R. J.; Li, B.; Vasiliu, M.; Dixon, D. A.; Liu, S.-Y. Angew. Chem. Int. Ed. 2015, 54, 7823–7827. 
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Scheme 4.23 Potential reactivity in Diels-Alder reaction of 1,2-azaborines 
 
 
 Furthermore, we previously observed self-arylation of C3-bromo-1,2-azaborines under 
C–O coupling reaction conditions similar to Molander’s BN-naphthalene chemistry 
(Scheme 4.24, eq. 1 and 2).15 Instead of C–O bond formation, the boron phenyl group in 
4.90 migrated to C3 position to form a C–C bond presumably induced by the initial 
formation of a thermodynamically stable B–Ot-Bu adduct. By combining this unique 
reactivity with potential Diels-Alder reaction of activated boronate species 4.95, it is 
feasible to synthesize a complex chiral molecule 4.96 featuring an oxazaborolidine unit 
(Scheme 4.24, eq. 3). 
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Scheme 4.24 Potential application by combination of self-arylation and Diels-Alder reaction 
 
 
4.4 Conclusions 
 We have developed an array of chemical transformations to functionalize the nitrogen 
of 1,2-azaborines. Electrophilic substitution reactions, N–C(sp2) bond forming reactions 
under  Buchwald-Hartwig amination  conditions, and N–C(sp) bond forming reactions 
using copper-catalyzed N-alkynylation afforded various N-functionalized 1,2-azaborines. 
This work expands the scope of possible functionality on the azaborine skeleton and 
enables further elaboration to complex BN-containing molecules applicable to studies in 
materials science and medicinal chemistry. Specifically, by utilizing an aziridine ring-
opening reaction, we successfully prepared a BN-lisdexamfetamine analog. We also 
described the first example of an unsubstituted BN-isostere of trans-stilbene, as prepared 
by an N-alkenylation reactions. 
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4.5 Experimental 
4.5.1 General Information 
 All oxygen- and moisture-sensitive manipulations were carried out under an inert 
atmosphere (N2) using either standard Schlenk techniques or a glove box. THF was purified 
by distillation from sodium benzophenone ketyl prior to use. Toluene was dried over CaH2 
and distilled under nitrogen atmosphere prior to use. Et2O, CH2Cl2 and pentane were 
purified by passing through a neutral alumina column under argon. Pd/C was purchased 
from Strem and heated under high vacuum at 100 °C for 12 hours prior to use. Silica gel 
(230-400 mesh) was dried for 12 hours at 180 °C under high vacuum. Flash 
chromatography was performed with this silica gel under an inert atmosphere. 
Allylbromide, ethyl iodide, benzyl bromide, 3-bromo-1-(trimethylsilyl)-1-propyne, 
benzoyl chloride were purified by distillation from CaH2 under nitrogen atmosphere prior 
to use. 1-Bromo-2-phenylacetylene and 1-bromo-2-(triisopropylsilyl)acetylene were 
prepared according to the previously reported methods.24e All other chemicals and solvents 
were purchased and used as received. 
 NMR spectra were recorded on a Varian VNMRS 600 MHz, VNMRS 500 MHz, 
INOVA 500 MHz, or VNMRS 400 MHz spectrometer. Deuterated solvents were 
purchased from Cambridge Isotope Labs. 11B NMR spectra were externally referenced to 
BF3•Et2O (δ 0). All NMR chemical shifts are reported in ppm relative to residual solvent 
for 1H and 13C NMR. Signals are quoted as singlet (s), doublet (d), triplet (t), quartet (q), 
quintet (quint), multiplet (m), and broad singlet (br s). Coupling constants are reported in 
Hz. Infrared spectroscopy was performed on a Bruker ALPHA-Platinum FT-IR 
Spectrometer with ATR-sampling module. High-resolution mass spectrometry analyses 
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were performed by direct analysis in real time (DART) on a JEOL AccuTOF DART 
instrument. Photoluminescence quantum yields were measured using an integrating sphere 
instrument. 
 
4.5.2 Synthesis of 1,2-Azaborines 
Synthesis of 1,2-Azaborine Starting Materials: 
Scheme 4.25 Synthesis of NK salt 4.72 
 
 
To a 250 mL round bottom flask containing 4.33 (5.00 g, 22.0 mmol) in Et2O 
(100 mL) a solution of phenyllithium (11.6 mL, 22.0 mmol, 1.9 M  in 
dibutylether) was added dropwise under nitrogen atmosphere at –78 oC. The reaction 
mixture was stirred for 12 h as it was slowly warmed to room temperature. The reaction 
mixture was filtrated through a glass frit and the solvent was removed under reduced 
pressure. The crude mixture was purified by silica gel column chromatography with 
pentane as the eluent. The desired product was isolated as a colorless oil (5.92 g, >99%). 
The spectra for 4.97 are consistent with the values reported in the literature.2c 
To a 500 mL round bottom flask containing 4.97 (9.46 g, 35.2 mmol) in THF 
(250 mL) a solution of tetrabutylammonium fluoride (38.7 mL, 38.7 mmol, 1.0 
M  in THF) was added dropwise under nitrogen atmosphere at room temperature. The 
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reaction mixture was stirred for 15 h. The reaction mixture was concentrated under reduced 
pressure and dissolved in Et2O (100 mL). The organic solution was transferred into a 
separatory funnel containing water (100 mL) and extracted with Et2O (3 x 50 mL). The 
combined organic layers were washed with brine (100 mL), dried with MgSO4, filtered and 
the solvent was removed under reduced pressure. The crude mixture was purified by silica 
gel column chromatography (100% pentane to 30% Et2O/pentane). The desired product 
was isolated as a white solid (4.63 g, 85%). The spectra for 4.28e are consistent with the 
values reported in the literature.5a 
To a 50 mL round bottom flask containing 4.28e (500 mg, 3.23 mmol) in Et2O 
(15 mL) a solution of potassium bis(trimethylsilyl)amide (7.10 mL, 3.55 mmol, 
0.5 M  in toluene) was added dropwise under nitrogen atmosphere at room temperature. 
The reaction mixture was stirred for 1 h. The resulting powder was filtrated and washed 
with Et2O, followed by pentane. The white powder was collected as the desired product 
and dried under reduced pressure (589 mg, 95%). 1H NMR (600 MHz, THF-d8):  8.14 (s, 
1H),  7.92 (d, J = 7.2 Hz, 2H), 7.39 (dd, J = 9.6, 6.6 Hz, 1H), 7.21 (t, J = 7.8 Hz , 2H), 7.08 
(t, J = 7.8 Hz, 1H), 6.67 (d, J = 10.8 Hz, 1H), 6.14 (t, J = 5.4 Hz, 1H). 11B NMR (160 MHz, 
THF-d8): δ 35.2. 13C NMR (151 MHz, THF-d8): δ 151.1 (br), 150.3, 140.7, 133.2, 128.2, 
126.3, 122.5 (br), 112.1. FTIR (thin film): 3072, 3012, 1651, 1612, 1542, 1458, 1414, 1378, 
1232, 1166, 980, 884, 713, 593 cm-1. HRMS (DART-TOF) calculated for C10H9BN ([M]–): 
154.0828, found: 154.0831. 
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Electrophilic Substitution (Table 4.5): 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 4.72 
(29.0 mg, 0.15 mmol), di-tert-butyl dicarbonate (36.0 mg, 0.165 mmol), and 
THF (2 mL). The reaction was stirred at room temperature for 24 h. The crude mixture was 
concentrated under reduced pressure and purified by silica gel column chromatography 
(100% pentane to 10% Et2O/pentane). The desired product was isolated as a white solid 
(33.6 mg, 88%). A duplicate reaction gave 91% yield. 1H NMR (500 MHz, CD2Cl2):  7.80 
(d, J = 7.5 Hz, 1H), 7.66 (dd, J = 11.0, 6.5 Hz, 1H), 7.45 (dd, J = 8.5, 2.0 Hz, 2H), 7.37-
7.29 (m, 3H), 6.87 (d, J = 11.0 Hz, 1H), 6.43 (t, J = 6.8 Hz, 1H), 1.22 (s, 9H). 11B NMR 
(160 MHz, CD2Cl2): δ 37.7. 13C NMR (151 MHz, CD2Cl2): δ 156.8, 145.5, 143.4 (br), 
133.7, 133.0 (br), 132.3, 127.9, 111.9, 84.5, 27.4. FTIR (thin film): 3206, 2981, 1741, 1619, 
1513, 1440, 1394, 1258, 1150, 966, 849, 743, 702 cm-1. HRMS (DART-TOF) calculated 
for C15H19BNO2 ([M+H]+): 256.15088, found: 256.15160. 
 In a dry box, an oven-dried 4 mL glass reaction vial was charged with 4.72 
(29.0 mg, 0.15 mmol), allylbromide (14.3 μL, 0.165 mmol), and THF (2 
mL). The reaction was stirred at room temperature for 2 h. The crude mixture was 
concentrated under reduced pressure and purified by silica gel column chromatography 
(100% pentane to 3% CH2Cl2/pentane). The desired product was isolated as a colorless oil 
(29.0 mg, 99%). A duplicate reaction gave 96% yield. 1H NMR (600 MHz, CD2Cl2):  7.67 
(dd, J = 10.2, 6.0 Hz, 1H), 7.55 (d, J = 7.2 Hz, 2H), 7.40-7.33 (m, 3H), 7.25 (d, J = 7.2 Hz, 
1H), 6.86 (d, J = 10.8 Hz, 1H), 6.44 (t, J = 6.9 Hz, 1H), 6.05-5.99 (m, 1H), 5.22 (d, J = 
11.4 Hz, 1H), 5.02 (d, J = 10.0 Hz, 1H), 4.46 (d, J = 3.6 Hz, 2H). 11B NMR (192 MHz, 
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CD2Cl2): δ 35.6. 13C NMR (151 MHz, CD2Cl2): δ 143.4, 142.0 (br), 139.2, 137.2, 133.4, 
131.5 (br), 128.1, 128.0, 116.7, 111.9, 56.3. FTIR (thin film): 3067, 3009, 1643, 1460, 
1402, 1205, 1118, 919, 684, 557 cm-1. HRMS (DART-TOF) calculated for C13H15BN 
([M+H]+): 196.12975, found: 196.13061. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 4.28e 
(23.3 mg, 0.15 mmol) and THF (2 mL). A solution of potassium 
bis(trimethylsilyl)amide (330 μL, 0.165 mmol, 0.5 M  in toluene) was added dropwise to 
the reaction, followed by ethyl iodide (13.2 μL, 0.165 mmol). The reaction was stirred at 
room temperature for 2 h. The crude mixture was concentrated under reduced pressure and 
purified by silica gel column chromatography (100% pentane to 5% CH2Cl2/pentane). The 
desired product was isolated as a colorless oil (27.5 mg, >99%). A duplicate reaction gave 
>99% yield. 1H NMR (500 MHz, CD2Cl2):  7.64 (dd, J = 11.0, 7.2 Hz, 1H), 7.53 (d, J = 
8.5 Hz, 2H), 7.40-7.32 (m, 4H), 6.79 (d, J = 10.5 Hz, 1H), 6.43 (t, J = 6.5 Hz, 1H), 3.87 (q, 
J = 7.0 Hz, 2H), 1.31 (t, J = 7.0 Hz, 1H). 11B NMR (160 MHz, CD2Cl2): δ 35.4. 13C NMR 
(151 MHz, CD2Cl2): δ 143.1, 142.5 (br), 138.7, 133.3, 131.5 (br), 128.1, 127.8, 111.9, 48.8, 
18.8. FTIR (thin film): 3068, 2975, 2897, 1608, 1515, 1405, 1259, 1209, 1114, 801, 781, 
597 cm-1. HRMS (DART-TOF) calculated for C12H15BN ([M+H]+): 184.12975, found: 
184.13024. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 4.28e 
(23.3 mg, 0.15 mmol) and THF (2 mL). A solution of potassium 
bis(trimethylsilyl)amide (330 μL, 0.165 mmol, 0.5 M  in toluene) was added dropwise to 
the reaction, followed by benzyl bromide (19.6 μL, 0.165 mmol). The reaction was stirred 
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at room temperature for 2 h. The crude mixture was filtrated through an acro-disc and the 
filtrate was concentrated under reduced pressure. The crude product was purified by silica 
gel column chromatography (100% pentane to 3% CH2Cl2/pentane). The desired product 
was isolated as a white solid (35.0 mg, 95%). A duplicate reaction gave 92% yield. 1H 
NMR (600 MHz, CD2Cl2):  7.70 (dd, J = 11.4, 6.6 Hz, 1H), 7.51 (d, J = 7.8 Hz, 2H), 7.36-
7.31 (m, 5H), 7.28-7.24 (m, 2H), 7.08 (d, J = 6.6 Hz, 1H), 6.92 (d, J = 11.4 Hz, 1H),  6.44 
(t, J = 6.0 Hz, 1H), 5.11 (s, 2H). 11B NMR (192 MHz, CD2Cl2): δ 35.8. 13C NMR (151 
MHz, CD2Cl2): δ 143.5, 142.3 (br), 140.4, 139.4, 133.4, 132.2 (br), 129.2, 128.2, 128.1, 
127.8, 127.4, 112.3, 57.2. FTIR (thin film): 3066, 3029, 3008, 1609, 1513, 1403, 1240, 
1137, 742, 702, 522 cm-1. HRMS (DART-TOF) calculated for C17H17BN ([M+H]+): 
246.14540, found: 246.14551. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged 
with 4.28e (23.3 mg, 0.15 mmol) and THF (2 mL). A solution of 
potassium bis(trimethylsilyl)amide (330 μL, 0.165 mmol, 0.5 M  in toluene) was added 
dropwise to the reaction and cooled to 0 oC. 3-Bromo-1-(trimethylsilyl)-1-propyne (27.0 
μL, 0.165 mmol) was added to the reaction at this temperature and the reaction was slowly 
warmed to room temperature while stirring for 17 h. The crude mixture was concentrated 
under reduced pressure and purified by silica gel column chromatography (100% pentane 
to 2% Et2O/pentane). The desired product was isolated as a colorless oil (20.2 mg, 51%). 
A duplicate reaction gave 55% yield. 1H NMR (500 MHz, CD2Cl2):  7.66 (dd, J = 11.0, 
6.5 Hz, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 7.0 Hz , 1H), 7.42-7.34 (m, 3H), 6.85 (d, 
J = 11.0 Hz, 1H), 6.47 (t, J = 6.5 Hz, 1H), 4.59 (s, 2H), 0.19 (s, 9H). 11B NMR (160 MHz, 
CD2Cl2): δ 35.6. 13C NMR (151 MHz, CD2Cl2): δ 143.6, 141.7 (br), 138.4, 133.7, 133.5, 
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131.9 (br), 128.3, 112.4, 103.1, 90.4, 44.3, 0.0. FTIR (thin film): 3070, 3010, 2959, 2180, 
1611, 1514, 1404, 1250, 1136, 1011, 841, 747, 683 cm-1. HRMS (DART-TOF) calculated 
for C16H21BNSi ([M+H]+): 266.15363, found: 266.15356. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 4.28e 
(23.3 mg, 0.15 mmol) and THF (2 mL). A solution of potassium 
bis(trimethylsilyl)amide (330 μL, 0.165 mmol, 0.5 M  in toluene) was added 
dropwise to the reaction, followed by benzoyl chloride (19.2 μL, 0.165 mmol). The reaction 
was stirred at room temperature for 16 h.  The crude mixture was concentrated under 
reduced pressure and purified by silica gel column chromatography (100% pentane to 3% 
Et2O/pentane). The desired product was isolated as a white solid (29.0 mg, 75%). A 
duplicate reaction gave 69% yield. 1H NMR (500 MHz, CD2Cl2):  7.81 (dd, J = 10.5, 6.0 
Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.57 (d, J = 7.0 Hz, 1H), 7.44-7.38 (m, 3H), 7.27 (t, J = 
7.5 Hz, 2H), 7.13 (t, J = 2.5 Hz, 3H), 7.07 (d, J = 11.5 Hz, 1H), 6.55 (t, J = 6.5 Hz, 1H). 
11B NMR (160 MHz, CD2Cl2): δ 36.6. 13C NMR (126 MHz, CD2Cl2): δ 178.8, 145.6, 140.4 
(br), 134.6, 134.2, 134.0, 133.7, 132.0 (br), 131.5, 128.9, 128.5, 128.0, 111.9. FTIR (thin 
film): 3069, 1705, 1612, 1506, 1441, 1262, 1229, 1074, 967, 736, 631 cm-1. HRMS 
(DART-TOF) calculated for C17H15BNO ([M+H]+): 260.12467, found: 260.12437. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 4.72 
(29.0 mg, 0.15 mmol), N-TBS-B-Cl-1,2-azaborine (4.33) (37.6 mg, 0.165 
mmol), and THF (2 mL). The reaction was stirred at room temperature for 
1 h. The crude mixture was concentrated under reduced pressure and purified by silica gel 
column chromatography (100% pentane to 2% Et2O/pentane). The desired product was 
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isolated as a colorless oil (51.2 mg, 99%). A duplicate reaction gave 97% yield. 1H NMR 
(500 MHz, CD2Cl2):  7.73 (dd, J = 10.5, 6.5 Hz, 1H), 7.65 (dd, J = 10.5, 6.5 Hz, 1H), 7.38 
(d, J = 6.0 Hz, 1H), 7.33 (d, J = 2.5 Hz, 2H), 7.26 (d, J = 6.5 Hz, 1H), 7.17 (d, J = 3.0 Hz, 
2H), 6.97 (d, J = 10.5 Hz, 1H), 6.53 (d, J = 11.0 Hz, 1H), 6.47 (t, J = 6.0 Hz, 1H), 6.42 (t, 
J = 6.0 Hz, 1H). 11B NMR (160 MHz, CD2Cl2): δ 36.1. 13C NMR (151 MHz, CD2Cl2): δ 
146.1, 144.0, 142.6 (br), 138.4, 135.0, 133.6 (br), 130.1 (br), 127.7, 112.3, 111.3, 27.4, 
19.6, –3.6. FTIR (thin film): 3067, 2930, 2859, 1604, 1501, 1392, 1272, 1233, 1148, 989, 
821, 789, 701 cm-1. HRMS (DART-TOF) calculated for C20H29B2N2O ([M+H]+): 
347.22861, found: 347.22893. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 
4.72 (29.0 mg, 0.15 mmol) and THF (2 mL). A solution of ethylene oxide 
(66 μL, 0.165 mmol, 2.5 M in THF) was added to the reaction. After stirring the reaction 
at room temperature for 4 h, hydrogen chloride solution (82.5 μL, 0.165 mmol, 2.0 M in 
diethyl ether) was added and the reaction was stirred for 5 min. The crude mixture was 
concentrated under reduced pressure and purified by silica gel column chromatography (10% 
Et2O/pentane to 100% Et2O). The desired product was isolated as a colorless oil (29.2 mg, 
98%). A duplicate reaction gave 95% yield. 1H NMR (500 MHz, CD2Cl2):  7.65 (dd, J = 
10.0, 7.0 Hz, 1H), 7.51 (d, J = 7.5 Hz, 2H), 7.39-7.30 (m, 4H), 6.80 (d, J = 11.0 Hz, 1H), 
6.41 (t, J = 6.5 Hz, 1H), 3.98 (t, J = 4.0 Hz, 2H), 3.73 (d, J = 8.3 Hz, 2H), 1.53 (s, 1H). 11B 
NMR (192 MHz, CD2Cl2): δ 35.9. 13C NMR (151 MHz, CD2Cl2): δ 143.5, 142.7 (br), 139.5, 
133.4, 131.7 (br), 128.2, 127.9, 111.8, 64.1, 55.9. FTIR (thin film): 3350, 3067, 3007, 2881, 
1607, 1513, 1402, 1238, 1142, 1053, 944, 866, 742, 701, 561 cm-1. HRMS (DART-TOF) 
calculated for C12H15BNO ([M+H]+): 200.12467, found: 200.12457. 
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In a dry box, an oven-dried 4 mL glass reaction vial was charged with 
4.72 (29.0 mg, 0.15 mmol), 3,4-epoxy-1-butene (13.3 μL, 0.165 mmol) 
and THF (2 mL). After stirring the reaction at room temperature for 4 h, hydrogen chloride 
solution (82.5 μL, 0.165 mmol, 2.0 M in diethyl ether) was added and the reaction was 
stirred for 5 min. The crude mixture was concentrated under reduced pressure and purified 
by silica gel column chromatography (10% Et2O/pentane to 30% Et2O/pentane). The 
desired product was isolated as a colorless oil (20.1 mg, 60%). A duplicate reaction gave 
60% yield. 1H NMR (500 MHz, CD2Cl2):  7.67 (dd, J = 11.0, 7.0 Hz, 1H), 7.54 (d, J = 
7.5 Hz, 2H), 7.41-7.33 (m, 4H), 6.83 (d, J = 11.0 Hz, 1H), 6.42 (t, J = 5.5 Hz, 1H), 5.76-
5.69 (m, 1H), 5.15 (d, J = 27.5, 1H), 5.12 (d, J = 20.5 Hz, 1H), 4.23 (br s, 1H), 4.03 (dd, J 
= 13.5, 4.0 Hz, 1H), 3.81 (dd, J = 13.5, 9.0 Hz, 1H), 1.85 (s, 1H). 11B NMR (160 MHz, 
CD2Cl2): δ 36.2. 13C NMR (151 MHz, CD2Cl2): δ 143.6, 142.5 (br), 140.0, 138. 4, 133.4, 
131.7 (br), 128.2, 127.9, 116.6, 111.5, 74.5, 59.5. FTIR (thin film): 3394, 3068, 3008, 2930, 
1607, 1513, 1403, 1237, 1145, 975, 927, 743, 702 cm-1. HRMS (DART-TOF) calculated 
for C14H17BNO ([M+H]+): 226.14032, found: 226.14134. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 
4.72 (29.0 mg, 0.15 mmol), tert-butyl 2-methylaziridine-1-
carboxylate (25.9 mg, 0.165 mmol) and THF (2 mL). After stirring the reaction at room 
temperature for 16 h, hydrogen chloride solution (82.5 μL, 0.165 mmol, 2.0 M in diethyl 
ether) was added and the reaction was stirred for 5 min. The crude mixture was 
concentrated under reduced pressure and purified by silica gel column chromatography (5% 
Et2O/pentane to 50% Et2O/pentane). The desired product was isolated as a colorless oil 
(39.5 mg, 84%). A duplicate reaction gave 89% yield. 1H NMR (500 MHz, CD2Cl2):  7.65 
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(dd, J = 11.0, 6.5 Hz, 1H), 7.53 (d, J = 7.5 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.36-7.33 (m, 
2H), 6.80 (d, J = 11.5 Hz, 1H), 6.43 (t, J = 6.5 Hz, 1H), 4.30 (br s, 1H), 3.90 (d, J = 5.5 Hz, 
2H), 3.81 (t, J = 5.5 Hz, 1H), 1.38 (s, 9H), 0.92 (d, J = 5.5 Hz, 3H). 11B NMR (160 MHz, 
CD2Cl2): δ 36.0. 13C NMR (151 MHz, CD2Cl2): δ 155.5, 143.4, 142.6 (br), 139.2, 133.3, 
131.5 (br), 128.3, 127.8, 111.9, 79.5, 58.5, 49.0, 28.7, 18.7. FTIR (thin film): 3339, 2976, 
1693, 1453, 1365, 1116, 1011, 975, 944, 881, 742, 703, 597, 462 cm-1. HRMS (DART-
TOF) calculated for C18H26BN2O2 ([M+H]+): 313.20873, found: 313.21021. 
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Buchwald-Hartwig Amination:  
Table 4.8 Ligand screening 
 
Table 4.9 Optimization 
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N–C(sp2) Bond Formation (Table 4.6): 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 4.28e 
(23.3 mg, 0.150 mmol), Pd2dba3 (2.7 mg, 0.0030 mmol), QPhos (8.5 mg, 0.012 
mmol), sodium tert-butoxide (21.6 mg, 0.225 mmol), bromobenzene (19.2 μL, 
0.180 mmol) and toluene (0.7 mL). The reaction mixture was stirred at 85 oC for 14 h. At 
the completion of the reaction, the reaction mixture was cooled to room temperature. The 
crude mixture was filtrated through an acro-disc using CH2Cl2 as solvent and the filtrate 
was concentrated under reduced pressure. The crude product was purified by silica gel 
column chromatography (3% CH2Cl2/pentane to 5% CH2Cl2/pentane). The desired product 
was isolated as a white solid (28.8 mg, 83%). A duplicate reaction gave 79% yield. 1H 
NMR (500 MHz, CD2Cl2):  7.76 (dd, J = 11.0, 6.5 Hz, 1H), 7.40 (d, J = 7.0 Hz, 1H), 7.35-
7.30 (m, 3H), 7.22-7.7.12 (m, 7H), 7.03 (d, J = 11.5 Hz, 1H), 6.48 (t, J = 7.0 Hz, 1H), 4.30 
(br s, 1H), 3.90 (d, J = 5.5 Hz, 2H), 3.81 (t, J = 5.5 Hz, 1H), 1.38 (s, 9H), 0.92 (d, J = 5.0 
Hz, 3H). 11B NMR (160 MHz, CD2Cl2): δ 35.2. 13C NMR (151 MHz, CD2Cl2): δ 148.5, 
143.9, 141.3 (br), 139.6, 134.4, 131.5 (br), 129.4, 127.9, 127.7, 127.6, 127.3, 111.4. FTIR 
(thin film): 3068, 3030, 1612, 1507, 1491, 1444, 1396, 1274, 1258, 1156, 1066, 761, 740, 
698. 551 cm-1. HRMS (DART-TOF) calculated for C16H15BN ([M+H]+): 232.12975, found: 
232.12987. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged 
with 4.28e (46.5 mg, 0.300 mmol), Pd2dba3 (5.5 mg, 0.0060 mmol), 
QPhos (17.1 mg, 0.0240 mmol), sodium tert-butoxide (43.2 mg, 
0.450 mmol), 1,4-dibromobenzene (42.5 mg, 0.180 mmol) and 
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toluene (1.5 mL). The reaction mixture was stirred at 85 oC for 16 h. At the completion of 
the reaction, the reaction mixture was cooled to room temperature. The crude mixture was 
concentrated under reduced pressure and purified by silica gel column chromatography (2% 
CH2Cl2/pentane to 5% CH2Cl2/pentane). The desired product was isolated as a white solid 
(32.3 mg, 56%). A duplicate reaction gave 52% yield. 1H NMR (600 MHz, CD2Cl2):  7.76 
(dd, J = 10.8, 6.0 Hz, 2H), 7.37 (d, J = 7.2 Hz, 2H), 7.29-7.27 (m, 4H), 7.23-7.21 (m, 6H), 
7.12 (s, 4H), 7.04 (d, J = 10.2 Hz, 2H), 6.49 (t, J = 6.0 Hz, 2H). 11B NMR (160 MHz, 
CD2Cl2): δ 35.4. 13C NMR (151 MHz, CD2Cl2): δ 147.0, 144.0, 139.4, 134.5, 131.8 (br), 
128.1, 127.9, 127.8, 111.7. FTIR (thin film): 3067, 3031, 1608, 1503, 1445, 1432, 1394, 
1254, 1156, 1106, 982, 846, 742, 701, 686 cm-1. HRMS (DART-TOF) calculated for 
C26H23B2N2 ([M+H]+): 385.20473, found: 385.20404. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 4.28e 
(23.3 mg, 0.150 mmol) and toluene (1.5 mL). A solution of n-butyllithium (63.0 
μL, 0.158 mmol, 2.5 M in hexane) was added at room temperature and the 
reaction was stirred for 5 min. To the reaction vial Pd2dba3 (2.7 mg, 0.0030 mmol), QPhos 
(8.5 mg, 0.012 mmol), and cis-1-bromo-1-propene (15.3 μL, 0.180 mmol) were added. The 
reaction mixture was stirred at 85 oC for 16 h. At the completion of the reaction, the reaction 
mixture was cooled to room temperature. The crude mixture was filtrated through an acro-
disc using CH2Cl2 as solvent and the filtrate was concentrated under reduced pressure. The 
crude product was purified by silica gel column chromatography (100% pentane to 2% 
CH2Cl2/pentane). The desired product was isolated as a white solid (27.6 mg, 94%). A 
duplicate reaction gave 90% yield. 1H NMR (500 MHz, CD2Cl2):  7.70 (dd, J = 11.0, 7.0 
Hz, 1H), 7.63 (d, J = 6.5 Hz, 2H), 7.37-7.30 (m, 3H), 7.22 (d, J = 6.5 Hz, 1H), 6.96 (d, J = 
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11.0 Hz, 1H), 6.78 (dd, J = 8.0, 2.0 Hz, 1H), 6.42 (td, J = 7.0, 1.5 Hz, 1H), 5.49 (quint, J = 
6.5 Hz, 1H), 1.56 (dd, J = 7.0, 1.5 Hz, 1H). 11B NMR (160 MHz, CD2Cl2): δ 34.8. 13C 
NMR (126 MHz, CD2Cl2): δ 144.0, 141.8 (br), 138.9, 135.9, 134.3, 131.6 (br), 128.3, 127.9, 
121.4, 111.1, 12.2. FTIR (thin film): 3069, 3031, 1660, 1607, 1509, 1445, 1398, 1295, 
1231, 977, 753, 701, 450 cm-1. HRMS (DART-TOF) calculated for C18H26BN2O2 
([M+H]+): 313.20873, found: 313.21021. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with 
4.28e (23.3 mg, 0.150 mmol) and toluene (1.5 mL). A solution of n-
butyllithium (63.0 μL, 0.158 mmol, 2.5 M in hexane) was added at room 
temperature and the reaction was stirred for 5 min. To the reaction vial Pd2dba3 (2.7 mg, 
0.0030 mmol), QPhos (8.5 mg, 0.012 mmol), and β-bromostyrene (23.8 μL, 0.180 mmol) 
were added. The reaction mixture was stirred at 85 oC for 16 h. At the completion of the 
reaction, the reaction mixture was cooled to room temperature. The crude mixture was 
filtrated through an acro-disc using CH2Cl2 as solvent and the filtrate was concentrated 
under reduced pressure. The crude product was purified by silica gel column 
chromatography (2% CH2Cl2/pentane to 5% CH2Cl2/pentane). The desired product was 
isolated as a white solid (25.7 mg, 67%). A duplicate reaction gave 74% yield. 1H NMR 
(500 MHz, CD2Cl2):  7.72 (d, J = 7.0 Hz, 2H), 7.65 (t, J = 6.5 Hz, 3H), 7.44-7.31 (m, 7H), 
7.25 (t, J = 6.5 Hz, 1H), 6.98 (d, J = 11.0 Hz, 1H), 6.71 (d, J = 14.0 Hz, 1H), 6.54 (t, J = 
6.5 Hz, 1H). 11B NMR (160 MHz, CD2Cl2): δ 36.3. 13C NMR (151 MHz, CD2Cl2): δ 144.3, 
140.9 (br), 136.4, 135.4, 134.5, 134.3, 132.0 (br), 129.3, 128.6, 128.2, 127.9, 126.7, 120.5, 
112.7. FTIR (thin film): 3068, 3026, 1641, 1609, 1509, 1492, 1402, 1238, 1150, 972, 948, 
686 
 
751, 703, 692 cm-1. HRMS (DART-TOF) calculated for C18H17BN ([M+H]+): 258.14540, 
found: 258.14438. 
Copper-Catalyzed N-Alkynylation (Table 4.7): 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with N-
H-B-n-butyl-1,2-azaborine (4.28d) (28.4 mg, 0.210 mmol) and toluene 
(1.0 mL) and cooled to –30 oC. A solution of n-butyllithium (80.0 μL, 
0.200 mmol, 2.5 M in hexane) was added at –30 oC and the reaction was stirred for 1h 
while slowly warming up to room temperature. To the reaction vial CuI (7.6 mg, 0.040 
mmol), pyridine (6.4 μL, 0.080 mmol), and a solution of 1-bromo-2-phenylacetylene (114 
mg, 0.630 mmol) in toluene (1.0 mL) were added. The reaction was stirred at room 
temperature for 22 h. The crude mixture was diluted with Et2O (3.0 mL) and washed with 
a 2:1 mixture of brine and concentrated NH4OH (2 x 5.0 mL). The combined aqueous 
layers were extracted with Et2O (2 x 5.0 mL). The combined organic layers were washed 
with brine (10 mL), dried with MgSO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by silica gel column chromatography (100% 
pentane). The desired product was isolated as a colorless oil (39.0 mg, 83%). A duplicate 
reaction gave 85% yield. 1H NMR (600 MHz, CD2Cl2):  7.53 (dd, J = 10.8, 6.0 Hz, 1H), 
7.49 (d, J = 6.0 Hz, 2H), 7.39-7.32 (m, 4H), 6.83 (d, J = 12.0 Hz, 1H), 6.30 (t, J = 6.0 Hz, 
1H), 1.64 (t, J = 7.2 Hz, 2H), 1.46-1.40 (m, 4H), 0.96 (t, J = 7.2 Hz, 3H). 11B NMR (160 
MHz, CD2Cl2): δ 41.3. 13C NMR (151 MHz, CD2Cl2): δ 143.4, 137.9, 131.8, 129.9 (br), 
129.0, 128.4, 123.5, 111.9, 88.7, 68.7, 28.6, 26.3, 18.8 (br), 14.5. FTIR (thin film): 2955, 
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2922. 2856, 2255, 1617, 1508, 1442, 1400, 1329, 1268, 1149, 1107, 753, 735, 690 cm-1. 
HRMS (DART-TOF) calculated for C16H19BN ([M+H]+): 236.16105, found: 236.16070. 
In a dry box, an oven-dried 4 mL glass reaction vial was charged with N-
H-B-mesityl-1,2-azaborine (4.87) (41.4 mg, 0.210 mmol) and toluene 
(1.0 mL) and cooled to –30 oC. A solution of n-butyllithium (80.0 μL, 
0.200 mmol, 2.5 M in hexane) was added at –30 oC and the reaction was stirred for 1h 
while slowly warming up to room temperature. To the reaction vial CuI (7.6 mg, 0.040 
mmol), pyridine (6.4 μL, 0.080 mmol), and a solution of 1-bromo-2-phenylacetylene (114 
mg, 0.630 mmol) in toluene (1.0 mL) were added. The reaction was stirred at room 
temperature for 22 h. The crude mixture was diluted with Et2O (3.0 mL) and washed with 
a 2:1 mixture of brine and concentrated NH4OH (2 x 5.0 mL). The combined aqueous 
layers were extracted with Et2O (2 x 5.0 mL). The combined organic layers were washed 
with brine (10 mL), dried with MgSO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by silica gel column chromatography (0.2% 
Et2O/pentane). The desired product was isolated as a colorless oil (58.4 mg, 98%). A 
duplicate reaction gave 98% yield. 1H NMR (500 MHz, CD2Cl2):  7.69 (dd, J = 11.0, 6.5 
Hz, 1H), 7.56 (d, J = 6.5 Hz, 1H), 7.25-7.23 (m, 3H), 7.09-7.07 (m, 2H), 6.92 (d, J = 11.0 
Hz, 1H), 6.89 (s, 2H), 6.48 (t, J = 6.0 Hz, 1H), 2.33 (s, 3H), 2.20 (s, 6H). 11B NMR (160 
MHz, CD2Cl2): δ 39.8. 13C NMR (151 MHz, CD2Cl2): δ 144.0, 140.2, 138.1, 137.9, 137.5 
(br), 131.5, 128.8, 128.3, 127.4, 123.2, 112.8, 89.1, 67.9, 22.7, 21.5 (the signal for the 
mesityl carbon next to boron is not observed). FTIR (thin film): 3031, 2915, 2255, 1614, 
1504, 1440, 1396, 1329, 1229, 1125, 936, 849, 753, 691, 515 cm-1. HRMS (DART-TOF) 
calculated for C21H21BN ([M+H]+): 298.17670, found: 298.17704. 
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In a dry box, an oven-dried 4 mL glass reaction vial was charged with 
N-H-B-mesityl-1,2-azaborine (4.87) (41.4 mg, 0.210 mmol) and 
toluene (1.0 mL) and cooled to –30 oC. A solution of n-butyllithium 
(80.0 μL, 0.200 mmol, 2.5 M in hexane) was added at –30 oC and the reaction was stirred 
for 1h while slowly warming up to room temperature. To the reaction vial CuI (7.6 mg, 
0.040 mmol), pyridine (6.4 μL, 0.080 mmol), and a solution of 1-bromo-2-
(triisopropylsilyl)acetylene (165 mg, 0.630 mmol) in toluene (1.0 mL) were added. The 
reaction was stirred at room temperature for 22 h. The crude mixture was diluted with Et2O 
(3.0 mL) and washed with a 2:1 mixture of brine and concentrated NH4OH (2 x 5.0 mL). 
The combined aqueous layers were extracted with Et2O (2 x 5.0 mL). The combined 
organic layers were washed with brine (10 mL), dried with MgSO4, filtered and the solvent 
was removed under reduced pressure. The crude product was purified by silica gel column 
chromatography (100% pentane). The desired product was isolated as a colorless oil (58.3 
mg, 77%). A duplicate reaction gave 81% yield. 1H NMR (500 MHz, CD2Cl2):  7.63 (dd, 
J = 11.0, 6.5 Hz, 1H), 7.46 (d, J = 6.5 Hz, 1H), 6.82 (d, J = 11.5 Hz, 1H), 6.76 (s, 2H), 6.40 
(t, J = 6.5 Hz, 1H), 2.23 (s, 3H), 2.10 (s, 6H), 0.88 (s, 21H). 11B NMR (160 MHz, CD2Cl2): 
δ 40.0. 13C NMR (126 MHz, CD2Cl2): δ 144.1, 139.8, 138.6, 137.7, 131.5 (br), 127.5, 112.5, 
102.7, 65.3, 22.7, 21.4, 18.8, 11.9 (the signal for the mesityl carbon next to boron is not 
observed). FTIR (thin film): 2941, 2891, 2864, 2180, 1615, 1506, 1439, 1393, 1275, 1232, 
1078, 976, 883, 827, 667, 496 cm-1. HRMS (DART-TOF) calculated for C24H37BNSi 
([M+H]+): 378.27883, found: 378.27837. 
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Synthesis of BN-Stilbene (Scheme 4.21): 
In a dry box, an oven-dried 50 mL round bottom flask was charged with 
N-H-B-benzyl-1,2-azaborine (4.81) (507 mg, 3.00 mmol) and toluene 
(15 mL) and cooled to –30 oC. A solution of n-butyllithium (1.26 mL, 
3.15 mmol, 2.5 M in hexane) was added at –30 oC and the reaction mixture was stirred for 
20 min while slowly warming up to room temperature. To the reaction mixture Pd2dba3 
(55 mg, 0.060 mmol), QPhos (170 mg, 0.240 mmol), and β-bromostyrene (476 μL, 3.60 
mmol) were added. The reaction mixture was stirred at 85 oC for 15 h. At the completion 
of the reaction, the reaction mixture was cooled to room temperature. The crude mixture 
was filtrated through an acro-disc using CH2Cl2 as solvent and the filtrate was concentrated 
under reduced pressure. The crude product was purified by silica gel column 
chromatography (2% CH2Cl2/pentane to 10% CH2Cl2/pentane). The desired product was 
isolated as a white solid (497 mg, 61%). 1H NMR (500 MHz, CD2Cl2):  7.70 (d, J = 14.5 
Hz, 1H), 7.60-7.54 (m, 2H), 7.48 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.0 Hz, 2H), 7.34-7.29 
(m, 3H), 7.25-7.22 (m, 2H), 7.18-7.16 (m, 1H), 6.65 (d, J = 14.0 Hz, 1H), 6.58 (d, J = 11.5 
Hz, 1H), 6.40 (t, J = 7.0 Hz, 1H), 2.91 (s, 2H). 11B NMR (160 MHz, CD2Cl2): δ 37.9. 13C 
NMR (151 MHz, CD2Cl2): δ 143.8, 143.0, 136.4, 134.1, 133.9, 131.0 (br), 129.7, 129.4, 
128.9, 128.1, 126.8, 124.9, 121.5, 111.8, 27.6 (br). FTIR (thin film): 3059, 3025, 1644, 
1611, 1511, 1492, 1401, 1356, 1260, 1117, 1008, 801, 751, 693, 517 cm-1. HRMS (DART-
TOF) calculated for C19H19BN ([M+H]+): 272.16105, found: 272.16078. 
In a dry box, an oven-dried 20 mL microwave vial was charged with 4.82 
(360 mg, 1.33 mmol), n-dodecanol (346 mg, 1.86 mmol), CuBr (19 mg, 
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0.13 mmol), pyridine (214 μL, 2.66 mmol), di-tert-butyl peroxide (293 μL, 1.59 mmol), 
and 13 mL toluene. The reaction mixture was stirred at 90 °C for 1 h. At the completion of 
the reaction, the reaction mixture was cooled to room temperature. The solvent was 
removed under reduced pressure. The crude oxidized product was purified by silica gel 
column chromatography (2% Et2O/pentane to 50% Et2O/pentane) to isolate a mixture of 
the desired product, B-OH, and BOB dimer, which was used directly to the next step. In a 
dry box, an oven-dried 25 mL round bottom flask was charged with the mixture of oxidized 
products and 10 mL Et2O and cooled to –30 oC. To the reaction mixture lithium aluminum 
hydride (15 mg, 0.40 mmol) was added at –30 oC and stirred for 30 min. Hydrogen chloride 
solution (395 μL, 0.790 mmol, 2.0 M in diethyl ether) was added at –30 oC and the reaction 
mixture was stirred for 30 min as slowly warmed to room temperature. The solvent was 
removed under reduced pressure. The crude product was purified by silica gel column 
chromatography (100% pentane to 2% Et2O/pentane). The desired product was isolated as 
a white solid (91.3 mg, 38% over 2 steps). 1H NMR (500 MHz, CD2Cl2):  7.68-7.64 (m, 
2H), 7.48 (d, J = 14.5 Hz, 1H), 7.45 (t, J = 8.5 Hz, 2H), 7.35 (t, J = 7.5 Hz, 2H), 7.26 (t, J 
= 7.5 Hz, 1H), 6.97 (d, J = 10.5 Hz, 1H), 6.79 (d, J = 14.5 Hz, 1H), 6.51 (t, J = 6.5 Hz, 1H), 
5.82-4.60 (br, 1H). 11B NMR (160 MHz, CD2Cl2): δ 33.2 (d, J = 109 Hz). 13C NMR (151 
MHz, CD2Cl2): δ 144.4, 136.9, 136.4, 134.1, 131.4 (br), 129.3, 127.9, 126.7, 118.8, 113.3. 
FTIR (thin film): 3063, 3022, 2539, 1650, 1604, 1508, 1404, 1262, 1152, 973, 755, 693, 
596 cm-1. HRMS (DART-TOF) calculated for C12H13BN ([M+H]+): 182.11410, found: 
182.11324. 
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Quantum Yield Measurement: 
 Fluorescence quantum yield, Φ, was measured by using an integrating sphere. 
Measurements were taken in degassed cyclohexane or directly at solid state with constant 
slit widths. 
Experimental Φ: 
BN-stilbene= 0.0388 in cyclohexane/ 0.127 at solid state 
CC-stilbene= 0.170 in cyclohexane/ 0.324 at solid state 
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Synthesis of BN-lisdexamfetamine derivative (Scheme 4.20): 
In a dry box, an oven-dried 20 mL scintillation vial was charged 
with 4.72 (108 mg, 0.561 mmol) and THF (3 mL), and cooled to 
0 oC. To the reaction mixture (S)-2-methylaziridine-1-carboxylic 
acid tert-butyl ester (97 mg, 0.62 mmol) in THF (1.5 mL) was added and stirred for 14 h 
as slowly warmed to room temperature. At the completion of the reaction, hydrogen 
chloride solution (100 μL, 0.200 mmol, 2.0 M in diethyl ether) was added at room 
temperature and the reaction mixture was stirred for 30 min. The crude mixture was 
concentrated under reduced pressure and purified by silica gel column chromatography (10% 
Et2O/pentane to 75% Et2O/pentane). The desired product was isolated as a colorless oil 
(140 mg, 80%). Spectra of the isolated compound 4.77j’ matches the values for compound 
4.77j (racemic product). 1H NMR (500 MHz, CD2Cl2):  7.64 (dd, J = 11.0, 6.5 Hz, 1H), 
7.51 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.35-7.31 (m, 2H), 6.77 (d, J = 11.5 Hz, 
1H), 6.41 (t, J = 6.5 Hz, 1H), 4.25 (br s, 1H), 3.90 (d, J = 5.5 Hz, 2H), 3.81 (t, J = 5.5 Hz, 
1H), 1.36 (s, 9H), 0.91 (d, J = 5.5 Hz, 3H). 11B NMR (160 MHz, CD2Cl2): δ 35.9. 13C NMR 
(126 MHz, CD2Cl2): δ 155.4, 143.4, 142.8 (br), 139.2, 133.3, 131.6 (br), 128.2, 127.8, 
111.9, 79.5, 58.5, 49.0, 28.7, 18.7. FTIR (thin film): 3348, 2977, 2931, 1691, 1609, 1514, 
1441, 1404, 1366, 1244, 1031, 976, 743, 704 cm-1. HRMS (DART-TOF) calculated for 
C18H26BN2O2 ([M+H]+): 313.20873, found: 313.20959. 
In a dry box, an oven-dried 20 mL scintillation vial 
was charged with 4.77j’ (395 mg, 1.27 mmol) and 
CH2Cl2 (10 mL). To the reaction mixture hydrogen 
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chloride solution (953 μL, 3.81 mmol, 4.0 M in dioxane) was added at room temperature 
and stirred for 14 h. The crude mixture was concentrated under reduced pressure and 
directly used for the next step. In a dry box, the crude reaction mixture was transferred to 
an oven-dried 50 mL round bottom flask and dissolved in CH2Cl2 (20 mL) and Boc-
Lys(Boc)-OSu (563 mg, 1.27 mmol) and N-methylmorpholine (NMM) (838 μL, 7.62 
mmol) were added. The reaction mixture was stirred at room temperature for 1 h. The crude 
mixture was concentrated under reduced pressure and purified by alumina column 
chromatography (0.25% MeOH/CH2Cl2 to 0.50% MeOH/CH2Cl2). The desired product 
was isolated as a white solid (657 mg, 96% over 2 steps). 1H NMR (500 MHz, CD2Cl2):  
7.63 (dd, J = 10.5, 6.5 Hz, 1H), 7.51 (d, J = 6.5 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.35-7.31 
(m, 2H), 6.77 (d, J = 11.0 Hz, 1H), 6.40 (t, J = 6.5 Hz, 1H), 5.80 (br s, 1H), 5.02 (br s, 1H), 
4.62 (br s, 1H), 4.10 (quint, J = 6.5 Hz, 1H), 3.97-3.89 (m, 2H), 3.81 (s, 1H), 3.12-2.98 (m, 
2H), 1.69-1.61 (m, 1H), 1.52-1.35 (m, 2H), 1.42 (s, 9H), 1.40 (s, 9H), 1.28-1.19 (m, 3H), 
0.92 (d, J = 6.5 Hz, 3H). 11B NMR (160 MHz, CD2Cl2): δ 36.1. 13C NMR (126 MHz, 
CD2Cl2): δ 172.3, 156.6, 156.3, 143.4, 142.4 (br), 139.2, 133.3, 131.7 (br), 128.3, 127.9, 
111.9, 80.2, 79.2, 67.4, 58.0, 56.0, 47.7, 40.4, 32.5, 30.2, 28.7, 23.1, 18.3. FTIR (thin film): 
3308, 2976, 2933, 1688, 1656, 1610, 1516, 1455, 1392, 1366, 1247, 1170, 976, 865, 746, 
706 cm-1. HRMS (DART-TOF) calculated for C29H46BN4O5 ([M+H]+): 541.35612, found: 
541.35529. 
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Crystallographic Data for 4.80b: 
Identification code  C26H22B2N2 
Empirical formula  C26 H22 B2 N2 
Formula weight  384.07 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 5.8491(3) Å  
 b = 11.3280(6) Å  
 c = 15.0312(7) Å  
Volume 995.10(9) Å3 
Z 2 
Density (calculated) 1.282 Mg/m3 
Absorption coefficient 0.559 mm-1 
F(000) 404 
Crystal size 0.400 x 0.060 x 0.050 mm3 
Theta range for data collection 7.075 to 66.802°. 
Index ranges -6<=h<=6, -13<=k<=13, -17<=l<=17 
Reflections collected 9940 
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Independent reflections 1751 [R(int) = 0.0393] 
Completeness to theta = 66.802° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.6758 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1751 / 0 / 136 
Goodness-of-fit on F2 1.029 
Final R indices [I>2sigma(I)] R1 = 0.0381, wR2 = 0.0960 
R indices (all data) R1 = 0.0468, wR2 = 0.1020 
Extinction coefficient na 
Largest diff. peak and hole 0.251 and -0.198 e.Å-3 
 
Crystallographic Data for 4.82: 
Identification code  C19H18BN 
Empirical formula  C19 H18 B N 
Formula weight  271.15 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P-1 
696 
 
Unit cell dimensions a = 5.7638(3) Å  
 b = 10.2966(6) Å  
 c = 13.4006(8) Å  
Volume 755.28(7) Å3 
Z 2 
Density (calculated) 1.192 Mg/m3 
Absorption coefficient 0.512 mm-1 
F(000) 288 
Crystal size 0.400 x 0.220 x 0.180 mm3 
Theta range for data collection 3.468 to 66.794°. 
Index ranges -6<=h<=6, -12<=k<=11, 0<=l<=15 
Reflections collected 2664 
Independent reflections 2664 [R(int) = ?] 
Completeness to theta = 66.794° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.4502 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2664 / 0 / 192 
Goodness-of-fit on F2 1.068 
Final R indices [I>2sigma(I)] R1 = 0.0724, wR2 = 0.2115 
R indices (all data) R1 = 0.0750, wR2 = 0.2146 
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Extinction coefficient n/a 
Largest diff. peak and hole 0.225 and -0.274 e.Å-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
698 
 
4.5.3 Spectral Data 
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